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Foreword
Dear Friends and Colleagues,
I am delighted to present to you CDC’s Influenza Division International Activities 2010 Annual Report. 
The report includes detailed updates on the global work supported by the Division including country 
briefs, research collaborations, training programs, and other influenza-related activities.  
In 2010, the Division provided funding support and technical assistance for influenza activities to 48 
countries in the form of direct cooperative agreements or indirectly through our partners. Under these 
agreements, partner countries have made significant progress in the development of their influenza 
surveillance capacity and pandemic preparedness.  Their collective progress is evident in the positive 
movement of scores captured in 2010 using the Division’s National Inventory of Core Capacities for 
Pandemic Preparedness and Response monitoring and evaluation tool (see page 258). There is no doubt 
the hard work countries have put in to developing both their laboratory and epidemiologic surveillance 
systems and strengthening their pandemic preparedness not only enhanced their response to the 2009 
influenza pandemic but has also helped to build general capacity for all emerging infectious diseases. 
In other achievements for 2010, China’s National Influenza Center in Beijing was designated a WHO 
Collaborating Center for Reference and Research on Influenza.  The Division has worked closely with 
the National Influenza Center in Beijing for over two decades and congratulates China on becoming just 
one of five such Centers globally.  Likewise, the Division wishes to congratulate its partner countries 
who achieved WHO National Influenza Center status in 2010 in the following locations: Guatemala City, 
Guatemala; Kathmandu, Nepal; Accra, Ghana; Ho Chi Minh City, Vietnam and Vientiane, Lao People’s 
Democratic Republic.
The findings in this report represent a substantial amount of work, cooperation and dedication  
from all involved.  I would like to take this opportunity to thank our country partners, international 
collaborators, field staff, CDC partners and the Atlanta-based team on their achievements for 2010,  
which are shared by all. 




Director, Influenza Division 
National Center for Immunization and Respiratory Diseases 
Centers for Disease Control and Prevention 
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Mission
Mission statement: The Centers for Disease Control and Prevention (CDC) Influenza Division 
(ID) provides scientific and programmatic foundation and leadership for the diagnosis, prevention, and 
control of influenza domestically and internationally. 
In carrying out its mission, the ID: 
(1) conducts global and domestic surveillance to guide vaccine formulation and understand the impact 
of influenza; 
(2) develops policy for the prevention and control of influenza; 
(3) conducts state-of-the-art research to better understand the evolution, antigenicity, genetic  
properties, antiviral susceptibility, transmissibility, pathogenicity, immune response, and other 
characteristics of influenza viruses for the purpose of developing better tools for the prevention  
and control of influenza; and 
(4) provides international technical assistance for outbreak investigations, the expansion of laboratory 
and epidemiologic capacity, and international and domestic training.
Background
CDC’s Influenza Division has a long history of supporting the World Health Organization (WHO) and 
its global network of National Influenza Centers (NICs).  With limited resources, most international 
assistance provided in the early years was through hands-on laboratory training of in-country staff, the 
annual provision of WHO reagent kits (produced and distributed by CDC), and technical consultations 
for vaccine strain selections.  The Influenza Division (at that time, the Influenza Branch) also conducted 
epidemiologic research including vaccine studies and serologic assays and provided international 
outbreak investigation assistance.  
In 1997, the first human cases of influenza A (H5N1) were reported in Hong Kong, and the Influenza 
Division played a key role in assisting with the outbreak investigations.  The re-emergence of fatal 
human cases of avian influenza A (H5N1) in China in 2003 following the outbreak of SARS, followed 
by human outbreaks caused by highly pathogenic avian influenza A (H5N1) viruses in Vietnam and 
Thailand in 2003 and 2004 led to a growing concern that a pandemic of influenza may emerge. These 
outbreaks highlighted several important gaps that needed to be closed to improve the ability to rapidly 
identify novel influenza viruses with pandemic potential. These included: 
•	 conspicuous geographic gaps in human influenza surveillance.
•	 critical gaps in information, laboratory and epidemiologic training and technology transfer for 
rapid identification and analysis of avian influenza viruses in many  affected countries.
•	 longstanding obstacles and gaps in the sharing of information, resources and specimens 
between agriculture and human health authorities.
These events fostered the beginning of a larger international program to improve global pandemic 
preparedness and enhance capacity for laboratory and epidemiologic surveillance of influenza and avian 
influenza.
In 2004, the U.S. government (Health and Human Services (HHS)/CDC) committed resources and 
developed a multi-faceted approach to support global capacity for seasonal influenza and pandemic 
preparedness. Support was made available through cooperative agreements to enhance the existing 
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WHO Global Influenza Program (GIP) and to help establish influenza surveillance in some countries 
not participating in WHO’s GIP. These cooperative agreements, paired with technical assistance, support 
the provision of training, staffing, direct assistance, supplies and reagents. The program accomplishes 
key goals by building on existing programs and infrastructure including WHO and its regional offices, 
CDC Global Disease Detection (GDD) sites and International Emerging Infections Program (IEIP) 
sites, Department of Defense (DoD) international program sites, and by utilizing the assistance of U.S. 
embassies. 
In April 2009, the first case of pandemic 2009 H1N1 influenza virus infection in the United States was 
identified. Subsequent cases were quickly identified in Mexico and other states. The influenza virus 
identified in these early cases was unique and contained a combination of gene segments that had not 
been previously reported in animals or humans. The 2009 H1N1 pandemic allowed many countries 
with cooperative agreements to showcase the progress they have made in the last few years. First-time 
investigations of influenza were conducted in response to the pandemic and labs that previously could 
not identify influenza virus were able to diagnose pandemic 2009 H1N1 using molecular techniques. 
Many countries that previously had not reported influenza routinely were able to report consistently and 
contribute to the global picture of influenza epidemiology during the pandemic.
Over the past six years the program has undergone remarkable growth [see Maps] and has expanded 
to provide support to over 40 countries, all WHO regional offices and WHO Headquarters. Partnerships 
have been developed with the DoD, United States Agency for International Development (USAID), 
Biosecurity Engagement Program (BEP) and other entities to enhance global surveillance and 
preparedness. Over 20 permanent staff have been placed in the field [see Map] to provide on-the-ground 
assistance and support to countries and to WHO, and to augment the GDD program. 
Influenza Division microbiologist inoculating 10-day old embryonated chicken eggs with a specimen containing an H5N1 avian influenza virus.
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Recognizing that needs vary by countries, the program is designed as a continuum to include: 
improvements to surveillance, efforts to enhance pandemic preparedness, implementation of burden 
of disease studies to measure the impact of influenza, and studies to determine the effectiveness of 
intervention measures such as vaccination. With the data generated through surveillance, each country 
can determine which populations are most vulnerable to influenza-related morbidity and mortality and 
who should receive influenza vaccine. Based on surveillance and other analyses, influenza vaccination 
policy and issues related to vaccine production can be approached on a country-by-country and a 
regional basis. In 2010, we embarked on placing more emphasis on the development of data to help 
countries evaluate the need and feasibility of vaccine policy. 
While the response to the 2009 H1N1 pandemic was an opportunity to show recent progress, avian 
influenza H5N1 outbreaks still pose a significant and ongoing global health threat. To sustain the 
gains made in the past years, a broad-based commitment to build and maintain influenza surveillance 
globally that is sustainable (and eventually 
self-sustainable) requires dedicated, annualized 
resources and staffing. It is our hope that these 
HHS/CDC resources and technical assistance 
will act as a catalyst for affected countries, 
neighboring countries and donor countries 
to commit resources to establish long-term 
influenza surveillance, prevention and control, 
and pandemic preparedness activities as high 
priorities. We also envision that each affected 
country will utilize the technical assistance and 
resources available to improve surveillance, 
develop influenza vaccination policy, make plans 
for the use of influenza vaccine both annually 
and during a pandemic, and work closely with 
regional and international partners to further 
preparedness. 
This program has implications beyond influenza. 
The capacity being developed for laboratory and 
epidemiologic surveillance of severe respiratory 
disease has served as the basis for capacity 
for the diagnosis and investigation of other 
infectious diseases, particularly other respiratory 
pathogens. Laboratory equipment and training 
has enabled the diagnosis and investigation of 
other diseases. Likewise, through the implementation of a global rapid response training program, CDC 
has provided training and materials for thousands of people in all WHO regions. These courses have 
enabled the trained teams to participate in outbreaks not only for the recent pandemic but for other 
respiratory diseases and many other pathogens including Rift Valley Fever, dengue, cholera, Ebola and 
rabies. Evidence shows that the technical assistance provided by the Influenza Division is assisting 
countries in increasing their capacity necessary for compliance with the new International Health 
Regulations (IHR). The generic approach, with a focus on influenza and avian influenza, contributes 
greatly to global capacity for laboratory, epidemiology and overall preparedness for emerging and 
re-emerging infectious diseases. Efforts are underway to plan for the sustainability of the gains that have 
been made. This report is the third annual update on the Influenza Division’s international activities
An electron micrograph of the 2009 H1N1 influenza virus taken in the  
CDC Influenza Laboratory.
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WHO Cooperative Agreement DoD Collaborations
U.S. CDC International Influenza Activities
and Support, FY 2004
Cooperative Agreement




CDC Influenza Division Field Staff
GDD Sites Cooperative Agreement
Indirect Funding
U.S. CDC International Influenza Activities
and Support, FY 2007
0 1,750 3,500 5,250 7,000875
Miles
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WHO Cooperative Agreement
DoD Collaborations





U.S. CDC International Influenza Activities
and Support, FY 2009
0 1,750 3,500 5,250 7,000875
Miles
U.S. CDC International Influenza Activities
and Support, FY 2010







0 1,750 3,500 5,250 7,000875
Miles
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U.S. CDC and WHO Collaborations—
Influenza
The HHS/CDC Influenza Division has maintained cooperative agreements with WHO Headquarters 
and the WHO Pan American (PAHO) and Western Pacific Regional Offices (WPRO) for many years to 
address seasonal and pandemic influenza. In 2006, new cooperative agreements were put in place with 
the WHO South-East Asia Regional Office (SEARO), the Africa Regional Office (AFRO), the Eastern 
Mediterranean Regional Office (EMRO) and the European Regional Office (EURO). The main purpose of 
the cooperative agreements is to address global and regional preparedness for influenza - both seasonal 
and avian - and to add support to enhance the WHO Global Influenza Surveillance Network (GISN) 
through development of standard surveillance guidelines and support to WHO and many countries. 
In addition, more recently we have supported efforts to develop guidelines for conducting burden 
of disease studies for influenza and projects on vaccine use, evaluation and policy. This effectively 
increases the number of countries participating in the global system and more importantly enhances 
the early warning capacity and communications so there is a greater chance for early identification of a 
pandemic. Information about the project activities for the regional offices is integrated under the specific 
regions. CDC’s Influenza Division provided funding and technical support to WHO Headquarters in 2010 
for multiple projects related to influenza, outlined below.
Activities supported through WHO:
Influenza Laboratory Surveillance
•	 Strengthening of global influenza laboratory surveillance through improved diagnostics  
capacity and enhanced shipping capacity of influenza viruses/specimens to WHO Collaborating 
Centers (WHO CCs).
•	 Strengthening global coordination and communication of GISN by conducting a third  
National Influenza Center (NIC) survey and feeding results of the analysis into a NIC meeting 
with all regions. 
•	 NICs were invited to attend the vaccine composition consultations in September and February 
to support this goal.
Influenza Epidemiology and Surveillance
•	 Strengthening influenza monitoring at the global level including development of automated 
analysis and visual presentation tools.
•	 Developing a pandemic assessment tool.
•	 Supporting developing countries in risk assessment and response.
•	 Supporting countries in the development of influenza surveillance systems and assessment of 
disease burden to inform vaccine and antiviral use decisions.
•	 Development of a tool for community-level risk assessment for H5N1 infection in collaboration 
with OIE (World Organisation for Animal Health) and FAO (Food and Agriculture Organization 
of the United Nations).
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Strengthening Influenza Pandemic Preparedness and Response Planning
•	 Review of national pandemic assessment and development of lessons learned to revise 
pandemic preparedness guidelines.
•	 Review of:
 ˏ measures and indicators of severity during a pandemic.
 ˏ the concept of pandemic phases for decision-making.
•	 Assessment of effectiveness of school closure in different settings.
•	 Maintenance and improvements to the digital library.
Public Health Leadership and Global Coordination 
•	 Provision of technical guidance and support to member states for:
 ˏ development of coordinated pandemic preparedness initiatives.
 ˏ developing future strategies aligned with WHO Headquarters and regional office guidance 
for global pandemic preparedness with a view toward longterm public health capacity for 
vulnerable populations.
•	 Dissemination of guidance:
 ˏ to minimize social and economic disruption.
 ˏ to other United Nations agencies and programs.
Seasonal Influenza Vaccine Introduction
•	 Collection and dissemination of information on influenza vaccine availability and utilization.
•	 Assurance of quality and safety of influenza vaccines by visiting manufacturing sites and 
technical reviews of production procedures.
•	 Support for influenza vaccination policy through the development of mathmetical models to 
estimate potential public health impact of various vaccine introduction strategies and potential 
impact of vaccine introduction on mortality among children younger than 5 years old.
•	 Capacity development and facilitation of influenza vaccine policy in WHO regions.
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Influenza Reagent Resource (IRR)
The Influenza Reagent Resource (IRR) was established by the U.S. CDC to provide registered users 
with reagents, tools and information for studying and detection of influenza virus. The IRR acquires, 
authenticates, and produces reagents that scientists need to carry out basic research and develop 
improved diagnostic tests, vaccines, and detection methods. Public health labs also use the reagents 
across the globe for the surveillance of newly emerging strains of influenza, such as H1N1 and H5N1. 
By centralizing these functions within the IRR, access to and use of these materials in the scientific and 
public health community is monitored and quality control of the reagents is assured.
The roles of IRR in pandemic preparedness and influenza research are:
•	 To manufacture and distribute influenza diagnostic kits, viruses, and reagents to public health, 
commercial, domestic, and international research laboratories.
•	 To improve pandemic preparedness, enhance detection and control of seasonal influenza, and 
provide better access to reagents via a secure, web-based system.
•	 To augment CDC’s international pandemic preparedness plan to provide a surge option (~$10+ 
million per year) which can be exercised to distribute reagents and diagnostic kits to domestic 
and international public health laboratories.
Post pandemic, CDC and IRR continue to provide reverse transcriptase polymerase chain reaction 
(RT-PCR) 2009 H1N1 and seasonal influenza diagnostic kits, ancillary reagents, reference viruses  
and other materials to 241 countries supporting more than 375 international laboratories. These kits  
and reagents were also provided to more than 150 public health laboratories domestically in 50 states 
and territories.
Product Total Kits International
# Countries 
Distributed




# of Domestic 
Distributed
# of U.S. State 
Labs Distributed Total Kits
H1N1 RT-PCR Kit 1,364
241 390
1,862
50 + DC + PR 184
3,226
Seasonal RT-PCR Kit 819 1,073 1,892
WHO reference Kit 406 104 153 262 52 163 668
IRR is currently available via fluorder@cdc.gov. The IRR website is live and displays over 150 different 
reagents and kits available to the public health labs globally. Registration to the IRR should commence 
in the near future, allowing registrants to order reagents electronically as well as view a large amount of 
information relating to influenza reagents. 
The IRR is providing better access to quality influenza-related reagents by manufacturing and 
distributing influenza viruses a la carte and as panels, recombinant proteins, antisera, monoclonal 
antibodies, ribonucleic acid (RNA) standards, non-influenza respiratory pathogens and more. Institutions 
that have access to these reagents are qualified domestic and international WHO NICs and public health 
laboratories, commercial test developers, vaccine manufacturers, and research institutions.
This WHO kit is sent out to the WHO NICs 
annually for surveillance and influenza 
type/subtype identification. It contains 
inactivated viruses (also known as 
antigens), antisera and receptor destroying 
enzyme (RDE) to perform HAI assays.  It 
also contains monoclonal antibodies 
for IFA testing of influenza. Instructions 
provided with the kit explain how to 
perform the assays and how to interpret 
the results.
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IRR Global Distribution
A map of IRR’s distribution of diagnostic kits and reagents to 241 countries globally since 2009. 
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WHO African  
Region  
(AFR)
WHO African Region (AFR) Overview
Currently there are 12 bilateral influenza cooperative agreements in the sub-Saharan region of Africa. 
These agreements are with Ministries of Health or institutions designated by the Ministry of Health 
(MOH) to work with CDC to build capacity to routinely identify, diagnose and respond to seasonal and 
pandemic influenza across the African continent. 
CDC direct country support via cooperative agreements is established in the following countries:
•	 Angola.
•	 Cote d’Ivoire.










In addition, CDC supports the WHO African Regional Office (AFRO) via a cooperative agreement.
The core activities of our bilateral agreements and technical assistance are:
•	 To build sustainable national capacity for seasonal influenza, pandemic influenza and other 
emerging diseases and preparedness for implementation of the International Health Regulations 
(IHR).
•	 To make routine contributions of surveillance data to the WHO Global Influenza Surveillance 
Network (GISN).
•	 To increase the geographic reach of WHO’s GISN.
•	 To provide earlier access to critical virus isolates from humans and birds for WHO’s GISN.
•	 To increase the numbers of shipments and influenza isolates provided by Africa influenza labs 
for analysis by WHO Collaborating Centers.
•	 To develop sustainable epidemiologic and virologic surveillance systems for severe influenza, in 
order to gain understanding of the burden of disease from influenza in the WHO AFR Region.
WHO African Region (AFR) 13
In additional to our bilateral work, we also partner with the Navy Medical Research Unit No. 3 






Influenza Division Contacts 
Atlanta 
Richard Davis, MSFS 
Public Health Advisor
Extramural Program - WHO Africa Region
Influenza Division/NCIRD/CDC
Email: rbdavis@cdc.gov
Inzune Hwang, MD, MPH (until Jan 2011)
Medical Officer Epidemiologist
International Epidemiology and Response Team
Influenza Division/NCIRD/CDC
Email: ihwange@cdc.gov
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WHO African Regional Office (AFRO)
0 540 1,080 1,620270
Miles






Influenza Research Cooperative Agreement
Influenza Indirect Funding
Influenza Sustainability Cooperative Agreement
Influenza Capacity Building Cooperative Agreement
International Influenza Activities:
CDC-AFRO 2010
U.S. CDC Direct WHO Regional Office Support
In 2006, a five-year cooperative agreement between CDC and WHO African Regional Office (AFRO) 
was initiated to support the strengthening of avian influenza preparedness and response in the WHO 
African Region (AFR). The overall objectives of the grant are to enhance epidemiological and virological 
surveillance of influenza, to reinforce response and containment of avian and pandemic influenza, and 
to strengthen preparedness and communication for avian and pandemic influenza in the Region. 
Surveillance
Before the agreement, AFR had implemented an Integrated Disease Surveillance and Response strategy 
(IDSR). This strategy included only limited influenza surveillance. Recognizing the system’s limitations, 
AFR undertook to revise the technical guidelines and training modules for IDSR to include surveillance 
for human influenza caused by new influenza subtypes, influenza-like illness (ILI), and severe acute 
respiratory illness (SARI).
Key Surveillance Activities
•	 The new IDSR guidelines incorporating ILI and SARI were revised and translated into three 
WHO AFR languages and disseminated to all Member States.  
•	 While preparing for a possible avian influenza pandemic, as well as during the 2009 H1N1 
pandemic, capacity for sentinel surveillance for influenza improved in all 46 Member States. 
WHO African Region (AFR) 15
Laboratory
With support from the grant and other partners, polymerase chain reaction (PCR) testing capacity 
for the detection of influenza viruses has been established in 24 countries in the Region. In addition, 
virus isolation capacity for influenza has been transferred to 12 out of the 24 countries with influenza 
laboratories. Twenty out of 24 countries are regularly reporting data on influenza to FluNet. In addition, 
13 countries are submitting isolates to WHO Collaborating Centers (WHO CCs). 
Key Laboratory Activities
•	 An annual influenza laboratory meeting was organized for lab staff located throughout Africa. 
•	 Burkina Faso, Malawi and Mozambique laboratories were assessed for setting up the detection 
of influenza virus using RT-PCR.
•	 The influenza External Quality Assessment Program (EQAP) has been introduced in 19 of these 
countries and plans have been drawn up to scale up this activity to all the influenza labs in the 
Region.
•	 Influenza laboratory staff in the Region has been trained on polymerase chain reaction (PCR), 
virus isolation, biosafety level (BSL) 3 laboratory operation, antiviral testing, sequencing, and 
safe shipment of infectious materials.
Preparedness
In August 2006, Member States adopted a resolution pertaining to the regional pandemic influenza 
preparedness and response plan. In August 2009, Member States adopted the resolution “Strengthening 
Outbreak Preparedness and Response in the African Region” in the context of the pandemic 2009 H1N1.
Key Preparedness Activities
•	 Rapid response teams have been established in the Region. 
•	 Pandemic 2009 H1N1 prompted most countries in the Region to establish national epidemic 
management and coordination committees.
•	 Contingency stocks of personal protective equipment for pandemic influenza including antiviral 
drugs, viral transport media (VTM) and triple packaging boxes are prepositioned and available 
at four sites in the Region; these materials were also sent to all Member States.
Training
WHO AFRO hosted the following training activities in 2010:
•	 Hands-on training for virus isolation. 
•	 Operation of BSL-3. 
•	 Influenza antiviral resistance testing. 
•	 Influenza sequencing. 
•	 Training on safe shipment of infectious substances.
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2009 H1N1 Activities, FY 2010
The Region continued to monitor the circulation of 2009 H1N1 and other influenza in 2010. Capacity for 
reporting and sharing isolates was improved in 2010.
Key 2009 H1N1 Activities, 2010
•	  An article “Pandemic (H1N1) 2009 in the WHO African Region” was published in the African 
Health Monitor Bulletin.
•	 WHO AFRO regularly provided feedback to countries on the 2009 H1N1 situation through 
weekly bulletins and quarterly reports.
CDC Assignee
Celia Woodfill, PhD
Avian Influenza Focal Point
CSR/AFRO/WHO
Brazzaville, Republic of Congo
Email: woodfill@afro.who.int 
Principal Collaborator
Francis Kasolo, MD, MSc, DTMandH (RCP), PhD  
Program Manager
WHO African Regional Office
Brazzaville, Congo
Email: kasolof@afro.who.int
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Angola
•	Capital: Luanda 
•	Area: 1,246,700 sq km 
•	Population: 13,338,541 ( July 2011 est.)
•	Age Structure: 0-14 years: 43.2% (male 2,910,981/female 
2,856,527); 15-64 years: 54.1% (male 3,663,400/female 
3,549,896); 65 years and over: 2.7% (male 157,778/female 
199,959) (2011 est.)
•	Life Expectancy at Birth: Total population: 38.76 years; 
male: 37.74 years female: 39.83 years (2011 est.)
•	Infant Mortality Rate: Total: 175.9 deaths/1,000 live births; 
male: 187.86 deaths/1,000 live births; female: 163.34 
deaths/1,000 live births (2011 est.)
•	Literacy Rate:  Total population: 67.4%; male: 82.9%; 
female: 54.2% (2001 est.)
•	GDP: $114.1 billion (2010 est.)
•	GDP per Capita: $8,700 (2010 est.)
U.S. CDC Direct Country Support
The Republic of Angola has been collaborating with the U.S. CDC on influenza control since 2006, 
through the cooperative agreement Support Preparedness and Response to Avian and Pandemic 
Influenza. The National Institute of Public Health (INSP) is the central reference laboratory of the MOH.
Support through the cooperative agreement has contributed to strengthening epidemiologic and 
virologic surveillance for influenza in the country. Notably, influenza laboratory diagnosis capacity has 
improved since the beginning of the collaboration. The agreement has also enhanced the general level 
of preparedness and response capacity for influenza and other emerging diseases in Angola.
Surveillance
The CDC has supported the implementation of national influenza protocols on the basis of the WHO 
generic protocol for influenza surveillance. CDC provides the MOH with technical assistance, training, 
and supplies to reinforce sentinel sites and laboratory capacity. This collaboration contributes to the 
implementation of the Field Epidemiology Laboratory Training Program (FELTP).
Key Surveillance Activities 
•	 CDC and INSP staff made several on-site visits in Luanda to provide refresher training to health 
workers on influenza sentinel surveillance techniques.
•	 Necessary equipment and supplies were purchased and distributed to three new sentinel sites 
in Luanda and provinces. 
•	 The INSP reports weekly data to the MOH epidemiology unit, WHO and CDC.
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Laboratory
CDC has supported the INSP laboratory with capacity building, supplies, and infrastructure upgrade. 
The INSP laboratory provides testing for seasonal flu, 2009 H1N1 flu, and avian flu. It participates in 
surveillance activities for SARI and ILI for MOH and WHO. 
Key Laboratory Activities
•	 In December 2009, MOH/INSP staff participated in the Africa Influenza Scientific Symposium in 
South Africa, where they presented two posters.
•	 In June 2010, a consultant from the Association of Public Health Laboratories (APHL) conducted 
a laboratory assessment to evaluate influenza diagnosis capacity in the central reference 
laboratory.
•	 In July 2010, MOH/INSP staff participated in a CDC international partners meeting and the 
International Conference on Emerging Infectious Diseases (ICEID) in Atlanta, where they 
presented three posters.
•	 Two new BSL-2 cabinets were installed at INSP in August 2010.
Preparedness
Preparedness activities began in 2005 after the threat of avian influenza was recognized by the 
Government of Angola. By presidential decree an inter-ministerial commission was created to implement 
measures for prevention and control of the 2009 H1N1 pandemic. The Angolan preparedness plan was 
collaboratively developed and updated with all stakeholders involved in the pandemic response.  
Key Preparedness Activities
Preparedness activities for Angola include the following:
•	 Ongoing sensitization and awareness sessions for air and sea companies’ workers.
•	 Production and distribution of educational and communication materials,  
i.e. pamphlets and fliers.
•	 Assurance of antiviral stock for severe influenza disease treatment.
•	 Training of rapid response teams in the 15 provinces of Angola.
Training
The MOH hosted the following training activities in 2010:
•	 Trainings were provided to air and seaport workers on surveillance and detection of flu signs 
and symptoms in Luanda and provinces.
•	 Two short courses were conducted by MOH/INSP and CDC: one in Luanda in December 2009 
that included participation of 20 epidemiologists from eight provinces, and another in March 
2010 that covered the southern regions of Angola. In addition to the MOH, the training included 
the participation of several sectors of government, including the military, police, customs and 
universities. The trainings were held to provide information on influenza sentinel surveillance 
techniques.
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2009 H1N1 Activities, FY 2010
From July to September of 2009, 37 cases of 2009 H1N1 flu were detected. Positive cases were detected 
in Luanda, Bengo and Huila provinces. No 2009 H1N1 cases were detected in 2010. Laboratory activities 
played an important role in surveillance; the MOH is currently improving coordination between 
laboratory activities and epidemiologic data.
Key 2009 H1N1 Activities, 2010
•	 Frequent inter-ministerial workgroup meetings.
•	 Presentations in medical conferences throughout the country.
•	 Launch of the Influenza Strategic Plan of Action.
•	 Enhancement and extension of surveillance sites to public and private hospitals.
•	 Training for more than 150 medical students and new medical staff in the surveillance network 
for data collection..
Other Notable Achievements in FY 2010 
•	 The avian influenza program contributes to the overall effort to establish an effective and 
sustainable field epidemiologic and public health laboratory workforce capacity for Angola. 
•	 The INSP participates in the genotyping study conducted by the National Institute for 
Communicable Disease (NICD) in South Africa for the African region.
•	 A national exercise to inventory core capabilities for pandemic influenza preparedness and 
response was completed.
Special Influenza Projects
•	 Implementation of the FELTP Program.
•	 An agreement between CDC and Agustinho Neto University (public university) to increase the 
number of surveillance officers.
Principal Collaborators
Filomena Gomes da Silva, BSc
Director 
National Institute for Public Health
Luanda, Angola
Email: filomenasilva5@yahoo.com.br
Fátima Valente, MD, MPH
National Epidemiologic Surveillance Officer 





National Institute for Public Health
Luanda, Angola
Email: yolanda.insp@gmail.com
Influenza sentinel surveillance training in Uíge Province, northwestern Angola.
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Democratic Republic of Congo
•	Capital: Kinshasa 
•	Area: 2,344,858 sq km 
•	Population: 71,712,867 ( July 2011 est.)
•	Age Structure: 0-14 years: 44.4% (male 16,031,347/female 
15,811,818); 15-64 years: 53% (male 18,919,942/female 
19,116,204); 65 years and over: 2.6% (male 767,119/
female 1,066,437) (2011 est.)
•	Life Expectancy at Birth: Total population: 55.33 years; 
male: 53.9 years; female: 56.8 years (2011 est.)
•	Infant Mortality Rate: Total: 78.43 deaths/1,000 live 
births; male: 82.2 deaths/1,000 live births; female: 74.55 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 67.2%; male: 80.9%; 
female: 54.1% (2001 est.)
•	GDP: $23.58 billion (2010 est.)
•	GDP per Capita: $300 (2010 est.)
U.S. CDC Direct Country Support
Surveillance of avian and pandemic influenza in DRC began in 2006, with the cooperative agreement 
between U.S. CDC and the Kinshasa School of Public Health (KSPH). The agreement is titled 
Surveillance and Response to Avian and Pandemic Influenza. This project aims to improve DRC 
capacity in surveillance, diagnosis, and provision of rapid response to avian and pandemic influenza 
outbreak.
Surveillance
In order to prepare DRC for a potential avian influenza outbreak event, the national surveillance system 
has been strengthened and has added seasonal influenza to the list of diseases to be reported to WHO. 
The country has set up ten sentinel sites out of the 50 planned.
Key Surveillance Activities 
•	 The MOH, in collaboration with CDC, developed surveillance protocol for influenza.
•	 During FY 2010, sites collected 1,836 samples from 1,115 patients with ILI, and 273 patients 
with SARI.
•	 Supervisors held monthly sentinel site visits.
Laboratory
•	 The National Institute for Biomedical Research (INRB) is the national influenza reference 
laboratory. It is well equipped and currently uses four trained staff to analyze samples in real 
time using RT-PCR testing. In Kinshasa, samples are collected daily from sentinel sites and 
delivered to INRB by car.
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Key Laboratory Activities
•	 From October 1, 2009, to September 30, 2010, the INRB analyzed 1,836 samples, of which 
265 (14.4 %) were positive for influenza A, 139 for influenza B (7.5%), and 20 cases were 
unclassified by real-time RT-PCR (7.5%).
•	 INRB distributes sample collection kits monthly to sentinels sites, and then provides analyzed 
results when testing is complete.
Preparedness
The avian influenza national plan, developed in 1996, was last revised in October 2009 by the Avian 
Influenza National Technical Committee. The aim was to adapt this plan according to the current 
epidemiologic context and available resources.
Training
The DRC MOH hosted the following training activities in 2010:
•	 In July 2010, the MOH provided refresher training on sample collection procedures for 20 
participants in Kinshasa.
•	 In September and October 2010, ten participants in Matadi attended a refresher course on 
sample collection procedures. 
2009 H1N1 Activities, FY 2010
Activities related to 2009 H1N1 began with the appearance of the pandemic throughout the world. A 
multi-sector committee was set up under the leadership of the DRC health ministry; this committee 
refined a strategic plan for response and surveillance. 
Key 2009 H1N1 Activities, 2010
•	 The multi-sector committee updated a communication plan and developed communication tools 
(pamphlets, pictures and traveler guidelines) in response to 2009 H1N1.
•	 The multi-sector committee also organized broadcasts regarding safe practices during the 2009 
H1N1 pandemic.
Other Notable Achievements in FY 2010 
•	 Students and pregnant women were taught how to prevent getting sick with the flu. 
•	 The health service in charge of quarantine distributed guidelines for travelers for influenza.
Principal Collaborators
Emile Okitolonda, MD, PhD
Professor of Epidemiology
Kinshasa School of Public Health
Kinshasa, DRC
Email: okitow@yahoo.fr 
Jean-Jacques Muyembe, MD, PhD
Director
National Institute for Biomedical Research
Kinshasa, DRC
Email: jjmuyembe@yahoo.fr PCR Equipment Room at the National Institute for Biomedical Research (INRB), Kinshasa, 
Democratic Republic of Congo.
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Ethiopia
•	Capital: Addis Ababa 
•	Area: 1,104,300 sq km 
•	Population: 90,873,739 ( July 2011 est.)
•	Age Structure: 0-14 years: 46.3% (male 20,990,369/
female 21,067,961); 15-64 years: 51% (male 22,707,235/
female 23,682,385); 65 years and over: 2.7% (male 
1,037,488/female 1,388,301) (2011 est.)
•	Life Expectancy at Birth: Total population: 56.19 years; 
male: 53.64 years; female: 58.81 years (2011 est.)
•	Infant Mortality Rate: Total: 77.12 deaths/1,000 live 
births; male: 88.03 deaths/1,000 live births; female: 65.88 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 42.7%; male: 50.3%; 
female: 35.1% (2003 est.)
•	GDP: $84.02 billion (2010 est.)
•	GDP per Capita: $1,000 (2010 est.)
U.S. CDC Direct Country Support
The cooperative agreement between the Federal MOH/Ethiopia Health and Nutrition Research Institute 
(EHNRI) and the U.S. CDC began in August 2007. This was a four-year project titled Preparedness 
and Response to Avian and Pandemic Influenza in the Federal Democratic Republic of Ethiopia. 
The overarching goal was to strengthen the public health emergency capacity to rapidly detect, assess, 
respond to, and contain the public health risks that could be brought about by a pandemic.
Surveillance
Sentinel surveillance has the potential to provide more complete data about some of the epidemiologic 
characteristics of severe acute respiratory infections (SARI). Ethiopia has selected 20 priority diseases 
with mandatory reporting. Among those that are required to be reported immediately are avian-human 
influenza, pandemic influenza, and SARS. The MOH Ethiopia started SARI/ILI sentinel surveillance 
activities in September 2008. Currently, there are a total of five sites – two are dedicated to SARI and 
three are dedicated to ILI; all are functional.
Key Surveillance Activities
•	 In 2010, three additional sentinel sites were established (one SARI, two ILI) in Addis Ababa. 
These sites feed into the National Influenza Laboratory (NIL). 
•	 In June 2010, a two-day national review meeting was conducted in conjunction with the NIL 
and CDC-Ethiopia (CDC-E). In attendance were 35 surveillance officers from all five sites and 
from animal health, and a WHO country representative. The objective of the meeting was to 
review activities carried out over the past 12 months.
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•	 In February 2010, EHNRI hosted a five-day on-site technical assistance visit from CDC-Atlanta, 
Influenza Division. Activities included participating in a monitoring and evaluation exercise for 
pandemic preparedness, making a sentinel surveillance site visit to clinics and hospitals in Addis 
Ababa, and discussing cooperative agreement planning and data management coordination. 
•	 CDC-E supervised and provided onsite orientation, technical assistance and feedback for all 
SARI/ILI sites.
Laboratory
The NIL at EHNRI is the only laboratory capable of influenza diagnostic testing in the country. The 
laboratory became functional in June 2009. The NIL has worked closely with CDC to establish a state of 
the art laboratory. Routine testing of respiratory samples collected through the SARI/ILI sites commenced 
in 2008, and testing services for flu were provided upon request from different health facilities and 
organizations in 2009. 
Key Laboratory Activities 
•	 The NIL participates in the EQAP to test proficiency of influenza virus testing using real-time 
PCR. The NIL correctly identified all samples in the last three panels. 
•	 The NIL’s findings have been presented at local and international scientific meetings, in the form 
of abstracts, oral presentations and posters.
•	 The NIL conducted PCR testing. From a total of 308 influenza specimens collected in 2010, 38 
(12.5%) of them tested positive for 2009 H1N1. 
•	 The NIL participated in outbreak investigations of respiratory illnesses reported in the country. 
NIL also participated in the training of health personnel on specimen collection for respiratory 
diseases at regional hospitals in the areas where outbreaks were reported.
•	 The CDC/APHL Influenza Laboratory Capacity Review tool was used to conduct an NIL capacity 
review in 2010. 
•	 The NIL sent 34 samples for confirmatory and additional antigenic characterization to the WHO 
CC Atlanta.
•	 The NIL participated in surveys to investigate frequency of pandemic flu occurrence among 
patients diagnosed with SARI in public and private hospitals in Addis Ababa.
•	 Lab equipment and reagents were received from CDC-Kenya, CDC-Atlanta, and USAID at 
various times throughout the year.
•	 The NIL forwarded weekly flu reports to the WHO.
Preparedness
An overhaul of the entire health sector was carried out in 2009, during which new organizational 
structures were set up, including the Public Health Emergency Management Center (PHEMC). This 
Center is responsible for preparedness, early warning and response to any public health emergencies 
including avian and human influenza (AHI) and pandemic influenza. This newly established body is 
now situated at EHNRI in order to spearhead epidemiological surveillance of diseases and events with 
the EHNRI laboratory providing the technical support. 
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Key Preparedness Activities
•	 The national influenza pandemic preparedness and response plan was reviewed to reflect 
critical action to be undertaken in light of the characteristics of the ongoing 2009 H1N1 flu 
pandemic. 
•	 Regularly-organized avian influenza and pandemic influenza meetings were held in which staff 
from the Federal MOH, EHNRI, CDC-E, and the WHO Country Office participated in order 
to exchange progress updates as well as to tackle any problems encountered during project 
implementation. 
•	 The Terms of Reference of the Public Health Emergency Management Taskforce-Technical 
(PHEMT-T), Ethiopia was prepared and endorsed. 
•	 Core capacity assessment for surveillance and response was conducted to evaluate the ability 
of existing national structures and resources to meet the minimum requirement of International 
Health Regulations (IHR).
Training
FMOH/EHNRI/CDC-E hosted the following training activities in 2010:
•	 The PHEMC in collaboration with NIL and CDC-E provided four days of training on influenza 
preparedness, surveillance and PHEMC core process for 764 public health officers in four  
mega regions - Amhara, Southern Nations, Nationalities, and People’s Region (SNNPR),  
Oromia, and Tigray. 
•	 Two laboratory personnel from NIL attended training on cell culture of influenza viruses, August 
2-13, 2010, at KEMRI-CDC Training Center in Nairobi, Kenya.
•	 Seventeen surveillance officers, sentinel sites coordinators, data managers, public health 
emergency management officers and flu lab professionals participated in a three-day 
international Epi Info training in Addis Ababa, Ethiopia.
•	 A training session was conducted on aspects of influenza surveillance and specimen handling 
for health professionals from different administrative regions of the country. 
•	 Thirty-five surveillance officers, health managers, sentinel sites coordinators and lab 
professionals received training at EHNRI on flu surveillance, epidemiology, data management 
and laboratory specimen processing.
The following trainings are planned for the near future:
•	 Pandemic Preparedness and Response.    
•	 Early Warning and Risk Communication.
•	 International Epi Info Statistical Package.
•	 Epidemiology.
•	 Epi and Lab Coordination.
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2009 H1N1 Activities, FY 2010
The first positive case of 2009 H1N1 infection was identified in June 2009 and the virus continues to 
co-circulate with seasonal viruses in Ethiopia. In 2010, it was the predominately circulating influenza 
virus (92%).
Key 2009 H1N1 Activities, 2010
•	 EHNRI organized and conducted a rapid survey to investigate frequency of pandemic flu 
occurrence among hospitalized SARI patients in randomly selected public and private hospitals 
in the capital city of Addis Ababa.
•	 Currently, 2009 H1N1 pandemic flu is part of the Integrated Disease Surveillance and Response 
system. It is one of the prioritized and immediately reportable diseases in Ethiopia.
•	 Based on the WHO recommendation, 2.5 million doses of 2009 H1N1 influenza vaccine were 
provided for priority groups sequentially.
•	 CDC-E provided advice on case management and control measures to health care workers 
including guidelines on appropriate specimen collection during outbreak investigations  
and site visits.
Principal Collaborators
Daddi Jima, MD, MPH
Deputy Director General




National Influenza Laboratory Head




Berhanu Amare, MD, MPH




‘Epi Info’ training in Addis Ababa, Ethiopia, September 2010.
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Ghana
•	Capital: Accra
•	Area: 238,533 sq km  
•	Population: 24,791,073 ( July 2011 est.)
•	Age Structure: 0-14 years: 36.5% (male 4,568,273/female 
4,468,939); 15-64 years: 60% (male 7,435,449/female 
7,436,204); 65 years and over: 3.6% (male 399,737/female 
482,471) (2011 est.)
•	Life Expectancy at Birth: Total population: 61 years; male: 
59.78 years; female: 62.25 years (2011 est.)
•	Infant Mortality Rate: Total: 48.55 deaths/1,000 live 
births; male: 51.99 deaths/1,000 live births; female: 45.01 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 57.9%; male: 66.4%; 
female: 49.8% (2000 census)
•	GDP: $38.24 billion (2010 est.)
•	GDP per Capita: $1,600 (2010 est.)
U.S. CDC Direct Country Support 
Influenza surveillance in Ghana is carried out through collaboration between the U.S. CDC, the Naval 
Medical Research Unit No. 3 based in Egypt (NAMRU-3), the Ghana Health Service (GHS), and the 
Noguchi Memorial Institute for Medical Research (NMIMR). This partnership has been in place since 
2007. Influenza surveillance in Ghana is conducted through sentinel sites located in all regions of the 
country. In addition, Ghana serves as a platform to assist regional neighbors in developing influenza 
surveillance systems. Countries benefiting from this partnership are Togo, Burkina-Faso, Mali, and 
Mauritania.
Surveillance 
Seasonal influenza surveillance began at sentinel sites in Ghana in September 2007. Between October 
1, 2009, and September 30, 2010, NMIMR, the country’s NIC, processed more than 6,000 influenza 
specimens, and cultured 336 isolates. Samples were collected from a total of 22 sentinel sites (civilian 
and military) located nationwide in all ten regions of Ghana. 
Key Surveillance Activities
•	 Sentinel surveillance sites for ILI were established and expanded in all ten regions in Ghana, 
including military sites.
•	 Surveillance staff was trained on sample collection, storage and transportation.
•	 A SARI site was established in Tamale, in the Northern region of Ghana.
•	 Surveillance staff received ethics training. 
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•	 In-country surveillance training was held in Burkina Faso and Togo in collaboration  
with NAMRU-3.
•	 Monitoring was conducted for 2009 H1N1 pandemic flu and other influenza circulating 
influenza strains. 
Laboratory 
During FY 2010, the national influenza reference laboratory in Ghana was officially recognized as a 
WHO NIC. The NIC, which is located at the Noguchi Memorial Institute for Medical Research at the 
University of Ghana campus, Legon, has been continuously provided with influenza reagents through 
the Influenza Reagents Resource (IRR) established by CDC. This provision enabled the NIC to process 
6,191 specimens during FY 2010. 
Key Laboratory Activities
•	 The NIC ensured availability of sample collection kits at all sentinel sites and also coordinated 
transportation of specimens from all sites within 48 hours. 
•	 The NIC worked closely with NAMRU-3 and WHO CC London to maintain high quality-control 
standards as well as influenza genotyping technology transfer. 
•	 The NIC submitted weekly and timely reports to WHO AFR and to FluNet. 
•	 NIC staff participated in international meetings and training workshops where they shared their 
work with other colleagues on the continent and worldwide. 
Preparedness
With the occurrence of pandemic 2009 H1N1 flu in April 2009, GHS, in collaboration with key influenza 
partners including NMIMR, CDC, NAMRU-3, USAID, WHO, United Nations Children’s Fund (UNICEF), 
Red Cross and the National Disaster Management Organization, took specific measures to mitigate the 
health, social and economic impacts of the pandemic in the country. 
Key Preparedness Activities 
•	 A health communication campaign was implemented to bring awareness to pandemic influenza 
and pandemic vaccine. 
•	 A communication strategy was activated and posters on 2009 H1N1 pandemic flu  
were distributed. 
•	 Technical support visits were made to regional and public health laboratories and sentinel 
surveillance sites.
•	 Meetings of the technical coordinating committee were held.
•	 Public education was intensified through mass media (i.e electronic, print).
•	 Surveillance and management of cases was continued by regional and district teams.
•	 Specimens were collected and transported from the sentinel sites to NIC.
Training
Ghana hosted the following training activities in FY 2010:
•	 Thirty-two training sessions were held for a total of 364 staff members from all SARI sites. 
Staff members were trained on acute respiratory illness (ARI) surveillance protocol, ethics for 
human subject research, informed consent and sample collection, packaging and transportation, 
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monitoring of enrollment, direct immunofluorescence (DFA) testing, and quality assurance and 
biosafety in the laboratory.
•	 The influenza team at Ridge Hospital in Accra was trained on case definitions and specimen 
collection. 
•	 Health care providers at all eight military sites were trained on use of the rapid diagnostic kits 
according to WHO guidelines. 
•	 All regional and public health reference lab staffs were trained on sample collection, packaging 
and transportation in January 2010. 
•	 A training session was organized for the six members of the Cape Coast Regional Hospital 
influenza team. 
•	 One lab staff member from the NIC participated in training on resistance testing and sequencing 
at WHO CC London in September 2010. 
•	 Two senior staff members - one epidemiologist and one laboratorian - attended an international 
epidemiology course at the Rollins School of Public Health at Emory University in Atlanta, 
Georgia in September and October 2010.
2009 H1N1 Activities, FY 2010
Prior to the confirmation of the first pandemic 2009 H1N1 case in Ghana, influenza surveillance was 
strengthened nationwide, especially at ports of entry, through the monitoring of travelers. Temporary 
surveillance sites were established and additional health staff was trained, including medical 
practitioners from the private sector. 
Key 2009 H1N1 Activities, 2010
•	 Reinforcement of surveillance allowed detection, care and treatment of people with confirmed 
cases of 2009 H1N1. 
•	 From October 1, 2009, to September 30, 2010, 1,018 cases of 2009 H1N1 flu were confirmed and 
two deaths were recorded. 
•	 The GHS developed and implemented communication campaigns for private and  
public radio and TV.
•	 The GHS provided 2009 H1N1 vaccine to high risk groups.
Other Notable Achievements in FY 2010
•	 The Noguchi Memorial Institute for Medical Research influenza lab was officially recognized as 
a WHO NIC.
•	 Real-time PCR capability was sustained at the NIC and diagnostic capacity was strengthened 
with the implementation of the gene-sequencing technique and drug resistance testing.
•	 A number of manuscripts presenting influenza data in Ghana are being prepared for 
publication. One of these manuscripts titled “Influenza Virus Strains Among Young Children in 
Accra, Ghana” will be submitted soon to a peer-reviewed journal. 
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Special Influenza Projects
•	 In the framework of the Integrated Hospital-based Infectious Disease Surveillance (IHBID) 
study, staff members at all SARI sites will be trained on the use of personal digital assistants 
(PDAs), which will speed up data capture, improve completion and quality of data, and allow 
for better reporting and faster feedback. 
•	 A population-based surveillance study will be implemented at the demographic surveillance site 
of Dodowa in the Dangme West District; this is a collaborative project between CDC, NAMRU-3, 
GHS and NMIMR. This study will generate data on denominators, the disease and economic 
burden of influenza, and risk factors for severe influenza morbidity and mortality in Ghana.
Principal Collaborators
Michael Adjabeng, MPH





Director of Public Health Division
Ghana Health Service
Accra, Ghana
Email: jaamankwa@yahoo.com   
William Ampofo, PhD
Head, National Influenza Center
Noguchi Memorial Institute for Medical Research
Legon, Ghana
Email: wampofo@noguchi.mimcom.org   
Talla Nzussouo Ndawouh, MD 
Regional Avian and Pandemic Influenza Advisor
U.S. Centers for Disease Control and Prevention (CDC) 
U.S. Naval Medical Research Unit No. 3 (NAMRU-3/GDDRP)
Accra, Ghana
Email: tallus5@yahoo.fr
Example of a traditional medical center in a community of the Greater 
Accra Region. Centers like these provide herbal treatment for several medical 
conditions including “cough”. 
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Kenya
•	Capital: Nairobi 
•	Area: 580,367 sq km 
•	Population: 41,070,934 ( July 2011 est.)
•	Age Structure: 0-14 years: 42.2% (male 8,730,845/female 
8,603,270); 15-64 years: 55.1% (male 11,373,997/female 
11,260,402); 65 years and over: 2.7% (male 497,389/
female 605,031) (2011 est.)
•	Life Expectancy at Birth: Total population: 59.48 years; 
male: 58.91 years; female: 60.07 years (2011 est.)
•	Infant Mortality Rate: Total: 52.29 deaths/1,000 live 
births; male: 55.03 deaths/1,000 live births; female: 49.49 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 85.1%; male: 90.6%; 
female: 79.7% (2003 est.)
•	GDP: $65.95 billion (2010 est.)
•	GDP per Capita: $1,600 (2010 est.)
U.S. CDC Direct Country Support 
The CDC Influenza Division has maintained a cooperative agreement with the Kenya Ministry of Public 
Health and Sanitation (MOPHS), formerly the MOH, since 2006. In addition to the cooperative agreement 
with the MOPHS, CDC-Kenya has an additional cooperative agreement with the Kenya Medical Research 
Unit (KEMRI), which also supports influenza work in-country.
The cooperative agreement aims to strengthen surveillance and detection for seasonal, avian and human 
influenza in the country. Cooperative agreement funds have been used to set up a sentinel surveillance 
system for influenza that includes 11 hospitals around the country. Testing is conducted at the KEMRI-
led NIC and the KEMRI/CDC International Emerging Infections Program (IEIP) laboratory. The 
cooperative agreement has also supported investigation of suspected outbreaks, avian-human interface 
surveillance, and surveillance for hospital-acquired infections.
Surveillance
Limited surveillance for influenza existed in Kenya prior to 2006. The current sentinel surveillance 
system includes 11 sites: six provincial hospitals, a district hospital, an outpatient clinic, two refugee 
camp hospitals, and the national referral hospital. Surveillance is conducted for both SARI and ILI, 
and samples are tested at one of two laboratories in Nairobi – the KEMRI-NIC or the CDC/KEMRI IEIP 
laboratory. 
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Key Surveillance Activities 
•	 CDC-Kenya followed the evolution of pandemic 2009 H1N1 influenza through sentinel sites in 
the country in late 2009 and early 2010, and coordinated with the following  
surveillance sites and the NIC:
 ˏ MOPHS-KEMRI/CDC sentinel surveillance system.
 ˏ Walter Reed Project/KEMRI sentinel surveillance network for ILI.
 ˏ Sanofi Pasteur sentinel provider network for ILI.
 ˏ CDC/KEMRI IEIP population-based surveillance sites.
•	 In addition, CDC-Kenya used the MOPHS-KEMRI/CDC sites to evaluate 2009 H1N1 vaccine 
effectiveness among health care workers in the country. 
•	 CDC-Kenya, in collaboration with the Kenyan Department of Veterinary Services, conducted 
monthly surveillance for influenza viruses in live bird markets in 2009 and 2010.
Laboratory
There are currently two functional laboratories in Kenya, the KEMRI-NIC and the CDC/KEMRI IEIP 
laboratory. Both laboratories are able to test for influenza by RT-PCR and culture. CDC/KEMRI has a 
new BSL-3 laboratory in Kisumu, where testing for animal samples for influenza is conducted.
Key Laboratory Activities
•	 Laboratory staff from East and West Africa were trained at NIC and at CDC/KEMRI laboratories 
in Nairobi.
•	 More than 9,000 respiratory specimens from sites across the country were tested for influenza 
types and subtypes.
•	 RT-PCR-positive specimens from surveillance sites and a 2009 H1N1 shedding study were 
cultured; viral isolates were sent to the WHO CC Atlanta for further characterization.
Preparedness
The MOPHS has conducted numerous national and provincial trainings on rapid response to an avian 
influenza outbreak. National and provincial response teams were deployed to investigate outbreaks of 
pandemic 2009 H1N1 influenza in mid-2009.
Key Preparedness Activities
•	 Outbreak response teams were deployed to investigate ongoing transmission of pandemic 
2009 H1N1 after the virus was first identified in Kenya in late June 2009; teams continued to 
investigate suspected outbreaks over the following three months.
•	 Kenya MOPHS supported trainings for Integrated Disease Surveillance and Response (IDSR), 
which strengthened surveillance in health facilities throughout the country.
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•	 In August 2010, the MOPHS, supported 
by CDC-Kenya, conducted a monitoring 
and evaluation meeting to assess the 
core capabilities for pandemic influenza 
preparedness and response.
Training
The following trainings were held in Kenya in FY2010:
•	 The NIC, together with CDC/KEMRI, provided a 
number of trainings for Kenya-based laboratory 
staff and regional laboratory staff on PCR 
testing for influenza, including pandemic 2009 
H1N1.
•	 The Kenyan MOPHS conducted regional 
trainings on IDSR.
•	 The MOPHS together with CDC conducted a 
training on 2009 H1N1 pandemic preparedness 
for sentinel surveillance officers and hospital officials.
2009 H1N1 Activities, FY 2010
Pandemic 2009 H1N1 was first identified in Kenya in late June 2009. The MOPHS and the Kenya Ministry 
of Medical Services worked together with the WHO, the NIC, and partners like KEMRI/CDC and the 
Walter Reed Project-Kenya to monitor the pandemic through continued surveillance and special studies.
Key 2009 H1N1 Activities, 2010
•	 The Kenya MOPHS together with KEMRI/CDC and CDC-Atlanta conducted a survey to measure 
knowledge, attitudes and practices of health care workers to inform communications strategy 
for a large pandemic 2009 H1N1 vaccination campaign in 2010.
•	 KEMRI/CDC conducted a viral shedding study to understand pandemic 2009 H1N1 shedding 
patterns in a poor, urban population in Nairobi in order to inform decisions about infection 
control policies for the new virus.
•	 The MOPHS conducted a pandemic 2009 H1N1 monovalent vaccine campaign using donated 
vaccine from the WHO. Over 200,000 Kenyans were vaccinated.
•	 The MOPHS and KEMRI/CDC conducted a 2009 H1N1 vaccine effectiveness evaluation among 
health care workers.
•	 The MOPHS, CDC-Kenya and the Field Epidemiology and Laboratory Training Program 
conducted an investigation into the first 50 hospitalized pandemic 2009 H1N1 cases in Kenya.
Special Influenza Projects and Other Notable Achievements in FY 2010 
•	 CDC-Kenya organized two writing workshops to help local and regional epidemiologists and 
laboratory staff finalize their influenza-related manuscripts for publication.
•	 CDC-Kenya conducted an evaluation of the relative performance of nasopharyngeal and oral-
pharyngeal specimens for influenza. 
•	 CDC-Kenya undertook the first year of a seasonal influenza vaccine effectiveness study in two 
CDC IEIP population-based sites.
Leonard Nderitu (seated) and Lillian Mayieka, both assistant 
laboratory research officers at CDC-Kenya, demonstrate how to take 
a nasopharyngeal swab during training for healthcare-associated 
infection surveillance officers in Nairobi.
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Public Health Importance
•	 The NIC and KEMRI/CDC laboratory staff now routinely test for respiratory viruses other than 
influenza.
•	 The MOPHS-KEMRI/CDC surveillance systems work together with the Walter Reed Project 
influenza surveillance system and the Sanofi Pasteur/KEMRI sentinel surveillance network to 
monitor ILI and ARI hospitalizations throughout the country.
•	 Laboratory training and development have made the Kenya laboratories more prepared to test 
for other pathogens by PCR.
Principal Collaborators
David Mutonga, MBchB, MSc
Chief, Division of Disease Surveillance and Response 
Ministry of Public Health and Sanitation
Nairobi, Kenya
Email: davidmutonga@yahoo.com
Philip Muthoka, MBchB, DTMPH
Influenza Focal Point
Divisions of Disease Surveillance and Response
Ministry of Public Health and Sanitation
Nairobi, Kenya
Email: epmmuthoka@gmail.com
Wallace Bulimo, MSc, PhD
Virologist, Walter Reed Project
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GDD-Kenya
The GDD (Global Disease Detection) Regional Center in Kenya (GDD-Kenya) was established in 2004; 
it collaborates with Kenya’s MOH and is recognized as a strong resource for disease detection and 
response throughout East Africa. GDD-Kenya helps the country and the region detect and respond to 
serious public health threats, including cholera, Ebola, extensively drug-resistant tuberculosis, influenza, 
Rift Valley fever, and typhoid. 
Coverage
GDD-Kenya has extended its coverage to more than ten countries in the region by developing regional 
public health leaders trained through the Field Epidemiology and Laboratory Training Program (FELTP). 
Most of these graduates hold leadership positions in countries throughout the region, including Ghana, 








In 2010, the GDD Regional Center in Kenya discovered one pathogen new to the region and increased 
their laboratory testing capacity by 22%. GDD-Kenya trained ten FELTP graduates and nearly 1,000 
participants in short-term regional and national trainings. GDD-Kenya responded to 43 outbreaks and 
provided lab support in 91% of these outbreaks. 
In-Country Field Staff
Rob Breiman, MD, MPH
Kenya GDD Regional Center Director
Mark Katz, MD, MPH
Influenza Lead
Principal U.S. CDC Program Collaborations In-Country 
•	 Influenza Division International Program
•	 International Emerging Infections Program
•	 Field Epidemiology and Laboratory Training Program
•	 Laboratory Systems Development Program
•	 Immigrant, Refugee, and Migrant Health
•	 International Emergency Preparedness Program
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Madagascar
•	Capital: Antananarivo 
•	Area: 587,041 sq km 
•	Population: 21,926,221 ( July 2011 est.)
•	Age Structure: 0-14 years: 43.1% (male 4,762,589/female 
4,693,259); 15-64 years: 53.8% (male 5,864,520/female 
5,938,029); 65 years and over: 3% (male 295,409/female 
372,415) (2011 est.)
•	Life Expectancy at Birth: Total population: 63.63 years; 
male: 61.62 years; female: 65.7 years (2011 est.)
•	Infant Mortality Rate: Total: 51.45 deaths/1,000 live 
births; male: 56.23 deaths/1,000 live births; female: 46.52 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 68.9%; male: 75.5%; 
female: 62.5% (2003 est.)
•	GDP: $20.73 billion (2010 est.)
•	GDP per Capita: $1,000 (2010 est.)
U.S. CDC Direct Country Support
FY 2010 is the first year of the U.S. CDC’s cooperative agreement with Pasteur Institute of Madagascar 
(IP-Madagascar). The agreement is titled Developing Seasonal, Pandemic, and Influenza Surveillance 
Networks. Madagascar’s NIC has had an influenza surveillance network in operation since 1972 when 
this network encompassed sentinel sites located in Antananarivo, the capital. In 2007, extension of the 
existing influenza surveillance network began with new sentinel sites opening across the entire country. 
The cooperative agreement awarded by the CDC in 2009 has strengthened influenza surveillance 
in Madagascar and has supported building capacity, which enhanced the level of preparedness and 
response of the country.
Surveillance
When the cooperative agreement began in 2009, the sentinel surveillance network encompassed 23 ILI 
sites and 15 SARI sites. This network is an integrated surveillance system that monitors several diseases 
with epidemic potential (i.e. malaria, arboviruses, influenza and febrile diarrhea). With the emergence of 
2009 H1N1 pandemic flu, efforts have been made to train clinicians and staff from the MOH for the early 
detection and monitoring of outbreaks.
Key Surveillance Activities
•	 The cooperative agreement supported clinician training for specimen sampling and shipping.
•	 The NIC expanded its influenza surveillance network to include 31 ILI and 17 SARI sites.
•	 The NIC set up active SARI surveillance, including sample and analyses, in one hospital.
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Laboratory
Before the cooperative agreement, the NIC in Madagascar already possessed all necessary capabilities 
for performing diagnostic tests including virus isolation, molecular diagnostic and serology. Nevertheless, 
the 2009 H1N1 pandemic demonstrated that there is room to improve diagnostic capacities, and there 
are additional ways to be prepared for surge in testing during future pandemics. The cooperative 
agreement supported the laboratory through the acquisition of new equipment and sampling materials, 
which allowed for an increase in the number of specimens that could be processed.
Key Laboratory Activities
•	 The NIC developed an assay for the detection of 14 respiratory viruses.
•	 The NIC participated in the WHO EQAP and scored 100% for quality assurance.
•	 The laboratory hired one technician dedicated to influenza diagnosis.
•	 The NIC trained biologists from the Democratic Republic of Congo and the Republic of Central 
Africa to diagnose influenza.
This vehicle is a mobile laboratory and used in rural and remote areas for outbreak investigations and 
conducting serological surveys to estimate the burden of influenza.
Preparedness
The National Steering Committee for the Fight against Avian Influenza (CNPLGA) was created in 
2006. The Integrated National Action Plan (INAP) was written in 2008. Since the beginning of the 
cooperative agreement, the MOH has updated its INAP and related communication materials have been 
produced and disseminated. 
Key Preparedness Activities
•	 A pool of trainers is available for training of regional task forces.
•	 NIC, MOH, and the Ministry of Livestock adapted and updated training materials for regional 
task forces.
•	 MOH trained regional task forces for response to avian and pandemic flu.
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Training
Madagascar hosted the following activities in 2010:
•	 Epidemiology surveillance and field outbreak investigation training was provided to ten public 
health officers from Madagascar, Mauritius and Seychelles.
•	 Antiviral resistance training was provided to five laboratory scientists from Madagascar, Central 
Africa, Cameroon and Senegal.
•	 Influenza surveillance training was provided to 50 doctors and nurses from ILI and SARI sites.
•	 Training on laboratory techniques for diagnosis of influenza infection was provided to two 
biologists from Democratic Republic of Congo and the Republic of Central Africa.
For FY 2011, another course on epidemiologic surveillance and field outbreak investigation is planned. 
Madagascar will train other regional task forces in order to cover all Malagasy regions. Finally, two 
biologists and four technicians from regional hospitals in Toamasina (East Coast) and Mahajanga (West 
Coast) will be trained for molecular diagnosis of influenza.
2009 H1N1 Activities, FY 2010
After the start of the 2009 H1N1 pandemic, the NIC received kits for RT-PCR testing from CDC. 
IP-Madagascar provided technical assistance to the MOH for detection and monitoring of pandemic 
influenza in Madagascar; training was provided to new staff in the laboratory, in order to increase lab 
capabilities for diagnostics and testing.
Key 2009 H1N1 Activities, 2010
•	 The MOH installed an ad hoc national task force in order to strengthen the response and 
contain the epidemic.
•	 A new algorithm for analysis of specimens was put in place at the NIC.
•	 The NIC delivered additional personal protective equipment (PPE) and sampling material upon 
request from MOH after MOH’s stock was depleted.
•	 Medical officers from SARI and ILI sentinel sites received refreshers on case definition, 
monitoring of patients, use of PPE, use of antiviral drugs, specimen collection, and shipment to 
the NIC. 
Other Notable Achievements in FY 2010 
•	 The MOH created a phone hotline to answer questions related to 2009 H1N1.
•	 In most of suspected cases of 2009 H1N1, NIC delivered results with a turn-around time of 12 to 
24 hours.
•	 The influenza sentinel network served as backbone for monitoring the spread and intensity of 
the pandemic in the country.
Special Influenza Projects
•	 The NIC developed an assay for detection of swine influenza viruses.
•	 The NIC detected human seasonal A/H3N2 in a specimen collected from pigs in July.
•	 Together with the Epidemiology Unit, the NIC tried to address the impact of the pandemic in 
rural parts of Madagascar through a serological survey.
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Principal Collaborators
Jean-Michel Heraud, PhD
Director of Virology Unit




Assistant scientist at NIC 
Pasteur Institute of Madagascar 
Antananarivo, Madagascar
Email: aorelle@pasteur.mg
Norosoa Harline Razanajatovo, BSc
Scientist at NIC





Pasteur Institute of Madagascar
Antananarivo, Madagascar
Email: laurence@pasteur.mg
WHO African Region (AFR) 39Madagascar         
Nigeria
•	Capital: Abuja 
•	Area: 923,768 sq km 
•	Population: 155,215,573 ( July 2011 est.)
•	Age Structure: 0-14 years: 40.9% (male 32,476,681/female 
31,064,539); 15-64 years: 55.9% (male 44,296,228/female 
42,534,542); 65 years and over: 3.1% (male 2,341,228/
female 2,502,355) (2011 est.)
•	Life Expectancy at Birth: Total population: 47.56 years; 
male: 46.76 years; female: 48.41 years (2011 est.)
•	Infant Mortality Rate: Total: 91.54 deaths/1,000 live 
births; male: 97.42 deaths/1,000 live births; female: 85.31 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: total population: 68%; male: 75.7% female: 
60.6% (2003 est.)
•	GDP: $369.8 billion (2010 est.)
•	GDP per Capita: $2,400 (2010 est.)
U.S. CDC Direct Country Support 
In 2006, the Nigerian Federal Ministry of Health (FMOH) secured a U.S. CDC five-year cooperative 
agreement titled Surveillance and Response to Avian and Pandemic Influenza Project. FY 2010 was 
the fourth year of the grant. 
The goal of the project is to establish a system of early detection and effective response to avian and 
pandemic influenza in Nigeria. The National Influenza Reference Laboratory (NIRL) with molecular 
diagnostic capacity and the National Influenza Sentinel Surveillance System (NISS) were established 
in 2007 and 2008 respectively and. The FMOH also developed a plan that guides preparedness and 
response to avian and pandemic influenza in the country.
Surveillance
Prior to the beginning of the FMOH/CDC cooperative agreement in 2006, there was no surveillance 
system to monitor influenza epidemiology in Nigeria. In 2008, the National Influenza Surveillance 
System (NISS) was established. Currently there are four sentinel sites, each with an ILI component in 
the outpatient clinic and a SARI component in the inpatient unit. The surveillance system also captures 
suspected cases of avian influenza and other pandemic influenza viruses, including 2009 H1N1. From 
the limited data available so far, Nigeria’s peak influenza activity appears to be concurrent with the dry 
harmattan season, which occurs between November and March.
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Key Surveillance Activities 
•	 Almost all of the reported cases of 2009 H1N1 in Nigeria were detected via the NISS.
•	 In 2010, the flu team started reporting epidemiological data via the WHO FluNet and FluID 
platforms.
•	 NISS data were presented at the 2010 International Conference on Emerging Infectious Diseases 
(ICEID), and the Options for Control of Influenza VII conference. 
•	 The NISS structure continues to provide a platform that supports surveillance for other priority 
diseases in the country. A case example is the detection of Lassa fever through the influenza 
surveillance system.
•	 The NISS continue to host the Nigeria Field Epidemiology and Laboratory Training Program 
(FELTP) students, providing them with needed field experience.
Laboratory
In 2007, the FMOH, with the financial and technical support of CDC, established a NIRL situated in 
Abuja, the nation’s capital. It is currently the only laboratory with a real-time RT-PCR diagnostic capacity 
for influenza in the country. Additional MOH laboratories with influenza diagnostic capacity are under 
construction and due to open from 2012.
Key Laboratory Activities
•	 In 2010, the lab tested over 2,400 samples from influenza sentinel sites and outbreak 
investigations.
•	 The NIRL participated in the WHO-AFRO laboratory network and WHO FluNet by sending 
weekly virology reports.
•	 The lab submitted specimens to WHO CC Atlanta. 
•	 During 2010, the NIRL participated two times in the WHO EQAP and received a perfect score 
for each proficiency test.
The National Influenza Reference Laboratory manager receives a CDC-donated automatic nucleic acid extractor. From right to left: Mr. Shilo 
Paul (Lab Manager, NIRL); Dr. Ibrahim Dalhatu (CDC Nigeria Influenza Focal Point); Dr. Muhammad Shakir Balogun (NFELTP Resident on 
Posting in the NIRL); Ms. Amaka Onyiah (NIRL); Ms. Amina Garba.
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Preparedness
In 2006, Nigeria initiated the development of its avian and pandemic influenza preparedness plan 
following the emergence of the global threat of influenza pandemic. In 2010, a tabletop exercise was 
conducted to test the revised version of the national avian and pandemic influenza preparedness and 
response plan. 
Key Preparedness Activities
•	 The FMOH avian and pandemic influenza control project prepositioned antivirals at the state 
MOH and at selected health facilities across the country.
•	 Federal, state and local government-level rapid response teams were retrained.
Training
The FMOH hosted the following training activities in 2010:
•	 In a bid to strengthen capacity of the flu surveillance team, one of the staff member was 
enrolled in the two-year Nigeria Field Epidemiology and Laboratory Training Program 
(N-FELTP) in 2010.
•	 Refresher training on influenza sentinel surveillance was offered to officers from all the 
influenza sentinel sites.
•	 Four staff of the NIRL participated in a two-week hands-on training on molecular diagnosis at 
CDC-Kenya.
•	 Eight laboratory personnel from clinical laboratories with RT-PCR capacity (under-construction) 
were provided hands-on training at the NIRL in Abuja.
Future Trainings
•	 The leadership of the NIRL will be participating in laboratory management training organized 
by CDC-Atlanta.
•	 All laboratory personnel will receive complete modular training in Quality Management System 
(QMS).
•	 NIRL laboratory personnel will be trained on virus culture.
•	 The data management focal points will be retrained on data management and report writing.
2009 H1N1 Activities, FY 2010
Following the reported outbreak of 2009 H1N1 in April 2009, the Nigerian MOH began enhanced 
surveillance by utilizing its existing Integrated Disease and Surveillance Reporting (IDSR) and the NISS. 
The first case of 2009 H1N1 was detected in October 2010; by the end of September 2010, about 100 
cases had been recorded.
Key 2009 H1N1 Activities, 2010
•	 More than 50 epidemiologists from all the states of the federation were trained on 2009 H1N1 
outbreak detection and response.
•	 Surveillance tools for 2009 H1N1 were developed and used.
•	 State MOHs and hospitals were provided with antivirals and clinical management guidelines.
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•	 With the help of partners, including CDC-Atlanta, the FMOH developed a 2009 H1N1 vaccine 
deployment strategy and campaign plan that was utilized for the administration of 2009 H1N1 
vaccine donated by WHO.
Other Notable Achievements in FY 2010 
•	 The FMOH/CDC avian and pandemic influenza project was relocated to the national 
epidemiology division for better integration and sustainability.
•	 In a bid for the NIRL to qualify for NIC designation, plans to begin performing viral culture in 
the NIRL were implemented.
•	 Support from the influenza project for establishing and training rapid response teams 
strengthened disease surveillance and response to all priority diseases in the country.
Principal Collaborators
Henry Akpan, MD, MPH, FMCPH
Chief Epidemiologist
Federal Ministry of Health
Abuja, Nigeria
Email: akpanhem@yahoo.com
Adebayo Adebayo,BSc, MSc, PhD
Principal Investigator 
CDC/Federal Ministry of Health
Abuja, Nigeria
Email: adedejiseyedeola@yahoo.com
Lawan Tahir, FCMA, CNA
Business Official/Financial Administrator




Ibrahim Dalhatu, MD, MPA, FMCPH
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Republic of Côte d’Ivoire
•	Capital: Yamoussoukro 
•	Area: 322,463 sq km 
•	Population: 21,504,162 ( July 2011 est.)
•	Age Structure: 0-14 years: 39.8% (male 4,312,133/female 
4,240,500); 15-64 years: 57.2% (male 6,262,802/female 
6,039,458); 65 years and over: 3% (male 320,396/female 
328,873) (2011 est.)
•	Life Expectancy at Birth: Total population: 56.78 years; 
male: 55.79 years; female: 57.81 years (2011 est.)
•	Infant Mortality Rate: Total: 64.78 deaths/1,000 live 
births; male: 71.54 deaths/1,000 live births; female: 57.83 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 48.7%; male: 60.8%; 
female: 38.6% (2000 est.)
•	GDP: $37.8 billion (2010 est.)
•	GDP per Capita: $1,800 (2010 est.)
U.S. CDC Direct Country Support 
The Ministry of Health and Public Hygiene (MSHP) of Côte d’Ivoire has obtained financial and technical 
support from U.S. CDC for pandemic preparedness and reinforcement of influenza surveillance. The 
National Institute for Public Hygiene (INHP) is the technical beneficiary at MSHP for the Developing 
Influenza Surveillance Networks Cooperative Agreement, which began in 2006. FY 2010 is the fourth 
year of the cooperative agreement.
During the 2009-2010 budget period, all planned operational activities were implemented. 
Implementation of these activities produced a number of results, namely the reinforcement of laboratory 
diagnostic capacities. Quick access to information and results has been improved by providing sentinel 
sites with surveillance and communication software. 
Surveillance 
Distribution of reporting tools and influenza surveillance policies to sentinel sites has become routine, 
and sample collection and transportation to the NIC is operational. 
To ensure timely information and availability of laboratory results, four new sentinel sites were provided 
with internet connections. In addition to internet access, the NIC located at the Insitut Pasteur of 
Côte d’Ivoire (IPCI) and eight sentinel sites received information technology equipment (i.e., desktop 
computer, uninterruptable power supply, scanner, printer, fax). 
Key Surveillance Activities
•	 A virologist from the IPCI took part at the first Africa Influenza Scientific Symposium held in 
Johannesburg, South Africa in December 2009, during which surveillance data were shared.
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•	 Two staff – one epidemiologist and one virologist – participated in the CDC Influenza Division 
International Partners and Disease Burden Meeting in Atlanta in July 2010. 
•	 One virologist from NIC (IPCI) presented a poster at the Options for the Control of Influenza 
VII conference held in Hong Kong, in September 2010.
•	 From October 1, 2009, to September 30, 2010, a total of 4,545 suspected cases of influenza were 
investigated. Suspected cases of avian influenza and 2009 H1N1 were investigated in numerous 
health districts of Côte d’Ivoire (Abidjan, Bingerville, Bouake, and Grand-Bassam). 
Laboratory 
The NIC located at IPCI was provided with reagents and laboratory materials through the cooperative 
agreement in order to fulfill its role as NIC and reinforce its operational capacity. The laboratory was 
able to analyze 338 influenza samples in the fourth quarter of 2009 and approximately 741 samples in 
first three quarters of 2010. 
Preparedness
•	 The MSHP organized two meetings which brought together supervisors from all 17 sentinel 
sites to present data, share experiences and discuss challenges. The first meeting was held in 
November 2009, and the second meeting was held in June 2010.
•	 During August 2010, a series of sensitization campaigns were conducted that engaged 12 cities 
in northern and southern Côte d’Ivoire. During these campaigns, leaflets and brochures that 
explained influenza infection, pandemic flu, and preventive measures, were distributed to the 
population.
Training
The MSHP hosted or participated in the following trainings:
•	 In October 2009, 24 laboratory technicians from sentinel sites were trained at the IPCI on 
sample collection, packaging, storage and transportation, as well as sample analysis (i.e., PCR), 
and cell culture. 
•	 A training workshop on pandemic influenza was organized for journalists and other media 
outlets at Grand-Bassam in November 2009, with the goal of improving communication with the 
general population.
•	 In March 2010, a training session for 185 medical health district directors and hospital directors 
provided information about detection, care and treatment of pandemic influenza cases.
•	 During the month of July 2010, an epidemiologist in charge of the surveillance of diseases 
with epidemiologic potential attended a two-week epidemiologic training course at Paris XI 
University, France. 
•	 In order to strengthen the capacity of epidemiologists at the INHP, in September 2010 
two epidemiologists participated in a international course in epidemiology and applied 
bioinformatics organized at the Regional Institute for Public Health at Ouidah, Republic of 
Benin.
•	 While conducting two supervisory visits to sentinel sites in October 2009 and June 2010, daily 
constraints, needs and challenges of health care workers were assessed. These visits allowed 
INHP/MOH to address health care workers’ concerns and to suggest solutions to enable them to 
operate more efficiently and improve their working skills. 
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2009 H1N1 Activities, FY 2010 
•	 Reinforcement of surveillance allowed for detection, isolation, care and treatment of confirmed 
cases of 2009 H1N1 flu.  
•	 From October 1, 2009, to September 30, 2010, 36 2009 H1N1 cases were detected and 
successfully treated.
•	 The INHP/MOH setup a hotline to provide answers to questions and guidance to the general 
public about the threat of 2009 H1N1 flu.
•	 The MOH developed a communication campaign and disseminated messages via private and 
public radio and TV.
•	 PPE was acquired by USAID for use by the MSHP.
•	 Large posters were developed (electronic and hard copies) and made available at airports, 
seaports and at different borders.
•	 Five thousand N-95 facemasks were purchased in 2010 for use by people with severe cases of 
2009 H1N1 flu. 
Other Notable Achievements in FY 2010 
•	 SARI surveillance was made routine at each of the medical teaching hospitals of Abidjan. 
•	 At the IPCI, real-time PCR techniques were made available and were sustained; diagnostic 
capacity was also strengthened. 
•	 The Ministry of Scientific Research procured a sequencing machine for the IPCI that improved 














Herve Kadjo-Adje, MD  
NIC Coordinator
Laboratory of Respiratory Viruses
Pasteur Institute of Côte d’Ivoire
Abidjan, Côte d’Ivoire
Email: rvkdjo@yahoo.fr
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Rwanda
•	Capital: Kigali 
•	Area: 26,338 sq km 
•	Population: 11,370,425 ( July 2011 est.)
•	Age Structure: 0-14 years: 42.9% (male 2,454,924/female 
2,418,504); 15-64 years: 54.7% (male 3,097,956/female 
3,123,910); 65 years and over: 2.4% (male 110,218/female 
164,913) (2011 est.)
•	Life Expectancy at Birth: Total population: 58.02 years; 
male: 56.57 years; female: 59.52 years (2011 est.)
•	Infant Mortality Rate: Total: 64.04 deaths/1,000 live 
births; male: 67.64 deaths/1,000 live births; female: 60.32 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 70.4%; male: 76.3%; 
female: 64.7% (2003 est.)
•	GDP: $11.84 billion (2010 est.)
•	GDP per Capita: $1,100 (2010 est.)
U.S. CDC Direct Country Support 
The cooperative agreement Preparedness and Response to Avian and Pandemic Influenza in 
Rwanda is a four-year grant between CDC Atlanta and the MOH/Center for Treatment and Research 
on AIDS, Malaria, Tuberculosis and other Epidemics (TRAC Plus). The cooperative agreement includes 
technical support from the CDC avian influenza country focal point. The project aims to strengthen 
preparedness and communication, to improve national diagnostic capabilities for avian influenza,  
to initiate human influenza surveillance, and to develop rapid response at the national and  
sub-national level.
The cooperative agreement began in 2007 and will close out in July 2011. FY 2010 is the fourth year of 
project implementation.
Surveillance
Influenza sentinel surveillance began in Rwanda in July 2008. A national protocol was developed by 
TRAC Plus with CDC assistance and endorsed by the MOH. According to the national strategy, six 
active sentinel sites were established in order to have one sentinel site in each province. These sentinel 
sites include two referral hospitals (Kigali University Teaching Hospital and Butare University Teaching 
Hospital) and four district hospitals (Gihundwe, Kibagabaga, Kibungo and Ruhengeri). The estimated 
population in the catchment area of each district hospital is approximately 200 to 300 thousand people 
whereas that of referral hospitals includes those seeking primary and secondary health care services 
not found at other levels of the health system. The selection of hospitals was based on willingness 
to participate, ease of transport of specimens, risk of avian influenza activity, and mix of urban/rural 
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locations. Influenza surveillance is conducted in outpatient department (OPD), pediatric and internal 
medicine wards. During the 2009 H1N1 flu outbreak in Rwanda, surveillance activities were intensified 
to include non-sentinel hospitals. 
Key Surveillance Activities
•	 MOH/TRAC Plus collected a total of 3,516 (ILI and SARI) samples from sentinel and non-
sentinel sites that have been tested with the positivity rate of 19.5% (686/3,516). 
•	 From sentinel sites, 2,996 specimens were collected and tested with a positivity rate of 13.8% 
(412/2,996) from July 2008 to December 31, 2010.
•	 50.4% (1510/2,996) of ILI and SARI patients were children age 0-4 years.
•	 From non-sentinel sites, 520 specimens were collected and tested during the 2009 H1N1 flu 
outbreak with a positivity rate of 52.8% (274/520).
•	 Seventy-six medical doctors, 260 nurses and 64 laboratory technicians trained in influenza 
sentinel surveillance.
•	 TRAC Plus conducts joint supervisory site visits with the National Reference Laboratory and 
CDC that include review of protocol and refresher training in influenza sentinel surveillance.
A nurse labels an influenza specimen collected from a child in the pediatric ward at Ruhengeri District Hospital, northwestern Rwanda. 
Laboratory
The National Reference Laboratory is equipped with three RT-PCR machines to test influenza samples 
by typing and sub-typing using CDC protocol and CDC-provided primers/probes and controls. One 
machine was acquired before the cooperative agreement began, the second was donated by USAID, 
and the third is a Fast RT-PCR machine acquired to improve turnaround time and standardize testing for 
quality control. 
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Key Laboratory Activities
•	 The Laboratory purchased and supplied specimen collection kits to sentinel sites.
•	 The Laboratory passed WHO EQAP testing with 100% score.




•	 Officials from the Rwanda Ministry of Agriculture and Animal Resources (MINAGRI), the MOH, 
the Ministry of Disaster Management and Refugees (MIDIMAR) and the Rwanda Development 
Board (RDB) participated in a tabletop exercise organized in country by the Emergency Centre 
for Transboundary Animal Diseases, part of the Food and Agriculture Organization of the 
United Nations, with other stakeholders.
Training
Rwanda/MOH hosted the following training activities in 2010:
•	 Surveillance officers and medical focal points at sentinel sites attended surveillance training 
conducted by CDC-Atlanta and TRAC Plus. 
•	 TRAC Plus provided sentinel surveillance training for surveillance officers. 
Training sessions planned for 2011 include:
•	 Laboratory management training for laboratory technicians by NICD, in South Africa.
•	 Outbreak investigation and response training for surveillance officers by Rwanda Field 
Epidemiology and Laboratory Training.
•	 Short Message Service (SMS texting) reporting of SARI, ILI, and total in- and outpatients training 
for surveillance officers by Tulane University in collaboration with TRAC Plus.
2009 H1N1 Activities, FY 2010
•	 In October 2009, a traveler returning from the United States developed an influenza-like illness 
and subsequently tested positive for 2009 H1N1 virus. An Emergency Working Group (EWG) 
was established by the MOH. The EWG began contact tracing to identify additional laboratory-
confirmed cases in households, primary and secondary schools, government offices, and health 
facility settings, as well as among airplane passengers.
•	 NRL tested 2,380 nasopharyngeal specimens.
•	 As of June 1, 2010, 525 laboratory-confirmed cases of 2009 H1N1 were identified from 19 (63%) 
of 30 Rwandan districts. 
•	 The last case of 2009 H1N1 was confirmed on June 1, 2010. 
•	 A deployment plan for vaccination was developed and currently waiting for implementation. 
•	 A donation from WHO of 200,000 doses of monovalent Pandemrix vaccine (GSK) was received 
by the Expanded Program of Immunization (EPI). The decision to use the vaccine is pending.
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Other Notable Achievements in FY 2010 
•	 A dispatch “2009 Pandemic Influenza A (H1N1) Virus Outbreak and Response –Rwanda, 
October, 2009 – April, 2010” was sent to the journal Plos One for publication.
•	 A manuscript “Influenza Sentinel Surveillance—Rwanda, 2008–2010” is being prepared for a 
supplement that will appear in the Journal of Infectious Diseases. 
Special Influenza Projects
•	 The Laboratory is planning to test for other respiratory pathogens by Multiplex-PCR.
•	 TRAC Plus is working on increasing the quality of the Integrated Disease Surveillance and 
Response (IDSR) system in order to provide reliable surveillance data baseline.
•	 Virus isolation capability is being planned in order to be eligible to apply for WHO NIC status. 
However, additional space is needed, so a plan is in place for lab expansion. 
Principal Collaborators
Thierry Nyatanyi, MD
Director, Epidemic Infectious Diseases Unit










Theogene Rutagwenda, DVM, PhD
Director-General
Rwanda Animal Resource Development Authority
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South Africa
•	Capital: Pretoria
•	Area: 1,219,090 sq km 
•	Population: 49,004,031 ( July 2011 est.)
•	Age Structure: 0-14 years: 28.5% (male 6,998,726/female 
6,959,542); 15-64 years: 65.8% (male 16,287,314/female 
15,972,046); 65 years and over: 5.7% (male 1,125,709/
female 1,660,694) (2011 est.)
•	Life Expectancy at Birth: Total population: 49.33 years; 
male: 50.24 years; female: 48.39 years (2011 est.)
•	Infant Mortality Rate: Total: 43.2 deaths/1,000 live births; 
male: 47.19 deaths/1,000 live births; female: 39.14 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 86.4%; male: 87%; female: 
85.7% (2003 est.)
•	GDP: $527.5 billion (2010 est.)
•	GDP per Capita: $10,700 (2010 est.)
U.S. CDC Direct Country Support 
The Influenza Program in South Africa has both a national and a regional focus. The cooperative 
agreement between CDC and the National Institute for Communicable Diseases (NICD)/National Health 
Laboratory Service (NHLS) began in August 2007. The cooperative agreement is called Preparedness 
and Response to Avian and Pandemic Influenza in South Africa and the main goals of this 
agreement are to strengthen the capacity of national health authorities for surveillance of SARI and 
ILI, and to strengthen the capacity for the diagnosis of influenza by the health authorities in selected 
countries of the Southern Africa Development Community (SADC). 
Surveillance
A number of influenza surveillance systems provide up-to-date data on influenza activity in South Africa. 
The Viral Watch Surveillance Programme is a long-standing ILI surveillance program with 256 outpatient 
sentinel sites in all nine provinces. SARI surveillance was introduced in 2009; currently, four hospital-
based sites are fully functioning.
Key Surveillance Activities 
•	 An additional SARI surveillance site, the Klerksdorp hospital complex, was added. The site 
includes one hospital for adults and one for pediatrics.
•	 The SARI case definition was expanded at two enhanced surveillance sites (Edendale Hospital, 
the Klerksdorp Hospital complex) to include patients admitted with a duration of symptoms 
greater than 7 days and suspected tuberculosis (TB). This will allow the NICD to describe the 
association between influenza and TB in this population.
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•	 Surveillance reports were circulated to all stakeholders on a weekly basis during the influenza 
season and on a monthly basis during the rest of the year. 
•	 The Epidemiology and Surveillance Unit (ESU) hosted the SARI annual investigators meeting in 
September 2010 to present program results and new and related projects to investigators and 
stakeholders, including the National Department of Health.
•	 NICD contributed influenza information to daily surveillance and outbreak reports for the 
National Health Cluster during the Soccer World Cup ( June 11 - July 12, 2010).
Laboratory
The Respiratory Virus Unit (RVU) at NICD (a WHO NIC) is earmarked as a WHO regional reference 
laboratory for influenza and plays a key role in the support for the establishment of influenza laboratory 
and surveillance capacity in the SADC.
Key Laboratory Activities
The RVU and Virus Isolation Unit (VIU) regularly test and type influenza samples collected under the 
Viral-Watch, SARI, and the enhanced surveillance systems for 2009 H1N1 flu. 
•	 The RVU performs molecular diagnosis and typing of influenza viruses as well as other 
respiratory viruses associated with SARI and investigates the molecular epidemiology of annual 
epidemics to assess genetic drift and viral resistance.
•	 Influenza strains are also isolated by the VIU on tissue culture and antigenic characterization is 
performed using hemagglutination inhibition (HAI) tests.
•	 The RVU provides diagnostic testing and training to neighboring countries when assistance  
is required.
•	 Weekly updates are provided to the WHO African and Global offices via FluNet.
The annual SARI surveillance investigator group meeting held at the Poliomyelitis Research Foundation (PRF) Centre on the campus of the National Institute for 
Communicable Diseases, a division of the National Health Laboratory Services. Johannesburg, South Africa. September 2010.
Preparedness
Much of the work to develop a pandemic influenza preparedness plan paid off as the country 
responded to the 2009 H1N1 pandemic. The state of the national preparedness plan for South Africa in 
2010 was greatly improved and significantly more efficient compared to its pre-pandemic status. Key 
factors contributing to this include the implementation of an influenza vaccination campaign steering 
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committee, mass vaccination campaign training in every province, influenza management training in 
many provinces, and empowering the main public health laboratories to test for influenza by PCR.
Key Preparedness Activities
•	 Formulation of national guidelines for health care workers in collaboration with the South Africa 
Department of Health and other partners.
•	 Implementation of provincial workshops in seven of the nine provinces, to reinforce adherence 
to the pandemic response plans and response guidelines.
•	 Provision of advice on clinical case management, control measures, and infection control 
guidance, as well as guidelines on appropriate specimen collection, including support with field 
work during outbreak investigations.
•	 Development of monthly communiqués to raise awareness on communicable diseases including 
2009 H1N1 and to update clinicians on case management; these communiqués were distributed 
to about 18,000 health professionals and published on the NICD website.
•	 Establishment of an influenza vaccination campaign steering committee.
•	 Implementation of provincial training with regard to both the mass vaccination campaign and 
influenza clinical management issues.
•	 Establishment of laboratory capacity for influenza testing at regional NHLS laboratories by 
providing guidance on protocols and quality control panels.
•	 Provision of confirmatory testing for SARI cases and deaths to private and public sector 
laboratories and testing of suspected H5N1 avian influenza cases in humans with a history of 
exposure or appropriate travel.
Training
NICD implemented the following training activities in 2010:
•	 From October 2009 to March 2010 the RVU trained laboratory scientists from Angola, Botswana, 
Mozambique, Zambia and Zimbabwe on the diagnosis of 2009 H1N1 using real-time RT-PCR.
•	 The RVU hosted a scientist from Malawi-Liverpool-Wellcome Trust Clinical Research Programme 
in Blantyre, Malawi from 19-21 July 2010. 
•	 The national public health laboratory in Lilongwe, Malawi hosted a scientist from the RVU to 
perform on-site training for influenza testing. 
Laboratory management training and phylogenetic analysis training planned in collaboration with and 
supported by CDC for African scientists are planned for February and March 2011. 
2009 H1N1 Activities, FY 2010
Enhanced surveillance was initiated at 11 hospitals in all 9 provinces around the country to capture 
specimens for virological surveillance from patients with SARI. A registry was established for all 2009 
H1N1 laboratory confirmed cases and severe cases and deaths, which allowed for monitoring the 
evolution and the severity of the epidemic. Surveillance was continued through the viral watch and 
SARI programs for influenza cases by routine testing for nine respiratory viruses including Influenza. All 
positive influenza A specimens were also subtyped and a selection of those were further characterized. 
Patients with ILI and SARI from the private sector and the port health authorities were also investigated 
to identify newly imported 2009 H1N1 cases outside of the influenza season. 
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Key 2009 H1N1 Activities, 2010
•	 A thorough investigation of the first 100 confirmed cases was carried out.
•	 These interventions detected risk factors for severe illness and death.
•	 This surveillance allowed for the estimation of the secondary attack rate, serial interval and 
basic reproductive number (R0) for the epidemic in the country.
•	 A molecular epidemiological investigation of 2009 H1N1 cases detected in 2009 and 2010 was 
carried out by comparison of strains detected through viral watch (ILI) and SARI surveillance 
from the start to the end of the pandemic.
•	 Surveillance for 2009 H1N1 at enhanced sites continued.  
Special Influenza Projects and Other Notable Achievements in FY 2010 
•	 A collaborative project between the RVU, the WHO Global Influenza Project Epidemiology Unit 
and numerous African countries has begun to investigate the epidemiological and virological 
characteristics of the 2009 H1N1 virus in Africa.
•	 Six publications by the Respiratory Virus Unit and the Respiratory and Zoonosis Programme at 
the Department of Medical Virology, University of Pretoria appeared in peer reviewed journals.
•	 Eleven posters and an oral presentation arising from various influenza projects were presented 
at the Options for the Control of Influenza VII conference held in Hong Kong, September 2010.
•	 A poster from the NIC on the molecular epidemiology of 2009 H1N1 in South Africa was 
awarded best poster at the WHO Meeting held in Morocco, Afriflu Alliance in June 2010. 
Public Health Importance
•	 Training and surveillance allowed rapid response to 2009 H1N1 concerns in South Africa.
•	 Surveillance for influenza has provided a platform to explore the role of other viral respiratory 
pathogens in causing pneumonia in South Africa.
•	 Robust estimates of influenza burden in specific populations (e.g. HIV-infected patients) have 
provided evidence for possible policy formulation on the use of influenza vaccine to prevent 
disease in target groups.
•	 Strengthening of pandemic preparedness and response capacity and knowledge at a provincial 
level has provided a platform for improved preparedness and response to other communicable 
diseases of public health concern.
•	 Annual updates to the WHO on circulating influenza A and B strains to be included in the 
Southern Hemisphere vaccine.
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Principal Collaborators
Marietjie Venter, BSc, MSc, PhD
Head, Respiratory Virus Unit (National Influenza Centre)
National Institute for Communicable Diseases
Johannesburg, South Africa
Email: marietjiev@nicd.ac.za  
Lucille Blumberg, MBBCH, MMed, FFTM, DCH, DTMandH, DOH
Head, Epidemiology Division
National Institute for Communicable Diseases
Johannesburg, South Africa
Email: lucilleb@nicd.ac.za  
Cheryl Cohen, MSc, MBBCH, DTMandH, FCPath(SA)(Micro)
Head, Epidemiology and Surveillance Unit




Stefano Tempia, DVM, MSc, PhD
Influenza Technical Advisor
CTS Global, Inc. (assigned to CDC)
Johannesburg, South Africa
Email: tempias@sa.cdc.gov 




Email: cohena@sa.cdc.gov (started Dec 2010)
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Tanzania
•	Capital: Dar es Salaam 
•	Area: 947,300 sq km 
•	Population: 42,746,620 ( July 2011 est.)
•	Age Structure: 0-14 years: 42% (male 9,003,152/female 
8,949,061); 15-64 years: 55.1% (male 11,633,721/female 
11,913,951); 65 years and over: 2.9% (male 538,290/
female 708,445) (2011 est.)
•	Life Expectancy at Birth: Total population: 52.85 years; 
male: 51.34 years; female: 54.42 years (2011 est.)
•	Infant Mortality Rate: Total: 66.93 deaths/1,000 live 
births; male: 73.7 deaths/1,000 live births; female: 59.95 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 69.4%; male: 77.5%; 
female: 62.2% (2002 census)
•	GDP: $62.22 billion (2010 est.)
•	GDP per Capita: $1,500 (2010 est.)
U.S. CDC Direct Country Support 
Tanzania began avian and pandemic influenza preparedness and response activities in 2006 by creating 
the National Multi-Sectoral Taskforce, and through the development of a national preparedness and 
response plan. In 2008, the Ministry of Health and Social Welfare (MOHSW), with the assistance of 
CDC, established the National Influenza Laboratory (NIL) in Dar es Salaam and initiated virologic and 
epidemiologic influenza sentinel surveillance in five hospitals around the country. This surveillance 
enhancement contributed to the country’s timely response to Rift Valley Fever in 2007, the 2009 H1N1 
influenza pandemic, and the Dengue Fever outbreak in 2010. FY 2010 was the fourth year of the 
cooperative agreement between CDC and the MOHSW. 
Surveillance
The influenza surveillance system in Tanzania uses both the Integrated Disease Surveillance and 
Response (IDSR) system on suspected cases of SARI from all 133 districts, and the sentinel surveillance 
of sampled ILI cases and all SARI cases in five sentinel hospitals.  
Key Surveillance Activities 
•	 All five sentinel sites actively conducted influenza surveillance, and a total of 903 samples were 
sent to the NIL.
•	 MOHSW hosted one meeting with stakeholders to evaluate achievements and challenges of 
influenza surveillance and came up with steps to tackle these challenges.
•	 MOHSW established enhanced influenza surveillance to strengthen the response to the 2009 
H1N1 pandemic.
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Laboratory
The influenza laboratory network consists of five sentinel hospital laboratories that are mainly specimen 
collection, storage and transportation points, and the NIL, which is the only laboratory in Tanzania with 
capacity to diagnose influenza.   
Key Laboratory Activities
•	 NIL tested a total of 2,096 influenza specimens (903 from sentinel hospitals, 1153 from 2009 
H1N1 outbreak sites).
•	 NIL submitted a total of 110 PCR positive samples to the WHO CC Atlanta as part of the WHO 
GISN.
•	 NIL conducted five supervisory visits and provided logical support to laboratories in the 
influenza surveillance network.
•	 Tanzania participated in the WHO EQAP.
Preparedness
Tanzania’s MOHSW continues to work with CDC, United Nations, and other stakeholders in the 
implementation of the preparedness and response plan for avian and pandemic influenza.
Key Preparedness Activities
•	 MOHSW developed 22,000 2009 H1N1 pandemic influenza leaflets in local language and 
distributed to the general public.
•	 The Tanzania Joint Human and Animal Technical Committee met nine times to share 
surveillance data from human and animal populations.
•	 MOHSW produced 3,500 travelers’ screening forms and distributed them to three major airports 
to gather health information about incoming travelers.
•	 MOHSW produced and broadcasted TV and radio spots on seasonal and pandemic  
influenza awareness.
Training
Tanzania MOHSW hosted the following training activities in 2010:
•	 A refresher training on 2009 H1N1 pandemic influenza for 31 staff members from  
sentinel hospitals.
•	 A training session on preparedness and response to avian and pandemic influenza for 20 district 
rapid response teams and five private hospital staff.
•	 For all five sentinel hospitals, training sessions were conducted on influenza sample collection, 
storage, and transportation techniques. 
•	 Two MOHSW senior staff attended an inter-ministerial conference on animal and pandemic 
influenza in Vietnam. 
The following trainings are planned for the near future:  
•	 Laboratory management for NIL.
•	 Preparedness and response to avian and pandemic influenza for ten additional district rapid 
response teams and ten private hospitals.
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•	 Virus isolation by culture for NIL.
•	 Refresher trainings for sentinel hospital staff.
Participants from Mawanza Regional Hospital take part in influenza surveillance training held by the Ministry of Health and Social Welfare (MOHSW) at the 
Mwanza sentinel site, northwestern Tanzania. 
2009 H1N1 Activities, FY 2010
The first 2009 H1N1 suspect case was identified through the travelers’ screening process at the main 
international airport in Dar es Salaam on July 4, 2009; this case was laboratory-confirmed within 
24 hours. Tanzania promptly distributed national guidance and procedures for surveillance and 
management of suspected/confirmed cases of 2009 H1N1 influenza.
Key 2009 H1N1 Activities, 2010
•	 MOHSW tested 652 samples (35 from sentinel hospitals, 617 from outbreak sites) that were 
positive for 2009 H1N1 virus by RT-PCR.
•	 MOHSW provided specimen collection materials, PPE, and antiviral drugs (where necessary) to 
health facilities in outbreak areas. 
Other Notable Achievements in FY 2010 
•	 MOHSW increased the amount of national influenza surveillance data; it shows prevalence 
trends and the types of influenza viruses that are circulating.
•	 Influenza surveillance and diagnosis capacity helped MOHSW to determine the presence of 
other viral outbreaks, including a dengue fever outbreak in 2010.
•	 MOHSW is now able to contribute positive samples to WHO GISN.
•	 MOHSW, through the influenza work in Tanzania, has increased collaboration between public 
and private health facilities on public health issues.
58 Influenza Division International Activities  |  Fiscal Year 2010 Annual Report Tanzania      
Special Influenza Projects
•	 Collaboration with the U.S. Department of Defense, Global Emerging Infections Surveillance 
(DoD-GEIS) to establish eight more sentinel sites. 
•	 Participation in the East African Community’s (EAC) trans-boundary avian influenza 
preparedness activities with Kenya, Uganda, Rwanda, and Burundi.
•	 Establishment of virus isolation by culture at the NIL.
Principal Collaborators
Peter Mmbuji, MD, MMed
Assistant Director of Epidemiology
Ministry of Health and Social Welfare
Dar es Salaam, Tanzania
Email mmbuji@yahoo.co.uk
Vida Mmbaga, MD, MPH
Avian Influenza Focal Person
Ministry of Health and Social Welfare




Tanzania National Influenza Centre






Dar es Salaam, Tanzania
mwasekagam@tz.cdc.gov
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Uganda
•	Capital: Kampala 
•	Area: 241,038 sq km 
•	Population: 34,612,250 ( July 2011 est.)
•	Age Structure: 0-14 years: 49.9% (male 8,692,239/female 
8,564,571); 15-64 years: 48.1% (male 8,383,548/female 
8,255,473); 65 years and over: 2.1% (male 291,602/female 
424,817) (2011 est.)
•	Life Expectancy at Birth: Total population: 53.24 years; 
male: 52.17 years; female: 54.33 years (2011 est.)
•	Infant Mortality Rate: Total: 62.47 deaths/1,000 live 
births; male: 66.05 deaths/1,000 live births; female: 58.77 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 66.8%; male: 76.8%; 
female: 57.7% (2002 census)
•	GDP: $41.7 billion (2010 est.)
•	GDP per Capita: $1,200 (2010 est.)
U.S. CDC Direct Country Support
In 2007, a proposal titled Strengthening National Capacity for Surveillance and Containment 
of Avian and Pandemic Influenza in Uganda requested funds to support the Uganda NIC. The 
purpose of these funds was to help support the national avian flu preparedness plan and to establish 
a sustainable influenza surveillance network in Uganda. Funds were provided by U.S. CDC under the 
influenza cooperative agreement that began in August 2007. Influenza sentinel surveillance for ILI and 
SARI is now well-established in Uganda with nine routine sites and three sites that provide specimens 
periodically. Also, the national preparedness plan is under implementation.
Surveillance
Although, influenza surveillance was initiated in Uganda in the 1960s at the time of the cooperative 
agreement, no influenza activities remained. Now, monitoring of influenza activity is carried out 
routinely in nine locations: five outpatient clinics, where ILI is assessed and four hospitals, where both 
ILI and SARI are assessed. A further three sites provide specimens periodically and the NIC also works 
together with the Makerere University Walter Reed Project (MUWRP), which has four hospital-based 
sentinel sites.
Key Surveillance Activities
•	 One sentinel site was opened in western Uganda, at Fort Portal Referral Hospital and another 
was opened in eastern Uganda, at Tororo District Hospital. Both sites conduct ILI and SARI 
surveillance.
•	 Pandemic influenza spread to Uganda at the end of June 2009 and was identified through the 
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surveillance system. Sentinel sites in central and western Uganda were active in identifying and 
collecting samples from pandemic influenza patients. 
•	 In order to facilitate the estimation of burden of disease due to influenza, data collection was 
initiated in Uganda. Data is now routinely collected and analysis is ongoing.
Laboratory
•	 The NIC is the only laboratory carrying out human influenza diagnostic testing in the country. 
The MUWRP and the CDC-funded influenza program work together in the NIC laboratory. 
Key Laboratory Activities
•	 The laboratory carries out RT-PCR testing to confirm diagnosis and typing, and also carries out 
virus culture and HAI for subtyping. 
•	 A subset of the influenza isolates were sent to the Atlanta CDC and for the first time some 
isolates were found to be resistant to adamantanes.
•	 The laboratory participated in the WHO EQAP panels and received a 100% score.
•	 The laboratory carried out training of personnel for capacity surge during pandemic situations. 
Influenza Program staff in front of the Uganda Viral Research Institute’s Influenza Surveillance 
Program building, Entebbe, Uganda. 
Preparedness
The national preparedness plan for Uganda was finalized in 2007. Activities to implement the plan were 
delayed because of funding. In 2010 the World Bank provided a US $10 million loan to facilitate its 
execution. Many related activities are now being undertaken by the Government of Uganda.
Key Preparedness Activities
•	 Training district personnel on identifying influenza patients and rapid response in case of 
outbreaks.
•	 Building isolation centers at regional levels.
•	 Building mechanisms for public awareness.
•	 Production of a communication strategy and production of information, education and 
communication (IEC) materials.
•	 Expanding and strengthening surveillance and reporting in the districts.
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•	 Regularly investigating SARI upsurges with laboratory support.
•	 Continuous revision of National Plan.
Training
Uganda NIC did not host any training, but the Uganda Viral Research Institute (UVRI) sent personnel to 
participate in trainings in Kenya and CDC-Atlanta.
2009 H1N1 Activities, FY 2010
The first cases of 2009 H1N1 influenza were detected in June 2009. The pandemic continued throughout 
2009 and early 2010. Sporadic cases continued throughout 2010 but with reduced speed and with 
reduced severity of disease. Cases continued in central and western Uganda and also spread northward 
into Arua and Koboko at the Uganda-Sudan border.
Key 2009 H1N1 Activities, 2010
•	 Participated in activities of the Integrated National Action Plan for Influenza.
•	 Strengthened the NIC capacity to test for 2009 H1N1 virus.
•	 Participated in simulation exercises to improve rapid response.
Other Notable Achievements in FY 2010
•	 Funds totaling US $250,000 have been approved for expansion of the influenza laboratories. 
These funds are from the World Bank loan that the NIC negotiated together with MOH and 
Ministry of Agriculture, Animal Industries and Fisheries (MAAIF) Uganda.
•	 UVRI received another ABI 7500 Fast RT-PCR machine, a centrifuge, a refrigerator and some 
additional supplies from USAID in support of 2009 H1N1 diagnostic activities.
Special Influenza Projects
•	 Initiated data collection for burden of diseases studies.
•	 Started to slowly shift from ILI surveillance to more SARI surveillance in hospitals.
Principal Collaborator
Julius Lutwama, PhD, SRO
Team Leader/Program Coordinator
UVRI/CDC Influenza Program, NIC
Uganda Virus Research Institute
Entebbe, Uganda
Email: jjlutwama03@yahoo.com
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Zambia
•	Capital: Lusaka 
•	Area: 752,618 sq km 
•	Population: 13,881,336 ( July 2011 est.)
•	Age Structure: 0-14 years: 46.7% (male 3,253,125/female 
3,228,844); 15-64 years: 50.8% (male 3,544,640/female 
3,508,344); 65 years and over: 2.5% (male 148,531/female 
197,852) (2011 est.)
•	Life Expectancy at Birth: Total population: 52.36 years; 
male: 51.13 years; female: 53.63 years (2011 est.)
•	Infant Mortality Rate: Total: 66.6 deaths/1,000 live births; 
male: 71.27 deaths/1,000 live births; female: 61.78 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 80.6%; male: 86.8%; 
female: 74.8% (2003 est.)
•	GDP: $20.03 billion (2010 est.)
•	GDP per Capita: $1,500 (2010 est.)
U.S. CDC Direct Country Support 
The CDC Influenza Division has a four-year (2009–2013) cooperative agreement with the Zambia 
MOH. This cooperative agreement will complement ongoing initiatives and help strengthen influenza 
surveillance and the surveillance of other communicable diseases in Zambia by strengthening the 
public sector laboratory and surveillance capacity for ILI and SARI. The cooperative agreement will be 
implemented by the University Teaching Hospital (UTH) and the Lusaka district health office on behalf 
of the MOH and in close collaboration with CDC-Zambia, CDC-South Africa, and the National Institutes 
for Communicable Diseases (NICD-South Africa) and WHO. 
Surveillance
Before the cooperative agreement, Zambia had a developing influenza surveillance system. The 
cooperative agreement has enabled Zambia to strengthen its surveillance system, and the surveillance 
of emerging pandemic viruses. Currently, Zambia has two ILI sites and two SARI surveillance sites, all in 
Lusaka.
Key Surveillance Activities 
•	 Clinical coordinators and virology laboratory staff designed a new influenza surveillance data 
collection tool. 
•	 The data manager at NICD-South Africa received Epi Info training.
•	 Nurse and clinical officer surveillance staff received additional training on the use of the new 
data collection tool. 
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•	 Surveillance officers from the MOH and the Ministry of Livestock and Fisheries in Chipata 
province and district received rapid response training from a team of six trainers (three human 
health and three animal health staff). 
•	 Andros Theo presented a poster at Options for the Control of Influenza VII conference in Hong 
Kong, September 2010. 
Laboratory
Since the introduction of the cooperative agreement, the virology laboratory has been strengthened 
through training of laboratory scientists and the provision of reagent and consumables. It now functions 
as the country’s reference laboratory and is on its way to becoming an accredited NIC. 
Key Laboratory Activities
•	 Real-time PCR training was provided for five laboratory staff at the Tropical Disease Research 
Center on the USAID-donated ABI 7500 Fast machine.
•	 A draft influenza manuscript was authored at a writing workshop in Nairobi, Kenya.
•	 CDC experts visited the virology laboratory and strengthened testing and data management 
through their expertise. 
Preparedness
The MOH conducts Integrated Disease Surveillance and Response (IDSR) for communicable diseases 
and is moving toward integrating influenza. This serves as an early-warning system for detection of 
outbreaks. 
Key Preparedness Activities
•	 MOH developed a national action plan for preparedness and response to influenza threats. 
Training
The MOH hosted the following training activities in 2010:
•	 Rapid response team (RRT) training activities in high risk provincial and district areas. 
•	 Additional pandemic preparedness and response training in conjunction with the disaster 
management and response unit under the office of the Vice President.
The following training is planned for the coming fiscal year:
•	 Training on the development of organizational business continuity plans. 
•	 RRT training in provinces that reported pandemic 2009 H1N1 outbreaks.
2009 H1N1 Activities, 2010
•	 MOH disseminated 2009 H1N1 data at a Zambia Medical Association meeting for practitioners.
•	 MOH finalized the pandemic 2009 H1N1 preparedness and response plan.
•	 The National Epidemic Committee is in the process of adopting 2009 H1N1 as a notifiable 
disease.
•	 The MOH developed and disseminated communication materials.
•	 Collaboration was established between animal and human health scientists.
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•	 Pandemic 2009 H1N1 preparedness and response at border entry points was strengthened by 
technical supervisory visits of MOH experts. 
Other Notable Achievements in FY 2010 
•	 WHO donated 2,000 doses of Tamiflu and 256,800 vaccine doses to the MOH.
•	 CDC donated respiratory masks to the MOH.
•	 Health staff was vaccinated against 2009 H1N1.
Special Influenza Projects
•	 The MOH is seeking to designate surveillance nurses to collect data on SARI in order to keep 
influenza patients separate from other patients in the UTH pediatric ward.
Principal Collaborators




Mwaka Monze, MBChB, PhD
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WHO Eastern Mediterranean Region 
(EMR) Overview
There are four bilateral influenza cooperative agreements in the Eastern Mediterranean Region (EMR). 
These cooperative agreements are with Ministries of Health or other institutions to build capacity 
to routinely identify, diagnose, and respond to seasonal and pandemic influenza in the Eastern 
Mediterranean Region.





In addition, CDC supports the WHO Eastern Mediterranean Regional Office (WHO EMRO) via a 
cooperative agreement to provide coordination and technical support to Member States.
The core activities of the bilateral agreements with countries are:
•	 To build sustainable national capacity for the detection, identification and response to seasonal, 
avian, and novel influenza.
•	 To develop interagency national preparedness plans.
•	 To build capacity for integrated laboratory and epidemiologic surveillance for ILI and SARI, 
which includes making routine contributions to WHO Global Influenza Surveillance Network 
(GISN) and implementing International Health Regulations (IHR).
•	 To develop and train local rapid response and containment teams.
Influenza Division Contacts 
Atlanta
Charlene Sanders, MPH, RD
Senior Program Manager
Extramural Program - WHO Eastern Mediterranean Region
Influenza Division/NCIRD/CDC
Email: csanders2@cdc.gov 
William Brady, MPH, PA (Oct – Dec 2009) 
Epidemiologist
International Epidemiology and Response Team
Influenza Division/NCIRD/CDC
Email: web0@cdc.gov   
Fatimah Dawood, MD (since Jun 2010)
Medical Officer Epidemiologist
International Epidemiology and Response Team
Influenza Division/NCIRD/CDC
Email: fdawood@cdc.gov
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Influenza Sustainability Cooperative Agreement
Influenza Capacity Building Cooperative Agreement
A five-year project titled Strengthening Surveillance and Response to Avian and Pandemic Influenza 
in the Eastern Mediterranean Region was launched in October 2006, under a cooperative agreement 
between the Eastern Mediterranean Regional Office (EMRO) of the WHO and the U.S. CDC. This is the 
fifth year of the cooperative agreement.
The overarching goal of this project is to strengthen the public health capacities of 22 countries in the 
Region to rapidly detect, assess, respond to and contain public health threats emanating from highly 
pathogenic avian influenza (HPAI) and human pandemic influenza. 
Surveillance
The Regional Office has undertaken a number of key activities aimed at strengthening the influenza 
surveillance and response capacities of the countries in the Eastern Mediterranean Region. At least 12 
countries in the region are participating in the virological surveillance for seasonal influenza as part 
of the Global Influenza Surveillance Network (GISN), and seven countries in the Region (Afghanistan, 
Egypt, Jordan, Iran, Morocco, Oman, and Tunisia) were provided with technical and financial support 
through the Regional Office resulting in ILI and SARI surveillance.
Key Surveillance Activities
•	 WHO EMRO organized an inter-country meeting on human pandemic influenza in Cairo, 
Egypt during the month of April 2010. Representatives from national health authorities at the 
policy- and decision-making levels from all 22 countries in the Region attended this meeting. 
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The meeting reviewed the ongoing epidemiological and virological surveillance systems of the 
countries. 
•	 The Regional Office organized an inter-country workshop in Cairo, Egypt in March 2010 on the 
use of International Health Regulations (IHR) for event notification and reporting of pandemic 
influenza and other Public Health Emergencies of International Concern (PHEIC). The IHR 
National Focal Points (NFPs) of all 22 countries in the Region attending this meeting.  
•	 The Regional Office conducted a preliminary assessment for setting up sentinel surveillance 
systems for ILI and SARI in three countries- occupied Palestine territory (OpT), Yemen and 
Pakistan. The assessment was conducted with a view of advising the national health authorities 
on optimal ways of generating adequate epidemiological and virological data on ILI and SARI. 
Laboratory 
Twelve NICs are now functional in the region owing to the technical and financial support provided 
to the countries through the cooperative agreement. Of these NICs, seven now have full capacity for 
influenza viral sequencing.
Key Laboratory Activities
•	 WHO EMRO and the Naval Medical Research Unit No. 3 (NAMRU-3) jointly conducted technical 
missions in Qatar and in the United Arab Emirates for assessment of influenza virus isolation 
units at the Central Public Health Laboratories of these two countries. Following completion of 
these training courses and assessments, the formal recognition process of WHO to designate 
these influenza laboratories as NICs has begun. 
•	 WHO EMRO conducted an inter-country meeting of the national influenza laboratory focal 
points in Muscat, Oman in September 2010. The purpose of this meeting was to strengthen the 
laboratory network of NICs in the region and to encourage the countries in the region to build 
and expand laboratory-based surveillance for ILI and SARI. 
•	 The Regional Office conducted a technical mission to Oman in March 2010 to develop a 
master plan on laboratory biosafety preparedness and response working jointly with WHO, the 
European Union, and the MOH, Sultanate of Oman. 
Preparedness 
The national preparedness plan for human pandemic influenza was developed for all 22 countries in the 
region. Technical support was provided in the areas of risk communication, infection prevention and 
control, and risk assessment. 
Key Preparedness Activities
The Regional Office:
•	 Provided technical, operational, and logistic support to six low-income countries and one 
middle-income country for the deployment of pandemic 2009 H1N1 vaccines and the 
organization of mass vaccination campaigns for high-risk populations.
•	 Provided strategic support for the development of a global guideline on event-based risk 
assessment through participation in the consultative meeting organized by WHO Headquarters 
in Geneva, Switzerland. 
•	 Produced and distributed a multi-lingual (Arabic, French and English) educational animated 
film on influenza titled Protect Yourself from Influenza (H1N1), which is designed for use 
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in schools. The Regional Office also developed a computer screen saver under the theme 
prevention is better than cure, as a risk communication product for 2009 H1N1. 
•	 Established a regional stockpile of influenza antiviral drugs (oseltamivir) in the WHO Logistic 
Hub in Dubai. 
•	 Provided a complete investigation kit containing PPE, bio-packaging materials, viral transport 
media (VTM) and other essential supplies. These kits were deployed to each of the WHO 
Country Offices to support in-country field investigation for clusters of cases of ILI and SARI.
•	 Launched a joint collaborative work to finalize the assessment manual for Patient Safety Friendly 
Hospital Initiative (PSFHI). A toolkit on measuring infection prevention and control practices 
in health care settings for epidemic and pandemic-prone acute respiratory disease is being 
developed.
Training 
The Eastern Mediterranean Regional Office of WHO conducted the following training activities in 2010 
under the cooperative agreement: 
•	 A regional training workshop on field investigation and response to outbreaks from influenza 
and other epidemic prone respiratory infections in Beirut, Lebanon. The 44 participants  
were trained on outbreak investigation and response to clusters of SARI or death during the 
influenza season. 
•	 Two cycles of a training course on influenza virus sequencing were offered to the established 
NICs in the Region at the NAMRU-3 laboratory in Cairo, Egypt in April 2010. 
•	 WHO EMRO and NAMRU-3 jointly conducted training courses to build and strengthen 
diagnostic capacity for isolation, typing, and sub-typing of influenza viruses using tissue culture 
and haemagglutination. Two virologists each from the NICs of Egypt, Iran, Morocco, Oman, 
Pakistan and Tunisia attended these training courses. 
2009 H1N1 Activities, FY 2010
Throughout the FY 2010, the Regional Office extended technical support to all the countries in the 
Region for improving public health response to the pandemic influenza, particularly in the areas of 
clinical management, community mitigation measures, risk communication, vaccine deployment and 
field investigation.
Key 2009 H1N1 Activities, 2010 
The Regional Office:
•	 Documented the process of its emergency operations response undertaken in response to 
2009 H1N1. The resulting report identified the key institutional strengths and weaknesses of its 
strategic health operational response. 
•	 Provided technical support to Afghanistan, Djibouti, Pakistan, Somalia, Sudan, Yemen and OpT 
for deployment of 2009 H1N1 vaccines. 
•	 Established a regional stockpile of influenza specific antiviral drugs (oseltamivir), which was 
intended to ensure timely access for all the 22 countries in the Region to strategic antiviral 
supplies.
•	 WHO EMRO provided appropriate equipment and logistics supplies to all the WHO Country Offices 
in the Region to facilitate in-country investigation and risk assessment missions for 2009 H1N1. 
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Other Notable Achievements in FY 2010
•	 The Regional Office publishes a weekly epidemiological report to inform the Member States of 
the evolution of pandemic influenza as well as of other public health emergencies of potential 
concern in the region. This is the third year of uninterrupted publication.
•	 The Regional Office extended technical assistance to conduct a training of trainers (ToT) course 
on field investigation of influenza and other epidemic prone acute respiratory diseases in south 
Sudan. Thirty-five state level surveillance officers of the Government of South Sudan (GoSS) 
attended this training course. 
•	 Seven out of the 12 NICs in the Eastern Mediterranean Region participated in the WHO EQAP 
with notable results.
Special Influenza Projects
The Regional Office, along with CDC-Atlanta, extended technical support to the health authorities of 
Kingdom of Saudi Arabia during the Hajj 2010 for strengthening field surveillance for influenza and 
other epidemic-prone respiratory infections during mass gatherings, using the Field Adapted Surveillance 
Toolkit (FAST) in conjunction with an enhanced routine disease surveillance system. 
Principal Collaborators
Hassan El Bushra, MBBS, MCM, MPH, PhD, MFPHM 
Regional Advisor, Emerging Diseases 
Communicable Disease Surveillance, Forecasting and Response 
WHO Regional Office for the Eastern Mediterranean 
Cairo, Egypt
Email: elbushrah@emro.who.int
L. Martin Opoka, MBBS, PG Dip (Food Science and Nutrition), MSc
Technical Officer
Communicable Disease Surveillance, Forecasting and Response
WHO Regional Office for the Eastern Mediterranean
Cairo, Egypt
Email: opokal@emro.who.int 
Sk. Md. Mamunur Rahman Malik, MBBS, Dip (Health Economics), MSc, MPhil
Epidemiologist
Communicable Disease Surveillance, Forecasting and Response
WHO Regional Office for the Eastern Mediterranean
Cairo, Egypt
Email: malikm@emro.who.int 
Ali Mafi, MD, MPH
Technical Officer
Communicable Disease Surveillance, Forecasting and Response
WHO Regional Office for the Eastern Mediterranean
Cairo, Egypt
Email: MafiA@emro.who.int
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Afghanistan 
•	Capital: Kabul 
•	Area: 652,230 sq km 
•	Population: 29,835,392 ( July 2011 est.)
•	Age Structure: 0-14 years: 42.3% (male 6,464,070/female 
6,149,468); 15-64 years: 55.3% (male 8,460,486/female 
8,031,968); 65 years and over: 2.4% (male 349,349/female 
380,051) (2011 est.)
•	Life Expectancy at Birth: Total population: 45.02 years; 
male: 44.79 years; female: 45.25 years (2011 est.)
•	Infant Mortality Rate: Total: 149.2 deaths/1,000 live births; 
male: 152.75 deaths/1,000 live births; female: 145.47 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 28.1%; male: 43.1%; 
female: 12.6% (2000 est.)
•	GDP: $29.81 billion (2010 est.)
•	GDP per Capita: $1,000 (2010 est.)
U.S. CDC Direct Country Support
The Islamic Republic of Afghanistan received cooperative agreement funding from the U.S.CDC 
for surveillance and response to avian and pandemic influenza in 2006. FY 2010 was the fifth year 
of cooperative agreement funding. These funds support the Afghan Public Health Institute (APHI), 
located in the Afghanistan Ministry of Public Health (MOPH), in planning and conducting pandemic 
preparedness and response, ILI and SARI surveillance, laboratory capacity building, health education, 
and training activities.
Surveillance
The primary surveillance system used in Afghanistan for disease surveillance is the Disease Early 
Warning System (DEWS) that was established in December, 2006, with funding from WHO and USAID. 
DEWS collects data for 15 reportable diseases in the country, including influenza. Specimen collection 
for ILI is mandatory in all provinces. Currently, regional DEWS officers submit weekly data to APHI from 
over 250 surveillance sentinel sites covering the 34 provinces in the country.  
Key Surveillance Activities
•	 The weekly reporting rate for the regional DEWS officers is greater than 98%.
•	 SARI surveillance has been established at military and police hospitals; this data is included in 
the weekly DEWS report. 
•	 There is daily electronic collection and reporting of ARI cases and deaths from all 34 provinces.
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Laboratory
The virology laboratory of the Central Public Health Laboratory (CPHL) was designated as a National 
Influenza Center (NIC) in 2009. The NIC is capable of performing RT-PCR, virus isolation and subtyping 
using HAI.  
•	 CPHL processed 2,172 ILI specimens.
•	 Nine hundred fifty-three specimens were positive for 2009 H1N1.
Preparedness
The national preparedness plan was approved by MOPH in 2009. The plan was developed with input 
from health sector stakeholders and used during the 2009 H1N1 pandemic period. The existing National 
Emergency Response Commission coordinated the response to the 2009 pandemic.
Key Preparedness Activities
•	 Fifty rapid response team members from 11 provinces were trained or retrained to respond to 
outbreaks.
•	 PPE kits, VTM, and 10,000 courses of Tamiflu were purchased and available for use, especially 
during outbreak investigations.
Training
Afghanistan hosted the following training activities in 2010:
•	 Twenty-five MOPH managers attended an intermediate-level epidemiology training program.
•	 More than 4,200 health care workers were trained on influenza case detection, reporting, and 
disease management.
2009 H1N1 Activities, FY 2010
The Command and Control Center in the MOPH was activated during the pandemic. Three established 
hotlines were open for calls and questions from the community.  
Key 2009 H1N1 Activities, 2010
•	 A toolkit for surveillance, case detection, and the management of pandemic 2009 H1N1 was 
developed and distributed to 15,000 health care workers in the provinces.
•	 A booklet on influenza prevention was developed by APHI and made available to pilgrims 
making the Hajj. 
•	 A 2009 H1N1 flu vaccination campaign for health workers was conducted in 34 provinces. 
•	 A campaign to vaccinate Hajj pilgrims for seasonal influenza was initiated.
Other Notable Achievements in FY 2010
•	 Two influenza isolation wards were established in the Indira Gandi Hospital and the Infectious 
Diseases Hospital in Kabul.
•	 A stock room at APHI was renovated to assure the safe storage of supplies and equipment 
related to influenza and DEWS.




Ministry of Public Health, APHI
Kabul, Afghanistan
Email: noormalb@yahoo.com
Khwaja Mir Islam Saeed, MD
Director, Surveillance/DEWS
Ministry of Public Health, APHI
Kabul, Afghanistan
Email: km_islam2001@yahoo.com
A view of Badakhshan Province, northeastern Afghanistan.
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Arab Republic of Egypt
•	Capital: Cairo 
•	Area: 1,001,450 sq km 
•	Population: 82,079,636 ( July 2011 est.)
•	Age Structure: 0-14 years: 32.7% (male 13,725,282/female 
13,112,157); 15-64 years: 62.8% (male 26,187,921/female 
25,353,947); 65 years and over: 4.5% (male 1,669,313/
female 2,031,016) (2011 est.)
•	Life Expectancy at Birth: total population: 72.66 years; 
male: 70.07 years; female: 75.38 years (2011 est.)
•	Infant Mortality Rate: Total: 25.2 deaths/1,000 live 
births; male: 26.8 deaths/1,000 live births; female: 23.52 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 71.4%; male: 83%; female: 
59.4% (2005 est.)
•	GDP: $500.9 billion (2010 est.)
U.S. CDC Direct Country Support
The Ministry of Health and Populations (MOHP) in the Arab Republic of Egypt was awarded funding in 
2009 for the cooperative agreement Surveillance and Response to Avian and Pandemic Influenza. 
Beginning in 2009, the funding was used to build laboratory and epidemiology capacity for influenza 
surveillance. The goals of the project are to prevent the emergence and spread of a pandemic influenza 
virus, to reduce morbidity and mortality caused by influenza viruses, and to improve the state of 
preparedness and the quality of response to an influenza pandemic. MOHP collaborates with Naval 
Medical Research Unit No. 3 (NAMRU-3) in Cairo and WHO EMRO to review and enhance ongoing 
national surveillance activities.
Surveillance
Egypt has multiple activities for influenza within the surveillance system. General influenza surveillance 
takes place in all government hospitals (up to 450 hospitals) and about 5,000 outpatient health clinics. 
Sentinel surveillance for ILI was established in 1999 in eight sites in outpatient clinics of selected 
fever and chest hospitals. Sentinel surveillance for SARI began in 2009 and occurs in eight sites in 
the inpatient wards of selected fever hospitals. Both ILI and SARI sentinel surveillance have been 
implemented and continue in collaboration with NAMRU-3. Avian influenza surveillance started in 
early 2006. Surveillance also occurs for suspected novel influenza viruses and pneumonia. Influenza 
surveillance data from hospitals throughout 29 governorate surveillance units is collated and then 
pooled and submitted electronically to the central Epidemiologic Surveillance Unit (ESU). 
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Key Surveillance Activities
•	 A weekly report is generated from surveillance data for pneumonia, avian influenza, and 2009 
H1N1.   
•	 A weekly report is also generated from sentinel SARI and ILI surveillance data and distributed to 
designated persons within the MOHP and to regional epidemiologists.  
Laboratory
The Central Public Health Laboratory (CPHL) serves as the NIC and provides laboratory support to 
the ESU for surveillance activities related to human influenza in Egypt. Four of the eight sentinel 
hospitals have subnational laboratories that perform RT-PCR testing for influenza. It is expected that two 
additional sub-national laboratories will begin functioning in 2011. 
Key Laboratory Activities
•	 CPHL has the capacity to detect and subtype seasonal, H5N1, and 2009 H1N1 influenza viruses 
using both molecular and culture-based techniques; culture is only used for viral isolation with 
specimens collected for ILI and SARI surveillance purposes.  
•	 Laboratory staff routinely provide training and offer technical support to the sub-national 
laboratories.
Preparedness
The MOHP has devoted time and resources to establishing and building capacity of rapid response 
teams (RRTs) to investigate and implement control measures to combat zoonotic transmission of H5N1, 
and to contain and mitigate pandemic influenza. 
Key Preparedness Activities
•	 RRTs from all levels (central, governorate and district) were trained on the preparedness 
guidelines outlined in the national preparedness pandemic plan.  
•	 Six thousand five hundred PPE sets were procured and stored for immediate use. 
Training
The MOHP conducted the following trainings in FY 2010:
•	 Four training courses were implemented for 164 participants (84 physicians and 80 nurses) to 
improve the awareness of physicians and nurses working in the pandemic. 
•	 Twelve training courses on enhancing human surveillance for H5N1 influenza infection were 
conducted for 381 participants in ten governorates.
•	 Three hundred and fourteen training courses were implemented for surveillance teams in 14 
governorates considered to be high risk.
•	 Training courses were held to improve capacity or immediate reporting and rapid response to 
sporadic cases or clusters of illness, including nine training courses for 325 participants from the 
29 governorates of Egypt.
•	 Training to improve the quality of infection control practices at all MOHP hospitals down to the 
district level was provided for infection control practitioners. 
2009 H1N1 Activities, FY 2010
•	 H5N1 surveillance and detection was enhanced throughout the country with direction  
from the MOHP.
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•	 2009 H1N1 influenza data was integrated into the established surveillance data collection 
system.
•	 A comprehensive national surveillance plan for ILI, SARI, and pneumonia was integrated into 
ongoing surveillance activities.
•	 Epidemiologists from ESU followed the global epidemiology situation daily and provided 
reports to MOHP.
•	 National and international data was reviewed and analyzed.
Hajj Pilgrim Measures
•	 Health fitness certificates were issued by 
MOPH for each person wanting to make the 
Hajj pilgrimage.
•	 Pilgrims were vaccinated with 2009 
H1N1vaccine and/or seasonal vaccine that 
included the 2009 H1N1 strain.
•	 The MOPH offered health education for 
pilgrims.
Vaccine Deployment
•	 The MOPH provided 300,000 doses of seasonal influenza vaccine for pilgrims and health care 
workers.
•	 MOPH contracted for five million doses of 2009 H1N1 vaccine, which they made available from 
October 2009 to March 2010.
•	 The MOPH deployed approximately two million doses of 2009 H1N1 vaccine during FY 2010. 
Some of those people vaccinated included pilgrims, primary school students, and health care 
practitioners.
Other Notable Achievements in FY 2010
•	 A project coordinator was hired and technical support staff was appointed to support the 
influenza project.
Special Influenza Project
•	 Population-based surveillance for SARI (with plans to expand to include ILI) is being conducted 
in Damanhour, Behera Governorate in conjunction with NAMRU-3.  
Principal Collaborators
Samir Refaey Abu-Zid, MD
Director of Epidemiology and Surveillance Unit (ESU)









Traditional sailing craft near a modern city in Egypt.
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GDD-Egypt
The GDD (Global Disease Detection) Regional Center in Egypt (GDD-Egypt) was established in 2006 as 
an extension of an established agreement between the U.S. CDC, WHO EMRO, and U.S. Naval Medical 
Research Unit No. 3 (NAMRU-3) to develop national and regional resources to control and combat 
infectious diseases that are the leading cause of death, disability, and illness in the region. 
Coverage
GDD-Egypt has provided support to more than 20 countries in the AFR, EMR, and EUR from its base 
at NAMRU-3. It is also the platform for much of CDC’s public health support to Iraq and Afghanistan. 
GDD-Egypt benefits from access to state-of-the-art laboratory facilities, including BSL-3 space from 
NAMRU-3. Egypt and the United States also work together to conduct joint surveillance activities, such 









In 2010, the GDD Regional Center in Egypt discovered one pathogen new to the region and increased 
their laboratory testing capacity by 17%. GDD-Egypt trained 14 FETP graduates and more than 2,400 
participants in short-term regional and national trainings. GDD-Egypt responded to 21 outbreaks; each 
outbreak involved laboratory support and was responded to in less than 24 hours. GDD-Egypt provided 
100% of the laboratory support. 
In-Country Field Staff
Erica Dueger, DVM, PhD
Egypt GDD Regional Center Director
Principal U.S. CDC Program Collaborations In-Country 
•	 Influenza Division International Program
•	 International Emerging Infections Program
•	 Field Epidemiology and Laboratory Training Program
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Morocco
•	Capital: Rabat 
•	Area: 446,550 sq km 
•	Population: 31,968,361 ( July 2011 est.)
•	Age Structure: 0-14 years: 27.8% (male 4,514,623/female 
4,382,487); 15-64 years: 66.1% (male 10,335,931/female 
10,785,380); 65 years and over: 6.1% (male 881,622/
female 1,068,318) (2011 est.)
•	Life Expectancy at Birth: total population: 75.9 years; 
male: 72.84 years; female: 79.11 years (2011 est.)
•	Infant Mortality Rate: total: 27.53 deaths/1,000 live 
births; male: 32.32 deaths/1,000 live births; female: 22.51 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: total population: 52.3%; male: 65.7%; 
female: 39.6% (2004 census)
•	GDP: $153.8 billion (2010 est.)
•	GDP per Capita: $4,900 (2010 est.)
U.S. CDC Direct Country Support 
The Kingdom of Morocco’s National Institute of Hygiene (NIH) is both the NIC and the recipient of U.S. 
CDC’s cooperative agreement for influenza surveillance titled Strengthening Influenza Surveillance 
Networks in Morocco. NIH was initially funded in 2006 to strengthen laboratory and epidemiology 
capacity for influenza surveillance.
NIH developed a web-based database to collect both epidemiologic and laboratory information related 
to ILI and SARI. The NIH collaborates with the MOH epidemiological disease and surveillance units on 
influenza surveillance activities in the 16 administrative regions in Morocco. 
Surveillance
The Morocco MOH uses multiple surveillance systems to characterize the epidemiology of pandemic 
influenza. These systems include those established to track seasonal influenza. SARI is tracked through a 
network of 16 regional hospitals where syndromic and virologic data is collected. ILI is tracked through 
a network of 380 health units and network of 110 private physicians. Sixteen of the health units collect 
both syndromic and virologic data.  
The internet database developed by NIH provides instant notification of influenza activity. Influenza data 
is entered into the database by the sentinel sites and the NIC. 
Key Surveillance Activities
•	 Non-seasonal 2009 H1N1 flu was made a notifiable disease during the pandemic, until October 
31, 2009.
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•	 Deaths related to 2009 H1N1 were investigated and reported. 
•	 During the 2009-10 influenza season, 1,219 cases of 2009 H1N1-associated ILI were identified, 
along with 342 cases of SARI, and 64 fatal cases. All were identified through the established 
sentinel surveillance system.
Crowds in Djemma El Fna Square, Marrakech, Morocco.
Laboratory
The Morocco surveillance network includes one NIC and 16 regional laboratories. The NIC has the 
capacity to carry out real-time PCR testing, virus culturing, HAI testing, and DFA testing. Four regional 
laboratories are equipped with PCR machines.
Key Laboratory Activities
•	 The project assures laboratory functioning by regularly ordering laboratory consumables and 
standards reagents, such as immunofluoresence (IFA) and PCR regents for the NIC and influenza 
network laboratories. 
•	 Six biosafety cabinets were purchased for regional laboratories.
•	 Morocco participated in the CDC/APHL Influenza Laboratory Capacity Review.
Preparedness
In response to the threat of 2009 H1N1 virus, Morocco’s MOH implemented unprecedented influenza 
surveillance in May 2009 in order to detect the introduction of pandemic H1N1 influenza and to monitor 
its spread and impact on public health in Morocco.
Key Preparedness Activities
•	 The national public health preparedness plan was updated during the 2009 H1N1 pandemic.
•	 Pandemic preparedness guidelines were developed and used to guide 2009 H1N1 pandemic 
response activities. 
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Training
The Morocco NIH hosted the following training activities in 2010:
•	 On-site technical assistance and hands-on training for regional laboratory staff in real-time PCR 
diagnostics.
•	 Supervision and monitoring visits to ensure the functioning of the sentinel surveillance system 
and the quality of the surveillance data.
2009 H1N1 Activities, FY 2010
The national preparedness plan was activated during the pandemic. The NIC played a key role in 
the overall response to the pandemic throughout the country. NIH worked collaboratively with other 
agencies within the MOH to provide accurate data analysis for the pandemic response. 
Key 2009 H1N1 Activities, 2010
•	 The NIC quickly handled the surge in testing for 2009 H1N1 by real-time PCR and provided 
in-country training for the regional laboratories for 2009 H1N1 testing. 
•	 The role of RT-PCR diagnosis for the 2009 H1N1 pandemic was decentralized to four regional 
laboratories which allowed the NIC to concentrate on confirmation testing and virus isolation.
Other Notable Achievements in FY 2010 
•	 The sentinel SARI and ILI surveillance system is fully operational in all sixteen regions of the 
country.
•	 The CDC/APHL Laboratory Capacity Review Tool was used to conduct an NIC capacity 
assessment in 2010. 
•	 CDC monitoring and evaluation and surveillance system tools were used to evaluate 
preparedness planning in Morocco and in the MOH influenza surveillance system.
Principal Collaborators
Rajae El Aouad, MD
Director






National Institute of Hygiene 
Rabat, Morocco
Email: amal.barakat@yahoo.fr
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Pakistan
•	Capital: Islamabad 
•	Area: 796,095 sq km 
•	Population: 187,342,721 ( July 2011 est.)
•	Age Structure: 0-14 years: 35.4% (male 34,093,853/female 
32,278,462); 15-64 years: 60.4% (male 58,401,016/female 
54,671,873); 65 years and over: 4.2% (male 3,739,647/
female 4,157,870) (2011 est.)
•	Life Expectancy at Birth: Total population: 65.99 years; 
male: 64.18 years; female: 67.9 years (2011 est.)
•	Infant Mortality Rate: Total: 63.26 deaths/1,000 live 
births; male: 66.52 deaths/1,000 live births; female: 59.85 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 49.9%; male: 63%; female: 
36% (2005 est.)
•	GDP: $451.2 billion (2010 est.)
•	GDP per Capita: $2,400 (2010 est.)
U.S. CDC Direct Country Support
The first year of funding from the cooperative agreement Developing Sustainable Influenza 
Surveillance Networks and Response to Avian and Pandemic Influenza supports the development 
of a state-of-the-art laboratory at designated sentinel sites in Pakistan for rapid confirmation of human 
and novel influenza cases. Funding also supports activities aimed at pandemic influenza preparedness 
through improved national influenza surveillance as well as the development of a national vaccine 
policy. Significant progress has been made in light of continuing social and political challenges. Five 
sentinel sites are located in outpatient departments of major tertiary care hospitals in four provinces 
and the federal capital, Islamabad. Sites were selected on the basis of a representative geographic 
distribution, high population density, and patient turnover rate. 
All sentinel sites are operational after biosafety enhancements, installation of lab equipment, and basic 
training of physicians for collection of epidemiological data and samples from ILI and SARI cases. 
Relevant standard operating procedures (SOPs) and protocols for laboratory techniques have been 
developed as per U.S. CDC protocols. 
Surveillance
There was no sentinel site lab-based influenza surveillance prior to the cooperative agreement. 
Currently, five sentinel sites are reporting ILI/SARI cases to the Pakistan National Institute of Health 
(NIH). 
Key Surveillance Activities
•	 Laboratory-based surveillance for ILI and SARI cases has been activated at five sentinel sites 
through both active and passive case finding.
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•	 Rapid response teams have been trained and activated for timely response.
•	 Case definitions, SOPs for sampling, storage, and sample transportation have been developed 
and periodically reviewed based on the emerging situation. 
•	 VTM is dispatched to provincial health departments and high-risk districts on a regular basis.
•	 Seasonal influenza vaccine has been procured and administered to personnel engaged in 
influenza surveillance. 
•	 Sentinel site and rapid response trainings were conducted in Hayatabad Medical Complex 
(HMC) and in the newly evaluated sentinel site at Gilgit-Baltistan. Evaluation at another 
proposed site at Azad Jammu Kashmir (AJK) is under process. 
•	 Epidemiological data on ILI and SARI is being submitted to FluID. 
Laboratory
The first CDC cooperative agreement (2004-2009) envisaged the establishment of a network of five 
key laboratories for lab-based influenza surveillance. The network consists of the central laboratory 
at NIH, which is engaged in virus isolation and molecular diagnosis of influenza viruses and sentinel 
influenza labs at the four provincial capitals. The Sindh sentinel laboratory at Civil hospital in Karachi 
started processing samples in 2010, and three other existing sentinel site laboratories routinely process 
specimens and send aliquots to NIH for confirmation and tissue culture. Under the second cooperative 
agreement with CDC, three additional sentinel influenza labs are planned at Multan (Punjab), Gilgit 
(Baltistan) and AJK. The preliminary evaluation of the designated sentinel site at Gilgit was completed in 
2010.
Key Laboratory Activities
•	 From the five sentinel surveillance sites, 1,086 samples were processed and reported in a timely 
manner.
•	 Logistic and technical support was provided to sentinel influenza laboratories.
•	 Seasonal and pandemic virologic data were consistently shared online via submission to GISN 
using FluNet.
•	 Development of a manual containing the influenza diagnostic protocols for distribution to 
various laboratories is ongoing.
Preparedness 
The national preparedness plan for prevention and control of avian and pandemic influenza, established 
at NIH, was developed by the multi-sectoral National Expert Committee in 2005. Based on this 
document, the MOH implemented a National Programme for Prevention and Control of Avian and 
Pandemic Influenza in 2006. Some of the Programme’s major components include emergency response, 
clinical health services, antiviral medicines, vaccine, containment and quarantine, and communication. 
Influenza surveillance has been strengthened through the cohesive efforts of the MOH and the NIH lab-
based project.
Training
•	 Physicians, public health professionals and lab personnel have been trained via a training 
program that was conducted throughout Pakistan.
•	 Seven surveillance trainings were conducted for 93 sentinel site physicians.
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•	 Rapid response training was conducted and attended by 26 persons in Gilgit District, a district 
considered at high risk for influenza transmission.
•	 Twenty-eight laboratory staff members at sentinel sites received PCR training.
2009 H1N1 Activities, FY 2010
The provincial influenza laboratories have strengthened the influenza surveillance and response network 
across Pakistan. The NIC also maintains a collaboration with the WHO, Navy Medical Research Unit 
No. 3 (NAMRU-3), and CDC. Since August 2010 (post-pandemic), 169 cases of now-seasonal 2009 H1N1 
influenza have been detected from over 400 samples received across Pakistan. 
Key 2009 H1N1 Activities, 2010 
Some of steps taken by the Government of Pakistan/MOH for prevention and control of pandemic 
influenza include:
•	 Relevant health education material and guidelines have been distribution to all sentinel sites.
•	 PPE kits have been dispatched from the National Influenza Project to the provincial health 
departments, Islamabad Capital Territory (ICT), AJK, Federally Administered Northern Areas 
(NA) and Federally Administered Tribal Areas.
•	 Oseltamivir (Tamiflu) has been prepositioned in the high-risk districts from the national pool.
•	 Regular meetings have been conducted with both electronic and print media for effective 
dissemination of information about influenza.
•	 Guidelines on influenza management and algorithms for management of adults and children 
have been dispatched to all lab focal persons of sentinel sites.
•	 Public health specialists from provincial health departments have become members on the rapid 
response teams of the Ministry of Food, Agriculture and Livestock (MinFAL). 
•	 SOPs for surveillance and rapid response to human cases of pandemic influenza have been sent 
to the provincial health departments and regional health departments of AJK and NA. 
•	 A SOP for collection, storage and transportation of specimen was dispatched to all high-risk 
districts. 
•	 Training of public health and health care professionals for surveillance of human cases and use 
of PPE has been conducted both through FELTP Pakistan and the National Influenza Project. 
•	 In order to strengthen influenza surveillance, the provincial and regional health departments 
have been asked to designate district surveillance officers. 
Special Influenza Projects
Funds from the Department of State Biosecurity Engagement Program were used to supplement 
biosafety and biosecurity needs at two provincial sentinel surveillance sites and the BSL-3 laboratory. 
These additional resources procured real-time PCR machines, biosafety cabinets, ultra-low temperature 
freezers, and PPE. 
84 Influenza Division International Activities  |  Fiscal Year 2010 Annual Report Pakistan    
Principal Collaborators
Birjees Mazher Kazi, MBBS, DCP, MPhil
Executive Director
National Institute of Health
Islamabad, Pakistan
Email: bmkazi@gmail.com
Syed Sohail Zahoor Zaidi, MPhil
Head of Virology 
Public Health Laboratories Division
National Institute of Health
Islamabad, Pakistan
Email: zaidis@pak.emro.who.int or sohailz@live.com
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WHO European Region (EUR) Overview
The WHO Regional Office for Europe (WHO EURO) and the European Center for Disease Control 
(ECDC) work collaboratively to support public health programs in 53 Member States in Europe. There 
are five bilateral Influenza cooperative agreements that support influenza activity in Eastern Europe, the 
Caucus region, and Central Asia. These cooperative agreements are with Ministries of Health or other 
institutions to work with CDC to build capacity to routinely identify, diagnose, and respond to seasonal 
and pandemic influenza.





•	 Ukraine (through Program for Appropriate Technology in Health – PATH).
In addition, CDC supports WHO EURO via a cooperative agreement to provide technical and 
coordination support to Member States. This cooperative agreement also supports influenza activities in 
Romania and Kyrgyzstan.
The core activities of these bilateral agreements are:
•	 To build sustainable national capacity for the detection, identification and response to seasonal, 
avian, and novel influenza.
•	 To develop interagency pandemic preparedness plans.
•	 To strengthen capacity for integrated laboratory and epidemiologic surveillance for ILI and 
SARI, which includes making routine contributions to WHO Global Influenza Surveillance 
Network (GISN) and implementing International Health Regulations (IHR).
•	 To develop and train local rapid response and containment teams.
Influenza Division Contacts 
Atlanta
Charlene Sanders, MPH, RD
Senior Program Manager
Extramural Program - WHO European Region
Influenza Division/NCIRD/CDC
Email: csanders2@cdc.gov 
Diane Gross, DVM, PhD 
Medical Epidemiologist 
International Epidemiology and Response Team
Influenza Division/NCIRD/CDC
Email: bwc3@cdc.gov




U.S. Department of Health and Human Services 
Centers for Disease Control and Prevention
Influenza Division, Epidemiology and Prevention Branch 




European CDC Assignee 
J. Todd Weber, MD
CDC Liaison
European Centre for Disease Prevention and Control
Stockholm, Sweden 
Email: jtodd.weber@ecdc.europa.eu
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WHO European Regional Office (EURO)
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Influenza WHO Direct Funding
Influenza Capacity Building Cooperative Agreement
U.S. CDC Direct Support
The WHO Regional Office for Europe (WHO EURO) is one of six WHO Regional Offices around the 
world. It serves the WHO European Region, which comprises 53 countries, covering a geographical 
area from the Atlantic to the Pacific Oceans. WHO EURO collaborates with a range of public health 
stakeholders in the region and globally, to ensure that coordinated action is taken to develop and 
implement efficient health policies and to strengthen health systems. WHO EURO is made up of public 
health, scientific and technical experts who are based in the main office in Copenhagen, Denmark, in 
five out-posted centers and in 29 Country Offices. The Influenza and other Respiratory Pathogens (IRP) 
program team, within the Division of Communicable Diseases and the Environment, WHO EURO, works 
collaboratively with the U.S. CDC to strengthen influenza virological and epidemiological surveillance 
across the region, to support the early warning infrastructure that is necessary for Member States to meet 
International Health Regulation (2005) (IHR) core capacities, and to enhance pandemic preparedness, 
the clinical management of influenza, and emergency response.
The CDC and WHO EURO are currently in the fifth year of collaboration on the cooperative agreement 
Surveillance and Response to Avian and Pandemic Influenza by Regional Offices of the WHO. 
The principle objectives of this collaboration have been to implement a coordinated plan to improve 
laboratory capacity in Member State NICs, to establish and enhance sentinel outpatient surveillance 
for ILI and ARI, to establish sentinel surveillance for SARI hospitalizations, to enhance detection and 
response to outbreaks of novel influenza and other pathogens with pandemic potential in humans, 
and to support pandemic planning and containment efforts in the Region. With support from this 
collaboration and coordination with the European Centre for Disease Prevention and Control (ECDC), 
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WHO EURO also maintains a regional platform for influenza surveillance called EuroFlu (www.euroflu.
org), which represents the Region’s population of 883 million people. EuroFlu provides weekly updates 
on the Region’s influenza situation, contributes data and reports to the annual determination of vaccine 
content, and provides relevant and timely situational awareness on influenza to health professionals 
and the general public. The weekly bulletin and user platform are both available in Russian. WHO 
EURO also coordinates activities with CDC, especially with regard to CDC implementation of direct 
cooperative agreement relationships with Armenia, Georgia, Kazakhstan, Republic of Moldova, Romania 
and Ukraine.
Surveillance
The IRP program team’s surveillance mission is focused on enhancing traditional virological and 
epidemiological surveillance, establishing new monitoring systems for severe influenza, and working 
directly and continuously with Member States to use surveillance data to estimate the burden of 
influenza and to inform influenza prevention and control programs.  
Key Surveillance Activities
•	 WHO EURO hosted the annual influenza surveillance meeting for WHO European Regional 
Member States in Brasov, Romania in September 2010. The Member States reviewed surveillance 
data, shared experiences from the 2009-2010 season, and set surveillance priorities for the 
upcoming year, including strengthening systems to routinely monitor severe influenza.  
•	 Surveillance data reported to the EuroFlu platform were comprehensively analyzed and an 
overview of the 2009-2010 pandemic season was created, detailing the timing and progression 
of the influenza season, the intensity of influenza activity in relation to historical data, risk 
factors from data on severe cases reported to EuroFlu, characteristics of circulating viruses, and 
surveillance priorities for the upcoming year. A report of these analyses was released on the 
WHO EURO public web site. 
•	 An evaluation of the EuroFlu weekly influenza bulletin was undertaken. All respondents were 
very satisfied (47%) or satisfied (53%) with the overall content of the bulletin. Suggestions to 
improve the bulletin included more information on vaccines, inclusion other respiratory viruses, 
more information on severe disease, and simplification of virological data presentation. The 
results of the evaluation were released on the WHO EURO public web site, and have directly 
informed EuroFlu work priorities for the current fiscal year. 
•	 The EuroFlu platform was expanded to monitor and report surveillance data for sentinel SARI 
surveillance.
•	 Throughout the 2009-2010 pandemic influenza season an average of 46 Member States in the 
WHO European Region contributed weekly data to the EuroFlu regional surveillance platform. 
Automatic data transfers were established between EuroFlu and the Tessy surveillance platform 
at the ECDC as well as with FluID, the platform that is being developed by the Global Influenza 
Programme at WHO Headquarters in Geneva.
•	 IRP staff undertook multiple missions to Member States, including visits to Romania, the Russian 
Federation, Serbia, Tajikistan, Turkey, and Ukraine, in order to enhance national virological and 
epidemiological surveillance. 
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Laboratory
The IRP currently implements multiple activities to support and strengthen influenza laboratory capacity 
throughout the Region. These activities include undertaking missions and training activities to ensure 
that existing NICs expand and improve upon current molecular and virological diagnostic capacities, 
implement laboratory quality programmes (including ongoing participation in WHO EQAP), and adhere 
to international biosafety and biosecurity practices. There are ten Member States in the Region that do 
not have a WHO-recognized NIC. WHO EURO coordinates with the WHO Global Influenza Program 
when assessing whether national influenza laboratories are in compliance with WHO terms of reference 
and if they are eligible to become WHO-recognized NICs. The IRP program team works to better 
ensure that international transport of influenza specimens within the WHO European Region adheres to 
international safety standards, and one staff of the IRP is a certified trainer in the shipment of infectious 
substances. Finally, the IRP works closely with the WHO Lyon Office to enhance regional laboratory 
capacity to meet IHR core capacity and early warning needs.
Key Laboratory Activities
•	 A document describing the process of how NICs obtain recognition by WHO has been 
published. It includes the WHO/Europe Laboratory Assessment Tool (LAT) for NIC. A pilot was 
performed in Malta in July, 2009, and the results were communicated to the network during the 
Annual Meeting in Brasov, Romania, September, 2009.  
•	 The WHO CC London continued to support WHO EURO activities. Staff from several NICs were 
trained for a period of two weeks at the WHO CC London in a range of techniques. Between 
January 2009 and December 2010, at least 145 shipments of influenza specimens and viruses 
from at least 25 countries were performed using the Shipment Fund Project with support from 
WHO EURO. Results from analyses were fed back to the laboratories and it was ensured that 
the data were submitted to EuroFlu. The WHO CC London has been part of the EuroFlu bulletin 
team since early 2009 and provides advice on the virological components of the EuroFlu 
platform.
•	 The IRP continued to support the Cantacuzino Institute in Romania as a sub-regional influenza 
reference center for southeastern European countries. The NIC Cantacuzino Institute continues 
to support the growth and autonomy of national laboratories in Albania and Republic of 
Moldova as their own sentinel surveillance systems grow, and report data to the EuroFlu 
surveillance platform. 
•	 A curriculum for laboratory management in relation to the establishment of core capacities 
requirements detailed in the IHR was developed by WHO in collaboration with CDC and the 
Clinical and Laboratory Standards Institute. 
•	 NICs throughout the region were supported in their participation in a global EQA Program for 
the molecular diagnosis of influenza A (H5N1, seasonal influenza H3N2 and H1N1, influenza B, 
and 2009 H1N1). Fifty-two laboratories in 43 Member States participated.
Preparedness
The IRP continues to review the experience of the 2009-2010 influenza season to improve local 
preparedness and response not only to influenza, but to other threats as well.
Key Preparedness Activities
•	 Between April and July, 2010, IRP staff completed visits to seven countries (Armenia, Bosnia 
and Herzegovina, Denmark, Germany, Portugal, Switzerland and Uzbekistan) and interviewed 
stakeholder groups from the national, regional and local level in each country in order to 
evaluate how pandemic preparedness aided the response to the 2009 H1N1 pandemic. In 
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October 2010, countries participating in the evaluation attended a workshop to discuss findings 
and future WHO activities and guidance. This resulted in a set of recommendations for good 
practice in pandemic planning, which has been published on the WHO EURO website.
•	 Drawing on lessons learned, WHO EURO has developed a framework and a tool for countries 
to perform their own national evaluation of the pandemic response.
2009 H1N1 Activities, FY 2010
•	 The WHO/IRP response to the pandemic involved activities in surveillance and reporting, 
laboratory capacity support, clinical support, pandemic vaccine deployment and outbreak 
response. The EuroFlu platform was rapidly modified to include reporting on influenza activity 
due to the 2009 H1N1 virus.
•	 Two workshops for pandemic vaccine deployment covering all 53 Member States were held in 
2009. 
•	 WHO EURO coordinated pandemic communications with WHO Country Offices, European 
Commission, the ECDC, and other partners.
•	 Throughout the 2009-2010 pandemic influenza season, the IRP in coordination with CDC-
Atlanta assured that needed diagnostic kits remained available to NICs in the region. Using the 
WHO Shipment Fund Project, from September, 2009, to April, 2010, 26 Member States made 43 
shipments to WHO CCs.
•	 IRP and CDC staff collaborated with MOH officials during the pandemic response in 
Ukraine.  
•	 Throughout the 2009-2010 pandemic season, IRP convened video conferences to share best 
practices in influenza clinical management among critical care doctors. These were undertaken 
in Russian and English. 
•	 A survey on seasonal vaccine use in the Region is currently ongoing.
Other Notable Achievements in FY 2010
•	 WHO EURO released recommendations for influenza vaccination during the 2010/2011 winter 
season. The recommendations provide advice to Member States about specific risk groups to be 
targeted for vaccination, the influenza viruses to be included in vaccine, and vaccine safety.
•	 WHO EURO, in collaboration with the Vaccine European New Integrated Collaboration Effort 
(VENICE) project and the ECDC, issued a survey on pandemic vaccine deployment in selected 
WHO Regional Member States. All 29 eligible countries responded to the survey. The reported 
vaccination coverage varied across countries from 0.4% to 59% for the entire population (n=22); 
2.6% to 68% for health care workers (n=12); 0% to 58% for pregnant women (n=11); 0.2% to 
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Armenia
•	Capital: Yerevan 
•	Area: 29,743 sq km 
•	Population: 2,967,975 ( July 2011 est.)
•	Age Structure: 0-14 years: 17.6% (male 279,304/female 
242,621); 15-64 years: 72.4% (male 1,006,312/female 
1,141,430); 65 years and over: 10.1% (male 112,947/
female 185,361) (2011 est.)
•	Life Expectancy at Birth: Total population: 73.23 years; 
male: 69.59 years/female: 77.31 years (2011 est.)
•	Infant Mortality Rate: total: 18.85 deaths/1,000 live 
births; male: 23.38 deaths/1,000 live births; female: 13.75 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 99.4%; male: 99.7%; 
female: 99.2% (2001 census)
•	GDP: $17.27 billion (2010 est.)
•	GDP per Capita: $5,800 (2010 est.)
U.S. CDC Direct Country Support
Armenia was funded under the cooperative agreement Surveillance and Response to Avian and 
Pandemic Influenza in 2006 to enhance and strengthen the epidemiological and laboratory capacity 
for influenza surveillance in the country. This was enacted through the implementation of an influenza 
epidemiological surveillance scheme and national standards that were developed and approved by 
the MOH. Armenia has attained the appropriate laboratory and diagnostic capacity to rapidly detect 
suspected cases of avian and pandemic influenza, to run sentinel surveillance for seasonal influenza, and 
to operate laboratory testing according to the developed influenza sentinel surveillance scheme. This is 
the fifth year of funding.
Surveillance 
Sentinel surveillance has been established in three sites: Yerevan City, Lori Marz, and Syunik Marz. The 
sentinel site in Syunik Marz became operational during this fiscal year. The three sites were selected to 
represent geographical and sociocultural differences across Armenia.
Key Surveillance Activities
•	 Epidemiologists from Yerevan and Vanadzor City made supervisory visits to influenza sentinel 
sites in those cities. 
•	 Local experts and epidemiologists updated the influenza sentinel surveillance standard 
following WHO requirements and CDC recommendations. 
•	 A team of medical doctors, nurses, and epidemiologists were selected to participate in influenza 
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surveillance in Syunik Marz. Roles and responsibilities were developed by the MOH with input 
from local experts.
•	 National guidelines for infection control of influenza were developed by local experts according 
to WHO and CDC guidelines.
•	 Local specialists along with MOH staff developed the procedural bylaw and the statute for the 
code of work for sanitary-quarantine border posts (SQP), according to IHR requirements.   
•	 Internet connectivity was established for the National Influenza Team, the regional centers of 
the State Hygiene and Anti-Epidemic Inspectorate, PCR laboratories, and sanitary-quarantine 
border posts, for about 35 connections in total.
•	 Subscriptions to relevant periodicals and scientific magazines on epidemiology, public health, 
and virology were purchased for the library/training room established at the State Hygiene and 
Anti-Epidemic Inspectorate.
Laboratory
There are three laboratories that support the sentinel surveillance network: the national laboratory at 
CDC/Yerevan and the PCR laboratories in Lori and Syunik Marzes. Marz and MOH virologists familiar 
with national surveillance standards and laboratory diagnostics serve as focal points for the sentinel 
surveillance network. 
Key Laboratory Activities
•	 The MOH procured laboratory reagents, PPE, and other laboratory supplies and equipment for 
the implementation of influenza sentinel surveillance.
•	 CDC/Yerevan Laboratory and Lori Marz PCR laboratories were operational during the influenza 
season. Both laboratories tested 500 samples from sentinel sites in Yerevan City and Lori Marz. 
•	 CDC/Yerevan Laboratory participated in the CDC-Atlanta/APHL laboratory assessment review. 
Training
Armenia hosted the following trainings in FY2010:
•	 Influenza sentinel surveillance training for 36 medical doctors, nurses, and epidemiologists from 
Yerevan City and Lori and Syunik Marzes sentinel sites.
•	 Training on the updated influenza sentinel surveillance standard for 85 medical doctors, nurses, 
and epidemiologists from sentinel sites in Yerevan and Lori and Syunik Marzes.
2009 H1N1 Activities, FY 2010
The MOH established the operational committee for pandemic 2009 H1N1. Through this committee, all 
WHO recommendations were translated and disseminated to medical personnel. The national pandemic 
preparedness plan was activated when the pandemic was announced.
Key 2009 H1N1 Activities, 2010
•	 Procedures were enhanced in all sanitary-quarantine border posts for early detection of 
suspected patients and for early detection of cases of 2009 H1N1.
•	 Five infrared imagers were procured, installed and implemented at five sanitary border posts 
around the country, including at the border post at the Zvartnots International Airport.  
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•	 The MOH conducted an intensive media campaign in order to adequately inform the population 
about appropriate measures to prevent influenza and what to do if the symptoms occur (TV 
interviews, video, billboards, articles and web sites).
•	 Surveillance for early detection and treatment of ILI, ARI and pneumonia was enhanced, and 
daily pneumonia monitoring was included. 
•	 Appropriate preventive measures were implemented in special population groups, including 
school-age children, military, police, and prisoners.
Other Notable Achievements in FY 2010
•	 The regulation “Influenza and other Acute Respiratory Diseases Surveillance in Armenia” that 
standardizes the implementation of sentinel surveillance in Armenia was written and approved.
•	 Syunik Marz sentinel surveillance site became operational.
Special Influenza Projects
•	 With the support of the WHO Country Office, rapid response teams were assembled and 
trained. The training was conducted November 4 – 9, 2010, with participation from 94 experts 
from infectious disease hospitals, emergency care departments, and outpatient clinics (including 
epidemiologists, medical doctors, and managers).
•	 Armenia was selected for and participated in an evaluation of the response to pandemic 2009 
H1N1 by WHO EURO and University of Nottingham.
Principal Collaborators
Gurgen Dumanyan, MD, PhD 
Director of Health Project Implementation Unit 
State Agency, Ministry of Health
Yerevan, Armenia
Email: healthpiu@gmail.com
Artavazd Vanyan, MD, PhD 




Armen Hayrapetyan, MD, PhD
Project Executive Coordinator










WHO European Region (EUR) 95Armenia           
Republic of Georgia
•	Capital: T’bilisi 
•	Area: 69,700 sq km 
•	Population: 4,585,874 ( July 2011 est.)
•	Age Structure: 0-14 years: 15.6% (male 383,856/female 
333,617); 15-64 years: 68.3% (male 1,511,844/female 
1,620,727); 65 years and over: 16% (male 293,143/female 
442,687) (2011 est.)
•	Life Expectancy at Birth: total population: 77.12 years; 
male: 73.8 years; female: 80.82 years (2011 est.)
•	Infant Mortality Rate: total: 15.17 deaths/1,000 live 
births; male: 17.1 deaths/1,000 live births; female: 13.02 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 100%; male: 100%; 
female: 100% (2004 est.)
•	GDP: $22.32 billion (2010 est.)
•	GDP per Capita: $4,800 (2010 est.)
U.S. CDC Direct Country Support
This is the fifth year of the cooperative agreement with the Georgia National Center for Disease Control 
and Public Health (NCDC). The agreement began in 2006. Since the cooperative agreement began, the 
influenza surveillance system of the Republic of Georgia has been greatly strengthened, in both the 
epidemiology and laboratory components of the system.  
There are two goals for the fifth year of the project. The first goal is to ensure sufficient laboratory 
and diagnostic capacity for routine surveillance of ILI in order to provide rapid confirmation of 
cases of avian influenza in humans. The second goal is to ensure sufficient epidemiological capacity 
and infrastructure for rapid reporting of highly pathogenic avian influenza cases in humans and the 
early recognition of changes in the pattern of influenza virus during outbreaks. This includes the 
strengthening of the surveillance system for timely detection of seasonal and avian influenza outbreaks, 
and the rapid detection of an outbreak of pathogenic influenza strains and ongoing monitoring of 
seasonal strains. 
Surveillance
All activities conducted during FY 2009 became a platform for the 2009 H1N1 pandemic period in 
Georgia. Monitoring the existing surveillance system gave the NCDC the opportunity to assess the 
knowledge of health care providers regarding influenza, pandemic 2009 H1N1 influenza, infection 
control, and influenza treatment and prevention issues. This information helped the NCDC to prepare 
training materials on all aspects relevant to these issues.  
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Key Surveillance Activities
•	 Data received from sentinel sites and routine surveillance was monitored by the Project 
Management Unit. The sentinel surveillance system precisely reflected trends reported by the 
national routine surveillance system.
•	 NCDC staff monitored 140 health care facilities in ten regions to reveal gaps and challenges in 
the influenza surveillance system.
•	 No co-circulation of seasonal influenza viruses was detected from the time the pandemic was 
declared in Georgia through September 2010.
•	 Sentinel and non-sentinel sites were provided with all necessary equipment and supplies, 
including liquid nitrogen, for adequate storage and transportation of collected specimens. A 
project vehicle transported specimens from sentinel sites to NCDC. 
•	 The NCDC rapid response team, which was established in 2008, was active during the 
pandemic.
Laboratory
The National Influenza Lab (NIL) was established at NCDC in 2006. Laboratory capacity was 
strengthened as a result of staff training on RT-PCR testing, virus isolation, and hemagglutination 
inhibition, and the procurement of essential equipment and supplies.  
Key Laboratory Activities
•	 A total of 5,026 specimens were tested for influenza at NIL from October 2009 to October 2010; 
1,270 samples were found to be positive for 2009 H1N1 and seven were positive for influenza 
B. Fifty 2009 H1N1 positive samples from the 2009-2010 flu season were sent to the WHO CC 
London for virus isolation, sequencing and resistance screening.
•	 One specialist from NIL was sent to NIMR to be trained and to conduct full genome sequencing 
of Georgia influenza viruses. A total of seven isolates were sequenced. Phylogenetic analysis 
revealed two slightly distinguished influenza strains circulating in Georgia during the 2009-2010 
season. 
•	 NIL capacity for influenza surveillance was enhanced with the implementation of gene 
sequencing at the facility.
Preparedness 
A draft of a national preparedness plan was developed in 2006, and approved by the MOH in 2009. This 
plan was activated during the pandemic with great success. During the pandemic, antiviral medications 
like Tamiflu and Relenza were free and available for the whole population, with priority given to people 
with severe cases requiring hospitalization, persons with underlying conditions, and pregnant women. 
Training conducted for health care providers throughout the country ensured their readiness and 
preparedness for the pandemic situation. 
Key Preparedness Activities
•	 WHO provided the country with 26,000 doses of Tamiflu in 2009. 
•	 The Georgian Government procured 26,400 doses of Relenza in 2009. 
•	 Distribution and administration of antiviral drugs was performed in accordance with the 
national preparedness plan.
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•	 In July, 2010, WHO provided Georgia with 100,000 doses of 2009 H1N1 influenza vaccine; the 
vaccine was free and available for defined risk groups, such as health care providers throughout 
the country, the elderly in elder care homes, and orphans. 
Training
Georgia hosted the following training activities in 2010: 
•	 The 2009 H1N1 pandemic resulted in a change to planned training activities. Instead of training 
on avian influenza, infection control and PPE use, a workshop titled “H1N1 Influenza Pandemic: 
Results and Perspectives” was conducted in Batumi, the capital city of the Autonomic Republic 
of Adjara in September 2010. Representatives from NCDC, Adjara Ministry of Health, Adjara 
regional and rayonal centers of public health, and epidemiologists and infectious disease 
doctors from leading hospitals participated in the workshop. 
•	 During monitoring visits to sentinel surveillance sites, on-site surveillance training was 
conducted for epidemiologists responsible for patient registration and reporting in order to 
improve their skills and to strengthen the system.
The village of Gergeti, with Mt Kazbegi in the background, lies in the Greater Caucasus mountain range in the Mtskheta-Mtianeti region, northeastern Georgia.
2009 H1N1 Activities, FY 2010
The pandemic 2009 H1N1 situation confirmed the necessity and importance of having strong 
influenza surveillance in the country in order to detect cases as soon as possible, to detect in-country 
transmission of the pandemic influenza virus, and to monitor the transmission trends in the population.
98 Influenza Division International Activities  |  Fiscal Year 2010 Annual Report Republic of Georgia           
After WHO declared the 2009 H1N1 pandemic, the NCDC began weekly reporting to the MOH. Also, 
leaflets describing influenza symptoms and recommended actions to take in case of symptoms were 
distributed at the borders. These measures were instrumental in leading to the detection of the first 
case of pandemic 2009 H1N1 by the sentinel surveillance system, and gave the country time to activate 
pandemic preparedness measures. Testing for influenza B was limited during the peak of the pandemic 
since both PCR machines available at the laboratory were extremely busy. This critical situation with the 
equipment revealed the necessity of enhancing laboratory PCR capacity. Subsequently, a 96-well plate 
real-time PCR machine was purchased.  
Other Notable Achievements in FY 2010 
•	 Lead NCDC staff attended international conferences and meetings. They participated in the 
European Scientific Conference on Applied Infectious Disease Epidemiology in Stockholm, 
the Influenza Regional Symposium Pre-Meeting in Cairo, the 14th International Congress on 
Infectious Diseases in Miami, FL, the Black Sea meeting in Istanbul, and the International 
Conference on Emerging Infectious Diseases in Atlanta, Georgia to share surveillance and 
pandemic experiences from the Republic of Georgia. Staff submitted three poster presentations 
and one oral presentation.
•	 Sentinel surveillance proved effective for monitoring the pandemic situation and activating a 
rapid and adequate response.
•	 Huge interest from the media and timely information from NCDC was very helpful for allaying 
the general public’s fears.
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National Center for Disease Control and Public Health
Tbilisi, Georgia
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Kazakhstan
•	Capital: Astana 
•	Area: 2,724,900 sq km 
•	Population: 15,522,373 ( July 2011 est.)
•	Age Structure: 0-14 years: 21.6% (male 1,709,929/female 
1,637,132); 15-64 years: 71% (male 5,373,755/female 
5,654,461); 65 years and over: 7.4% (male 392,689/female 
754,407) (2011 est.)
•	Life Expectancy at Birth: Total population: 68.51 years; 
male: 63.24 years; female: 74.08 years (2011 est.)
•	Infant Mortality Rate: Total: 24.15 deaths/1,000 live 
births; male: 28.44 deaths/1,000 live births; female: 19.62 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 99.5%; male: 99.8%; 
female: 99.3% (1999 est.)
•	GDP: $197.7 billion (2010 est.)
•	GDP per Capita: $12,800 (2010 est.)
U.S. CDC Direct Country Support
Kazakhstan was funded in 2005 to develop an influenza surveillance network. This is the last year of the 
cooperative agreement. Routine surveillance of influenza and acute respiratory virus infection (ARVI) 
has existed in Kazakhstan for more than forty years. A network of seven sentinel surveillance sites has 
been established in-country, with additional support from USAID and Naval Medical Research Unit No. 3 
(NAMRU-3) for ILI and SARI surveillance.
Surveillance 
At each sentinel surveillance site, trained epidemiologists and clinicians collect epidemiological and 
clinical information, as well as nasal and pharyngeal swabs from a sample of patients who meet WHO 
ILI or SARI case definitions. Epidemiologic data is reported to the Republican Sanitary Epidemiologic 
Service for analysis. The sentinel surveillance system also provides information to make decisions on the 
initiation of community mitigation measures. 
Key Surveillance Activities
•	 All seven sites collect epidemiological and clinical information, which is then entered into an 
EPI-INFO database; data is analyzed and presentations are made at local meetings.
•	 During the 2009-2010 influenza season, the seven sentinel sites collected information from 517 
ILI patients and 500 SARI patients.
•	 The first cases of 2009 H1N1 influenza were detected in August, 2009, in the Astana City 
surveillance site by lab specialists trained under the project.
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Laboratory
Fourteen oblast (provincial) Sanitary and Surveillance (SES) laboratories and two city SES laboratories 
are capable of performing virus isolation, immunofluorescence microscopy, and serological 
investigations. Six oblasts and the NIC are capable of PCR (Rotogene) testing using either CDC/WHO-
provided kits or Russian Amplisense test kits.
Key Laboratory Activities
•	 Five oblast sentinel laboratories performed PCR testing of flu samples for the first time in 
FY2010; three labs at Taldy-Kurgan, Astana, and Petropavlovsk had positivity rates of 22%, 
17.2%, and 16% respectively.
•	 Positivity rates for SARI patients were higher: 26% among all SARI patients. The highest rates 
were from two laboratories, Taldy-Kurgan (45%) and Petropavlovsk (39.5%).
•	 The first 12 cases of the 2009 H1N1 were diagnosed by PCR in Astana sentinel laboratory and 
confirmed in the Kazak NIC.
•	 Two Rotorgene PCR machines were ordered for the sentinel sites at Uralsk and Taraz.
Preparedness
The national pandemic plan was developed collaboratively with input from local specialists and CDC/
Central Asia Regional Office. The Prime Minister signed the plan in August 2009. Tabletop exercises 
were performed with epidemiologists from all 14 oblasts and two cities in 2009. 
Key Preparedness Activities
A one-day meeting was held to address the approaching risk of a pandemic in November 2009. Four 
people each from 14 oblasts and two cities were invited; participants included epidemiologists, infection 
disease specialists, laboratorians, and journalists. 
Training
The following trainings were hosted or facilitated in Kazakhstan in 2010
•	 An Epi INFO training was held in February of 2010 for epidemiologists from each sentinel 
site, which helped them not only to perform better analysis of their own data but to better 
understand WHO ILI and SARI case definitions.
•	 A consultant from Interlabservice conducted onsite PCR training in five oblasts sentinel 
laboratories.
•	 Two lab specialists from the NIC were sent to Kiev for virus isolation training.
•	 Alla Mironenko from Kiev, Ukraine trained ten specialists from seven sentinel sites and three 
specialists from non-sentinel sites on virus isolation.
•	 Epi INFO training took place in October 2010 to analyze the data from the 2009-2010 season; 
two epidemiologists from each site attended. 
Other Notable Achievements in FY 2010 
Two abstracts were submitted and accepted for the Options for the Control of Influenza VII conference 
in Hong Kong, September 2010.
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Principal Collaborators
Ainagul Kuatbayeva, MD, PhD 
Chief Epidemiologist
The Scientific-Practical Center of Sanitary Epidemiological Expertise and Monitoring
Almaty, Kazakhstan
Email: kainagul@yahoo.com    
Elmira Utegenova, MD, PhD
Chief of Virology Laboratory




John Moran, MD, MPH (Atlanta-based since April 2010)
Influenza Advisor
CDC Central Asia Regional Office
Almaty, Kazakhstan
Email: jsm@cdc.gov
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GDD-Kazakhstan
The GDD (Global Disease Detection) Regional Center in Kazakhstan (GDD-Kazakhstan) was established 
in 2008 as an extension of the U.S. CDC’s presence and success through the Field Epidemiology Training 
Program (FETP), which began in 2003. CDC has collaborated with Ministries of Health in Central Asia 
since 1995 to better recognize and respond to serious public health threats. This alliance has improved 
laboratory capability for influenza and other communicable diseases, built surveillance systems for acute 
infectious respiratory illness, and strengthened health institutions at the national, regional, and local 
levels through training in field epidemiology and outbreak response.
Coverage
GDD-Kazakhstan covers five countries in Central Asia (Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, 
and Uzbekistan) and has relied heavily on the expertise of U.S. CDC’s Influenza Division to link 
surveillance and laboratory confirmation of new and emerging pathogens. 







In 2010, the GDD Regional Center in Kazakhstan increased their laboratory testing capacity by 10%. 
GDD-Kazakhstan trained seven FETP graduates and more than 200 participants in short-term regional 
and national trainings. GDD-Kazakhstan responded to 19 outbreaks, of which 63% were responded to in 
less than 24 hours. 
In-Country Field Staff
George Schmid, MD, MSc
Kazakhstan GDD Regional Center Director
Gulzhan Muratbayeva, MD, PhD
Epidemiologist, Influenza Program
Principal U.S. CDC Program Collaborations In-Country 
•	 Influenza Division International Program
•	 International Emerging Infections Program
•	 Field Epidemiology and Laboratory Training Program
•	 International Emergency Preparedness Program
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Kyrgyz Republic
•	Capital: Bishkek 
•	Area: 199,951 sq km 
•	Population: 5,587,443 ( July 2011 est.)
•	Age Structure: 0-14 years: 29.3% (male 834,024/female 
801,750); 15-64 years: 65.4% (male 1,790,534/female 
1,865,521); 65 years and over: 5.3% (male 114,200/female 
181,414) (2011 est.)
•	Life Expectancy at Birth: Total population: 70.04 years; 
male: 66.04 years; female: 74.24 years (2011 est.)
•	Infant Mortality Rate: Total: 29.27 deaths/1,000 live 
births; male: 34.01 deaths/1,000 live births; female: 24.28 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 98.7%; male: 99.3%; 
female: 98.1% (1999 census)
•	GDP: $11.85 billion (2010 est.)
•	GDP per Capita: $2,200 (2010 est.)
U.S. CDC Direct Country Support
The Kyrgyz Republic (Kyrgyzstan) MOH does not have a cooperative agreement with U.S. CDC, but 
works very closely with the Influenza Team at the Global Disease Detection Center in the CDC Central 
Asia Regional Office (CDC/CAR) based in Almaty, Kazakhstan. The MOH receives support through the 
CDC cooperative agreement with WHO EURO. The MOH epidemiology department has well-trained 
epidemiologists and laboratory specialists who work on influenza surveillance in Bishkek and Osh, the 
two major cities in the country.  
Surveillance
Kyrgyzstan has undertaken influenza sentinel surveillance activity since 2008. Surveillance started with 
the observation of SARI patients in two hospitals in Osh and in the largest infectious disease hospital 
in Bishkek. There are now two hospitals in each city that are working on SARI surveillance. In 2009, 
Kyrgyzstan started ILI surveillance of outpatients in two polyclinics in each of these cities. CDC/
CAR worked closely with the Kyrgyz sites to provide technical assistance and training to improve the 
knowledge and skills of epidemiology and laboratory specialists. The Kyrgyz NIC detected the 2009 
H1N1 in August 2009. Samples were collected from ILI and SARI patients and confirmed at CDC-Atlanta, 
Naval Medical Research Unit No. 3 (NAMRU-3) and a laboratory in Novosibirsk, Russia. 
Key Surveillance Activities
•	 Established laboratory surveillance was reconfigured to include epidemiological surveillance, 
which now allows for the calculation of ILI and SARI rates.
•	 Laboratory equipment and supplies were purchased and delivered to participating influenza 
sentinel surveillance sites.
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Laboratory
The laboratory specialists at the NIC in Kyrgyzstan are successfully doing PCR testing on influenza 
viruses and performing virus isolation. They regularly send their samples to CDC-Atlanta and/or 
NAMRU-3 for confirmation.
Key Laboratory Activities
•	 The NIC can now perform PCR and virus isolation. 
•	 Samples are regularly sent to WHO CC Atlanta and NAMRU-3. The rate of confirmation is 
approximately 95%.
•	 Plans are in progress to purchase a PCR machine for Bishkek City Sanitary and Epidemiologic 
Service so that the NIC will work only on confirmation of samples from two sub-regional 
laboratories.
Preparedness
CDC/CAR together with WHO worked very closely with epidemiologists from Department of State 
Sanitary and Surveillance (DSSS) on developing a national pandemic plan and the plan was approved by 
the Kyrgyz MOH in April 2009. The pandemic was announced in Kyrgyz Republic in August 2009. 
Key Preparedness Activities
•	 The national pandemic plan was activated during the pandemic and worked well in some 
areas; the plan will be reviewed and revised to make improvements based on the pandemic 
experience. 
•	 Training of epidemiologists and infectious disease specialists was held by local specialists in 
each region (county) of the country in 2009 for preparation for the pandemic.
Training
Kyrgyzstan hosted the following training activities in 2010:
•	 During the 2009-10 season, two on-the-job PCR trainings were performed at the Kyrgyz NIC, the 
Bishkek lab and the Osh sub-regional lab.
•	 Two lab specialists were sent by CDC/CAR to the WHO-recognized NIC in Kiev, Ukraine to be 
trained by Dr. Alla Mironenko on virus isolation.
•	 Analysis of 2009-10 flu season ILI and SARI data from both cities – Osh and Bishkek – was 
performed during Epi Info training held in August 2010. Presentations based on the analysis 
were prepared and presented at a meeting in Kyrgyzstan and at the annual WHO EURO flu 
meeting, which was held in September 2010 in Romania.
•	 Site trainings were held in Bishkek and Osh to restructure the surveillance system to include 
both laboratory and epidemiologic components. As a result of the site trainings, Kyrgyz 
doctors in the ILI and SARI sentinel sites are counting all ILI and SARI cases; they now take ILI 
specimens for lab investigation based on an established algorithm and collect specimens from 
SARI cases from all different age groups.
2009 H1N1 Activities, FY 2010
There was intensive work on ILI and SARI surveillance during the pandemic season of 2009-2010. 
Epidemiological data was collected and entered into the Epi Info database. Specimens were collected 
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from patients for laboratory analysis. The NIC received the diagnostic kit for the pandemic virus and 
successfully utilized the reagents for testing. The positive and unsubtypable samples were sent to CDC-
Atlanta for confirmation. 
Key 2009 H1N1 Activities, 2010
•	 The NIC was able to recognize 2009 H1N1; PCR results showed that all positive results were 
2009 H1N1 virus.
•	 All unsubtypable samples were also confirmed at CDC Atlanta as 2009 H1N1 viruses. 
Other Notable Achievements in FY 2010 
•	 Four poster presentations on 2009 H1N1 were presented in Atlanta in July 2010 at the meeting 
for international influenza partners and at the 2010 ICEID meeting.
•	 An oral presentation on the developing pandemic in Kyrgyzstan was presented at the WHO 
EURO Regional Meeting at Brasov, Romania in September 2010.
•	 WHO EURO epidemiologist, Pernille Jorgensen, travelled to Bishkek, Kyrgyzstan for a 
monitoring and evaluation visit.
•	 Three Kyrgyz epidemiologists started to work on upgrading their scientific degrees in order to 
specialize in influenza; CDC and WHO are supportive of these scientific activities.
Special Influenza Projects
•	 A Kyrgyz Field Training and Epidemiology (FETP) student worked on a special study 
investigating SARI surveillance in the Republican Infection Disease Hospital in Bishkek. The 
results of the study helped to understand how SARI surveillance was being conducted in the 
country, the areas of strengths and weaknesses, and recommendations for improvement. 
•	 A Kyrgyz FETP student performed an additional study in 2010 that resulted in the recognition 
of a problem with ARI in the Republican Infectious Disease Hospital in Bishkek, especially 
among children under one year of age. Therefore, two additional studies are currently ongoing 
in Bishkek: an investigation of influenza and other respiratory viruses among children under 
one year of age, and; an investigation of influenza and other respiratory viruses and diarrheal 









Chief of Virology Laboratory
Republican Sanitary Epidemiological Service
Bishkek, Kyrgyzstan
Email: kasymbekova@list.ru
Mark Witschi, MD, MPH
Medical Officer
WHO Country Office in Kyrgyzstan
Bishkek, Kyrgyzstan
Email: wim@euro.who.int 
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Republic of Moldova
•	Capital: Chisinau (Kishinev) 
•	Area: 33,851 sq km 
•	Population: 4,314,377 ( July 2011 est.)
•	Age Structure: 0-14 years: 15.5% (male 344,101/female 
325,995); 15-64 years: 74% (male 1,550,386/female 
1,643,108); 65 years and over: 10.4% (male 164,512/
female 286,275) (2011 est.)
•	Life Expectancy at Birth: Total population: 71.37 years; 
male: 67.68 years; female: 75.28 years (2011 est.)
•	Infant Mortality Rate: Total: 12.43 deaths/1,000 live 
births; male: 13.85 deaths/1,000 live births; female: 10.92 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 99.1%; male: 99.7%; 
female: 98.6% (2005 est.)
•	GDP: $11.01 billion (2010 est.)
•	GDP per Capita: $2,500 (2010 est.)
U.S. CDC Direct Country Support
The cooperative agreement Enhancing Pandemic Preparedness and Response Capacity in the 
Republic of Moldova began in August 2009. FY2010 was the second year of funding through the 
agreement. The Moldovan MOH is working with U.S. CDC under this agreement to strengthen human 
and infrastructure capacities for pandemic preparedness, surveillance, monitoring and early response, 
communication, and infection control. 
Cooperative agreement activities were implemented by national counterparts from the ministries of 
agriculture, information, education, internal affairs, and trade and tourism, in close collaboration with 
WHO Regional and Country Offices, and other international partners such as the World Bank and 
UNICEF.  
Surveillance
In 2006 the Republic of Moldova implemented hospital-based surveillance in nine sentinel sites, where 
data was collected on ARI, ILI, and SARI. National counterparts began to update the documents for 
implementing the integration of laboratory-based surveillance in accordance with recommendations 
made by CDC on a site visit in May, 2010. The MOH plans to start laboratory-based surveillance in five 
sites within the CDC cooperative agreement in 2011. The NIC publishes regular surveillance reports 
regarding epidemiological and laboratory data and reports weekly information through WHO EuroFlu 
network. 
WHO European Region (EUR) 107Republic of Moldova           
Key Surveillance Activities
•	 Guidelines for data collection in the early-warning networks were adapted to international case 
definitions.
•	 Guidelines for sample shipment from the sentinel sites to the National Viral Laboratory (NVL) 
were developed.
•	 Plans for implementing laboratory-based sentinel-site surveillance are in progress.
•	 Five sites were chosen to participate in integrating hospital and laboratory-based surveillance.
Laboratory 
The NVL for seasonal influenza was renovated for BSL-2 and BSL-2+ capabilities with the financial 
support of a World Bank project. The laboratory was equipped with new equipment to support these 
levels of influenza testing. Experts from CDC and WHO assessed laboratory capacity, provided some 
recommendations for improvement, and provided assistance to the national counterparts in the NVL in 
their efforts to become a NIC. The NVL uses PCR and virological assay diagnostic techniques.   
Key Laboratory Activities
•	 Standard operating procedures were developed for the shipment of samples from sentinel sites 
to the NVL.
•	 Consumables and reagents for diagnosis of SARI were procured.
•	 Hardware for the reporting of results from the influenza laboratory network at the national level 
to WHO and other international partners was purchased.
Preparedness
The 2009 H1N1 influenza pandemic revealed challenges and gaps in the National Pandemic 
Preparedness Plan (NPPP) in 2009. Intersectoral interaction, coordination and communication proved 
to be weaker than expected, and public and private sector organizations and essential services providers 
were not sufficiently engaged in pandemic preparedness and response. A NPPP working group is in the 
process of updating the plan to ensure a high-level political commitment and involvement by the whole 
of society.
Key Preparedness Activities
•	 An intersectoral working group was established to review and update the NPPP.
•	 The existing legal framework for pandemic preparedness and sentinel surveillance was adjusted 
based on the recommendations of the NPPP working group and international experts: 1) case 
definition guidelines and clinical management protocols were elaborated; 2) a set of documents 
related to preventive measures was issued; and 3) the process of updating documents for 
implementing laboratory-based sentinel surveillance was initiated.
Training
The Republic of Moldova hosted the following training activities in 2010:
•	 A workshop on data collection and analysis of ARI, ILI and SARI data from the sentinel sites, for 
50 participants.
•	 A series of training courses on the surveillance of influenza and pandemic response, for 100 
people. 
108 Influenza Division International Activities  |  Fiscal Year 2010 Annual Report Republic of Moldova           
•	 A workshop on strengthening the informational system for epidemiological alert and sentinel-
based surveillance, for 30 participants.
•	 Regional seminars in the following topics, for 120 participants: 
 ˏ Improvement of sample collection by ensuring the shipment to the National Viral 
Respiratory Lab. 
 ˏ Improvement of the process of information collection for SARI and/or severe respiratory 
disease based on a standard case definition.
 ˏ Strengthening the reporting system of SARI and/or severe respiratory illness by improving 
the process of preparing and providing regular weekly reports at the national and 
international levels.
 ˏ Improvements of the storage condition of original clinical materials to ensure cold chain 
condition was conducted for epidemiologists, laboratory staffs, and clinicians.
2009 H1N1 Activities, FY 2010
The MOH focal point for International Health Regulations (IHR) notified WHO of the number of 
confirmed cases and deaths due to 2009 H1N1.
Key 2009 H1N1 Activities
•	 During the 2009 influenza season, 21,904 suspect influenza cases were reported to the MOH; 
the NVL confirmed 2,590 2009 H1N1 cases.
•	 During the 2010 pandemic season, 14,091 suspect influenza cases were reported to the MOH, 
with 143 lab-confirmed 2009 H1N1 cases. 
•	 Cooperative agreement project staff acquired 2009 H1N1 and seasonal influenza test kits from 
U.S. CDC.
•	 Project staff and local experts provided technical assistance in strengthening the surveillance 
and laboratory capacity.
•	 Project staff, with input from partners, developed guidelines for notifying, investigating and 
treating cases of 2009 H1N1.
Other Notable Achievements in FY 2010
•	 The NVL participated in the WHO EQAP for the detection of influenza virus subtypes A and B.
•	 More than 200 clinical samples were confirmed by the WHO CC London. The WHO Shipment 
Funds Project covered the transportation cost.
Special Influenza Projects
The Avian Influenza Control and Human Pandemic Preparedness and Response (AIHP) project financed 
by World Bank started in Moldova in 2006. The project is a part of the Global Program for Avian 
Influenza Control and Human Pandemic Preparedness and Response (GPAI). Laboratory staff were 
trained in influenza surveillance methods, infection control, clinical management of patients, pandemic 
response, sample collection, biosafety measures, and virus isolation. An intensive care unit was built and 
equipped with specialized medical equipment and furniture.
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Principal Collaborators 
Radu Cojocaru, MD, PhD 
Director, National Viral Laboratory
National Centre for Public Health 
Chisinau, Moldova 
Email: radu_cojocaru@hotmail.com or rcojocaru@cnsp.md   
Angelina Ursu, MD 
Executive Coordinator 
Avian Influenza Control and Human Pandemic Preparedness and Response 
National Centre for Public Health 
Chisinau, Moldova 
Email: cphm_md@yahoo.com
Ion Bahnarel, MD, PhD
General Director 
National Centre for Public Health 
Chisinau, Moldova 
Email: ibahnarel@cnsp.md
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Romania
•	Capital: Bucharest 
•	Area: 238,391 sq km 
•	Population: 21,904,551 ( July 2011 est.)
•	Age Structure: 0-14 years: 14.8% (male 1,667,894/female 
1,579,458); 15-64 years: 70.4% (male 7,684,514/female 
7,725,957); 65 years and over: 14.8% (male 1,314,132/
female 1,932,596) (2011 est.)
•	Life Expectancy at Birth: total population: 73.98 years; 
male: 70.5 years; female: 77.66 years (2011 est.)
•	Infant Mortality Rate: total: 11.02 deaths/1,000 live 
births; male: 12.44 deaths/1,000 live births; female: 9.52 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: total population: 97.3%; male: 98.4%; 
female: 96.3% (2002 census)
•	GDP: $253.3 billion (2010 est.)
•	GDP per Capita: $11,500 (2010 est.)
U.S. CDC Direct Country Support
Romania is supported in its efforts to enhance laboratory and surveillance capacity to detect and 
respond to avian, seasonal, and pandemic influenza through the CDC cooperative agreement with WHO 
EURO. The National Professional Officer (NPO) assigned to the WHO Country Office in Bucharest 
works collaboratively with officials from the MOH, the National Institute of Public Health (NIPH), and 
the National Institute for Research and Development in Microbiology and Immunology Cantacuzino 
(NIRDMI Cantacuzino) to facilitate the implementation of influenza activities. The NIPH is the designated 
NIC in Romania.
Surveillance
ILI and ARI sentinel surveillance is organized in 21 out of 42 districts of Romania. In each district there 
are 12 voluntary family doctors (general practitioners) and in the Bucharest municipality there are 30 
sentinel family doctors. The doctors swab ILI cases following a case definition and sampling algorithm. 
They report ILI and ARI cases on a weekly basis to the designated epidemiologist from the district 
public health department. The sentinel population for influenza surveillance is more than 2% of the 
country’s population, and the 285 sentinel physicians represent over 1% of the total number of family 
doctors of the country. Each sentinel district reports data to the National Public Health Institute (NPHI).
Key Surveillance Activities
•	 SARI surveillance began in ten Romanian hospitals in five districts in October 2009. SARI 
surveillance expanded to 26 hospitals in nine districts in October 2010.
•	 The hospital epidemiologists for nosocomial infections control accepted the responsibility for 
SARI surveillance at the designated sentinel surveillance sites.
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Laboratory
The NIRDMI Cantacuzino is the only laboratory that performs confirmatory ILI and SARI testing on 
suspected influenza case samples in Romania. During the 2009-2010 pandemic, approximately 13,200 
samples for ILI and approximately 360 samples for SARI were tested. Maximum laboratory testing 
capacity is about 200 samples per day. Four regional laboratories have been upgraded and at least two 
are performing RT-PCR.
Key Laboratory Activities
•	 NIRDMI Cantacuzino conducts molecular diagnostics, virus isolation, antigenic characterization, 
genetic and phenotypic assessment of antiviral sensitivity, and sequencing of influenza viruses.
•	 NIRDMI Cantacuzino provides both national and regional support for training, specimen testing/
confirmation, and quality control.
Preparedness
The national preparedness plan was revised in June 2009. The plan was reviewed and revised again in 
March 2010 to incorporate lessons learned during the pandemic.
Key Preparedness Activities
The national preparedness plan was updated in the following areas:
•	 clinical and laboratory management of cases (including intensive care).
•	 domestic pandemic vaccine production and distribution.
•	 antiviral therapy and antibiotic therapy of bacterial complication.
•	 non-pharmaceutical measures.
•	 communication.
•	 inter-sectorial intervention planning. 
Training
Romania hosted the following training activities in 2010:
•	 In June, epidemiologists from the National Center of Disease Control (NCDC)-NIPH, the 
MOH and NIRDMI Cantacuzino held two, one-day SARI sentinel surveillance trainings for 
epidemiologists from five districts and over 120 medical staff from 12 infectious diseases and 
pediatric hospitals.
•	 Epidemiologists from NCDC-NIPH and the MOH and virologists from NIRDMI Cantacuzino 
trained medical staff from 26 infectious diseases and pediatric hospitals and epidemiologists 
from nine districts selected for SARI sentinel surveillance. Sessions consisted of one day of 
on-site training in June 2010, and a one-day training session in September 2010, with over 60 
participants at each session.
•	 Epidemiologists from NCDC-NIPH and the MOH and virologists from NIRDMI Cantacuzino 
trained family doctors and epidemiologists on ILI and ARI in two sessions; the sessions were 
held in June and September of 2010 and each had over 200 participants.  
•	 Epidemiologists from NCDC-NIPH and the MOH and virologists from NIRDMI Cantacuzino 
visited the sentinel sites (primarily SARI sites) and conducted monitoring and evaluation.
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•	 Sentinel site family physicians and epidemiologists were trained on the topic of samples 
collection, transport and storage in June and September 2010.
•	 ILI molecular diagnostic and antigenic characterization training was conducted for eight 
participants from Republic of Moldova in June and September 2010.
•	 ILI molecular diagnostic training for ten participants from Romania and Republic of Moldova 
was conducted in September 2010.
Prahova county sentinel physicians attend training on influenza, acute respiratory infections and SARI surveillance.  Bucharest, Romania. 
2009 H1N1 Activities, FY 2010
In 2010, the NIRDMI Cantacuzino participated in ILI surveillance throughout Romania, and SARI 
surveillance from ten hospitals in five districts during the pandemic period. NIRDMI Cantacuzino 
continued to play an important role in supporting influenza surveillance regionally. 
Key 2009 H1N1 Activities, 2010
•	 NIC Cantacuzino supported Albania by testing ILI samples during the pandemic.
•	 The Republic of Moldova received support for antigenic typing and subtyping of isolates and 
training of specialists.
Other Notable Achievements in FY 2010 
•	 The NIC was involved in clinical trials (involving both adults and children) of pandemic vaccine 
manufactured in NIRDMI Cantacuzino.   
•	 Laboratory tests for immunogenicity and persistence of antibodies were conducted  
during the study.
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•	 NIC Cantacuzino participated in the training of family physicians, epidemiologists and 
laboratory specialists.
Special Influenza Projects
•	 NIRDMI Cantacuzino was the recipient of the WHO influenza vaccine production capacity 
building grant.
•	 NIC Cantacuzino participated in the European Multicenter project I-MOVE (2008-2009 and 2009-
2010) coordinated by EpiConcept and financed by the ECDC case-control study measuring the 




Influenza and other Respiratory Pathogens
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Ukraine
•	Capital: Kyiv (Kiev)
•	Area: 603,550 sq km 
•	Population: 45,134,707 ( July 2011 est.)
•	Age Structure: 0-14 years: 13.7% (male 3,186,606/female 
3,014,069); 15-64 years: 70.8% (male 15,282,749/female 
16,673,641); 65 years and over: 15.5% (male 2,294,777/
female 4,682,865) (2011 est.)
•	Life Expectancy at Birth: Total population: 68.58 years; 
male: 62.79 years; female: 74.75 years (2011 est.)
•	Infant Mortality Rate: Total: 8.54 deaths/1,000 live 
births; male: 10.71 deaths/1,000 live births; female: 6.23 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 99.4%; male: 99.7%; 
female: 99.2% (2001 census)
•	GDP: $306.3 billion (2010 est.)
•	GDP per Capita: $6,700 (2010 est.)
U.S. CDC Direct Country Support  
FY 2010 was the fifth year of the cooperative agreement Influenza Surveillance and Pandemic 
Preparedness in Ukraine. The U.S. CDC has provided funds to the Program for Appropriate Technology 
in Health (PATH) to assist the Ukraine MOH in its efforts to strengthen influenza surveillance and 
pandemic preparedness. 
Activities have been focused in the following areas: 
•	 Strengthening the NIC in Kiev.
•	 Establishing sentinel site virologic and epidemiologic surveillance for ILI and SARI  
from influenza. 
•	 Developing national guidelines for health services of Ukraine that outline planning and 
organization measures to combat pandemic influenza.
•	 Enhancing the nationwide early warning system and epidemiological capacity to detect and 
respond to human illness caused by 2009 H1N1 virus infections or infections from other 
respiratory pathogens with pandemic potential.
Surveillance    
MOH and PATH have established a fully functioning sentinel influenza surveillance system in Kiev, 
Odessa, Dnepropetrovsk and Khmelnitsky and developed a website to support electronic reporting, 
data analysis, presentation, and other aspects of the system. The sentinel surveillance network includes 
18 hospitals and polyclinics. Data findings suggest that in the 2009-2010 season, 27% of ILI and 39% of 
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SARI cases were caused by influenza, and 2009 H1N1 was responsible for 99% of the confirmed cases. 
Information on seasonal and pandemic influenza is routinely submitted to EuroFlu.
Key Surveillance Activities
The Ministry of Health and PATH coordinated the following activities:
•	 A fourth sentinel site (Khmelnitsky) was added to the surveillance system.
•	 NIC and MOH updated the national guidelines for sentinel surveillance in partnership with, 
WHO and CDC. 
•	 NIC added new features and analyses to the electronic data system. These include: incidence by 
age group; risk factors; efficiency of laboratory testing by method and by specimen collection 
day; timeliness of data reporting and lists of missing test results.
•	 Reporting timeliness and data quality were improved at all sites.
•	 The surveillance system was evaluated to identify areas for priority attention in the next year.    
Laboratory      
Funding from the partnership between CDC, PATH and the Ukraine MOH continued to support the 
NIC in Kiev and four regional virologic laboratories in the sentinel sites with equipment, reagents, 
consumables and other items to maintain optimal functionality of the labs. These laboratories can 
perform PCR and virus isolation in cell culture. Samples from Ukraine are routinely submitted to the 
WHO CC Atlanta and the WHO CC London.
Key Laboratory Activities
•	 Continued supporting labs with equipment and consumables. 
•	 Continued participation in the WHO GISN.
•	 Trained sentinel site virologists in influenza virus isolation and identification, and real-time  
PCR investigation.
•	 Tested 2,400 SARI and ILI cases in the sentinel sites during the 2009-2010 season: 36% were 
2009 H1N1 positive.
Preparedness
The partnership on pandemic preparedness between the Ukraine MOH, PATH, CDC, and WHO has 
resulted in the development of the national guidelines for health services of Ukraine that outlines 
planning and organization measures to combat pandemic influenza. The guidelines were approved by 
the academic council of the Ukrainian Institute of Epidemiology and Infectious Diseases and endorsed 
by WHO EURO. The guidelines were used to develop pandemic preparedness simulation exercises in 
Ukraine, Kazakhstan and the Kyrgyz Republic, and to guide the MOH pandemic 2009 H1N1 influenza 
response activities during the 2009-2010 pandemic surge.      
Key Preparedness Activities
•	 Assessed national capabilities for pandemic preparedness and response together with the CDC 
using the CDC monitoring and evaluation tool to optimize planning. 
•	 Carried out pandemic preparedness exercises in Ukraine and two countries in the region. 
•	 The guidelines were activated and steered the MOH pandemic preparedness and response 
activities during the pandemic.
116 Influenza Division International Activities  |  Fiscal Year 2010 Annual Report Ukraine           
Training
PATH continues to provide technical assistance and training to ensure the functioning of the sentinel 
surveillance system, quality of the surveillance data, prompt data analysis, and integration of the 
information into preparedness and response activities. In 2010, the following trainings were organized  
in Ukraine:  
•	 Training of four regional Sanitary Epidemiological Service (SES) virologists in influenza virus 
isolation and identification at the NIC. 
•	 Eight training workshops for 120 health staff involved in sentinel surveillance work in  
all four sites.
•	 Two pandemic preparedness exercises for members of regional committees.  
•	 Representatives of the NIC and PATH also participated in the CDC and WHO influenza 
surveillance and influenza burden of disease meetings in Cairo, Egypt, Atlanta, Georgia, Brasov, 
Romania, and Tunis, Tunisia.  
2009 H1N1 Activities, FY 2010
•	 MOH, NIC, SES, and PATH staff were trained through 
the partnership to provide technical guidance to health 
workers nationwide.
•	 Influenza pandemic preparedness and influenza 
outbreak response guidelines developed in partnership 
with PATH and CDC were used to guide response 
activities in the country. 
•	 Laboratory equipment and consumables purchased 
through the partnership were used to detect 2009 H1N1 
cases.
•	 The sentinel surveillance system operating in four sites 
complemented routine ARI surveillance designed to 
monitor the 2009 pandemic. 
•	 The partners analyzed lessons learned during the 
pandemic to optimize future planning.  
Other Notable Achievements in FY 2010 
•	 The sentinel SARI and ILI surveillance system is now fully operational in all sites.
•	 CDC-led assessment of core national capabilities for pandemic influenza preparedness and 
response demonstrated significant improvement in country planning and pandemic response in 
the past two years.
•	 Lessons learned from developing a new sentinel influenza surveillance system in Ukraine and 
results of the above assessment were presented by the NIC, PATH and CDC at the Options for 
the Control of Influenza VII conference in Hong Kong; three abstracts for poster presentations 
were accepted.
•	 The partners began developing a sustainability plan to coordinate and address transitioning of 
the project. 
A view of St. Andrew’s Church constructed 1747-1754, Kiev, Ukraine.
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WHO Region of the Americas (AMR) 
Overview
Currently there are five bilateral influenza cooperative agreements in the Region of the Americas. These 
agreements with Ministries of Health (MOHs) or institutions designated by the MOHs work with PAHO 
and U.S. CDC to build capacity to routinely identify and respond to seasonal and novel influenza strains 
across the Americas.  






In addition, CDC supports the WHO Pan-America Health Office (PAHO) via a cooperative agreement. 
CDC also supports activities with the Center for Central America and Panama program (CDC-CAP) at 
the CDC GDD (Global Disease Detection) site in Guatemala. These activities support programs in eight 
Central American/Caribbean countries including Belize, Guatemala, El Salvador, Honduras, Nicaragua, 
Costa Rica, Panama, and Dominican Republic.
CDC staff visit an influenza sentinel surveillance site based at the San Jeronimo Health Center in the city of Cusco, Southeastern Peru. From left to right: Joel Montgomery, 
Ann Moen, Marc-Alain Widdowson, and Tomas Rodriguez.
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The core activities of our bilateral agreements and technical assistance are:
•	 To build sustainable national capacity to identify and respond to seasonal influenza,  
pandemic influenza and other emerging diseases in accordance with International Health 
Regulations (2005).
•	 To make routine contributions of surveillance and virology data to the WHO Global Influenza 
Surveillance Network (GISN).
•	 To increase the geographic reach of WHO GISN.
•	 To provide earlier access to critical virus isolates from humans and birds for the WHO GISN.
•	 To increase the numbers of shipments and influenza isolates provided by local influenza labs 
for analysis by WHO Collaborating Centers.
•	 To develop sustainable epidemiologic and virologic surveillance systems for severe influenza in 
order to gain understanding of the disease and economic burden caused by influenza and other 
respiratory viruses. 
•	 To sustain and leverage quality sentinel surveillance and study cohorts to explore the potential 
cost-effectiveness of expanding vaccination and incorporating new delivery mechanisms, 
formulations, and novel influenza vaccines in the PAHO Region.
In additional to our bi-lateral work, we also partner with the Naval Medical Research Unit No. 6 
(NAMRU-6) in Lima, Peru, to jointly support South American countries that are starting influenza 
surveillance.  
Influenza Division Contacts 
Atlanta 
Tomas Rodriguez, MA 
Public Health Advisor
Extramural Program - WHO Pan American Region
Influenza Division/NCIRD/CDC 
Email: trr0@cdc.gov 
Eduardo Azziz-Baumgartner, MD, MPH (Atlanta-based since Aug 2010)
Medical Officer Epidemiologist
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Pan American Health Organization 
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Influenza Capacity Building Cooperative Agreement




U.S. CDC Direct Country Support
The Pan American Health Organization (PAHO) promotes the development of National Influenza 
Pandemic Preparedness Plans (NIPPs) and supports all Member States in this effort. The Generic 
Protocol for Influenza Surveillance (GPIS) was developed by the U.S. CDC and PAHO to standardize 
influenza surveillance throughout the Region. It has been a model for other WHO Regions. In addition 
to the development of NIPPPs, the goal of the technical cooperation is to strengthen countries’ core 
capacities for surveillance and response while preparing for disease-specific requirements, as mandated 
by the WHO in their International Health Regulations (2005). 
In late April 2009, a novel influenza A virus capable of infecting humans was detected in North 
America. This particular H1N1 strain had not circulated previously in humans and demonstrated high 
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person-to-person transmissibility. From its initial focus in North America, the virus spread  
worldwide, resulting, by the end of the pandemic, in 18,449 deaths, of which 8,557 were in the  
Region of the Americas. 
The emergence and circulation of this novel virus in the Region of the Americas resulted in a shift 
in technical cooperation from preparedness to response and mitigation.  The pandemic allowed for 
countries and PAHO to test the systems that had been implemented for preparedness, surveillance, and 
response, over the prior years and identify gaps. 
There were several key lessons learned during the pandemic— that surveillance of severe acute 
respiratory diseases must be strengthened, that laboratory staff need the technical skills to provide basic 
analysis and interpretation of their laboratory data, and that alternate sources of mortality data, such as 
death certificates, can provide the much needed regional-estimates of influenza disease burden. 
Surveillance
Considering these lessons learned during the 2009 pandemic, PAHO directed its technical cooperation 
to address these gaps. First, from the surveillance standpoint, it was determined that there needed to 
be increased importance given to the detection of unusual health events and surveillance of severe 
respiratory disease cases. This was due to the fact that these cases, in a hospital setting, are easier to 
capture, that they are smaller in number than the milder ambulatory cases, and that during a pandemic, 
information about severe cases is of paramount importance for making decisions about response. The 
first step taken was to draft a guideline that utilized as its backbone, the PAHO-CDC Generic Protocol 
for Influenza Surveillance, but focused on strengthening SARI surveillance and expanding it beyond 
selected sentinel sites. This protocol was entitled, PAHO Protocol for Nationwide Enhanced SARI 
Surveillance. Next, the tasks of sensitizing the countries and implementing the protocol proved to 
be relatively easy, as countries had identified this lack of data on severe cases to be important and 
were eager to improve their SARI surveillance. In 2010, this protocol was implemented in selected 
Caribbean countries, through technical cooperation with CAREC and also in the Southern Cone in 
Uruguay. Key to the success of this strategy is an information system that allows for easy data capture 
and dissemination and minimizes double data entry. To that end, PAHO has been working with an 
information systems engineer to develop a system that allows for data entry, linkage between hospital 
(i.e. clinical-epidemiologic) and laboratory (i.e. virologic) data, and generates automated data outputs. 
This information system was implemented in Uruguay in 2010 and is currently being modified for 
use in other countries. Finally, in terms of long-term sustainability of this SARI surveillance, it was 
important to consider how to integrate this surveillance with other surveillance programs. To that end, 
given that many hospitals are currently building programs of health-care associated infection (HAI) 
surveillance and mandatory reportable disease surveillance, it made sense to consider incorporating 
SARI surveillance as part of these activities and to raise awareness among all health care workers about 
the need to report any unusual health event that might signal nosocomial spread, an outbreak ongoing 
in the surrounding community/catchment area of the facility, (an) imported case(s) and that deserve 
immediate investigation and implementation of control measures. This concept is being developed by 
promoting the idea that hospitals should develop departments of epidemiology and surveillance, under 
which all of these activities would fall. 
Key Surveillance Activities 
•	 Guidelines for detection, assessment, and reporting of unusual health events have been 
developed and disseminated in 14 countries in the Region, and implemented in 11 of them. 
•	 Online information system to monitor SARI cases in 100% of hospitals with intensive care units 
and 80% of hospitals overall in Uruguay.  
(https://trantor.msp.gub.uy/epidemiologia/servlet/iraggrafmenu)
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•	 SARI surveillance established in the national hospital in Barbados, Dominica, Jamaica, St Lucia, 
St Vincent and the Grenadines, Trinidad and Tobago and weekly laboratory and clinical data are 
being provided to CAREC/PAHO.
Laboratory
From the laboratory standpoint, considering the challenges faced during the pandemic, technical 
cooperation was directed to improve the capacity in the laboratory to process specimens for real-
time RT-PCR, through the purchase of automated extractors and vacuum extractors. Additionally, as 
laboratory staff were not equipped to analyze and disseminate their data, PAHO, in collaboration with 
the University of North Carolina at Chapel Hill, developed a 2.5-day training course on epidemiologic 
analyses of influenza laboratory data. More than 45 persons, representing all PAHO sub-regions, were 
trained as part of this course, and the course is currently available online in both English and Spanish. 
Additionally, PAHO has continued to support the strengthening of laboratory capacity for the diagnosis 
of influenza and other respiratory viruses, including through the limited decentralization of real-time RT- 
PCR for influenza, through refresher courses for real-time RT-PCR and immunofluorescence, and through 
participation in the WHO EQAP. Through these activities, PAHO has continued to work to strengthen the 
regional laboratory network, which now consists of 23 NICs in Latin America and the Caribbean. 
Key Laboratory Activities
•	 Developed a 2.5 day training course in collaboration with the University of North Carolina at 
Chapel Hill to train laboratory staff in the analysis and dissemination of influenza laboratory 
data.
 ˏ Course available online (http://cphp.sph.unc.edu/paho/precurso.html).
 ˏ Trained 50 persons from each of the four sub-regions.
•	 Fifteen Qiacubes purchased to automate the extraction procedure for real-time RT-PCR.
Preparedness
Due to the 2009 H1N1 pandemic, PAHO activated its Emergency Operation Center (EOC) in Washington, 
D.C., to coordinate activities and deploy rapid response teams into the Region. The EOC served as 
the point of contact for communication between technical areas and MOHs. PAHO has supported all 
countries’ efforts to create situation rooms and EOCs to centralize data and coordinate national actions. 
Key Preparedness Activities
•	 Rapid response missions were deployed to Bolivia, Nicaragua, Guatemala, Ecuador, Paraguay 
and Dominican Republic.
•	 PAHO developed education materials on infection control for the influenza pandemic and 
disseminated these to Spanish and English speaking countries.
•	 PAHO developed guidelines on epidemiological surveillance of health care-associated infections 
and provided these to all partner countries.
Training
PAHO hosted the following trainings in FY 2010:
•	 Three two-day training courses on epidemiologic analyses of laboratory data were held in 
Washington, D.C., for epidemiologists and laboratory staff from Central America, the Andean 
region, and the Southern Cone. In total, about 30 persons were trained. 
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•	 A two-day training course was held in the Caribbean to train epidemiologists and laboratory 
staff on epidemiologic analyses of laboratory data. In total, about 20 persons were trained. The 
course is available online in English and Spanish.
2009 H1N1 Activities, FY 2010
The emergence of 2009 H1N1 sparked a demand for direct support from the member countries. 
Technical cooperation has continued to promote integrated strategies of capacity building, planning 
tools, and simulation exercises.
Key 2009 H1N1 Activities
•	 As a way of supporting country messaging, consistency, and communication coordination, 
PAHO worked with the countries to implement knowledge, aptitude and practice studies. 
•	 Based on past 2009 H1N1 activities, PAHO has developed online risk communication courses in 
Spanish and English.
Special Influenza Projects 
•	 PAHO has supported all countries in the introduction of the pandemic influenza vaccine and 
has developed technical guidelines for the use of the pandemic vaccine. Twenty-two countries 
and territories received pandemic influenza vaccine and approximately 50 million doses were 
used.
•	 Another goal is to enhance development of technical and financial assistance to the Caribbean 
and Southern Cone countries in South America. These regions have epidemiology departments 
that are chronically under-staffed. 
Public Health Importance
•	 PAHO continues to be a leader in promoting the standardized improvements to influenza 
surveillance that are needed to better understand the transmission of influenza in the Region 
and to fulfill International Health Regulations 2005 requirements.
•	 PAHO is a critical partner in better understanding influenza vaccine utilization, coverage, and 
needs in the Region.
•	 CDC anticipates working closely with PAHO during the coming years to continue to streamline 
and standardize influenza surveillance and vaccination policies using evidenced-based data 
gathered in partnership with regional countries.
CDC Assignee
Rakhee Palekar, MD, MPH
CDC Medical Officer
Pan American Health Organization 
Washington, DC
Email: palekarr@paho.org or ggj1@cdc.gov
Principal Collaborators
Otavio de Oliva, MD, MPH
Influenza Coordinator
Communicable Disease Unit
Pan American Health Organization 
Washington, DC
Email: olinaota@paho.org
Mauricio Cerpa, MD, MPH
Influenza Surveillance Specialist
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Washington, DC
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Argentina
•	Capital: Buenos Aires
•	Area: 2,780,400 sq km 
•	Population: 41,769,726 ( July 2011 est.)
•	Age Structure: 0-14 years: 25.4% (male 5,429,488/female 
5,181,289); 15-64 years: 63.6% (male 13,253,468/female 
13,301,530); 65 years and over: 11% (male 1,897,144/
female 2,706,807) (2011 est.)
•	Life Expectancy at Birth: Total population: 76.95 years; 
male: 73.71 years; female: 80.36 years (2011 est.)
•	Infant Mortality Rate: Total: 10.81 deaths/1,000 live 
births; male: 12.08 deaths/1,000 live births; female: 9.48 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 97.2%; male: 97.2%; 
female: 97.2% (2001 census)
•	GDP: $596 billion (2010 est.)
•	GDP per Capita: $14,700 (2010 est.)
U.S. CDC Direct Country Support
Funded through a cooperative agreement by the U.S. CDC since September 2006, Argentina has 
strengthened its influenza surveillance system by systematically adding well-functioning sentinel 
surveillance sites in key provinces and developing an on-line surveillance reporting and analysis 
system. During 2010, CDC funding also supported a review of the epidemiology and laboratory network 
protocols. Based on this needs-assessment, CDC funds were used to purchase RT-PCR supplies and 
reagents for reference laboratories.
Argentina has three regional NICs, and its virologic surveillance network consists of over 60 laboratories 
in both public and private health care settings. Each NIC works with sentinel units located within local 
provincial health authorities to conduct virologic and epidemiologic surveillance. The NICs perform 
virus isolation with typing and subtyping of isolates and share virus isolates with the WHO Collaborating 
Center in Atlanta. 
Surveillance
The Argentina MOH adopted the CDC/Pan American Health Organization (PAHO) influenza surveillance 
generic protocol, which it helped to draft, as their template for surveillance throughout their provinces. 
Epidemiologic surveillance has improved with the implementation of the National Health Surveillance 
System. Currently Argentina has 29 sentinel sites (one per province) that provide information to the 
three NICs. Argentina also developed an internet database that provides instant notification of their 
influenza activity. These data are summarized weekly and disseminated to stakeholders. 
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Key Surveillance Activities 
•	 The MOH Epidemiology Directorate increased the number of sentinel sites collecting quality 
epidemiology and viral data from 19 to 29 sites to provide better geographic representation of 
viral activity throughout Argentina.
•	 The MOH Epidemiology Directorate improved their web management system for sentinel data 
collection, analyses and weekly dissemination to stakeholders.
•	 The MOH increased the number of joint collaborations with the Ministry of Agriculture. 
•	 The MOH has actively collaborated with local academic and provincial partners, PAHO, and 
CDC to better understand the clinical manifestations of 2009 H1N1, estimate the burden of 
seasonal and pandemic influenza disease, and evaluate the impact of the influenza vaccine 
program. These valuable lines of inquiry that leverage data collected by sophisticated 
surveillance systems have thus far yielded one manuscript that is currently in clearance and 
two that are in development. The findings of these investigations are anticipated to help guide 
national and regional influenza prevention. 
Laboratory
There are three NIC laboratories in Argentina. The main laboratory (Malbrán) is in Buenos Aires; the 
other two laboratories are in Mar del Plata (north) and Cordoba (south). The Malbrán laboratory receives 
specimens primarily from Buenos Aires where approximately one third of the country’s population 
resides. The laboratories in Cordoba and Mar del Plata primarily receive samples from neighboring 
provinces. There are 60 additional laboratories in the network that perform influenza testing, of which 
30 have PCR capability. 
Key Laboratory Activities
•	 During June 2010, Malbrán staff trained representatives from 12 laboratories on how to use their 
recently acquired PCR instrumentation.
•	 Argentina laboratory staff also participated in Panel 9 WHO Proficiency Testing Program quality 
assurance verifications.  
•	 NIC laboratory staff evaluated their protocols, data management, and reporting protocols, which 
helped to improve their processes and identify needed reagents, equipment and supplies.
Preparedness
The MOH established a specific pandemic influenza situation room and an influenza pandemic 
emergency operation center, which is equipped with desktop and notebook computers, and an LCD-TV 
to display and interpret large amounts of data. The emergency operating center serves as a contingency 
center to guide supply logistics of disposable PPE, pharmaceuticals (e.g. antivirals), and laboratories 
reagents and supplies.  
Key Preparedness Activities
•	 The MOH established an epidemiology expert advisory committee that provides input into their 
pandemic emergency plan.
•	 Surveillance reviews have increased the quality and geographic representativeness of 
epidemiology and virology data generated by sentinel sites throughout the country.
•	 Laboratory review and improvements have allowed the NICs to streamline processes, identify 
weaknesses in the reagent supply chain and increase the amount of data they are able to 
process for subsequent public health emergencies of international concern. 
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•	 Domestic investigations into clinical management, influenza burden, and vaccine program 
impact have provided the MOH and the PAHO office in Argentina with valuable insight about 
needed risk communication messages, prioritization of risk groups, and potential impact of 
interventions.
Training
The following trainings were held in Argentina in FY 2010:
•	 Argentina trained 24 provincial and local hospital health care providers on the latest influenza 
clinical management guidelines. 
•	 Argentina has developed a local communication training workshop to improve communication 
activities during any future pandemic among their 24 provinces. The workshops were 
developed based on lessons learned during the pandemic.
•	 NIC staff trained laboratory staff from 12 provincial laboratories on the use of RT-PCR.
2009 H1N1 Activities, FY 2010 
During FY 2010, among other activities, Argentina took some important steps with regard to better 
estimating the burden of influenza. The MOH developed a three-city study that took place in Santa 
Fe, Tucuman and Mar del Plata to determine the burden of seasonal influenza in order to help with 
prevention efforts. Specialized computer software to identify any respiratory illness causing deaths in 
hospitals was also developed by the MOH.   
A colorful example of the health communication materials that were distributed in Argentina during the 2009 H1N1 pandemic. 
Key 2009 H1N1 Activities, 2010
•	 With technical assistance from CDC’s Influenza Division, the MOH was able to develop a 
model concerning influenza-associated diseases. The model was used to estimate the burden of 
influenza-associated hospitalization and death by age group, sex and country region.
•	 Based on experience of the 2009 H1N1 pandemic, the laboratories structures were decentralized 
and strengthened.
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Other Notable Achievements in FY 2010 
•	 The MOH completed data collection in three key sentinel cities to investigate the burden of 
2009 H1N1. A manuscript to disseminate findings to the public health community has been 
drafted and is currently in circulation among co-investigators.
•	 The MOH and its academic partners have completed a thorough 2009 H1N1 decedent case 
series, which is currently in clearance and intended for peer review publication. 
•	 The MOH developed a model which capitalizes on quality mortality and laboratory-confirmed 
influenza surveillance to estimate the seasonal and pandemic influenza-associated mortality rate. 
A manuscript to disseminate findings to the public health community has been drafted and is 
currently in circulation among co-investigators. 
Public Health Importance
•	 Argentina continues to demonstrate leadership in the surveillance of influenza in South America. 
Argentina collaborates with PAHO and CDC to disseminate lessons learned about influenza 
surveillance, burden, and prevention in the region. 
Principal Collaborators
Echenique Horacio, MD 
Director of Epidemiology
Ministry of Health 
Buenos Aires, Argentina
Email:  horacioechenique@gmail.com
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Brazil
•	Capital: Brasilia
•	Area: 8,514,877 sq km 
•	Population: 203,429,773 ( July 2011 est.)
•	Age Structure: 0-14 years: 26.2% (male 27,219,651/female 
26,180,040); 15-64 years: 67% (male 67,524,642/female 
68,809,357); 65 years and over: 6.7% (male 5,796,433/
female 7,899,650) (2011 est.)
•	Life Expectancy at Birth: total population: 72.53 years; 
male: 68.97 years; female: 76.27 years (2011 est.)
•	Infant Mortality Rate: total: 21.17 deaths/1,000 live 
births; male: 24.63 deaths/1,000 live births; female: 17.53 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: total population: 88.6%; male: 88.4%; 
female: 88.8% (2004 est.)
•	GDP: $2.194 trillion (2010 est.)
•	GDP per Capita: $10,900 (2010 est.)
U.S. CDC Direct Country Support 
Brazil launched its national influenza surveillance system in 2000. Brazil has had a cooperative 
agreement with the CDC since September 2006. In 2010, Brazil developed the fourth version of their 
influenza pandemic plan, which is based on the lessons learned from the 2009 H1N1 pandemic. 
Protocols were developed to deal with weaknesses that were discovered during the pandemic, such as 
specific protocols for actions at ports of entry (i.e. airports and borders) and for clinical management 
and enhanced influenza surveillance procedures. 
Surveillance
Brazil has a surveillance network comprised of 50 Centers on Strategic Information and Rapid Response 
Health (CIEVS). The Centers are spread throughout all the states of Brazil and in strategic cities. Their 
aim is to develop activities for crisis management and epidemic emergencies. Currently the MOH has 
two information systems for influenza, and both are online; the first influenza system, Sinan, is for 
hospitalization data and the second, Sivep-Gripe, is for sentinel influenza data.
Sentinel surveillance provider units collect clinical samples from suspect cases for laboratory diagnosis 
and consolidate data from outpatients with ILI. Surveillance is obtained from 63 units, and all states have 
surveillance for severe cases of influenza. Sivep-Gripe data are simultaneously available at all levels of 
the surveillance network.  
Key Surveillance Activities
The MOH developed the fourth influenza pandemic plan based on the 2009 H1N1 pandemic and 
included updated guidance for improving communication and coordination from the local level to the 
national level.
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•	 Brazil developed a routine structure for SARI surveillance.
•	 Protocols were developed for influenza surveillance at airports and in Brazilian border regions.
Laboratory
Brazil has three NICs: one each in Rio de Janeiro, Sao Paulo, and Para. There are 27 public health labs 
(LACEN) in all state capitals, which develop diagnosis for seasonal influenza by immunofluorescence, 
and then send their samples to regional NICs. 
Key Laboratory Activities
•	 Brazil’s NICs routinely isolate viruses, share samples with other international agencies, and 
provide information to FluNet.
•	 Brazil’s NICs have regular communication with local and regional laboratories to provide 
technical assistance and monitor influenza testing activities.
•	 Brazil´s NICs conduct training and provide additional equipment to enhance the diagnostic 
capacity of their reference laboratories.
Preparedness
Review and adjustment of the fourth version of the national preparedness plan was undertaken with 
the participation of representatives of 16 agencies that form the National Group Executive. The main 
purpose of this updated plan is to strengthen federal and local systems to reduce the impact of any 
future pandemic. The 2010 version of the plan incorporates lessons learned from the 2009 H1N1 
pandemic, including the need to engage neighboring countries in joint preparedness planning and 
border control activities. 
The creative front page of Brazil’s H1N1 Prevention Campaign Strategy.
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Brazil improved their preparedness on a national level by installing videoconference capabilities that 
allow for simultaneous communication with states and federal districts. Videoconferences were held to 
assess and coordinate response at the local level. Although improvements were intended for the health 
sector, the Brazilian preparedness plan to combat pandemic influenza also addresses the role that 
society and the population play during a pandemic. 
Key Preparedness Activities
•	 Brazil updated influenza pandemic protocols for the following areas: clinical management of 
severe cases, primary health, epidemiological surveillance, and airports and borders.
•	 Specific protocols have been designed for actions at ports of entry (i.e. airports and borders) for 
clinical management and epidemiological surveillance. 
Training
The following trainings were held in Brazil in FY 2010:
•	 The MOH developed a comprehensive peer training activity for professional workers in the 
following parts of the national health system: basic health, family health, high complexity 
services, emergency care, rescue, and public education. These professionals then provided 
the same training to their state partners. The training contains a DVD called Vademecum 
Influenza, with a manual, treatment and clinical management protocols, instructional videos, 
and scientific papers. This material is the basis for all the regional courses for professional 
qualification and is available on the MOH web site. 
•	 The NICs provided training in real-time RT-PCR for the 2009 H1N1 influenza diagnosis for the 
state lab network.
•	 The Brazil MOH provided train-the-trainer sessions to develop rapid response teams in all 
states, including remote states.
•	 The Brazil MOH developed media training on pandemic issues for communication staff in each 
department at national and local areas.
2009 H1N1 Activities, FY 2010
After the pandemic in 2009, the MOH received additional resources to strengthen the SARI surveillance 
system in Brazil by reinforcing early warning and surveillance systems.  
Key 2009 H1N1 Activities, 2010
•	 Hospitals were upgraded to continue monitoring and notifying the MOH of SARI cases.
•	 Brazil’s MOH was able to vaccinate 47% of the total population against pandemic influenza 
through prioritizing risk groups.
•	 Routine videoconferences with state surveillance coordinators were developed for general 
discussion about influenza and pandemic preparedness.
Special Influenza Projects
•	 The MOH has provided a structured audiovisual lab training course related to providing 
consistency in all laboratory activities in all local and regional laboratories. 
•	 The MOH provided influenza pandemic training for all federal level employees.
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Public Health Importance
•	 The MOH developed influenza training in a DVD format entitiled Vademecum Influenza. The 
training contained a manual with treatment and clinical management protocols, instructional 
videos, and scientific papers. 
•	 The MOH published in the Bulletin Epidemiological Review several papers on the pandemic 
that provide lessons for future pandemics.
Principal Collaborators
Eduardo Hage, MD




Marcia Lopes Carvalho, MD





WHO Region of the Americas (AMR) 133Brazil        
Influenza Program of  
GDD Response  
Center for Central America and 
Panama (GDD-RC/CAP)
U.S. CDC Direct Country Support 
Influenza Program activities in Central America and Panama (CDC-CAP) began in July, 2005, and were 
incorporated into the U.S. CDC GDD Response Center during 2006. Influenza activities occur in eight 
regional countries: Belize, Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica, Panama and the 
Dominican Republic. The main focus of the program has been to build national capacity to detect 
and respond to avian and pandemic influenza within the framework of preparedness and worldwide 
response. 
Surveillance
Evaluations of the surveillance systems suggested the need to standardize surveillance protocols, in 
order to improve the quality of data collected at sentinel sites and influenza diagnostic capacity at local 
laboratories. The full implementation of the generic CDC/PAHO influenza surveillance protocol in 2007 
and the implementation of 15 sentinel units and six NICs have contributed to the consolidation of a 
regional influenza surveillance network.  
Key Surveillance Activities 
•	 Influenza surveillance operating procedures have been updated and standardized in sentinel 
units of all participating countries.  
•	 Systems to capture and manage influenza surveillance data have been implemented in three 
new countries: Guatemala, Honduras and Costa Rica.
•	 Two new platforms have been created to register and follow surveillance cases.
•	 Investigation of outbreaks has been carried out in Santa Ana, El Salvador and Cartago, Costa 
Rica.
•	 All professionals working in sentinel surveillance systems in all eight countries have been 
trained on laboratory and surveillance techniques.  
Laboratory
In the context of the influenza pandemic, six out of eight regional countries are now official NICs and 
play an important role in the WHO Global Influenza Surveillance Network. Seven out of eight National 
Reference Laboratories (NRLs) have the capacity to identify influenza A and B viruses, adenovirus, 
parainfluenza 1, 2 and 3, and respiratory syncytial virus.  
Key Laboratory Activities
•	 The immunofluorescence laboratories in ten sentinel units are fully operational according to the 
developed standard operating procedures. 
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•	 CDC-CAP has provided reagents and supplies to these laboratories to further support their 
influenza surveillance in the region.
Preparedness
The second version of CDC’s National Inventory of Core Capabilities for Preparedness and Response 
for Influenza Pandemic in Central America was administered in June 2010. A combination of previous 
efforts, incentives and additional resources for the pandemic have allowed breakthroughs in routine 
influenza surveillance, communications, health sector response, outbreak response and community-
based interventions. 
Central American countries have adopted seasonal influenza vaccine into their immunization programs 
targeting different populations for different objectives and achieving variable coverage. The introduction 
of 2009 H1N1 vaccine in all the eight countries allowed the implementation of new strategies to rapidly 
detect adverse events potentially associated with the vaccine and to evaluate vaccine effectiveness. 
Key Preparedness Activities
•	 Administered and analyzed the results of the CDC’s National Inventory of Core Capabilities for 
Preparedness and Response for Pandemic Influenza in 2010 for all eight countries of the region. 
Preliminary results have been presented and discussed with key health authorities in each 
country. 
•	 Networking between different ministries and departments of health, and other agencies such as 
PAHO and Council of Ministers of Health of Central America (COMISCA) has been enabled and 
supported. 
•	 National health authorities used their national experience in influenza preparedness and 
response to improve organization and implementation capacities to comply with International 
Health Regulations. 
•	 CDC-CAP has continued to work with all countries to advocate for increased funding for the 
seasonal vaccine and for the harmonization of immunization policies against influenza.   
•	 CDC-CAP has continued to update their vaccination strategies based on vaccination program 
experiences in El Salvador and Nicaragua.   
•	 CDC-CAP has developed an active surveillance of adverse effects potentially attributed to the 
2009 H1N1 influenza vaccine in cohorts in El Salvador and Costa Rica.   
•	 Evaluation of the cost-effectiveness of the 2010 seasonal influenza vaccine has been completed 
in El Salvador.   
Training
The Influenza Program for Central America hosted the following training activities during 2010:
•	 Two training courses on influenza were conducted jointly with the Regional Health Care 
Training Center of Gorgas Memorial Institute where 105 health professionals from eight 
countries attended.
•	 Eight health professionals from Dominican Republic, Costa Rica, Honduras, El Salvador and 
Guatemala were enrolled in the advanced level (Master of Field Epidemiology) of the Field 
Epidemiology Training Program (FETP), and have completed all modules.
•	 A comprehensive training module on public health surveillance for rapid response teams and 
other key health professionals was developed; it is now available for all countries.
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•	 The third of a series of training workshops for health professionals from the eight countries 
was completed. The workshop provided a forum for the 30 participants to discuss risk 
communications during public health emergencies.
•	 Three training workshops were held on time-series analysis for surveillance staff at the 
ministries of health in Guatemala and Nicaragua, and the Costa Rica Social Security Fund during 
which 29 persons were trained.  
•	 Two regional workshops were held on scientific writing, systematization of surveillance data 
and influenza prevention for the staff of the El Salvador MOH and the Costa Rican Social 
Security Fund.  
2009 H1N1 Activities, FY 2010
Technical assistance for the improvement of the early warning systems, laboratory capacity to detect 
novel influenza viruses, and implementation of the influenza surveillance generic protocol were 
provided to facilitate the implementation of the International Health Regulations, 2005, in the region.
Key 2009 H1N1 Activities, 2010
•	 Technical assistance was provided through the COMISCA to design and implement an integrated 
health information system to support integrated surveillance in the region.
•	 Technical assistance was provided to members of the WHO Global Outbreak Alert and 
Response Network (GOARN) team for response during the 2009 H1N1 pandemic.
Other Notable Achievements in FY 2010 
•	 The clinical and epidemiological profile of laboratory-confirmed, 2009 H1N1 cases was 
characterized in patients who were infected in Central America.
•	 The excess of SARI hospital mortality in 2009 in Guatemala, El Salvador, Nicaragua, and all 
hospitals of the Social Security in Costa Rica was described.
•	 The CDC/APHL International Laboratory Capacity Review was implemented at each NRL and 
was completed in June 2010.
•	 The influenza seasonality model in El Salvador was developed and established, showing a 
Southern Hemisphere pattern during 2003–2009.
•	 The analysis of influenza burden of disease using data from the sentinel sites of El Salvador was 
carried out and completed.
Principal Collaborators
Jorge Jara, MD, FES
Influenza Activities Coordinator
Health Training Center, University of Guatemala
Guatemala City, Guatemala 
Email: jjara@gt.cdc.gov 
Percy Minaya, MD, MSc
Influenza Activities Coordinator
Training Programs in Epidemiology and Public Health Interventions Network
Guatemala City, Guatemala 
Email: pminaya@taskforce.org  
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Rafael Chacón, MD, MPH
Influenza Activities Coordinator
Council of Ministers of Health of Central America and Dominican Republic 
San Salvador, El Salvador 
Email: rchacón@sica.int
Influenza Project Investigators in  
Central American Countries
Ethan Gough, MD, MPH 
Director, Epidemiology Unit
Ministry of Public Health
Belize City, Belize
Email: egough@health.gov.bz
Francisco Ardón, MD, MPH
Director, National Epidemiology Center
Ministry of Public Health
Guatemala City, Guatemala
Email: fardonp@yahoo.com
Julio Armero, MD, MSc
Health Surveillance Director
Ministry of Public Health
San Salvador, El Salvador
Email: jarmero@mspas.gob.sv
Tomas Guevara, MD, MPH




Guiselle Guzmán Saborío, MD, MSc
Collective Health Director
Health Security Service
San Jose, Costa Rica
Email: gguzmans@ccss.sa.cr
CDC Field Staff
Nivaldo Linares-Pérez, MD, MSc, PhD
Team Leader, Influenza Program
CDC Regional Office for Central America and Panama
Guatemala City, Guatemala
Email: nlinares@gt.cdc.gov 
Wilfrido Clará, MD, MSc, MPH
Epidemiologist
CDC Regional Office for Central America and Panama
San Salvador, El Salvador
Email: aclara@gt.cdc.gov
Edmundo Sánchez, MD, MSc
National Health Surveillance Director
Ministry of Public Health
Granada, Nicaragua
Email: dgvs@minsa.gob.ni
Lourdes García, MD 
Director, National Epidemiology Department
Ministry of Public Health
Panama City, Panama
Email: lgarcia@minsa.gov.pa
Raquel Pimentel, MD, MSc
Director
National Epidemiology Unit
Ministry of Public Health
Santo Domingo, Dominican Republic
Email: raquelpimentel@sespasdigepi.gob.do
A poster encouraging kids to wash their hands, used in Ecuador 
during the H1N1 pandemic. 
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GDD-Guatemala
The GDD (Global Disease Detection) Regional Center in Guatemala (GDD-Guatemala) was established 
in 2006, building on U.S. CDC’s more than 30 year history of programs, activities, and partnerships in 
Central America, the Dominican Republic, and Panama. Together with partners, including PAHO, CDC 
has helped the region detect and respond to serious public health threats, including influenza, diarrheal 
and neurological diseases, and febrile illnesses, such as rickettsia and dengue.  
Coverage
GDD-Guatemala covers eight countries: Guatemala, Belize, Honduras, Dominican Republic, Nicaragua, 
El Salvador, Costa Rica, and Panama. The influenza program subsidizes an epidemiologist in each of 
the eight Central America and Panama (CAP) region countries, providing links to the MOHs and better 
collaboration during outbreak investigations. GDD-Guatemala has worked across the region in pandemic 









In 2010, the GDD Regional Center in Guatemala increased their laboratory testing capacity by 22%. 
GDD-Guatemala trained 11 FETP graduates and more than 4,000 participants in short-term regional and 
national trainings. GDD-Guatemala responded to 24 outbreaks. Of those 24 outbreaks, GDD-Guatemala 
provided laboratory support for 71% and yielded a confirmed cause. 
In-Country Field Staff
Wences Arvelo, MD, MPH
Acting Guatemala GDD Regional Center Director
Nivaldo Linares Perez, MD, MSc, PhD
Influenza Lead
Principal U.S. CDC Program Collaborations In-Country 
•	 Influenza Division International Program
•	 International Emerging Infections Program
•	 Field Epidemiology and Laboratory Training Program
•	 Laboratory Systems Development Program
•	 International Emergency Preparedness Program
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Mexico
•	Capital: Mexico City (Distrito Federal) 
•	Area: 1,964,375 sq km 
•	Population: 113,724,226 ( July 2011 est.)
•	Age Structure: 0-14 years: 28.2% (male 16,395,974/female 
15,714,182); 15-64 years: 65.2% (male 35,842,495/female 
38,309,528); 65 years and over: 6.6% (male 3,348,495/
female 4,113,552) (2011 est.)
•	Life Expectancy at Birth: Total population: 76.47 years; 
male: 73.65 years; female: 79.43 years (2011 est.)
•	Infant Mortality Rate: Total: 17.29 deaths/1,000 live 
births; male: 19.14 deaths/1,000 live births; female: 15.36 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 86.1%; male: 86.9%; 
female: 85.3% (2005 Census)
•	GDP: $1.56 trillion (2010 est.)
•	GDP per Capita: $13,800 (2010 est.)
U.S. CDC Direct Country Support
Since September 2006, the U.S. CDC has supported influenza surveillance in Mexico through a 
cooperative agreement. The agreement has helped to strengthen federal and regional influenza 
surveillance sites by funding training, equipment and coordination of activities of laboratories and 
epidemiology units. The Mexican National Laboratory Network consists of a National Influenza Center 
(InDRE) that coordinates training, quality control and reporting for 31 state laboratories. The cooperative 
agreement has assisted Mexico’s Ministry of Health (MOH) by increasing influenza laboratory capacity in 
Mexican states and improving diagnostic protocols.
Mexico’s outbreak response begins with local level investigations that are then assisted, if needed, by 
the Mexican Federal MOH. This response system was instrumental during the pandemic and remains the 
cornerstone of bi-national collaboration during the investigation of public health events of international 
concern. 
Surveillance
Mexico’s influenza surveillance system is based on local sentinel sites that are spread out in all 31 states. 
Over the course of the CDC cooperative agreement the surveillance network has grown; it started with 
less than 100 sites and now has grown to 739 units. The purpose of the units is to collect influenza 
samples from hospitals and community health centers to monitor influenza strains. Epidemiologic and 
laboratory data are collected at the local level and sent to centralized databases that facilitate rapid 
analyses, interpretation, and response to influenza activity throughout the country.
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Key Surveillance Activities
•	 The MOH develops a weekly newsletter that is distributed to the national epidemiological 
network. 
•	 The MOH developed and sustained a web-based laboratory and clinical-epidemiological 
reporting system that facilitates rapid identification of unusual activity and response to potential 
public health events of international concern. 
•	 An updated national plan for influenza preparedness was developed to include inter-agency 
coordination activities with the Mexico MOH, Army, Navy, and the Ministries of Agriculture, 
Communication and Transportation.
•	 Based on lessons learned from the 2009 H1N1 pandemic, the MOH has updated and improved 
the quality of data that is collected in the Mexican National Influenza Surveillance System. 
Laboratory
InDRE serves as a full-service national public health laboratory, performing surveillance and diagnostic 
testing for a broad range of agents and diseases, including respiratory viruses, rabies and arboviruses. 
As Mexico’s NIC, InDRE cultures influenza viruses, conducts PCR testing for respiratory samples and 
sequences viral isolates. InDRE also provides oversight and proficiency testing for the national network 
of laboratories. 
Key Laboratory Activities
•	 InDRE has the capacity to do full antigenic and genetic characterization of influenza viruses, 
and has the capacity to isolate influenza viruses.
•	 The MOH has developed an online platform to centralize data access and improve the 
communication system between the 31 state laboratories and InDRE.
Preparedness
The national influenza preparedness plan was updated after the 2009 H1N1 pandemic. The National 
Laboratory Network was fully strengthened with diagnosis protocols based in IFA, RT-PCR, real-time 
RT-PCR and viral culturing. Mexico is part of the North American Plan for Animal and Pandemic 
Influenza (NAPAPI), in partnership with Canada and the United States. In December 2010, Mexico 
hosted the ministerial meeting of the Global Health Security Initiative, where post-pandemic lessons 
were reviewed.
Key Preparedness Activities
•	 The national preparedness plan has been updated to include the coordination of local and state 
plans and activities. 
•	 There are now 31 state preparedness plans that work together and are accessible through the 
internet, as is the national plan.
•	 Each state in Mexico has a rapid response team that is equipped and includes medical doctors, 
an epidemiologist, and laboratory staff.
•	 The MOH has a memorandum of understanding and agreement with major pharmaceutical 
companies to store and distribute antiviral medications. 
•	 During the pandemic, there was successful distribution of antiviral medications to states and 
institutions.
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Training
Mexico’s MOH hosted the following training activities in 2010:
•	 Updated National Laboratory Network influenza leaders with regard to pandemic coordination.
•	 Held refresher courses on epidemiologic analysis with the National Institute of Public Health for 
local health departments. 
•	 Developed an Incident Command System basic course to provide technical assistance to all 32 
State Health Secretaries, in cooperation with the Public Health Agency of Canada.
A gorge in the state of Nuevo Leon, northeast Mexico.
2009 H1N1 Activities, FY 2010
In Mexico, the General Health Council declared the 2009 H1N1 pandemic to be over in June 2010.
Many lessons were learned from the pandemic that will aid in preparing for any future public health 
emergencies. The preparedness activities involved important mobilization of resources, the organization 
of different activities and the coordination of many partners. As an example, collaboration was forged 
between local and state health departments along the U.S.-Mexico border region through coordinating 
and sharing supplies, personnel, and lab testing.
WHO Region of the Americas (AMR) 141Mexico          
Key 2009 H1N1 Activities, 2010
•	 Coordinated activities were developed during the pandemic that became part of the 
government’s daily activities, including regular meetings between the Health Secretary and 
Agriculture Secretary.
•	 In preparation for possible future pandemics and to assess the impact of 2009 H1N1 
monovalent vaccine on the population, Mexico MOH staff attended and participated in a WHO/
PAHO decision modeling workshop and a CDC influenza modeling workshop.
Special Influenza Projects
•	 Mexico completed analysis of data from an influenza seroprevalence survey aimed at estimating 
the burden of disease during the pandemic.
•	 Mexico plans to merge animal and human influenza epidemic surveillance activities in an effort 
to integrate their surveillance strategies.
•	 Laboratorians are integrating seroprevalence activities into the country’s routine  
surveillance reports.
Principal Collaborators
Hugo López-Gatell, MD, PhD
Assistant Director-General of Epidemiology




Celia Alpuche-Aranda, MD, PhD
Assistant Director-General
Institute for Epidemiologic Diagnosis and Reference (InDRE)





Director, DGE Inter-Institutional Liaison Office
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Paraguay
•	Capital: Asunción 
•	Area: 406,752 sq km 
•	Population: 6,459,058 ( July 2011 est.)
•	Age Structure: 0-14 years: 28.5% (male 936,298/female 
905,285); 15-64 years: 65.4% (male 2,121,632/female 
2,100,740); 65 years and over: 6.1% (male 183,440/female 
211,663) (2011 est.)
•	Life Expectancy at Birth: Total population: 76.19 years; 
male: 73.59 years; female: 78.93 years (2011 est.)
•	Infant Mortality Rate: Total: 23.02 deaths/1,000 live 
births; male: 26.94 deaths/1,000 live births; female: 18.91 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 94%; male: 94.9%; female: 
93% (2003 est.)
•	GDP: $33.27 billion (2010 est.)
•	GDP per Capita: $4,900 (2010 est.)
U.S. CDC Direct Country Support
Since August 2009, the U.S. CDC has provided funds to the Paraguay Directorate General of  
Health Surveillance via a cooperative agreement to help the Paraguay MOH strengthen influenza 
surveillance. These funds are intended to support sub-national influenza preparedness and national 
communication strategies. 
Surveillance
Paraguay has been using the PAHO generic protocol surveillance standards and plan to adopt a new 
SARI surveillance protocol. Through their 12 sentinel sites, Paraguay collects influenza samples that are 
sent to their NIC. They continue to prioritize the strengthening of their surveillance at sub-national levels 
including rural areas.  
Key Surveillance Activities 
•	 The number of reporting sentinel sites was increased for ILI and SARI; there are currently five 
sentinel sites for ILI and 12 sentinel hospitals for SARI. 
•	 Information and data management capacity was improved at each sentinel site.
•	 The MOH developed national guidelines for ILI and SARI surveillance. 
•	 Information and characterization of the epidemiology of seasonal influenza in Paraguay  
was improved. 
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•	 The MOH’s communication capacity at local and national level was enhanced via the provision 
of internet connections and cellular phones at each sentinel site. 
•	 Each sentinel site was visited to oversee the development of their surveillance activities.
Laboratory
In 1998, Central Public Health Laboratory (LCSP) initiated viral isolation in cell culture and became 
Paraguay’s NIC. The laboratory collects samples from each of their l2 sentinel hospital laboratories. With 
CDC funding and technical assistance, Paraguay has been increasing the capacity of local laboratories to 
collect and send samples to the NIC. The NIC is capable of performing influenza diagnostics including 
virus isolation, hemagglutination inhibition assays and real-time RT-PCR for seasonal, 2009 H1N1 and, 
H5N1 viruses. Paraguay has been working on improving their ability to send samples out of the country.
Key Laboratory Activities
•	 Sent representative isolates of influenza virus strains to the WHO CC Atlanta for 
characterization, the selection of vaccine strains for the Southern Hemisphere, and monitoring 
antiviral drug sensitivity. 
•	 Provided weekly updates on influenza activity in Paraguay to WHO FluNet. 
•	 Participated in the WHO EQAP that demonstrated the competence of the NIC to identify 
seasonal, 2009 H1N1, and avian influenza in accordance with WHO global standards. 
•	 Developed and enhanced the integrated laboratory surveillance network for influenza. This 
included improving laboratory infrastructure, training staff, and providing resources for sentinel 
sites laboratories. 
•	 Provided technical support and confirmatory testing for other influenza laboratories  
in the country.
Preparedness
Paraguay has rapid response teams at the national level and has been continuing their process of 
developing rapid response teams at the local area.  Allocating staff and equipment to increase their 
regional area preparedness is a high priority area.    
Key Preparedness Activities
•	 Established a communication network at the sub-national level that included communicators 
and educators from all eighteen health regions.
•	 Developed a workshop regarding lessons learned from the pandemic. Workshop objectives 
included the following: discussion of experiences in the management of the epidemic and 
lessons learned that would improve performance in future pandemics; evaluation of the 
response plan and its implementation, and; agreement regarding future development of tools for 
prevention and guidelines on the containment and mitigation of future pandemics.
•	 Established a multidisciplinary team of people from national and sub-national levels to analyze 
the lessons learned from 2009 H1N1. Results of the analysis will be used to develop new 
operational plans for pandemic preparedness.
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Training
•	 Media spokespersons and national and regional communicators were trained in  
risk communication. 
•	 Two biochemists from sentinel sites were trained in the technique of IFA for the detection of 
respiratory viruses. 
•	 The NIC participated in training on IFA and the acquisition of related new equipment, reagents 
and consumables for the implementation of the technique. 
•	 During July and August, the MOH trained staff to conduct ILI and SARI surveillance, to use 
analytical tools to perform basic data analysis, and to ship samples correctly. 
•	 Training was provided for rapid response teams at the national and sub-national level. 
•	 Workshops with simulation exercises were provided for six regions, including two at the 
national level and four at the sub-national level. 
•	 Six NIC professionals were trained in techniques of viral isolation in cell cultures by experts 
from CDC-Atlanta.
•	 CDC trained NIC staff and provided technical assistance with regard to the following topics: 
freezing and thawing of cells, isolation of seasonal influenza, maintenance of cell line, internal 
quality control, increasing yield of tissue culture, and bio-security management standards.
Other Notable Achievements in FY 2010 
•	 Developed exercises for rapid response teams for outbreaks in two national and four sub-
national areas.
•	 Enhanced epidemiologic research and communication capacity by providing equipment 
(notebook, global position system devices, digital recorders, and camera), internet connections 
and cellular phones for each rapid response team.
•	 Increased the number of sentinel surveillance sites to 20 during the pandemic.
•	 Published a weekly national influenza bulletin that reported counts and trends of ILI, SARI, 
deaths, and confirmed influenza cases.
Principal Collaborators












Marta von Horoch, MD    
Medical Coordinator 




Mercedes Carrillo, MD 
Laboratory Officer
Director
National Laboratory of Paraguay (LCSP)
Asunción, Paraguay
Email: direccion@lcsp.gov.py
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Peru
•	Capital: Lima
•	Area: 1,285,216 sq km 
•	Population: 29,248,943 ( July 2011 est.)
•	Age Structure: 0-14 years: 28.5% (male 4,245,023/female 
4,101,220); 15-64 years: 65.1% (male 9,316,128/female 
9,722,258); 65 years and over: 6.4% (male 885,703/female 
978,611) (2011 est.)
•	Life Expectancy at Birth: Total population: 72.47 years; 
male: 70.55 years; female: 74.48 years (2011 est.)
•	Infant Mortality Rate: Total: 22.18 deaths/1,000 live 
births; male: 24.49 deaths/1,000 live births; female: 19.77 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 92.9%; male: 96.4%; 
female: 89.4% (2007 Census)
•	GDP: $277.2 billion (2010 est.)
•	GDP per Capita: $9,200 (2010 est.)
U.S. CDC Direct Country Support 
Peru is the third largest country in South America, with a population of over 29 million people. Peru 
is entering their fifth year of the CDC cooperative agreement.  Their influenza surveillance system 
uses sentinel sites to identify ILI and SARI case-patients throughout the country. Laboratory testing for 
influenza takes place in the 15 regional laboratories, as well as the NIC, located in the National Institute 
of Health (INS) in Lima. In addition, pneumonia reporting is mandatory for local health care centers.
Surveillance
Since 1998, Peru’s Ministry of Health (MOH) has conducted virological surveillance of influenza and 
other respiratory viruses. 
In 2006, to strengthen the national Peruvian surveillance program, the MOH sub-Committee for Influenza 
Surveillance invited the Virology Department of the U.S. Naval Medical Research Unit No. 6 (NAMRU-6) 
in Lima to assist in increasing surveillance coverage by establishing new sentinel sites. Since then, 
NAMRU-6 has augmented the existing program by supporting the collection and processing of samples 
at new sentinel sites as well as providing these data to the General Directorate of Epidemiology (DGE) 
and the INS. 
Sentinel surveillance has been implemented in 50 health centers throughout the country. This includes 
both ILI and SARI surveillance. SARI surveillance takes place at 21 sentinel hospitals. Epidemiological 
and clinical information, as well as nasal or pharyngeal swabs are obtained from case-patients identified 
through the surveillance system.  
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Key Surveillance Activities
•	 A web-based database for submission of laboratory and epidemiologic data was updated by the 
DGE, INS, and NAMRU-6.
•	 Burden estimates due to the impact of secondary 2009 H1N1 pandemic are underway, including 
mortality and hospitalization figures, as well as total number of symptomatic cases. In addition, 
Peru has used 10 years of syndromic pneumonia and influenza data to estimate the burden of 
influenza disease among hospitalized children aged less than five years.
•	 During the 2009 influenza pandemic, INS was in charge of the laboratory diagnosis for the 
country, NAMRU-6 supported their activities upon request.
•	 DGE disseminates information to the public and to the national epidemiology network through 
its website (www.dge.gob.pe) using a virtual situation room (http://www.dge.gob.pe/salasit.
php) and posting online reports of the Epidemiology Bulletin (http://www.dge.gob.pe/boletin.
php), as well as publications in national and international journals.
Laboratory
Peru has 15 regional laboratories, all of which receive respiratory samples from influenza sentinel sites. 
Samples are tested by IFA, and those that are positive are then sent to the country’s NIC in Lima for 
testing by RT-PCR. At the NIC, specimens are tested on the same day they are received, and results 
are reported within 72 hours. Influenza positive samples are also cultured in Madin-Darby Canine 
Kidney (MDCK) cells. Positive isolates are shared with CDC at least three times per year for further 
characterization. 
Key Laboratory Activities
•	 The NIC actively participates in WHO global influenza surveillance, submitting virus isolates 
during the year. 
•	 Laboratory staff at the NIC completed training in preparation for testing to begin at the new 
BSL-3 laboratory facilities.
•	 INS has implemented an online lab results reporting system (www.netlab.ins.gob.pe) where the 
case reporting centers can access the lab results information in real time.
Preparedness
Peru’s MOH updated influenza preparedness and response plan has incorporated an animal health 
component and involves other sectors (i.e. private sector, armed forces and police). This plan was 
published online and was widely disseminated among government sectors, including those at the 
regional level. 
Key Preparedness Activities
•	 Peru’s MOH updated its pandemic preparedness and response plans and is strengthening both 
ILI and SARI surveillance implementing daily media monitoring of suspect events and twice 
daily reporting to the national level.
•	 Peru implemented a communication preparedness campaign using radio announcements and 
posters to raise awareness among target audiences (health care workers, general population and 
poultry workers).
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2009 H1N1 Activities, FY 2010
Peru’s MOH identified the need to improve communication between the central and regional health 
departments and therefore acquired additional equipment and services to extend the coverage of 
communication to sub-regional levels.  
Key 2009 H1N1 Activities 
•	 Weekly updates of influenza activity.
•	 A vaccination campaign against 2009 H1N1 was developed and implemented for  
high-risk groups.
Special Influenza Projects
Plans for new influenza projects and strengthening of existing projects include the following:
•	 The MOH has strengthened ILI and SARI sentinel surveillance and a new directive was 
discussed last week with site coordinators.
•	 A cohort study of health workers and their families is underway.
•	 A study to determine factors associated with severe respiratory disease and death related to 
SARI and influenza is ongoing.
•	 The MOH is strengthening the local and regional ‘Alert – Response’ teams.
•	 The MOH is strengthening diagnostic capabilities at the regional level.
Principal Collaborators
Luis Antonio Nicolas Suarez Ognio, MD




Cesar Augusto Cabezas Sanchez, MD




Juan Carlos Arrasco Alegre, MD




Jorge Gomez Benavides, MD
Epidemiologist, National Institute of Health
Ministry of Health
Lima, Peru
Email: jgomez@dge.gob.pe  
Fredy James Condori Yujra, BS
Coordinator, Influenza and other Respiratory Virus




An airport poster encouraging good cough etiquette during the 
2009 H1N1 pandemic, Peru. 
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WHO South-East Asia Region (SEAR) 
Overview
The CDC Influenza Division funds eight non-research bilateral influenza cooperative agreements in the 
South-East Asia Region (SEAR). Cooperative agreements with Ministries of Health (MOHs) or institutions 
designated by the MOHs build capacity to routinely identify, diagnose, and respond to seasonal, avian 
and pandemic influenza.  
In SEAR, cooperative agreements are established with the following countries and WHO Regional Office:
•	 Bangladesh.
•	 India.




•	 WHO South-East Regional Office (SEARO) Headquarters in New Delhi.
In 2009, three countries--India, Indonesia and Thailand—were awarded sustainability grants. The 
grants support the countries for a second five years. Countries are expected to create and implement 
a sustainability plan that phases out U.S. government funding, to develop and maintain a surveillance 
Backyard chicken. Comilla city, southeastern Bangladesh.
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system that allows countries to rapidly detect, identify and respond to seasonal, novel and pandemic 
influenza and to participate in the WHO Global Influenza Surveillance Network (GISN). 
In addition, CDC supports multiple influenza-related research grants in Bangladesh and India.  
Core activities include improving laboratory and epidemiologic capacity and infrastructure for influenza 
virologic and disease surveillance; developing sentinel hospital-based surveillance for ILI and SARI; 
integrating lab and epidemiologic flu surveillance; developing and maintaining surveillance for cases and 
clusters of respiratory illnesses; training local rapid response and containment teams; and implementing 
infection control guidelines in public health care settings for prevention of avian and pandemic flu.
As of FY 2010, all SEAR countries with CDC influenza cooperative agreements had active National 
Influenza Centers (NICs).




Extramural Program - WHO South-East Asia Region
Influenza Division/NCIRD/CDC  
Email: ksiener@cdc.gov   
Fatimah Dawood, MD (since June 2010)
Medical Officer Epidemiologist
International Epidemiology and Response Team
Influenza Division/NCIRD/CDC
Email: hgj0@cdc.gov 
Danielle Iuliano, MPH, PhD
Research Scientist
International Epidemiology and Response Team
Influenza Division/NCIRD/CDC
Email: aoi0@cdc.gov  
Katie LaFond, MPH
Epidemiologist
International Epidemiology and Response Team
Influenza Division/NCIRD/CDC
Email: gmj3@cdc.gov 
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WHO National Influenza Centre
SEARO Headquarters
SEARO Member States
Influenza Research Cooperative Agreement
Influenza Sustainability Cooperative Agreement
Influenza Capacity Building Cooperative Agreement
The five-year cooperative agreement Surveillance and Response to Pandemic and Avian Influenza 
by Regional Offices of the World Health Organization (WHO) began in September 2006 and is in its 
fourth year of a five-year cooperative agreement.   
The WHO South-East Asia Regional Office (SEARO) is located in New Delhi, India. The Office serves 11 
countries; together their population exceeds 1.7 billion people. Member countries include Bangladesh, 
Bhutan, DPR Korea, India, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand and Timor-
Leste. Six of the 11 countries receive CDC Influenza Division cooperative agreement funds: Thailand, 
Indonesia, Bangladesh, India, Nepal, and Sri Lanka. In 2010, WHO SEARO staff provided training, 
support and technical assistance to member countries to strengthen preparedness, surveillance and 
response and laboratory capacity.
In 2011, WHO SEARO will focus on assisting countries with reviewing laws, regulations and policies 
related to the use of influenza vaccine, building partnerships for regional production of influenza 
vaccine, enhancing the capacity to monitor respiratory disease activity (including SARI and ILI 
surveillance) and harmonizing reporting in the Region. WHO SEARO is committed to scaling up 
regional influenza laboratory diagnostic capacity, improving capacity in monitoring the emergence of 
drug resistance, and convening an annual regional NIC meeting. WHO SEARO will continue to provide 
support for infection prevention and control and health care facility preparedness.
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Surveillance
With the exception of Thailand, Indonesia and India, which have a history of conducting virological 
surveillance to monitor circulating influenza virus strains, there was limited influenza surveillance in 
the SEAR prior to outbreaks of avian influenza H5N1 and the 2009 H1N1 pandemic. The pandemic 
drew attention to the need for both virological surveillance and reliable sentinel influenza systems 
in outpatient and hospital settings to collect epidemiological information on acute respiratory illness. 
These events have demonstrated the importance of establishing and strengthening influenza surveillance 
capacity in all countries in the Region. 
Key Surveillance Activities 
•	 ILI surveillance was initiated for the first time in two SEAR countries; the Democratic Republic 
of North Korea and Bhutan.
•	 Hospital-based SARI surveillance was initiated in Sri Lanka.
Laboratory
Although laboratory capacity is varied across countries, in the past five years laboratory infrastructure 
and technical capacity has improved throughout the SEAR. There are now eight NICs in the Region. NIV, 
Pune in India is an H5 reference laboratory and the NIC in Thailand became a WHO Regional Influenza 
Reference Laboratory for Southeast Asia in 2010.  
Key Laboratory Activities 
•	 Several SEAR Member States began to regularly report the number of specimens they tested for 
influenza and results of that testing by subtype to SEAR and FluNet. 
•	 For the first time, the Maldives established PCR facilities for influenza diagnosis using WHO 
support. Efforts are being made to establish similar facilities in Bhutan and Timor Leste, the two 
countries in the Region without the facilities. 
Preparedness 
By the end of 2006, all countries in SEAR had prepared generic pandemic preparedness plans. By the 
end of 2008 their plans had been tested in multi-sector tabletop exercises, and rapid response teams 
had been trained. The pandemic influenza preparedness and response plans were activated during the 
2009 H1N1 pandemic. Although these plans were geared towards an H5N1 scenario with anticipation 
of high mortality, the Member States found them extremely useful in responding to the pandemic. The 
pandemic also offered an opportunity for Member States and WHO SEARO to assess real-time response 
to obligations under International Health Regulations (2005). 
Key Preparedness Activities 
•	 In December 2009, WHO SEARO, in close collaboration with the Global Influenza Program, 
brought together the countries of Southeast Asia for a workshop on pandemic influenza 
preparedness and response. SEAR countries were provided with new pandemic preparedness 
and response guidelines and guidance documents. Revisions to the national pandemic 
preparedness plans were discussed, including revisions to sections related to surveillance and 
response, mass gatherings, logistics and supplies, and clinical management. Future steps for 
regional pandemic preparedness and response were identified.
•	 WHO SEARO collaborated with partners in the development of a training package for hospital 
preparedness and infection control.
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Training   
SEARO, in conjunction with selected Member States, hosted the following regional and inter-country 
trainings in FY 2010:
•	 A regional consultation on vaccine production was held in New Delhi, India in October 2009.
•	 WHO SEARO, CDC, WHO and India hosted an inter-country train-the-trainers workshop on 
respiratory infection control and hospital preparedness in New Delhi, India in November 2009.
•	 The training Regional Pandemic Influenza Preparedness and Response: Lessons Learned was 
held in Male, Maldives, December 2009.
•	 In November 2009 and September 2010, regional and country sessions dedicated to training 
trainers on risk assessment and risk management were conducted. 
•	 Extended training on the use of PCR kits was held in Nepal and the Maldives.
•	 A regional NIC meeting took place in July 2010.
2009 H1N1 Activities, FY 2010
•	 WHO SEARO organized a regional meeting of vaccine manufacturers to discuss vaccine 
production capacity and regulatory agencies.
•	 WHO SEARO strengthened laboratory diagnostic capacity in the Region.
•	 WHO SEARO provided support for pandemic influenza vaccine deployment activities. 
Special Influenza Projects and Other Notable Achievements in FY 2010 
•	 WHO SEARO convened a regional pandemic preparedness and response meeting to document 
and share response and control measures that have been implemented during the 2009 H1N1 
influenza pandemic in the SEAR.
•	 WHO SEARO provided technical assistance to Nepal to establish a NIC. 
•	 WHO SEARO supported countries in revising pandemic preparedness and response plans based 
on experiences and knowledge gained during the pandemic.
Public Health Importance
•	 Pandemic vaccine provided to nine SEAR countries was used to protect the health of pregnant 
women, health care workers and other high risk groups. 
•	 Regional training in PCR testing procedures for the diagnosis of influenza strengthened regional 
laboratory capacity to diagnose other viral illnesses.
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Bangladesh
•	Capital: Dhaka 
•	Area: 143,998 sq km
•	Population: 158,570,535 ( July 2011 est.)
•	Age Structure: 0-14 years: 34.3% (male 27,551,594/female 
26,776,647); 15-64 years: 61.1% (male 45,956,431/female 
50,891,519); 65 years and over: 4.7% (male 3,616,225/
female 3,778,119) (2011 est.)
•	Life Expectancy at Birth: Total population: 69.75 years; 
male: 67.93 years; female: 71.65 years (2011 est.)
•	Infant Mortality Rate: Total: 50.73 deaths/1,000 live 
births; male: 53.23 deaths/1,000 live births; female: 48.13 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 47.9%; male: 54%; female: 
41.4% (2001 Census)
•	GDP: $259.3 billion (2010 est.)
•	GDP per Capita: $1,700 (2010 est.)
U.S. CDC Direct Country Support
The Institute of Epidemiology, Disease Control, and Research (IEDCR), a part of the Ministry of Health 
and Family Welfare of the Government of Bangladesh, is in their fifth year of a cooperative agreement 
that began in 2006. IEDCR is the nation’s focal point for conducting disease surveillance and outbreak 
investigations. Their CDC-funded influenza project concentrates on strengthening disease surveillance, 
laboratory capacity and pandemic response. IEDCR works closely with the International Centre for 
Diarrheal Disease Research, Bangladesh (ICDDR,B), which also receives CDC funding to characterize the 
epidemiology of seasonal influenza and to help identify clusters of SARI and pneumonia that may be of 
international concern. The two agencies collaborate on surveillance, training and research. Bangladesh 
has made substantial progress in the field of respiratory illness since the start of the cooperative 
agreement and collaboration with ICDDR,B and CDC.   
Avian influenza outbreaks and the spread of pandemic influenza are of great concern for a country 
like Bangladesh because of the high population density and frequent interaction between humans and 
poultry. Bangladesh is a country with over 180 million poultry, 50% of which are raised in backyards. 
Collaborations on human and animal health also include the Bangladesh Department of Livestock 
Services (DLS), FAO, WHO and USAID.  
Surveillance
CDC funding enabled IEDCR and ICDDR,B to establish Bangladesh’s first influenza sentinel sites. 
Together they have been conducting hospital-based influenza surveillance in 12 tertiary hospitals across 
the country. Four of these hospitals expanded surveillance in 2008. These data have allowed Bangladesh 
to estimate its influenza disease and economic burden. In FY 2010, IEDCR expanded their government 
surveillance system by establishing 14 new national influenza surveillance sites at district hospitals, 
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raising the total national surveillance sites to 26. The current surveillance identifies cases of SARI, ILI, 
and severe pneumonia. In addition, an event-based component of the surveillance system identifies 
clusters of severe disease, and all patients are screened for exposure to sick or dead poultry and  
tested for H5N1. The system effectively shares staff, resources and data between ICDDR,B and IEDCR, 
with increasing ownership over time by public health authorities in Bangladesh. This strategy is 
anticipated to allow for sustainable influenza surveillance by IEDCR, with expanded investigations  
into disease transmission, burden, and cost-effectiveness of respiratory disease interventions in 
collaboration with ICDDR,B. 
Bangladesh continues to experience outbreaks of highly pathogenic avian influenza (H5N1). DLS, 
IEDCR, and ICDDR,B conduct surveillance for avian influenza in domestic poultry in Bangladesh. 
ICDDR,B performs monthly live bird market surveillance at 11 sites and will soon add a twelfth. Also, 
ICDDR,B performs active surveillance in 32 villages around the country. In addition to surveillance 
activities, DLS, IEDCR, and ICDDR,B participate in joint avian influenza outbreak investigations.
Key Surveillance Activities 
•	 IEDCR is expanding their web-based disease surveillance reporting, which collects information 
from 64 districts and over 450 upazila (sub-districts). With this expansion, facilities all over the 
country will build capacity to submit reports of ILI and SARI electronically.
•	 Specimens are now collected and tested for influenza virus from 14 new surveillance sites. 
•	 During FY 2010, over 5,000 specimens obtained through surveillance activities were tested for 
influenza A virus. Influenza A virus subtypes H1N1, H3N2 and 2009 H1N1 as well as influenza 
B viruses were circulating throughout Bangladesh during that period. There were two separate 
peaks of influenza activity, one in September 2009 due to the circulation of pandemic 2009 
H1N1, and one in July 2010 during the regular influenza season that occurs annually from May 
through October.
•	 Data generated by the surveillance system and its associated burden of disease and economic 
burden studies have allowed the Government of Bangladesh to develop national treatment 
guidelines for groups at high risk of complications from influenza. These data have also guided 
pandemic preparedness efforts and informed seasonal influenza prevention strategies.
•	 Influenza surveillance results are publically reported with monthly updates on the  
IEDCR website.
•	 IEDCR and ICDDR,B continue to send detailed surveillance reports to CDC and WHO on a 
weekly basis during the influenza season.
•	 Approximately 200 poultry samples tested positive for influenza A virus, of which one 
fourth were positive for H5 by real-time RT-PCR in the BSL-2 animal virology laboratory at 
ICDDR,B. The poultry-related work of the DLS and the health sectors in IEDCR has improved 
communication between the groups and has resulted in routine surveillance among persons 
who are involved in culling poultry infected with H5N1.
Laboratory
In 2007, IEDCR was nominated as a NIC by the WHO and has contributed specimens to the GISN. An 
upgrade of IEDCR’s BSL-2 laboratory was completed in 2010. State-of-the-art equipment was purchased 
and the new BSL-2 laboratory is performing real-time and conventional PCR to identify seasonal, 
pandemic 2009 H1N1, and H5N1 influenza viruses.  
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Key Laboratory Activities
•	 With funding from World Bank, IEDCR has installed a prefabricated BSL-3 laboratory, which 
should be operational in 2011. The BSL-3 facility will enable IEDCR to isolate viruses. 
•	 The BSL-3+ laboratory at ICDDR,B was accredited in July 2010. A new BSL-2 animal laboratory 
initiated poultry sample testing in November 2009, allowing them to identify outbreaks of  
avian influenza. 
•	 In 2009, the upgraded IEDCR lab began to test influenza samples. Previously, all influenza 
samples were tested in the ICDDR,B lab.
•	 IEDCR and ICDDR,B send subsets of samples, including unsubtypables, to a WHO CC for 
further characterization.   
Preparedness
IEDCR, with key partners, has periodically updated their pandemic response and avian influenza plan 
with lessons learned from the pandemic.  
Key Preparedness Activities
•	 Standard operating procedures to roll out non-pharmaceutical interventions, triage, and  
alternate care facilities during a pandemic were updated to reflect lessons learned during  
the 2009 H1N1 pandemic. 
•	 An emergency operations center (EOC) was recently built and equipped to help centralize a 
government response during major outbreaks and pandemics. 
Training 
•	 During the pandemic, IEDCR routinely trained public health officials and clinical providers 
from the district and sub-district levels on management of patients with suspected pandemic 
influenza using evidence-based recommendations generated from collaborative IEDCR, 
ICDDR,B, and CDC research.
•	 The Bangladesh Ministry of Environment and Forests, FAO, ICDDR,B, EcoHealth Alliance, and 
other partners participated in a workshop and training on wild bird capture and sampling for 
avian influenza. 
•	 ICDDR,B evaluated interventions and trainings by Cooperative for Assistance and Relief 
Everywhere (CARE) and Stamping out Pandemic and Avian Influenza (STOP AI) on promoting 
biosecurity and preventing avian influenza in backyard and commercial poultry farms.  
2009 H1N1 Activities, FY 2010
During 2010, WHO and other international partners donated 15.5 million doses of monovalent 2009 
H1N1 vaccine to Bangladesh in an effort to protect those at highest risk of complications from influenza 
illness. While the Government of Bangladesh vaccinated the high risk groups, IEDCR, ICDDR,B, and 
CDC scientists estimated the effectiveness of the vaccine among health care workers.
Key 2009 H1N1 Activities, 2010
•	 IEDCR and ICDDR,B monitored viral circulation and provided weekly reports to key domestic 
and international partners.
•	 Bangladesh supported a 2009 H1N1 vaccination campaign and performed vaccine effectiveness 
and cost-effectiveness evaluations.
•	 Bangladesh performed antiviral (oseltamivir) effectiveness studies.
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•	 Messages developed from ICDDR,B’s research on respiratory hygiene helped inform the 
Government of Bangladesh’s response to the pandemic.
Special Influenza Projects
•	 IEDCR, ICDDR,B, and CDC estimated the disease and economic burden of influenza in 
Bangladesh, generated influenza mortality rates, and piloted scalable non-pharmaceutical 
interventions to control influenza.
•	 IEDCR continues to demonstrate its leadership within the Government of Bangladesh to guide 
the country through the 2009 H1N1 pandemic response.
Other Notable Achievements in FY 2010
IEDCR implemented a system to collect and investigate daily news reports about suspected outbreaks. 
An early version of this event-based surveillance system can be credited with the early detection of 
pandemic influenza weeks before the virus was circulating in the general population.
Public Health Importance
•	 Bangladesh strengthened its communicable disease surveillance system and reporting to 
increase the timeliness of outbreak response and compliance with International Health 
Regulations, 2005.
•	 IEDCR strengthened the laboratory testing capacities at the NIC. 
•	 IEDCR and ICDDR,B estimated disease and economic burden for respiratory viruses, which is 
anticipated to facilitate priority setting and funding allocation to programs intended to decrease 
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India
•	Capital: New Delhi 
•	Area: 3,287,263 sq km 
•	Population: 1,189,172,906 ( July 2011 est.)
•	Age Structure: 0-14 years: 29.7% (male 187,450,635/
female 165,415,758); 15-64 years: 64.9% (male 
398,757,331/female 372,719,379); 65 years and over: 5.5% 
(male 30,831,190/female 33,998,613) (2011 est.)
•	Life Expectancy at Birth: Total population: 66.8 years; 
male: 65.77 years; female: 67.95 years (2011 est.)
•	Infant Mortality Rate: Total: 47.57 deaths/1,000 live 
births; male: 46.18 deaths/1,000 live births; female: 49.14 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: definition: Total population: 61%; male: 
73.4%; female: 47.8% (2001 census)
•	GDP: $4.046 trillion (2010 est.)
•	GDP per Capita: $3,400 (2010 est.)
U.S. CDC Direct Country Support
India received their first five-year influenza cooperative agreement in September 2004. In 2009, they 
received a second award, a five-year sustainability cooperative agreement Developing Sustainable 
Influenza Surveillance Networks and Response to Avian and Pandemic Influenza. India provides 
a unique setting in which to study influenza transmission and prevalence among various populations 
because of the socioeconomic, ethnic, and geographic diverse population. The U.S. CDC, in 
coordination with other U.S. government agencies, supports international response measures for avian 
and pandemic influenza in India through multiple implementing partners.  
India’s NIC, located at the National Institute of Virology (NIV), Pune, is part of Indian Council of Medical 
Research (ICMR), Department of Health Research within the Ministry of Health and Family Affairs 
(MOHFW). The bilateral agreement between the India NIC and CDC has been ongoing since 2004, and 
has provided resources for a greatly expanded surveillance system, including surveillance for H5N1 and 
2009 H1N1.  
Surveillance
ICMR conducts epidemiologic and virologic influenza surveillance in different geographic areas 
of India by collaborating with ten regional centers. They regularly send viral isolates for antigenic 
characterization to a WHO CC. Surveillance for seasonal and pandemic influenza allows for the 
identification of circulating strains, unusual epidemiological trends, and seasonality of influenza 
in different geographic settings. Since the CDC-ICMR influenza network began in 2004, more than 
22,849 specimens have been collected from surveillance sites and almost 600 isolates have been 
well-characterized.  
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Key Surveillance Activities
•	 The influenza network has collected 4,652 respiratory specimens; 580 were influenza positive 
by real-time PCR. Of these, greater than 100 representative isolates have been characterized, and 
54 isolates have been sent to CDC Influenza Division for further antigenic analysis.  
•	 India is analyzing influenza surveillance data in combination with climate, geography, and 
demographic data to explore trends of influenza seasonality.
•	 ICMR task force members, together with CDC team members, led an independent review of 
surveillance network laboratories at Kochi, India, in February, 2010. Written recommendations 
developed during the review were provided to the principal investigator, followed by an 
internal network review in mid April at NIV, Pune to implement the recommendations made by 
the review committee. The recommendations have further strengthened the network operations, 
including expansion of SARI surveillance sites.
•	 Dr. M. Chadha, NIV, Pune participated in the WHO Informal Consultation for Improving 
Influenza Vaccine Virus Selection during June 14-16, 2010 in Geneva, Switzerland.  
•	 Dr. Varsha Potdar, NIV, Pune, participated in a regional workshop on monitoring drug resistance 
of influenza viruses  in August  2010 in Bangkok, Thailand.
Laboratory
The India NIC has worked closely with CDC to establish state-of-the art laboratories. NIC laboratorians 
have trained extensively with CDC-Atlanta scientists on typing, subtyping, PCR, real-time PCR, and 
reverse genetics techniques. Notable progress in laboratory surveillance capacity has been achieved over 
the past five years, and the success of this partnership has led to significant enhancements benefiting 
both India and the GISN. The Indian influenza surveillance network now includes ten laboratories 
throughout India.
Staff from CDC, National Institute of Virology, and the King Edwards Memorial Hospital’s Vadu Rural Health Program, outside Vadu Hospital near Pune, India. 
Left to right: Avinash Deoshatwar (NIV), Dipanjan Roy (CDC India), Fatimah Dawood (CDC Atlanta), Pallavi Marathe (Vadu Rural Health Program), Katie Lafond (CDC 
Atlanta), Karen Siener (CDC Atlanta).
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Key Laboratory Activities
•	 The India NIC provides training and quality control for Indian network members as well as 
other influenza surveillance laboratories in the Southeast Asia region.
•	 The CDC Influenza Reagent Resource program provided standard reagents such as HA/HI 
reagents, and PCR reagents to influenza network laboratories in India.
Preparedness
Many of the preparedness activities related to increased awareness and response to minimize the risk of 
spread of human infections and disease were carried out with MOHFW and WHO partners prior to 2009. 
These efforts contributed to India’s ability to respond to the 2009 H1N1 pandemic.   
Key Preparedness Activities
•	 CDC provided technical guidance for the development and implementation of training modules 
for infection control in health care facilities jointly developed by the Indian MOHFW, CDC, and 
WHO.
•	 NIV, Pune conducted pandemic influenza awareness programs for physicians.
Training
Indian MOHFW hosted the following training activities in 2010:
•	 November 4-8, 2009, Respiratory Infection Prevention and Control in Healthcare Facilities was 
held in New Delhi, India. The training included case management guidelines for avian and 
pandemic influenza and training in appropriate use of PPE for health care workers.  
•	 April 19-21, 2010, the NIC at NIV conducted a BSL-3 training at Pashan, NIV, Pune.
2009 H1N1 Activities, FY 2010
The ICMR network expanded influenza surveillance to include pandemic 2009 H1N1 surveillance in four 
centers. The objectives of the surveillance include characterizing influenza virus circulation, providing 
isolates for vaccine strain selection, and monitoring antiviral drug sensitivity. 
Key 2009 H1N1 Activities, 2010
•	 The NIC at NIV led periodic in-country refresher trainings on pandemic response activities.
•	 The NIC at NIV conducted full-length sequencing and phylogenetic analysis of Indian 2009 
H1N1 isolates and identified that the majority of isolates belonged to the Clade 7 cluster.
•	 The NIC confirmed that 2009 H1N1 isolates were susceptible to oseltamivir. 
Special Influenza Projects
•	 Influenza projects in FY 2010 included development of broad activities encompassing the 
epidemiologic, basic and applied research aspects of seasonal and pandemic influenza with 
multiple partners in India. The ongoing research programs include:
•	 Evaluation of direct and indirect protection provided by influenza vaccine given to children  
in India. 
•	 Assessment of population-based incidence of influenza disease burden in rural communities  
of India.
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•	 Research programs to assess host-viral interacting proteins at the molecular level to better 
understand the pathogenesis of influenza in different host species.
Other Notable Achievements in FY 2010
•	 Team members gave more than 24 presentations at three major international conferences.
•	 Team members received two prestigious International Research Scholarship Awards given by the 
Options for Control of Influenza VII, Hong Kong, and the Program for Appropriate Technology 
in Health. 
•	 The influenza network identified greater than 12% influenza positivity in 2010, and 
demonstrated that novel influenza and influenza type B co-circulated during the rainy and 
winter seasons in India.
•	 India conducted an extensive analysis of seasonal influenza surveillance data and documented 
that influenza seasonality varies according to geographic location and that the peak of influenza 
activity usually coincides with the rainy season. This observation has implications for the 
implementation of influenza vaccination programs in India where Northern Hemisphere vaccine 
is currently imported and given prior to winter season.
•	 Genetic analysis of HA sequences from influenza type A pandemic H1 (n=11), H3 (n=3), and 
type B (n= 37) demonstrated that all circulating strains in India clustered with corresponding 
vaccine strains during 2010.
•	 Phylogenetic analysis of all eight gene segments of 23 2009 H1N1 identified that Indian isolates 
belong to clade 7, with great than 99% identity at the amino acid level. 
•	 Active weekly surveillance allowed the program to estimate the incidence rate of 2009 H1N1 to 
be at least six times higher during the peak pandemic phase (175 cases per 1,000 person-years 
from Oct 2009–Jan 2010), when compared to seasonal influenza viruses (60 cases per 1,000 
person-years). 
Participants from the regional workshop on Respiratory Infection Prevention and Control in Healthcare Facilities, New Delhi, November 2009.
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Public Health Importance
CDC activities have focused on supporting pandemic influenza preparedness programs and helping 
advance the field of influenza research (seasonal avian and pandemic) in India. Outcomes of these 
collaborative efforts include: 
•	 Quick and timely response to 2009 H1N1; active surveillance allowed for estimation of 
pandemic influenza incidence rates. 
•	 Presence of strategies related to influenza containment in health care settings after receiving 
training on respiratory infection control.
•	 Existence of well-trained, deployable rapid response teams in India. 
•	 Timely availability of seasonal influenza isolates for vaccine strain selection and genetic analysis 
has revealed that all circulating strains are closely related to the selected global vaccine strains. 
•	 A H5N1 vaccine candidate was created and submitted to the GISN. 
•	 Also, the diagnostic team received the Public Health Impact Award from the National Center 
for Immunization and Respiratory Diseases, CDC, for work that provided global impact from 
distribution and on-site testing for 2009 H1N1 (Aug 2010). 
Principal Collaborators
Akhilesh Mishra, PhD
Director, National Institute of Virology 
Pune, India
Email: acm1750@rediffmail.com
Shobha Broor, MD              
Professor, Department of Microbiology
All India Institute of Medical Sciences
New Delhi, India 
Email: shobha.broor@gmail.com
Asha Mary Abraham, MD, PhD
Professor, Department of Clinical Virology
Christian Medical College, Vellore
Tamil Nadu, India 





New Delhi, India 
Email: rbl3@cdc.gov or LalR@state.gov
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Indonesia
•	Capital: Jakarta 
•	Area: 1,904,569 sq km 
•	Population: 245,613,043 ( July 2011 est.)
•	Age Structure: 0-14 years: 27.3% (male 34,165,213/female 
32,978,841); 15-64 years: 66.5% (male 82,104,636/female 
81,263,055); 65 years and over: 6.1% (male 6,654,695/
female 8,446,603) (2011 est.)
•	Life Expectancy at Birth: Total population: 71.33 years; 
male: 68.8 years; female: 73.99 years (2011 est.)
•	Infant Mortality Rate: Total: 27.95 deaths/1,000 live 
births; male: 32.63 deaths/1,000 live births; female: 23.03 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 90.4%; male: 94%; female: 
86.8% (2004 est.)
•	GDP: $1.033 trillion (2010 est.)
•	GDP per Capita: $4,300 (2010 est.)
U.S. CDC Direct Country Support  
The Republic of Indonesia is the world’s fourth most populous country. The country is spread over 5,300 
km of longitude with over 17,000 islands, 6,000 of which are inhabited. Surveillance for influenza occurs 
within the MOH.
There are two cooperative agreements between the Indonesian MOH and U.S. CDC. The cooperative 
agreement Developing Influenza Surveillance Networks with the Center for Biomedical and Basic 
Technology of Health (CBBTH), National Institute of Health Research and Development (NIHRD) began 
in September 2004 and is in its second year of a sustainability cooperative agreement. The cooperative 
agreement with the Directorate General of Disease Control and Environmental Health (DG DC&EH) 
began in September 2006 and is in its fifth and final year. The goal of both agreements is to establish 
a comprehensive epidemiologic and virologic surveillance system for influenza that can identify and 
respond to seasonal and avian influenza in a timely manner. Key partners include CDC, WHO and 
USAID.
Surveillance
In FY 2010, NIHRD oversaw ILI surveillance in a representative network of 20 primary care facilities 
across Indonesia. Between January and October 2010, 2,770 ILI specimens were collected from 20 sites; 
20% were positive for influenza. 
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Key Surveillance Activities
•	 In 2010, NIHRD began to regularly upload data on WHO FluNet.
•	 DG DC&EH expanded the country’s Early Warning and Response System (EWARS) for 22 
priority diseases including ILI, pneumonia, and avian influenza to three provinces: North 
Sulawesi, West Kalimantan, and South Kalimantan. In 2011, EWARS, with funding from CDC, 
MOH and other donors, will be expanded to additional provinces.
Laboratory 
The Center for Biomedical and Basic Technology of Health in NIHRD was designated a WHO NIC in 
1975. A newly constructed laboratory with an entire floor dedicated to influenza and a BSL-3 facility has 
recently been certified. Currently, NIHRD performs molecular analysis and real-time and conventional 
RT PCR and sequencing. NIHRD also provides laboratory testing and support to DG DC&EH for avian 
influenza surveillance activities.
Key Laboratory Activities
•	 In 2010, NIHRD, in collaboration with USAID Deliver and CDC, conducted a laboratory logistics 
assessment. With this information USAID designed a laboratory logistics management system 
and prepared a laboratory logistics standard operating procedure (SOP). SOP trainings and 
socialization were then conducted in four regional laboratories. The project will be rolled out in 
other sentinel sites and laboratories at the end of 2010. 
•	 A network of four regional laboratories performs ILI real-time PCR testing. 
•	 NIHRD participated in a CDC lab assessment where a number of recommendations were made.
Preparedness 
After the 2009 H1N1 pandemic, the national influenza pandemic preparedness plan was reviewed and 
updated. Given the wide scale H5N1 epizoonotic in Indonesia and the continued occurrence of H5N1 
infection in humans, epicenter containment and pandemic preparedness are a high priority. The MOH 
continued to train private and public health doctors in diagnosing and treating avian influenza infection 
in Sumatra. MOH, veterinary and livestock services and the Health Promotion Centre are working 
together to develop written guidance related to managing suspected avian influenza cases.
Training
Using CDC funds, the MOH conducted several training activities in 2010:
•	 EWARS surveillance training was held in North Sumatra, West Kalimantan and South Kalimantan.
•	 Laboratory logistics training was held in DKI Jakarta, South Sulawesi, Bali, and Central Java.
•	 Influenza BSL-2 and BSL-3 safety training for personnel working with human influenza viruses 
was conducted by CDC.
•	 DG DC&EH conducted trainings in several provinces on avian influenza case definition and 
detection for doctors in health centers and private practices.
•	 NIHRD is hosting a national meeting with international partners in early 2011 to develop a 
strategic plan for surveillance activities of the NIC.
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2009 H1N1 Activities, FY 2010
•	 NIHRD monitored the pandemic 2009 H1N1 ILI network.
•	 DG DC&EH conducted trainings which provided pandemic response guidance and treatment 
recommendations.
Special Influenza Projects 
An enhanced surveillance project for avian and seasonal influenza in East Jakarta is being planned. 
The project will be managed by the zoonosis sub-directorate in collaboration with the Ministry of 
Agriculture, WHO, FAO, and CDC-Atlanta. The project focuses on the human and animal interface and 
identifying sources of H5N1 infection. Human disease surveillance will be conducted in four primary 
care facilities and six hospitals and the MOH will conduct enhanced surveillance among poultry 
throughout the market chain.
Public Health Importance
•	 Since the inter-sectoral local government team in Bali was trained in pandemic influenza 
outbreaks and response, collaboration has improved between the health sector and other 
sectors. This is seen in their response to other outbreaks, such as suspected rabies.
•	 The port health offices and referral hospitals have learned from the influenza pandemic 
response experience and are now better able to quickly put a screening system in place  
at the port. 
Birds sold as pets at the Pasar Burung Jatinegara Market. Jakarta, Indonesia.
Principal Collaborators
Ondri Dwi Sampurno, MSi, Apt.
Director
Center for Biomedical and Basic Technology of Health
National Institute of Health Research and Development
Jakarta, Indonesia
Email: odsam19@yahoo.co.id 
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Dorshinta Simangunsong, SE
Head, Finance Division 




Vivi Setiawaty, MBiomed 
Virology Laboratory Coordinator
Center for Biomedical and Basic Technology of Health
National Institute of Health Research and Development
Jakarta, Indonesia
Email: vilitbang@yahoo.com 
Hikmah Sari Loebis, MScPH
Head, Treasury Subdivision
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Nepal
•	Capital: Kathmandu
•	Area: 147,181 sq km 
•	Population: 29,391,883 ( July 2011 est.)
•	Age Structure: 0-14 years: 34.6% (male 5,177,264/female 
4,983,864); 15-64 years: 61.1% (male 8,607,338/female 
9,344,537); 65 years and over: 4.4% (male 597,628/female 
681,252) (2011 est.)
•	Life Expectancy at Birth: Total population: 66.16 years; 
male: 64.94 years; female: 67.44 years (2011 est.)
•	Infant Mortality Rate: Total: 44.54 deaths/1,000 live 
births; male: 44.54 deaths/1,000 live births; female: 44.55 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 48.6%; male: 62.7%; 
female: 34.9% (2001 census)
•	GDP: $35.31 billion (2010 est.)
•	GDP per Capita: $1,200 (2010 est.)
U.S. CDC Direct Country Support
Nepal is a mountainous country where transportation is a challenge. Most of the population lives in 
rural areas and many are dependent on poultry and animal farming. Nepal’s Patan Academy of Health 
Sciences (PAHS), a public health science university at Patan Hospital, was awarded their first influenza 
cooperative agreement in September 2009. Key goals of the Influenza Pandemic Preparedness and 
Response Project (IPPRP) include supporting Nepal’s Ministry of Health and Population (MOHP) in 
establishing routine influenza virologic and epidemiologic surveillance in three sentinel hospitals, 
characterizing circulating influenza viruses, understanding the pattern of respiratory illness in the 
country, and supporting the MOHP in outbreak management. Although Nepal has experienced H5N1 
avian outbreaks, no human cases have been detected to date.
The grantee works closely with the National Public Health Laboratory (NPHL), MOHP, Walter Reed 
Research Unit Nepal (WARUN), WHO, and USAID, all of which are based in Katmandu Valley, Nepal.
Surveillance
With CDC funds PAHS established their first influenza sentinel site at Patan Hospital in January 2010. 
A new collaboration between PAHS, NPHL, and WARUN will establish a network of 10 sentinel sites 
around the country. PAHS will be responsible for collecting epidemiologic data and specimens from 
three sites, NPHL will be responsible for collecting from five new sites, and WARUN will be responsible 
for collecting from their two existing sites. PAHS, NPHL, and WARUN are working closely with MOPH’s 
Epidemiology and Disease Control Division to design the new surveillance system. Surveillance  
forms and protocols have been developed with technical assistance from the CDC and are  
currently being tested. 
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Key Surveillance Activities 
•	 Patan Hospital started SARI surveillance in 2010 and collects specimens and key information 
from all hospitalized SARI cases. ILI epidemiologic data has been collected since January 2010 
and ILI specimen collection started in January 2011. 
•	 Plans are in place to start similar influenza surveillance in early 2011 in Western Nepal at 
Nepalgunj Medical College Hospital and in eastern Nepal at BP Koirala Institute of Health 
Sciences (BPKIHS).
•	 For ILI cases, PAHS and NPHL are setting up a system to collect and report to the MOPH the 
total number of outpatients seen, the proportion of ILI by age and gender and the number 
and percent of cases testing positive. For SARI cases, PAHS and NPHL will collect and report 
information that includes the number of cases by age and gender, the total number of hospital 
inpatients, the proportion of SARI cases and the number of deaths due to SARI.
Laboratory
NPHL became a WHO NIC in 2010. The World Bank provided funds to expand the NPHL laboratory 
to include additional BSL-2 laboratory space and equipment, with some specifically for influenza. The 
laboratory maintains conventional and real-time RT-PCR machines. In their new virology laboratory, 
NPHL plans to start culturing cells and isolating viruses. 
Key Laboratory Activities
•	 PAHS hired a virologist and is using CDC funds to purchase equipment needed for their new 
molecular laboratory, including their first real-time and conventional PCR machines. They plan 
to start testing SARI and ILI specimen samples in early to mid 2011. Until then Patan Hospital 
will send all samples to NPHL. 
•	 NPHL participated in the CDC/APHL Influenza Laboratory Capacity Review in which CDC 
provided technical assistance and provided recommendations on the new laboratory layouts at 
NPHL and Patan Hospital. 
•	 To date, testing has been limited to 2009 H1N1. With assistance from CDC, NPHL and the Patan 
laboratory will be able to start testing for influenza A H1, H3, H5 and B in 2011. 
•	 NPHL has tested 31 SARI samples from Patan Hospital; five samples were positive for 2009 H1N1. 
Preparedness
In 2006 Nepal prepared and endorsed a joint national health and agriculture avian and pandemic 
influenza preparedness and response plan. That same year Nepal wrote an operational plan for 2007-
2011, detailing separate implementation plans for human and animal health. The country plans to 
update the national plan in 2011 with lessons learned from managing the 2009 H1N1 pandemic. 
Key Preparedness Activities
•	 PAHS is a member of the National Risk Communication Technical Committee. 
•	 PAHS is participating in risk communication activities along with the MOHP. 
•	 PAHS conducted the CDC Influenza Division Core Capabilities for Pandemic Influenza review 
and plans to look closely at the areas in which they are strongest and weakest. 
WHO South-East Asia Region (SEAR) 169Nepal           
Training
Nepal hosted the following training activities in FY 2010: 
•	 With NPHL and WARUN, PAHS held an orientation meeting for clinicians and laboratory 
personnel from all ten sentinel sites. 
•	 In January 2011, NPHL and Patan staff visited sentinel sites to review influenza protocol for 
collecting and sending data and specimens.
2009 H1N1 Activities, FY 2010
Influenza testing was set up during the 2009 H1N1 pandemic in October 2009. The NPHL NIC was the 
only laboratory in Nepal capable of testing for 2009 H1N1. 
Key 2009 H1N1 Activities, 2010
•	 Patan Hospital established an isolation room in its ICU for suspected SARI cases. 
•	 Patan Hospital, under the leadership of its director, formed a committee to provide technical 
and managerial support for ongoing surveillance activities in the hospital.
Other Notable Achievements in FY 2010 
•	 Government and nongovernment partners held a three-day event to review ongoing health risk 
communication activities and strategies. PAHS is collaborating with the Department of Health 
Services to design, produce and distribute messages and materials to educate the public and 
health care workers about influenza prevention and response. 
•	 The MOHP formed a high level committee, led by the Secretary of Health, which meets  
every six months to review the progress of PAHS’s influenza project and to provide guidance 
and support.
View of the Himalayas. Nepal. 




Patan Academy of Health Sciences
Kathmandu, Nepal
Email: drakarki@pahs.edu.np
Kedar Baral, MD, MPH
Professor of Community Health Services 





National Public Health Laboratory, NIC 
Department of Health Services, Ministry of Health and Population
Kathmandu, Nepal
Email: nphl@wlink.com.np
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Sri Lanka
•	Capital: Colombo 
•	Area: 65,610 sq km 
•	Population: 21,283,913 ( July 2011 est.)
•	Age Structure: 0-14 years: 24.9% (male 2,705,953/female 
2,599,717); 15-64 years: 67.2% (male 6,993,668/female 
7,313,440); 65 years and over: 7.9% (male 720,219/female 
950,916) (2011 est.)
•	Life Expectancy at Birth: total population: 75.73 years; 
male: 72.21 years; female: 79.38 years (2011 est.)
•	Infant Mortality Rate: total: 9.7 deaths/1,000 live births; 
male: 10.68 deaths/1,000 live births; female: 8.68 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: total population: 90.7%; male: 92.3%; 
female: 89.1% (2001 census)
•	GDP: $104.7 billion (2010 est.)
•	GDP per Capita: $4,900 (2010 est.)
U.S. CDC Direct Country Support 
Sri Lanka is a developing nation with a sound public and curative health infrastructure. The 
Epidemiology Unit of the MOH, which is the government agency responsible for communicable disease 
surveillance, control and prevention, was awarded their first cooperative agreement in September 2009. 
The agreement is currently in its second year. The program’s goal is to build the country’s capacity to 
detect and respond to pandemic threats by building routine influenza surveillance, laboratory, planning 
and communications capacities.
Key collaborating partners include the Medical Research Institute (MRI), the national laboratory which 
serves as the country’s NIC, the Health Education and Promotion Bureau and the Department of Animal 
Production and Health.
Surveillance 
Human and animal influenza surveillance in Sri Lanka began in 2005 as part of their avian influenza 
preparedness program. With World Bank funding, the MOH established 20 sentinel hospitals, each of 
which set up ILI surveillance. CDC funds are now used to help maintain the ILI surveillance and carry 
out SARI surveillance in three of the 20 sentinel sites.  
Key Surveillance Activities
•	 Three sentinel hospitals began targeted SARI surveillance in 2010.
•	 In order to strengthen the surveillance program, the Epidemiology Unit provided all ILI 
surveillance sites with infrared digital thermometers and cold carriers to transport specimens. 
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•	 The Epidemiology Unit directly supervised ILI surveillance at selected sentinel hospitals through 
review visits. 
•	 Sri Lanka regularly enters virological data on WHO FluNet. 
Laboratory 
MRI was designated a WHO NIC in 1968. MRI also functions as the main national diagnostic laboratory 
in the MOH. The NIC has capacity to conduct real-time RT-PCR and viral isolation. Two laboratories, 
one in central and one in south Sri Lanka, will be trained to perform influenza testing in 2011. Due to 
limited resources they will perform immunofluorscence.  
Key Laboratory Activities
•	 NIC processed 1,372 ILI samples and 2,322 SARI samples in 2010 and handled a very high 
workload during both waves of the pandemic.
•	 MRI characterizes the influenza type and subtype of seasonal/circulating influenza viruses as 
well as influenza A (H5) using real-time RT-PCR and conventional PCR.
•	 The NIC submits seasonal influenza samples to WHO CCs twice a year and fulfills NIC 
requirements as outlined by the WHO.
•	 The NIC participated in a CDC/APHL Laboratory Review. The lab is in the process of using CDC 
funds to purchase equipment and supplies recommended by CDC and APHL in the review.   
Preparedness
The National Influenza Preparedness Plan (NIPP) was drafted in 2005 and revised once in 2006. 
Updates for the Plan are underway, following the two waves of the pandemic; the updated version will 
include a business continuity plan.
Key Preparedness Activities
•	 Epidemiologists at central and regional levels held regular capacity-building sessions.
•	 An operational cell that handles activities related to influenza preparedness began its work at 
the Epidemiology Unit with programme assistants, data entry operators and IT professionals.
•	 The grantee began to develop a web-based data linking system between the Epidemiology  
Unit and NIC. 
•	 The National Technical Committee on Influenza Preparedness held monthly meetings to plan 
the country response to the second wave of the pandemic.
Training
 The Epidemiology Unit hosted the following training activities in 2010:
•	 Health care workers in sentinel hospitals were trained in pandemic preparedness and the NIPP.  
•	 Infection control nursing officers who are responsible for ILI and SARI surveillance at sentinel 
hospitals were trained in laboratory and epidemiological components of ILI and SARI 
surveillance. 
•	 Regional epidemiologists attended trainings on field epidemiology, including influenza 
surveillance and pandemic preparedness.
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•	 Hospital administrators and senior medical officers in outpatient departments from all sentinel 
hospitals attended training sessions on the importance of ILI surveillance and pandemic 
preparedness.
•	 In 2011, the Epidemiology Unit plans to train regional rapid response teams in outbreak 
investigations and pandemic response.
2009 H1N1 Activities, FY 2010
The first wave of the pandemic waned by February. Sri Lanka had reported a total of 642 confirmed 
cases and 48 deaths. The second wave appeared in late September. By the end of 2010, an additional 
458 confirmed cases and 24 deaths had been reported. All response activities were coordinated by the 
Epidemiology Unit. 
Key 2009 H1N1 Activities, 2010
•	 The Epidemiology Unit revised management guidelines, updated hospital staff and supplied 
urgent consumables to health care institutions.
•	 The NIC was responsible for testing all samples that arrived from throughout the country during 
the pandemic periods.
•	 During the second wave of the pandemic, the Health Education Bureau educated the public 
using materials developed for the first wave.
Other Notable Achievements in FY 2010
•	 The Epidemiology Unit and NIC together revived the routine ILI surveillance activities in the 
sentinel hospitals after they had collapsed during the first wave of the pandemic.
•	 Routine ILI surveillance in one of the hospitals detected the second wave of the pandemic in 
the last week of September.
•	 Three ILI sentinel surveillance hospitals formally began SARI surveillance activities.   
Principal Collaborators
Paba Palihawadana, MD, MSc, MBBS 
Principal Investigator and Chief Epidemiologist 
Epidemiology Unit
Ministry of Healthcare and Nutrition
Colombo, Sri Lanka
Email: paba@health.gov.lk 
Geethani Wickramasinghe, MBBS, Dip, MD
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Thailand
•	Capital: Bangkok
•	Area: .513,120 sq km
•	Population: 66,720,153 ( July 2011 est.)
•	Age Structure: 0-14 years: 19.9% (male 6,779,723/female 
6,466,625); 15-64 years: 70.9% (male 23,410,091/female 
23,913,499); 65 years and over: 9.2% (male 2,778,012/
female 3,372,203) (2011 est.)
•	Life Expectancy at Birth: Total population: 73.6 years; 
male: 71.24 years; female: 76.08 years (2011 est.)
•	Infant Mortality Rate: Total: 16.39 deaths/1,000 live 
births; male: 17.38 deaths/1,000 live births; female: 15.35 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 92.6%; male: 94.9%; 
female: 90.5% (2000 census)
•	GDP: $580.3 billion (2010 est.)
•	GDP per Capita: $8,700 (2010 est.)
U.S. CDC Direct Country Support 
The Thai National Institute of Health (NIH) in the Department of Medical Sciences at the Ministry 
of Public Health (MOPH) was awarded their first five-year influenza cooperative agreement in 2004. 
In September 2009, they received a second award, a five-year sustainability cooperative agreement 
Strengthening Thailand’s Influenza Surveillance Network to Support Influenza Control Policy 
and Improve Pandemic Preparedness. The program’s goal is to establish a sustainable influenza 
surveillance system that can detect and identify circulating influenza viruses and effectively respond to 
outbreaks.    
NIH works closely with the Department of Disease Control, Bureau of Epidemiology (BOE) and Bureau 
of Emerging Infectious Diseases in the MOPH. U.S. CDC supports a wide range of influenza activities in 
Thailand including sentinel and population-based surveillance, training and applied research.  
Surveillance
There were four ILI sentinel sites prior to the CDC cooperative agreement. Since the CDC grant began 
in 2004, NIH expanded the number of sites to 11, three of which now also conduct surveillance for 
SARI in hospitalized patients. More recently, the BOE established an additional 13 sites, expanding the 
surveillance system to 24 sites throughout the country’s five regions and the Bangkok Metropolitan area. 
Key Surveillance Activities
•	 The 11 sentinel NIH sites tested 3,095 ILI specimens; 704 (23%) were positive for influenza 
viruses and 63% of those were positive for 2009 H1N1. 
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•	 NIH hosted an annual project meeting on sentinel hospital influenza surveillance to review and 
improve the harmonized virological and epidemiological influenza surveillance systems. 
•	 MOPH continued to support efforts to link human and animal influenza surveillance data.
Laboratory
The NIC, housed at NIH, was recognized by WHO in 1972. Thailand NIC staff is skilled at detecting 
influenza viruses and can process up to 50 samples per day. To improve efficiency, real-time RT-PCR is 
the primary means of identifying influenza viruses, and 20% of the positive samples are grown in culture 
and sequenced for further characterization. There is a network of 14 participating Regional Medical 
Science Centers, all of which can perform RT-PCR diagnostics for influenza viruses. In July 2010, the NIC 
became a WHO Regional Influenza Reference Laboratory for Southeast Asia.  
Key Laboratory Activities
•	 CDC and NIH conducted a review of the influenza virus diagnostic capacity at NIH. 
•	 NIH continued to build capacity for the network of influenza laboratories by improving 
university and private laboratory capacity through proficiency testing and bio-safety training.
•	 NIH continued to submit specimens to a WHO Collaborating Center twice a year.       
•	 NIC developed a standard operating procedure for guidance in detecting influenza viruses by 
real-time RT-PCR for the 14 regional laboratories.
Preparedness
The National Strategic Plan for Avian Influenza Control and Pandemic Preparedness in Thailand, 
2005-2007, was revised and is now called The Second National Strategic Plan for Prevention and 
Control of Avian Influenza and Preparedness for Influenza Pandemic, 2008-2010. Thailand is 
drafting a new version that will be broader and cover threats from emerging infections in general.
Key Preparedness Activities
•	 MOPH conducted their second national 
inventory of core capacities for pandemic 
influenza preparedness and response in 
September 2010. The review showed the 
strongest capabilities in the areas of laboratory 
capacity, routine influenza surveillance and 
in-country planning. 
•	 Each province conducted an annual exercise of 
the pandemic preparedness plan.
•	 MOPH published Self-Learning Guide for 
Business Continuity Plan for Pandemic  
Influenza Preparedness 2009 (Thai  
and English).
•	 MOPH published Guideline for Tabletop Exercise on Influenza Pandemic Preparedness at 
the Provincial Level for Exercise Organizers and Facilitators 2010 (Thai and English).
Panel discussion at the Sentinel Hospital Influenza Surveillance Project 
Meeting. Chiang Rai, Thailand. 
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Training
Thailand hosted the following training activities in FY 2010:
•	 A workshop on the diagnosis, treatment and prevention of human influenza for health 
professionals. 
•	 Training in cell culture techniques and viral isolation of influenza and other respiratory viruses 
in February 2010.
•	 The First Annual National Seminar on the Diagnosis and Clinical Management of Seasonal 
Influenza and Pandemic Influenza A (H1N1) 2009 (700 people attended).
•	 Three train-the-trainer sessions related to infection control (228 people attended).
2009 H1N1 Activities, FY 2010
Since the introduction of 2009 H1N1 virus into Thailand in May 2009, the MOPH has continued to 
aggressively track the virus. Since 2008, Thailand has made aggressive efforts to prevent influenza illness 
through implementation of vaccine policy.
Key 2009 H1N1 Activities, 2010
•	 NIH continued to test a portion of influenza viruses, including 2009 H1N1 viruses, for antiviral 
resistance. 
•	 NIC/NIH and the Thai Department of Disease Control completed national guidelines (available 
in Thai) on molecular testing of 2009 H1N1 which were used to train medical technologists and 
laboratory technicians from 25 regional hospitals. Consequently, laboratories at four regional 
hospitals and one private laboratory received accreditation from the Thai Bureau of Laboratory 
Quality Standard. 
•	 Vaccine recommendations that were expanded during the pandemic remain in effect for 
seasonal influenza and are subject to future review.
Special Influenza Projects 
•	 Thailand is conducting a Phase 3 clinical trial of a locally produced live-attenuated  
influenza vaccine.  
•	 CDC maintains a Global Disease Detection (GDD) program and International Emerging 
Infections Program (IEIP) in Thailand and has had a CDC influenza epidemiologist in Thailand 
since 2007. The IEIP influenza-related projects include working with the Thai BOE to conduct 
surveillance for influenza-pneumonia hospitalizations in two provinces; that work has enabled 
Thailand to estimate influenza disease burden. 
Other Notable Achievements in FY 2010
•	 The Weekly Epidemiology Surveillance Report (WESR) combines virological and 
epidemiological surveillance data. ILI data and laboratory results are analyzed weekly and 
reported on the website, www.thainihnic.org. The network system allows for rapid reporting 
and easy accessibility for partners.  
•	 Over two million doses of trivalent seasonal influenza vaccine were purchased by the 
government and supplied to high risk groups.  
Public Health Importance
•	 Disease burden data has been used to help identify target groups for influenza vaccination 
and to estimate the potential impact of influenza vaccine in Thailand. In 2008, the MOPH 
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recommended seasonal influenza vaccination for persons 65 years and older with underlying 
medical conditions. In 2009, during the 2009 H1N1 pandemic, influenza vaccine policy in 
Thailand was expanded again to align the country with global recommendations for the 
pandemic vaccine. The changes remained in place for seasonal influenza vaccination in 2010 
and are subject to future review.
•	 The capacity built for detection of influenza viruses has contributed to the detection of other 
respiratory viruses such as adenoviruses, human metapneumovirus, human parainfluenzaviuses 
and respiratory syncytial virus. 
•	 Lessons learned from the 2009 H1N1 pandemic are being used to help Thailand better prepare 
for future disasters. 
•	 Having an antiviral resistance monitoring system in place enables the country to determine a 
medication’s effectiveness and to establish appropriate protocols for distribution. 
•	 The increased laboratory capacity enables Thailand to quickly recognize and respond to 
emerging infectious diseases such as 2009 H1N1.
Principal Collaborators
Pathom Sawanpanyalert, MD, DrPH
Deputy Director General 
Department of Medical Sciences
Ministry of Public Health 
Nonthaburi, Thailand
Email: pathom@health.moph.go.th or pathoms@loxinfo.co.th 
Krongkaew Supawat, MSc
Acting Director, NIH 
Department of Medical Sciences
Ministry of Public Health 
Nonthaburi, Thailand
Email: krongkaew.s@dmsc.mail.go.th or krongkaewdaeng@yahoo.com 
Malinee Chittaganpitch, MSc
Chief
SEAR WHO Regional Reference Laboratory for Influenza and Thailand NIC
Thailand National Institute of Health
Department of Medical Sciences
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GDD-Thailand
The GDD (Global Disease Detection) Regional Center in Thailand (GDD-Thailand) was established in 
2004, building on existing support from national and regional partners to support essential public health 
functions to rapidly detect and respond to Southeast Asia’s emerging and reemerging infectious disease 
threats. These health threats range from pneumonia, including influenza and pandemic influenza threats, 
to hand, foot and mouth disease, tuberculosis, and zoonotic diseases. CDC has worked with the Ministry 
of Public Health (MOPH) and other key institutions in Thailand since 1980 to address the major public 
health challenges of the country, and increasingly, the region.
Coverage
GDD-Thailand is connected by field activities throughout the Southeast Asia region and is founded on 
a history of collaboration that dates back to 1980 when the world’s first Field Epidemiology Training 
Program (FETP) was established. This foundation has provided some of the most innovative public 
health work in the world, including the first site of CDC’s International Emerging Infections Program 
(IEIP) in 2001 and support for responses to the 2001 U.S. anthrax events, SARS, and the subsequent 
threat of avian influenza.







In 2010, the GDD Regional Center in Thailand discovered three pathogens new to the region and 
increased their laboratory testing capacity by 17%. GDD-Thailand trained 11 FETP graduates and more 
than 2,700 participants in short-term regional and national trainings. GDD-Thailand responded to 16 
outbreaks. Of those 16 outbreaks, GDD-Thailand responded to 94% in less than 24 hours and provided 
laboratory support that subsequently yielded a confirmed cause for 75%. 
In-Country Field Staff
Susan Maloney, MD, MPH
Thailand GDD Regional Center Director
Sonja Olsen, MD
Influenza Lead
Principal U.S. CDC Program Collaborations In-Country 
•	 Influenza Division International Program
•	 International Emerging Infections Program
•	 Field Epidemiology and Laboratory Training Program
•	 Laboratory Systems Development Program
•	 International Emergency Preparedness Program
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WHO Western Pacific Region (WPR) 
Overview
Currently there are seven bilateral influenza cooperative agreements in the Western Pacific Region of 
Asia. These agreements with Ministries of Health (MOH) or institutions designated by the MOH work 
with CDC to build capacity to routinely identify, diagnose, and respond to seasonal and pandemic 
influenza.  




•	 Secretariat of the Pacific Community (SPC).
•	 Philippines.
•	 Vietnam (2 agreements).
In addition, CDC supports the WHO Western Pacific Regional Office (WPRO) via a cooperative 
agreement. Through this cooperative agreement, CDC indirectly provides assistance to the following 
countries in collaboration with WHO:  
•	 Fiji.
•	 Laos.
•	 Papua New Guinea.
Boats along the Yangtze River in China’s heartland.
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The core activities of CDCs Influenza Division’s bilateral agreements and technical assistance are:
•	 To build sustainable national capacity for seasonal influenza, pandemic influenza and other 
emerging diseases and preparedness for implementation of the International Health Regulations 
(IHR).
•	 To make routine contributions of surveillance data to the WHO Global Influenza Surveillance 
Network (GISN).
•	 To increase the geographic reach of the WHO GISN.
•	 To provide earlier access to critical virus isolates from humans and birds for the WHO GISN.
•	 To increase the numbers of shipments and influenza isolates provided by WPR influenza labs 
for analysis by WHO Collaborating Centers.
•	 To develop sustainable epidemiologic and virologic surveillance systems for severe influenza, in 
order to gain understanding of the burden of disease from influenza in the WPR.




Extramural Program - WHO Western Pacific Region
Influenza Division/NCIRD/CDC  
Email: vdw8@cdc.gov  
Danielle Iuliano, MPH, PhD
Epidemiologist
International Epidemiology and Response Team
Influenza Division/NCIRD/CDC
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U.S. CDC Direct Region Support 
The WHO Western Pacific Regional Office (WPRO) is located in Manila, the Philippines. The Office 
serves 37 countries and areas that contain approximately 1.6 billion people, nearly one-third of the 
world’s population. The Region stretches over a vast area, from China in the north and west, to New 
Zealand in the south, and French Polynesia in the east. One of the most diverse of the WHO Regions, 
the Western Pacific Region (WPR) constitutes some of the world’s least developed countries as well as 
the most rapidly emerging economies. It includes highly-developed countries such as Australia, Japan, 
New Zealand, the Republic of Korea and Singapore; and fast-growing economies such as China and 
Vietnam.
In recent years, the Region has been an epicenter for emerging diseases, resulting in significant impacts 
on health, social and economic development. Protecting the Region from acute public health threats 
is, therefore, a top priority. The Asia Pacific Strategy for Emerging Diseases (APSED) was launched 
in 2005 as a common strategic framework for countries and areas of the Region to strengthen their 
capacity to manage and respond to emerging disease threats, including influenza pandemics. APSED, 
which is endorsed by Member States through the Regional Committee, has served as a road map to 
guide countries and areas in the Region towards fulfilling IHR core capacity requirements, thus ensuring 
regional and global health security.
The five-year cooperative agreement between U.S. CDC and WHO WPRO that began in September 
2006 has supported the implementation of APSED through three pillars of work: preparedness and 
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communications, surveillance and detection, and response and containment. The agreement also 
includes funds directed to Member States through WHO Country Offices in Cambodia, China, Federated 
States of Micronesia, Fiji, Lao People’s Democratic Republic (Lao PDR), and Papua New Guinea.
Surveillance
The availability of data from most of the countries and areas in the Western Pacific Region during the 
2009 H1N1 influenza pandemic is a testament to the great strides made across the Region in terms 
of strengthening surveillance systems, including the establishment of laboratory facilities for case 
confirmation.
Key Surveillance Activities
•	 WHO WPRO supported the Fourth Meeting of the National Influenza Centres of the Western 
Pacific Region in Manila, Philippines, June 2010.
•	 WHO WPRO supported the technical officer for surveillance and response in Papua New 
Guinea.
•	 WHO WPRO supported technical staff in Fiji and the Federated States of Micronesia in their 
support of the NIC in Fiji (Mataika House) and the rolling out syndromic surveillance in the 
Pacific.
Cambodia
The number of ILI sentinel sites stabilized at eight sites. The following activities were supported to 
strengthen ILI surveillance:
•	 Refresher training for staff from ILI sentinel sites.
•	 Supervision of ILI sentinel sites by U.S. CDC-supported WHO staff along with MOH staff.
•	 Publication of quarterly and annual reports from the ILI surveillance system.
China
•	 Weekly data collection and analysis activities at the China NIC were supported throughout the 
year.
Lao PDR
•	 The WHO continues to support an electronic indicator-based surveillance tool (Lao EWARN) at 
central and provincial levels. 
•	 An established ILI project has existed since 2006; currently there are seven sentinel sites in three 
central hospitals and four provincial hospitals.
•	 SARI sentinel sites were established in one central hospital and three provincial hospitals in 
collaboration with the Surveillance and Investigation of epidemic situation in South East Asia 
(SISEA) project in 2010.
Vietnam
•	 Supervision of surveillance sites was supported.
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Laboratory
During FY 2010, the National Centre for Laboratory and Epidemiology in Vientiane, Lao PDR was 
recognized as a NIC, bringing the total number of NICs in 15 countries in the WPR that belong to the 
GISN to 21. During this same period, there were two WHO Collaborating Centers in the WPR, one each 
in Australia and Japan; however, the NIC in China was recognized as a WHO CC on October 28, 2010. 
•	 Nineteen out of 21 (90%) NICs participated in the WHO EQAP in 2010, and 18 out of 19 scored 
100%.
•	 Twenty out of 21 (95%) NICs had virus isolation capacity in 2010.
•	 Twelve out of 15 (80%) countries with NICs participated in FluNet in 2010.
Preparedness
The Bi-regional Consultation on the Asia Pacific Strategy for Emerging Diseases and Beyond was 
conducted May 24-27, 2010 in Kuala Lumpur, Malaysia. The meeting produced one of the important core 
publications, APSED Technical papers, which served as a basis for developing the bi-regional strategy, 
APSED 2010. 
Cambodia
•	 National infection control policy was developed and approved by the MOH.
Lao PDR
•	 The influenza pandemic provided ample lessons and opportunities for self-assessment to 
improve the pandemic planning process in Lao PDR. Pandemic response evaluation was done 
using a WHO tool in June 2010. 
•	 Consultants assisted the MOH with development of a communication plan and messages for 
pandemic 2009 H1N1 and the post-pandemic period. 
•	 Technical assistance was provided for pandemic vaccine deployment planning, surveillance 
of adverse events following immunization, and a communication campaign to support the 
distribution of donated pandemic 2009 H1N1 vaccine. 
•	 Two reviews of the National Work Plan for Emerging Infectious Disease (EID) 2007-2010 
were conducted in light of the Asia Pacific Strategy for EID followed by the first planning 
meeting for the National Work Plan for Emerging Infectious Disease (EID) 2011-2015. 
•	 National epidemiologists (human and animal health) and clinicians attended the  
Western Pacific Global Outbreak and Response Network (GOARN) regional meeting  
in Cambodia in March 2010.
Training
Cambodia
•	 Refresher training was conducted for rapid response teams (RRTs). 
•	 Training for respiratory infection control was conducted at referral hospitals  
throughout the country.
Lao PDR
•	 Refresher training was conducted for provincial staff throughout Lao PDR.
•	 A representative from Communicable Disease Surveillance and Response (CSR) attended the 
International Conference on Emerging Infectious Disease (ICEID) in July 2010.
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Public Health Importance
•	 In Cambodia, many cases of 2009 H1N1 and cholera were detected and investigated by RRTs 
during this reporting period. Although training and investigation initially focused on 2009 H1N1, 
emphasis transitioned to also investigating acute watery diarrhea and, in particular, suspected 
cholera cases.
•	 In the Pacific, WHO WPRO supports surveillance staff that conduct trainings for syndromic 
surveillance for not only ILI, but also diarrhea, prolonged fever, and acute fever and rash.
•	 WHO WPRO supported professional staff from the Regional Office in their attendance of the 
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Cambodia
•	Capital: Phnom Penh 
•	Area: 181,035 sq km 
•	Population: 14,701,717 ( July 2011 est.)
•	Age Structure: 0-14 years: 32.2% (male 2,375,155/female 
2,356,305); 15-64 years: 64.1% (male 4,523,030/female 
4,893,761); 65 years and over: 3.8% (male 208,473/female 
344,993) (2011 est.)
•	Life Expectancy at Birth: Total population: 62.67 years; 
male: 60.31 years; female: 65.13 years (2011 est.)
•	Infant Mortality Rate: Total: 55.49 deaths/1,000 live 
births; male: 62.54 deaths/1,000 live births; female: 48.13 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 73.6%; male: 84.7%; 
female: 64.1% (2004 est.)
•	GDP: $30.13 billion (2010 est.)
•	GDP per Capita: $2,000 (2010 est.)
U.S. CDC Direct Country Support
Since 2006, U.S. CDC has provided support to Cambodia through the following non-research cooperative 
agreements: Development of Influenza Surveillance Networks Overseas with Cambodia’s MOH, 
Surveillance and Response to Avian and Pandemic Influenza with the WHO Country Office, and 
Avian Influenza Community Based Risk Reduction Project with CARE Cambodia. The collective goals 
of these cooperative agreements have been to build human and infrastructure capacity in surveillance, 
response, laboratory diagnosis, and pandemic preparedness of influenza. Other key in-country partners 
include the Institute Pasteur Cambodia (IPC) and the Naval Medical Research Unit No. 2 (NAMRU-2). 
Implementation of these cooperative agreements has resulted in the establishment of laboratory-based 
influenza surveillance, national public health laboratory capacity to perform molecular detection of 
influenza viruses, and strengthening of national and local response to avian influenza (AI), pandemic 
influenza, and other communicable disease outbreaks. 
Surveillance
Influenza surveillance did not exist in Cambodia prior to CDC support. Since the implementation  
of the cooperative agreement, laboratory-based ILI and SARI surveillance systems have been  
established under MOH with technical guidance from WHO, CDC, and IPC. Currently, ILI surveillance 
involves 13 sites (health centers and hospital outpatient departments) located in seven provinces and 
Phnom Penh. SARI surveillance consists of four hospitals from Phnom Penh, Siem Reap Province, and 
Kandal Province. Influenza surveillance has clearly demonstrated the existence of annual influenza 
seasonality in Cambodia. 
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Key Surveillance Activities
•	 ILI surveillance utilizing mobile phone short message service (SMS) reporting was maintained 
during the 2010 project year.
•	 Four new ILI sites – two health centers in each of the Mondulkiri and Kampot Provinces – were 
added to strengthen the ILI system. Necessary equipment, supplies, and training were provided 
to these sites.
•	 Testing for RSV and parainfluenza viruses was implemented as part of SARI surveillance.
•	 Microbiologic testing was implemented as part of SARI surveillance.
•	 NIPH continued 2009 H1N1 testing as part of ILI and SARI surveillance.
•	 Site visits were conducted at all ILI health centers and hospitals.
•	 A monthly Respiratory Disease and Influenza Bulletin was produced.
Laboratory
Support from the CDC/MOH cooperative agreement has resulted in substantial strengthening of 
laboratory capacity, including skills of technicians, at the MOH’s National Institute of Public Health 
(NIPH). NIPH is able to perform real-time RT PCR testing for all major influenza virus subtypes, 
including H5N1 and 2009 H1N1, in addition to multiplex PCR testing for other selected respiratory 
viruses. NIPH can also perform gram stain, culture and identification for various clinical specimens and 
supports development of microbiology labs at national and provincial hospitals.
Key Laboratory Activities
•	 Multiplex PCR testing for RSV and parainfluenza viruses was established at NIPH.
•	 SARI surveillance was strengthened to incorporate microbiologic testing of sputum and blood 
culture samples, resulting in significantly greater lab activity than previously at NIPH.
•	 The floor plan designs for BSL-2, BSL-2+, and cell culture rooms were completed. NIPH 
reviewed applications from four companies for the implementation of these enhancements. 
NIPH also participated in the CDC/APHL assessment of NIPH’s molecular laboratory.
•	 NIPH participated in the WHO EQAP for the detection of influenza virus type A by PCR.
•	 One full-time molecular laboratory technician and two full-time microbiology laboratory 
technicians were hired at NIPH. Two NIPH technicians were sent to a training workshop on 
Strengthening of GISN-International Air Transport Association (IATA) Licensing for NICs in the 
Western Pacific, Vietnam. Both technicians earned certificates after successfully completing 
course attendance and examination.
•	 Internal quality control was performed for media preparation, antimicrobial susceptibility 
testing, and gram stain at NIPH microbiology laboratory.
•	 The completion of microbiology laboratory enhancements was funded at Takeo and Kandal 
Provincial Hospitals.
•	 NIPH provided technical support and supplies to the microbiology laboratory at Khmer-Soviet 
Friendship Hospital (KSFH), a SARI site, to facilitate onsite testing of specimens.
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Preparedness
CDC support through WHO has considerably advanced pandemic influenza preparedness and planning 
in Cambodia. The National Committee for Disaster Management, together with partnering ministries, 
have continued to work on a national pandemic plan while MOH and WHO have led the development 
of a health sector response plan. Furthermore, in 2009, a multi-sector pandemic planning pilot project 
was successfully completed in Siem Reap Province, resulting in a model planning process for use in 
other provinces.
Key Preparedness Activities
•	 A draft of a national health sector pandemic response plan and a draft of a national plan for 
pandemic communication were both completed during 2010.
•	 Preparedness of national and provincial hospitals was strengthened to manage an increased 
number of patients with respiratory diseases.
•	 Workshops at several hospitals were conducted on the management of severe  
respiratory diseases.
Influenza researchers at the National Institute of Public Health Laboratory, Phnom Penh, Cambodia. From left to right: Mr. Chin, 
Savuth; Mr. Sok, Siyeatra; Ms. Leang, Chhay Heng; Ms. Nuth, Dara; Ms. Chhum, Chan Ravy; Mr. Ann, Vuth; Mr. Unn, Thy. 
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Training
The Cambodian MOH hosted the following training activities in 2010:
•	 ILI surveillance refresher training was provided for staff from all sites.
•	 SARI surveillance refresher training was held in May and October for staff from all sites.
•	 Training on proper blood culture sample collection was provided at each SARI site.
•	 An influenza outbreak investigation workshop was conducted for SARI surveillance staff from all 
sites.
•	 Basic microbiology training was conducted at NIPH for technicians from Battambang Provincial 
Hospital and KSFH.
•	 Microbiology and clinical laboratory training was held at NIPH for students from the Technical 
School for Medical Care and staff from the Ministry of National Defense.
2009 H1N1 Activities, FY 2010
The first confirmed case of 2009 H1N1 in Cambodia occurred in June 2009. Soon thereafter, the NIPH 
molecular laboratory acquired the capacity to detect 2009 H1N1 and, together with IPC, performed 
RT-PCR testing for 2009 H1N1 as part of ILI, SARI, and event-based surveillance, as well as outbreak 
investigation. ILI surveillance first detected 2009 H1N1 in September 2009, and while more ILI samples 
tested positive for 2009 H1N1 throughout the rest of the influenza season, 2009 H1N1 was not the 
predominate circulating subtype for most of this period. In addition, SARI surveillance data suggests that 
2009 H1N1 did not cause more severe disease than H3N2. In 2010, 2009 H1N1 surveillance remained 
integrated into both ILI and SARI surveillance systems. Overall, 2009 H1N1 did not significantly impact 
influenza activity, and three months into the influenza season, either H3N2 or B predominated on a 
weekly basis throughout the rest of the year.
Key 2009 H1N1 Activities, 2010
•	 NIPH and IPC continued to test influenza surveillance samples for 2009 H1N1.
•	 Through WHO support, the MOH provided over 1.8 million doses of 2009 H1N1 vaccine to 
targeted groups at high risk: all health care workers, pregnant women, infants six to 24 months 
of age, and individuals with chronic lung disease.
Special Influenza Projects and Other Notable Achievements in FY 2010
•	 NIPH molecular laboratory achieved a perfect score on Panel 8 of the WHO EQAP for the 
detection of influenza virus type A by PCR.
•	 MOH, with technical assistance from WHO, completed the National Strategic Plan for 
Infection Control in Health Care Facilities, 2011-2015.
•	 MOH, with technical assistance from WHO, completed the Infection Prevention and Control 
Guidelines for Health Care Facilities.
Public Health Importance
•	 Strengthening of the NIPH microbiology laboratory allowed for the detection of Vibrio cholerae 
O1 (Ogawa and Inaba serotypes) from stool samples as part of separate clusters of severe acute 
watery diarrhea in various parts of the country.
•	 NIPH laboratory detected V. cholerae non-O1 non-O139 from a stool sample of a case of acute 
gastroenteritis as part of an outbreak possibly linked to contaminated noodles.
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•	 Previous AI and 2009 H1N1 outbreak response training of Rapid Response Teams (RRTs) led to 
more effective response, including rapid assessment and active surveillance for suspect human 
avian influenza cases, during a confirmed H5N1 outbreak in poultry.
•	 Previous integrated outbreak training of RRTs resulted in improved investigations of individual 
cases and clusters of cholera.
•	 CARE Cambodia’s external evaluation of the village surveillance team (VST) model as a 
surveillance system for AI revealed that the VST model could be potentially adapted to other 
emerging zoonotic diseases besides AI.
Principal Collaborators
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China
•	Capital: Beijing
•	Area: 9,596,961 sq km 
•	Population: 1,336,718,015 ( July 2011 est.)
•	Age Structure: 0-14 years: 17.6% (male 126,634,384/
female 108,463,142); 15-64 years: 73.6% (male 
505,326,577/female 477,953,883); 65 years and over: 8.9% 
(male 56,823,028/female 61,517,001) (2011 est.)
•	Life Expectancy at Birth: Total population: 74.68 years; 
male: 72.68 years; female: 76.94 years (2011 est.)
•	Infant Mortality Rate: Total: 16.06 deaths/1,000 live 
births; male: 15.61 deaths/1,000 live births; female: 16.57 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 91.6%; male: 95.7%; 
female: 87.6% (2007)
•	GDP: $9.872 trillion (2010 est.)
•	GDP per Capita: $7,400 (2010 est.)
U.S. CDC Direct Country Support
The project Developing Sustainable Influenza Surveillance Networks and Response to Avian and 
Pandemic Influenza is China’s second five-year cooperative agreement with U.S. CDC; it began in 
August 2009. Fiscal year 2009-2010, the first year of the sustainability agreement, was a special year 
for the Chinese National Influenza Center (CNIC). First, facing the influenza pandemic challenge, 
CNIC successfully responded to the pandemic by confirming 2009 H1N1 cases and providing technical 
guidance to the entire National Influenza Surveillance Network (NISN) on the pandemic response. 
Second, after years of effort and preparation, CNIC welcomed the WHO onsite assessment of CNIC’s 
application to be designated a WHO Collaborating Center for Reference and Research on Influenza 
(WHO CC) in December 2009, and finally received the official designation in October 2010. Third, the 
NISN was expanded in 2009 as part of the response to the influenza pandemic. The number of sentinel 
hospitals increased from 197 to 556 and network laboratories increased from 63 to 411. 
Surveillance 
The influenza surveillance network contains a total of 411 network laboratories and 556 sentinel 
hospitals that cover all provincial, prefectural and municipal-levels of China Center for Disease Control 
(CDC) and some important county level CDCs. 
Key Surveillance Activities
•	 The weekly report on influenza surveillance was published and distributed in both Chinese and 
English to share information with national and international partners.
•	 The influenza surveillance information system was improved to include more functions and the 
construction of a comprehensive influenza database. 
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•	 Circulating influenza virus strains isolated by CNIC were submitted to the WHO GISN.
Laboratory 
CNIC has been designated a WHO CC. To meet the terms of reference for a WHO CC, a great effort has 
been made to improve the influenza laboratory surveillance in China.  
Key Laboratory Activities
•	 The current nucleic acid detection reference kit was optimized and used to assess nucleic acid 
detection quality in all 556 network laboratories.
•	 A new zanamivir resistance surveillance method was developed using a fluorescence-based NA 
inhibition assay.
•	 CNIC strengthened its capacity to conduct egg-based virus isolation in network laboratories.
•	 A ferret model was scaled up for anti-serum preparation.
•	 The whole genome sequence was determined for various subtypes of previous viruses collected 
over the last 50 years in China, and for currently isolated viruses.
•	 The evolution of influenza antigens was analyzed using an antigenic cartography analytic 
technique.
•	 A laboratory platform was established for surveillance of multiple respiratory pathogens.
Preparedness 
The national plan for influenza surveillance was renewed and issued by the China MOH in 2010. In the 
new plan, the provincial reference laboratories were assigned greater responsibilities and additional 
functions.
Training
China NIC hosted the following trainings in FY 2010:
•	 Nucleic acid detection training for approximately 700 technicians at network laboratories.
•	 Training for 2,000 clinical workers in sentinel hospitals to enhance the quality of ILI 
surveillance.
•	 Medium and long-term hands-on-training conducted by the CNIC for 13 technicians in network 
laboratories.
2009 H1N1 Activities, FY 2010
•	 A national cross-sectional serological survey was conducted to understand the seroprevalence of 
2009 H1N1 virus.
•	 Summary reports of the influenza epidemic situation were provided at monthly meetings 
organized by China MOH.  
Other Notable Achievements in FY 2010
In order to better evaluate the progress of the first five-year cooperative agreement, understand 
the current state of influenza surveillance, and identify strengths and weaknesses of the influenza 
surveillance system in China, a joint review of the influenza surveillance system in China was conducted 
by U.S. CDC and China CDC from August 18 to August 31, 2010. 
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Processed ducks for sale in a Chinese market. Ducks are important natural reservoirs for Influenza A viruses.
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GDD-China
The GDD (Global Disease Detection) Regional Center in China (GDD-China) was established in 2006 
as the China-U.S. Collaborative Program on Emerging and Reemerging Infectious Diseases (EID). EID 
integrates essential public health functions to rapidly detect and respond to China’s infectious disease 
and health threats. For more than 20 years, U.S. CDC has supported and collaborated with the Chinese 
national influenza laboratory. In 2001, the China Field Epidemiology Training Program (FETP) began 
its first cohort and today has graduated more than 100 public health officers who work in leadership 
positions throughout China’s public health community. The EID program integrates these established 
activities with new abilities in emerging infections and health communication for greater health effect.
Activities in China are directed at helping the country reach its population of 1.5 billion people. The 
program strengthens infectious disease outbreak investigations and response at the national and 
provincial levels, enhancing avian influenza and pandemic preparedness, and improving strategic 
development of infectious disease surveillance systems. Responses have included pandemic 2009 H1N1 
influenza, multi-drug resistant tuberculosis, human enterovirus 71, Streptococcus suis, plague, and 








In 2010, the GDD Regional Center in China increased their laboratory testing capacity by 18%. GDD-
China trained 14 FETP graduates and nearly 2,000 participants in short-term regional and national 
trainings. GDD-China responded to 33 outbreaks, of which 100% were responded to in less than 24 
hours and involved laboratory support that subsequently yielded a confirmed cause. 
In-Country Field Staff
Jeffrey McFarland, MD
China GDD Regional Center Director
Influenza Lead
Principal U.S. CDC Program Collaborations In-Country 
•	 Influenza Division International Program
•	 International Emerging Infections Program
•	 Field Epidemiology and Laboratory Training Program
•	 International Emergency Preparedness Program
•	 Health Communications
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Lao People’s Democratic Republic (Lao PDR)
•	Capital: Vientiane (Viangchan) 
•	Area: 236,800 sq km 
•	Population: 6,477,211 ( July 2011 est.)
•	Age Structure: 0-14 years: 36.7% (male 1,197,579/female 
1,181,523); 15-64 years: 59.6% (male 1,908,176/female 
1,950,544); 65 years and over: 3.7% (male 107,876/female 
131,513) (2011 est.)
•	Life Expectancy at Birth: Total population: 62.39 years; 
male: 60.5 years; female: 64.36 years (2011 est.)
•	Infant Mortality Rate: Total: 59.46 deaths/1,000 live 
births; male: 65.49 deaths/1,000 live births; female: 53.18 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 73%; male: 83%; female: 
63% (2005 Census)
•	GDP: $15.68 billion (2010 est.)
•	GDP per Capita: $2,400 (2010 est.)
U.S. CDC Direct Country Support
U.S. CDC established a collaborative working relationship with the MOH and Ministry of Forestry 
and Agriculture (MOFA) under a single Government of Laos (GOL) recognized Memorandum of 
Understanding (MOU) in May 2006, reflecting first time in-country representation, with focus on 
pandemic and seasonal influenza activities. CDC operations are managed through the U.S. Embassy 
in Vientiane Capital, and coordinated with and through the WHO Western Pacific Regional Office 
(WPRO) in Laos. The focus on capacity building with emphasis on pandemic planning, surveillance 
and laboratory, outbreak response, clinical case management and infection control have significantly 
contributed to control and mitigation efforts of pandemic H5N1 and 2009 H1N1 threats. 
A new year five-year CDC MOU is currently being discussed with the MOH; this MOU will allow for 
expanded recognition of CDC-supported country activities, including those supported through Global 
Disease Detection (GDD)/Bangkok and Center for Global Health (CGH), which are coordinated and 
supported by the Country Representative. Also, support will continue through a cooperative agreement 
support with WHO WPRO in Laos. This agreement is intended to develop capacity building gains in 
support of International Health Regulations (IHR) to provide for more evidence-based findings leading 
to sustainable efforts in minimizing the impact of seasonal influenza (including vaccination initiatives) 
and pandemic threats. CDC country representation has continued to provide de-facto representation 
for “other” USG sponsored health activities, including USAID, DoD and USDA-Animal and Plant Health 
Inspection Service (APHIS).
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Surveillance
The absence of laboratory detection capabilities precluded ILI/SARI surveillance start-up in Laos until 
January 2007. Three ILI sites and one SARI hospital site were concentrated in Vientiane Capital at this 
time. Planned expansion throughout the country of both surveillance networks coincided with 2009 
H1N1, with three additional provincial hospitals added in June 2009. The current network reflects data 
and specimen collections from seven provinces, and has provided first-time data on seasonal influenza 
in Laos, and served to enable the country’s contribution of 197 specimens and viral isolates through the 
WHO GISN.
Key Surveillance Activities
•	 The GOL submitted their first contribution of surveillance findings to WHO FluNet.
•	 Lao participated in the WHO GISN for the first time by sharing 94 isolates with the WHO CC 
Atlanta.  
•	 Three new SARI and two ILI hospital sites were added to the surveillance network, representing 
both the northern and southern provinces.
•	 The circulation of 2009 H1N1 virus continued as the dominant subtype transitioned from 
pandemic to seasonal influenza.
•	 Laos completed its preliminary five year National Surveillance Strategy.
•	 The management of the ILI/SARI surveillance system was transitioned from the WHO-U.S. CDC 
Collaboration to the National Laboratory.
Laboratory
The National Center for Laboratory and Epidemiology (NCLE) with support from the CDC-WHO 
collaboration has transformed diagnostic capacity in Laos since 2007; established testing capabilities 
now include conventional and real time PCR and cell culture and hemagglutination inhibition testing 
(HI). Systems have also been put in place to ensure quality assurance and bio-safety. A new initiative to 
develop molecular capabilities for carrying out in-country partial and full genomic sequencing of H5N1 
and 2009 H1N1 in describing phylogenic evolution is underway. A new planning effort is underway to 
decentralize testing functions in key regional provincial hospital laboratories.  
Key Laboratory Activities
•	 Newly developed cell culture capabilities, taking advantage of CDC training, allowed for first-
time contribution of “viral isolates” through WHO GISN.
•	 Laboratory staff from Laos received training for the first time from CDC in establishing molecular 
capabilities, allowing for partial genomic sequencing of H5N1 and 2009 H1N1 isolates.
•	 Real-time PCR testing was validated as 100% accurate through the WHO EQAP which NCLE has 
participated in since 2007.
•	 All laboratory functions have been temporarily relocated to other facilities while bio-safety 
enhancement upgrades are on-going at NCLE.
•	 CDC sponsored APHL to conduct an assessment of laboratory capabilities as part of the 
requirements to obtain the WHO NIC designation.
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Preparedness
Pandemic preparedness planning and actions were sustained through 2010, in recognizing and 
mitigating a less dramatic second 2009 H1N1 wave. The adaption of the U.S. CDC Automated Disaster 
and Emergency Planning Tool (ADEPT) model allowed provinces to modify prepared pandemic plans 
to accommodate a much less severe than anticipated pandemic. Preparedness experience enabled the 
GOL to manage outbreak threats associated with the Southeast Asian (SEA) Games in Vientiane, which 
attracted over 30,000 visitors during the influenza pandemic.
Key Preparedness Activities
•	 Regional pandemic training workshops were held by GOL in the Northern and Southern 
provinces to adapt evidence-based pandemic 2009 H1N1 findings into local plans.
•	 A successful series of national and provincial planning exercises were held by GOL in 
preparation for Laos to host the December 2009 SEAGAMES in Vientiane Capital.
•	 GOL established Infection Control Committees at all national and provincial hospitals, and 
workshops were conducted in translating newly established guidelines in practice.
•	 GOL held outbreak response re-training sessions in three key regional provinces.
Training
MOH and MOFA hosted numerous training activities in 2010, with support and technical assistance 
provided by the CDC – WHO Collaboration and the CDC in partnership with USDA/APHIS and DoD. 
These included:
•	 CDC laboratory training in strengthening of real-time PCR and establishment of cell culture 
capabilities, February 2010.
•	 CDC-Atlanta training of NCLE staff in establishing sequencing capabilities, March 2010.
•	 Training of newly-established sequencing team in genomic phylogenic analysis in Ho Chi Minh 
City (HCMC) Vietnam, June 2010.
•	 Infection control workshops in disseminating new infection control (IC) guidelines and 
establishing IC committees, February and September 2010.
•	 Refresher training for all ILI/SARI surveillance hospitals, in each province represented in 
network, and at NCLE, September 2010.
•	 Training workshops for pandemic vaccination teams throughout the country,  
April and May 2010.
•	 Clinical management and IC workshop in formulating national 2009 H1N1 strategy, August 2010.
•	 Veterinary H5N1 laboratory training at National Animal Health Center, August 2010.
•	 Veterinary epidemiological training on H5N1 in Xiengkhouang Province, September 2010.
•	 National outbreak and surveillance workshop, Thalat, June 2010.
2009 H1N1 Activities, FY 2010
Activities related to 2009 H1N1 in 2010, in addition to ongoing surveillance and laboratory detection, 
were focused on vaccine deployment to high-risk and prioritized populations. Significant technical 
consultations with the GOL prompted acceptance of a delivery strategy. Planning and execution led to 
successful vaccine deployment, which WPRO recognized as being highly successful. 
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Key 2009 H1N1 Activities, 2010
•	 Vaccine and ancillary materials were brought into Laos through the CDC – WHO Collaboration.
•	 Vaccines were delivered to an estimated 1 million targeted groups in Laos.
•	 Field Epidemiology Training (FET) led investigation into adverse reactions associated with 
delivery of vaccine, with and without tetanus toxoid vaccination in pregnant women.
•	 The ILI/SARI surveillance network expanded in the North and South to identify a “second wave” 
of the 2009 H1N1 pandemic.   
Special Influenza Projects and Other Notable Achievements in FY 2010 
•	 Lao NCLE became an NIC.
•	 Laos contributed influenza viral isolates to WHO GISN through CDC.
•	 An influenza component was added to non-malaria fever study/surveillance.
•	 Molecular sequencing training was initiated, providing in-country capacity to describe 
phylogenic evolution of H5N1 and 2009 H1N1.
•	 ILI surveillance enabled early recognition of a “second wave” of the 2009 H1N1 pandemic.   
•	 FET led investigation of adverse reactions associated with 2009 H1N1 vaccine delivery.
•	 FET graduated its first class of 8 students and began the second year of the program.
•	 First Infection Control Committees were established in all national and provincial hospitals.
•	 A senior MOH delegation visited CDC-Atlanta for the first time, for consultations on expanding 
scope and depth of relationship.
Public Health Importance
•	 Laos established a field epidemiology field training program (FETP), which provided critical 
human resources in responding to pandemic and seasonal influenza threats; it allowed NCLE 
to address a host of outbreak entities, including cholera, Japanese encephalitis virus ( JEV), 
dengue, measles, and anthrax.
•	 Real-time PCR capabilities developed for influenza detection were used to establish first-
time in-country recognition of human anthrax and circulating dengue serotypes, both during 
outbreak conditions.
•	 Pandemic influenza plans and processes were adapted to address disease impact resulting from 
severe flooding conditions in the south of Laos.
•	 Anticipated sequencing capabilities will be applied to rabies and other zoonotic disease entities.
•	 CDC supported outbreak investigative activities allowed for detection and containment of 
measles, dengue, human anthrax, cholera and JEV.
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Principal Collaborators
Bounlay Phommasack, MD, MPH, PhD
Director




Email: bphommasack@gmail.com  
Phengta Vongphrachanh, MD, DTMandH, MPH
Director




Bounlom Douang Ngeun, DVM, MSc
Director
National Animal Health Center
Ministry of Agriculture and Forestry
Vientiane, Lao PDR
Email: bounlom@gmail.com 
Darouny Phonekeo, MD, MTM
Deputy Chief of Laboratory Division
National Center for Laboratory and Epidemiology
Ministry of Health
Vientiane, Lao PDR
Email: darounyphonekeo@hotmail.com  
Bouaphanh Khamphaphongphan
Chief of Epidemiology Division














Email: ViengphoneK@state.gov  
Bounheuang Kounnavong, DVM
Agricultural Scientist
USDA-Animal and Plant Health Inspection Service
U.S. Embassy
Vientiane, Lao PDR
Email: bounheuang.kounnavong@aphis.usda.gov  
WHO Assignee
Reiko Tsuyuoka, PhD   
Team Leader of ESR/NTD (Neglected Tropical Diseases)
WHO - Regional Office for the Western Pacific
Vientiane, Lao PDR
Email: tsuyuokar@wpro.who.int
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Mongolia
•	Capital: Ulaanbaatar 
•	Area: 1,564,116 sq km
•	Population: 3,133,318 ( July 2011 est.)
•	Age Structure: 0-14 years: 27.3% (male 437,241/female 
419,693); 15-64 years: 68.7% (male 1,074,949/female 
1,076,455); 65 years and over: 4% (male 54,415/female 
70,565) (2011 est.)
•	Life Expectancy at Birth: Total population: 68.31 years; 
male: 65.85 years; female: 70.89 years (2011 est.)
•	Infant Mortality Rate: Total: 37.26 deaths/1,000 live 
births; male: 40.26 deaths/1,000 live births; female: 34.11 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 97.8%; male: 98%; female: 
97.5% (2000 census)
•	GDP: $10.08 billion (2010 est.)
•	GDP per Capita: $3,300 (2010 est.)
U.S. CDC Direct Country Support 
FY 2010 is the second year of the U.S. CDC/Mongolia sustainability cooperative agreement Developing 
Sustainable Influenza Surveillance Network (2009-2014). The previous agreement Development of 
Influenza Surveillance Network was completed in 2004-2009. 
Influenza-like illness has been a serious public health challenge in Mongolia since the 1970s, due to 
rapid growth in population size and urbanization. The NIC in Mongolia was established in 1974, and 
joined the GISN in 1978. The system was damaged seriously due to economic difficulties in the 1990s in 
connection with political and economic transition. The CDC/Mongolia cooperative agreement activities 
that began in 2004 have restored the system and improved its quality to meet the requirements of the 
WHO for NIC designation.
Surveillance
Until 2004, ILI surveillance was seasonal (from October 1 to June 30) and based only on weekly 
phone reporting of ILI incidences among outpatient visits in Ulaanbaatar, the capital city, and 21 
aimag (province) centers. Starting in the 2004-2005 season, influenza sentinel surveillance sites (ISSSs) 
were equipped with consumables for nasopharyngeal sample collection and refrigerators at 28 family 
group practices (FGP) in Ulaanbaatar City and two aimag (province) centers. The ISSSs have increased 
gradually in number to 158 and, as of October 2009, cover the whole country. ILI surveillance became 
a year-round activity in the 2006-2007 season, along with hospital-based surveillance of pneumonia and 
SARI events. 
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Key Surveillance Activities
•	 Countrywide, 121 outpatient ISSSs report registered ILI cases to the Mongolia NIC by  
telephone on a daily basis. The registered ILI morbidity was 2,170.9 /10,000 population during 
the 2009-2010 season (7.9% of all registered outpatient visits), an increase of 2.1 times over the 
previous season.
•	 Thirty-seven hospital-based ISSSs in Ulaanbaatar City and aimag centers reported diagnosed 
pneumonia and SARI cases among hospitalized patients; 25,031 pneumonia cases with 100 
(0.4%) deaths were registered. 
•	 Weekly surveillance information was posted in real time on the NIC website www.flu.mn in 
Mongolian and English.
Laboratory
Influenza virological surveillance in Mongolia is based on weekly collection of samples from ISSSs and 
detection and identification of viral agents in the samples by isolation in cell culture, direct fluorescent 
antibody (DFA) and polymerase chain reaction (PCR). Until August 2009, all samples submitted to the 
NIC were inoculated first into MDCK cell line and then the isolates were identified by PCR using primers 
supplied by World Health Organization Collaborating Centers (WHO CCs). Beginning in August 2009, all 
samples were tested first with real-time RT-PCR and then PCR positive samples were inoculated in cell 
culture.  DFA of R-Mix cells inoculated from randomly selected samples have been used for detection of 
other respiratory viruses since the 2008-2009 season. The Virology Laboratory at NIC joined the WHO 
External Quality Assessment Program at the beginning of 2007 and the last seven panels were tested 
with 100% accuracy.
Key Laboratory Activities
•	 A total of 2,102 (25.6%) influenza viruses were detected by real time RT-PCR from 8,200 
samples. Among them, 1,796 (85.5%) were 2009 H1N1 viruses and 306 (14.5%) were B viruses. 
•	 The number of samples tested doubled in comparison to the previous season.
•	 A total of 387 (4.7%) influenza viruses were isolated by inoculation of MDCK cell culture  
from 8,200 samples. Among them, 279 (71.3%) isolates were 2009 H1N1 viruses and 108 (28.7%) 
were B viruses.
•	 In 2008-2010, 317 influenza strains were isolated and tested for oseltamivir resistance by  
a chemoluminescence-based NA inhibition quantitative assay. Two (0.6%) resistant strains  
were detected.
•	 Thirty-four genes (3 PB2, 2 PB1, 3 PA, 9 HA, 3 NP, 4 NA, and M, and 3 NS) of 10 2009 H1N1 
strains were sequenced and submitted to and released by GenBank.
•	 Thirty new influenza isolates were sent to WHO CCs in Tokyo, Japan and Atlanta, United States 
for more detailed analysis.
•	 Seventy (9.3%) virus-specific antigens were detected by DFA with R-Mix hybrid cell line (DHI, 
USA) from 749 tested samples. Among them were: 21 (30%) influenza A, 17 (24.3%) influenza B, 
23 (43.5%) parainfluenza, 8 (11.4%) adenovirus. and 1 (1.4%) RSV. 
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Preparedness
The National IPPP assessment was first conducted in April 2008 and in November 2008 (retrospective 
for 2003) using the CDC’s National Inventory of Core Capabilities for Pandemic Influenza Preparedness 
and Response assessment tool. In March 2009, IPPP assessments were conducted nationwide (including 
among sub-national or provincial governments) using a modified CDC inventory with the financial 
support of the World Bank Project Avian Influenza Control and Human Pandemic Preparedness  
and Response.
Key Preparedness Activities
•	 The National Influenza Workshop 5 was held in October 2009; 220 participants representing 
all concerned parties convened. They issued recommendations for the government and other 
stakeholders and called for urgent actions to prepare for pandemics.
•	 A revised guideline “Influenza pandemic preparedness and response” was issued by the 
Mongolia MOH in April 2010.
•	 A National IPPP re-assessment, combined with the Influenza Laboratory Assessment, was 
conducted in June 2010 using CDC guidelines and CDC instructors. 
Training
The following trainings included participants from Mongolia in FY 2010:
•	 Forty-five training workshops (a total of around 3,500 hours) on infectious disease 
surveillance and prevention, including influenza control, were organized by National Center 
of Communicable Diseases (NCCD), MOH with the support of WHO, World Bank and Asian 
Development Bank.  Participants included 8,845 directors, doctors, epidemiologists and 
laboratory scientists and their assistants.  
•	 The project manager of the cooperative agreement project and a laboratory scientist from the 
Virology Laboratory at the NIC participated in the CDC Influenza Division International Partners 
Workshop in Atlanta, Georgia in July 2010.
•	 An epidemiologist and two laboratory scientists received two months of on-the-job training 
on hemagglutination inhibition testing (HI) and (micronuetralization) MN for serological 
surveillance at the Department of Virology, Tohoku University, Sendai, Japan and China CDC, 
Beijing, China. 
2009 H1N1 Activities, FY 2010
The 2009 H1N1 pandemic was the first influenza pandemic documented in Mongolia.  
Key 2009 H1N1 Activities, 2010
•	 The first laboratory confirmed 2009 H1N1 influenza case was detected on October 12, 2009 in 
the capital city through routine influenza surveillance activity. It was followed with an explosive 
2009 H1N1 outbreak throughout the country within three weeks, peaking at epidemiological 
week 45 of 2009. 
•	 The National Emergency Committee was nominated on November 3, 2009 under the 
chairmanship of the Vice Prime Minister; the Committee coordinated all control measures. 
The Government of Mongolia approved a budget of 6.4 billion Tugriks (approximately USD 
4.4 million) for response to the pandemic, including logistical support and mobilization of 
additional health personnel. The Parliament issued a Special Act on November 4, 2009 regarding 
the tax exemption of pharmaceuticals, medical equipment and supplies (including disinfectant) 
needed for 2009 H1N1 infection control and 2009 H1N1 pandemic vaccine. 
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•	 The MOH issued several orders: releasing additional funds for the treatment of the  
hospitalized patients, establishment of expert groups for urgent guidance of medical staff 
throughout country, and the mobilization of post-graduate medical students to work at  
primary health care (PHC).
•	 The Government of Mongolia quickly purchased more than 30,000 tablets of Tamiflu and an 
additional 50,000 were supplied by WHO.
•	 The Government of Mongolia purchased the first 60,000 doses of 2009 H1N1 pandemic vaccine 
in December 2009 for vaccination of health care workers.
•	 The first part of WHO vaccine supply arrived in Mongolia in January 2010 and a total of 500,000 
people (around 20% of the whole population) were vaccinated in 2010.
A traditional yurt or “ger” house of nomadic herders in Mongolia. Most rural Mongolians live in single tent-houses such as this, with the whole family sharing one room. 
This close proximity may facilitate the spread of influenza.
Other Notable Achievements in FY 2010 
•	 Two additional virology laboratories in Darkhan and Erdenet (Mongolia’s two most populous 
cities after Ulaanbaatar) were established and equipped with RT-PCR equipment and personnel 
received on-the-job training at the NIC using funding from the World Bank Project. The 
laboratories have been fully functional since March 2010.
•	 A total of 5,000 sera were collected in June 2009, November 2009 and June 2010 from 
apparently healthy individuals of all age groups for serological surveillance history of 2009 
H1N1 virus transmission in Mongolia. MN and HI tests have been performed with these sera by 
WHO Western Pacific Region (WPR) 205Mongolia           
Mongolian researchers in collaboration of Department of Virology, Tohoku University, Sendai, 
Japan and China CDC, Beijing, China.  Both organizations provided financial and technical 
support, along with WHO and World Bank. The statistical analysis and interpretation of results 
are on-going. 
•	 In response to a request by and financial support from the World Bank Project, a nationwide 
assessment of ILI reporting was completed in March and April 2010. Based on the 
recommendations of this assessment, a computer program called Flu Information System 
(FIS) for on-line ILI reporting was developed in March and April 2010. Testing and training of 
personnel was organized from May through October 2010 and the online ILI reporting system is 
in experimental operation for the 2010-2011 season.
Special Influenza Projects
•	 An influenza transmissibility study started in Baganuur District, Ulaanbaatar City in October 
2010 with technical and financial support of Tohoku University, Sendai, Japan.
Principal Collaborators
P. Nymadawa, MD, PhD, DSc(Med)
Project Director
National Influenza Center
National Center of Communicable Diseases
Ministry of Health
Ulaanbaatar, Mongolia 
Email: nymadawa@gmail.com   
B. Darmaa, MD, PhD 
Head, Virology Laboratory
National Center of Communicable Diseases
Ministry of Health
Ulaanbaatar, Mongolia 
Email: darmaa2001@yahoo.com   
A. Burmaa, MD, MSc
Head, Early Warning and Response Unit
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The Philippines
•	Capital: Manila
•	Area: 300,000 sq km 
•	Population: 101,833,938 ( July 2011 est.)
•	Age Structure: 0-14 years: 34.6% (male 17,999,279/female 
17,285,040); 15-64 years: 61.1% (male 31,103,967/female 
31,097,203); 65 years and over: 4.3% (male 1,876,805/
female 2,471,644) (2011 est.)
•	Life Expectancy at Birth: Total population: 71.66 years; 
male: 68.72 years; female: 74.74 years (2011 est.)
•	Infant Mortality Rate: Total: 19.34 deaths/1,000 live 
births; male: 21.84 deaths/1,000 live births; female: 16.71 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: Total population: 92.6%; male: 92.5%; 
female: 92.7% (2000 census)
•	GDP: $353.2 billion (2010 est.)
•	GDP per Capita: $3,500 (2010 est.)
U.S. CDC Direct Country Support 
The Philippines completed its first year under the Developing Sustainable Influenza Surveillance 
Networks and Response to Avian and Pandemic Influenza cooperative agreement in August 2010. 
The previous five-year agreement Developing Influenza Surveillance Networks lasted from September 
2004 through August 2009. The Research Institute for Tropical Medicine (RITM) is the NIC for the 
Philippines. Activities conducted under the present cooperative agreement include the continuation of 
surveillance activities at established sentinel sites and burden of disease activities.  
Surveillance
In 2010, a total of 7,684 ILI cases were reported from 29 surveillance sites. Specimens were collected 
from 2,823 (37%) of these reported cases. The 2010 ILI trend showed a steady rate of cases from January 
to March 2010, compared to low ILI case reports in previous years during the same timeframe.  
Key Surveillance Activities 
•	 RITM held a meeting with stakeholders in December 2009 as a first step toward ensuring the 
viability and sustainability of the functional influenza surveillance system in country. Participants 
included the local government units, regional directors from the 12 Regional Centers for Health 
Development and other local officials. Progress on surveillance activities was discussed; an 
initial discussion regarding sustainability strategies also took place.
•	 Two scientific papers are being written for publication: one methods paper describing the 
experience, challenges and difficulties in setting up the influenza surveillance network and 
strategies to overcome them, and a second paper describing the seasonality of influenza in the 
Philippines and its circulating strains.
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Laboratory
RITM is the NIC for the Philippines and is responsible for maintaining and enhancing  
laboratory capacity. 
Key Laboratory Activities
•	 RITM, through the National Center for Health Facilities Development under the Department of 
Health (NCHFD-DOH), provided technical assistance in setting up four sub-national laboratories 
for the molecular detection of 2009 H1N1. These sub-national laboratories are located in the 
National Capital Region, the Cordillera Autonomous Region, Visayas, and Mindanao.    
•	 RITM has initiated communications with WHO CC Melbourne to schedule training on the use 
of egg-based culture methods to isolate viruses that are difficult to grow by standard culture 
methods. The RITM NIC and the Bureau of Animal Industry are in continuing negotiations for 
the acquisition of eggs to be used for this purpose.  
Training
Philippines/RITM hosted the following training activities in 2010:
•	 January 18-22, 2010, the molecular biology laboratory at RITM conducted a workshop on 
molecular diagnosis of influenza that provided basic and proficiency training to NIC medical 
technologists on molecular techniques. Participants included NIC virology staff and staff  
from other laboratories within the NIC; the training ensured that staff could meet surge  
capacity needs.
•	 A refresher training was conducted October 22-23, 2009, for the regional influenza surveillance 
officers, nurses and physicians from the National Capital Region sentinel health centers. 
2009 H1N1 Activities, FY 2010
During the 2009 H1N1 pandemic, the National Epidemiology Center (NEC) was primarily in charge of 
the outbreak investigations, while the NIC laboratory contributed significantly by providing the data 
necessary for the investigations.
Key 2009 H1N1 Activities, 2010
•	 A total of 11,713 specimens were tested by the molecular laboratory at RITM for 2009  
H1N1; 5,790 (49.4%) were positive for 2009 H1N1; more than 57.4% were from the National 
Capital Region.
•	 The molecular biology laboratory at RITM began 2009 H1N1 testing in May 2009. Cases 
occurred in people aged three days to 95 years of age; 61% of cases were from those 19 years 
and younger. More than half of the cases were female.
Other Notable Achievements in FY 2010 
•	 A total of 11,010 influenza burden of disease health center consultations were recorded from 
September 2009 to March 2010; 1,860 were ILI consultations.  
•	 ILI consults comprised 16% of total health center visits, and 16-17% of all health  
center consultations.  
•	 In Baguio City, specimen was collected from 819 ILI cases (40%). The virus positivity rate was 
21% while the influenza positivity rate was around 5%.
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Principal Collaborators
Remigio Olveda, MD, CESO III
Principal Investigator
Director IV, Research Institute for Tropical Medicine
Alabang, Muntinlupa City, Philippines
Email: roleveda_ritm_doh@yahoo.com 
Eric Tayag, MD, FETP, FPSMAD
Director IV, National Epidemiology Center
Philippines Department of Health
Manila, Philippines  
Email: eriqtayag4health@yahoo.com
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Secretariat of the Pacific 
Community
U.S. CDC Direct Country Support 
The Secretariat of the Pacific Community (SPC) is an international organization with a membership of 
22 Pacific Island Countries and Territories (PICTs). Established in 1947, SPC was created to support the 
development of the region’s land, marine, and human resources. 
Within the framework of SPC is the Pacific Public Health Surveillance 
Network (PPHSN), a joint initiative of SPC and WHO, which is 
dedicated to communicable control and surveillance. 
The current Influenza Surveillance Networks Cooperative 
Agreement between SPC PPHSN and the U.S. CDC began in 2005 
and supports the development of influenza surveillance networks 
across a vast area, including both the North and South Pacific, 
covering ten time zones and wide geographic, socio-political, and 
cultural diversity. Key collaborating organizations include WHO, 
Pacific Islands Health Officers Association (PIHOA), PICT Ministries and Departments of Health and 
reference laboratories in Australia, New Zealand, Fiji and New Caledonia. 
Surveillance
Influenza is not seasonal in PICTs and can occur at any time of the year, usually associated with 
introduction by travelers. Prior to the cooperative agreement with CDC, influenza testing and 
surveillance capacity was very limited in PICTs. During the five years of the project, immunofluorescence 
assay (IFA) testing capability for influenza has been introduced into PICTs and a network of 48 
sentinel sites has been established. Sample referral arrangements have been established with reference 
laboratories in Australia, New Zealand, Fiji and New Caledonia. During this time WHO and partners 
have supported the introduction of influenza PCR into Mataika House, Suva, Fiji.
Key Surveillance Activities
•	 Project staff supported the development of a standardized syndromic surveillance system for 
PICTs under a joint WHO/SPC initiative. The system includes the use of a ILI case definition and 
weekly reporting of data.
•	 Links between PICT laboratories and reference laboratories were strengthened and sample 
referral mechanisms were streamlined.
•	 In consultation with key stakeholders, a strategic approach for further enhancement of influenza 
surveillance in PICTs, including consideration of country-specific and regional solutions, was 
developed.
•	 PICTs were encouraged to report their experience with the 2009 H1N1 outbreak in the SPC 
bulletin, Inform’ACTION.
•	 Viral Transport Media (VTM) was introduced into suitable PICTs as storage and transport 
facilities become available to allow the culture of live virus at reference laboratories.
•	 The project provided support to laboratories in Niue, Tokelau, Tuvalu and Nauru, which  
do not have influenza testing capability, in order to allow for transport of samples to  
reference laboratories.
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Laboratory
PICT laboratories face a range of challenges in maintaining laboratory-based influenza surveillance 
including high turnover of staff, inexperience with IFA techniques and irregular shipments of 
nasopharyngeal supplies for testing. Regular follow-up visits to PICTs are undertaken by project staff 
and recent efforts have focused on supporting PICT laboratory staff with training on sample collection, 
IFA techniques and sample packaging and transport. Collaboration between human and animal health 
laboratory staff is also being supported. Strategic development of the Pacific laboratory network is a key 
role for LabNet which operates under the umbrella of PPHSN.
Key Laboratory Activities
•	 IFA testing was established in 15 sites in 14 PICTs. One nasopharyngeal swab is tested locally 
and another is sent for confirmatory testing. Thirty-three laboratory technicians have received 
on-site training on IFA. To facilitate the collection and storage of samples in VTM for live virus 
detection at reference laboratories, -80OC freezers were purchased for nine PICTs. 
•	 Links have been established with Pacific-based biomedical engineers to support the regular 
servicing and repair of immunofluorescence microscopes.
•	 External Quality Assurance has been established through the WHO CC Melbourne, which 
provides a panel of IFA slides for testing and reporting by PICT laboratories. Excellent results 
were achieved for the six laboratories reporting in 2010. WHO CC Melbourne also provides 
additional control slides for PICT laboratories.  
•	 Intensive laboratory training at WHO CC Melbourne was provided for three PICT laboratory 
staff in September 2010, bringing the total to 23 technicians who have received training  
at the Centre.  
•	 Human and animal health laboratory staff received training and accreditation on packaging of 
infectious substances for airline transport of samples.
•	 Fine, flexible, flocked swabs were introduced to improve the collection of  
nasopharyngeal specimens.
•	 Project staff provided advice and support for the development of a BSL-2 facility in Guam.
•	 A LabNet meeting in November 2010 strengthened the links between human and animal 
health laboratories and between PICT-based and reference facilities. The formation of a LabNet 
Technical Working Group will support the development of laboratory services in the region. 
Preparedness
PPHSN focuses on outbreak-prone diseases, with influenza being one of the priority conditions. 
The project works within the PPHSN framework and with the SPC-based Pacific Influenza Pandemic 
Preparedness Project (PRIPPP) in supporting pandemic planning, emergency exercises, health risk 
communication, procurement and stockpile strategies, and surveillance and outbreak response. 
Improved collaboration between human and animal health laboratory staff has been achieved through 
the project.
The 2009 H1N1 outbreak highlighted the importance of well-established sample transport and 
confirmatory testing arrangements. 
Key Preparedness Activities
•	 The role of reference laboratories in supporting outbreak investigation and response  
has been strengthened.
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•	 Project staff contributed to the development of the standardized syndromic surveillance  
guide and outbreak response manual and supported the implementation of syndromic 
surveillance in PICTs.
•	 Project staff participated in the Third Pacific Avian and Pandemic Influenza Task Force 
meeting held in Fiji in May 2010, supporting the One Health approach that recognizes the 
interdependence of people, animals and environment.
Training
The following trainings occurred in FY 2010 in SPC member countries:
•	 A five-day influenza workshop in May 2010 was organized by the project for Polynesian 
countries for seven participants from human and animal health laboratories in Cook Islands, 
Samoa, American Samoa, Tonga and Tokelau. The training included intensive IFA instruction, 
PCR demonstration, presentations and exercises on influenza surveillance as well as training and 
certification for packaging of infectious substances. 
•	 Mataika House, Suva Fiji hosted a five-day influenza workshop for human and animal laboratory 
staff from Fiji, Kiribati, Vanuatu, Solomon Islands and Papua New Guinea. Eighteen participants 
achieved certification in sample packaging and transport and training on IFA and PCR.
•	 The WHO CC in Melbourne hosted laboratory staff from Saipan, Tonga, Solomon Islands, Fiji 
and Pohnpei for one week of intensive influenza training including IFA instruction and PCR. 
•	 A LabNet regional workshop was held November 1-4, 2010 in Suva, Fiji for 19 countries from 
the Pacific Islands. The meeting’s specific objectives included the following: provide an update 
on the role of laboratories in surveillance; define the role of SPC in the implementation of 
the WHO Asia-Pacific Strategy for Strengthening Health Laboratory Services; support the 
linkages between PICTs laboratories and reference laboratories in Australia, New Zealand and 
Hawaii; and discuss specific testing methods and training needs of laboratory staff.
•	 Training was provided on the packaging of infectious substances to meet International Air 
Transport Association requirements.
Further training is planned to occur at three levels; in-country training during follow-up visits, sub-
regional workshops for human and animal health staff and intensive training at reference facilities. 
2009 H1N1 Activities, FY 2010
The 2009 H1N1 pandemic presented a huge challenge to PICTs, which generally have limited diagnostic 
facilities and developing surveillance and response capacity. PPHSN supported PICTs through the 
communication mechanisms of PacNet and associated networks, which allowed for rapid dissemination 
of information and feedback from PICTs. The pandemic highlighted the importance of surveillance and 
well-established sample referrals mechanisms. A key challenge during 2010 was to build on and sustain 
these fragile systems.
Key 2009 H1N1 Activities, 2010
•	 Information on 2009 H1N1 was disseminated through the PacNet and PacNet restricted 
communication services during the outbreak. 
•	 PHSSN supported the National Task Forces and the development or revision of National 
Influenza Pandemic Preparedness plans during in-country visits.
•	 PICTs continued to receive communication materials on cough and sneeze etiquette and 
information related to infection control. 
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•	 Scientific literature was consulted regarding the use of rapid test kits and IFA in the detection 
of 2009 H1N1. In-country visits were used as opportunities to discuss with laboratory staff and 
clinicians the limitations of rapid tests kits and IFA in the diagnosis of influenza.
Other Notable Achievements in FY 2010 
•	 Most PICTs have been unable to send live virus samples because of the difficulties of storage 
and transport of samples in VTM. For most PICTs that meant that samples in alcohol were sent 
for PCR testing. Funding provided by CDC was used for the procurement of -80OC freezers for 
nine PICTs. The logistics of purchasing, sending and establishing freezers in the PICTs proved 
a challenge. Country visits have been used to provide training on the use of the freezers and 
the method of packing samples in dry ice. The use of VTM will allow for culture, antiviral 
susceptibility testing and further characterization of influenza viruses found in the Pacific region.
•	 Successful sub-regional workshops undertaken at NCBID and Mataika House in 2010 along 
with a 2009 workshop in Guam for the U.S.-affiliated Pacific islands established a new approach 
to the organization of laboratory influenza surveillance networks in the Pacific region. The 
workshops were highly valued and significantly increased participants’ knowledge and 
experience of influenza testing and surveillance.
•	 The establishment of a standardized syndromic surveillance system for PICTs, including a 
standard ILI definition, is contributing to improved influenza surveillance in the region.
Special Influenza Projects
The technical difficulty of IFA along with high staff turnover means that proficiency with IFA testing is 
difficult to maintain in PICT laboratories. The use of digital images taken on-site in PICT laboratories 
and transmitted to a reference laboratory will be tested. If successful, this system would help to maintain 
technical expertise and would be an adjunct to current quality assurance. 
Principal Collaborators
Justus Benzler, MD 
Communicable Disease Surveillance Specialist 
Public Health Surveillance and  
Communicable Disease Control Section (PHS&CDC) 
Secretariat of the Pacific Community
Noumea, New Caledonia
Email: justusb@spc.int (Until August 2010)
Tom Kiedrzynski, MD 
Epidemiologist 
PHS&CDC 
Secretariat of the Pacific Community
Noumea, New Caledonia
Email: tomk@spc.int  
Sala Elbourne, PGD/PH, BMLS 
Laboratory Specialist 
PHS&CDC 
Secretariat of the Pacific Community
Noumea, New Caledonia
Email: salae@spc.int
Anthony Kolbe, MPH, MIntl&CommunityDev
Influenza Surveillance Specialist 
PHS&CDC 
Secretariat of the Pacific Community
Noumea, New Caledonia
Email: anthonyk@spc.int (Until August 2010)
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Vietnam
•	Capital: Hanoi
•	Area: 331,210 sq km 
•	Population: 90,549,390 ( July 2011 est.)
•	Age Structure: 0-14 years: 25.2% (male 11,945,354/female 
10,868,610); 15-64 years: 69.3% (male 31,301,879/female 
31,419,306); 65 years and over: 5.5% (male 1,921,652/
female 3,092,589) (2011 est.)
•	Life Expectancy at Birth: total population: 72.18 years; 
male: 69.72 years; female: 74.92 years (2011 est.)
•	Infant Mortality Rate: total: 20.9 deaths/1,000 live births; 
male: 21.27 deaths/1,000 live births; female: 20.48 
deaths/1,000 live births (2011 est.)
•	Literacy Rate: total population: 90.3%; male: 93.9%; 
female: 86.9% (2002 est.)
•	GDP: $278.1 billion (2010 est.)
•	GDP per Capita: $3,100 (2010 est.)
U.S. CDC Direct Country Support 
In 2005, CDC Influenza Division placed an assignee in Vietnam to support collaboration on avian 
influenza (AI) with the Government of Vietnam. A cooperative agreement with Vietnam’s MOH was 
established in 2005 to develop a national influenza surveillance system that would include surveillance 
for human influenza H5N1 cases. In 2006, a second cooperative agreement began, to address the three 
pillars of influenza prevention and control: preparedness and communication, surveillance and early 
detection of signs of an influenza pandemic, and rapid response and containment of disease outbreak.
In 2009, a second person, a medical epidemiologist, was assigned to Vietnam. The team works 
collaboratively to support the Animal-Human Interface (AHI) work, which looks more closely at the 
risk factors for cross-species transmission of influenza and other zoonotic diseases, and provides for 
stronger collaboration between the animal health and human health sectors. A research cooperative 
agreement with the MOH began in 2009 for research related to influenza and other emerging and 
re-emerging infectious diseases. In 2010, a sustainability cooperative agreement for national influenza 
surveillance with the MOH began and a letter of intent with the Vietnam Ministry of Agriculture and 
Rural Development (MARD) to enhance partnership at the animal-human interface of influenza and 
other zoonotic disease surveillance and research in Vietnam was assigned. 
Surveillance
In 2005, CDC entered into a five-year cooperative agreement with the Vietnam MOH National Institute 
of Hygiene and Epidemiology (NIHE) to establish a national influenza surveillance system. Developed 
primarily as an outpatient surveillance system for ILI, the system initially had four sites. Later, a total of 
15 sites were strategically located throughout the country’s four geographic regions. The system also 
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included nationwide passive surveillance, which detected cases of unexplained severe pneumonia in 
hospitals, including the vast majority of Vietnam’s confirmed human H5N1 cases. The second five-year 
cooperative agreement started in 2010 with a similar design, and expanded surveillance to include 
inpatient SARI. Currently, there are 11 sentinel sites in this sustainability cooperative agreement, 
including five sites for both ILI and SARI surveillance and six sites for ILI-only surveillance. 
Key Surveillance Activities 
•	 NIHE completed the first five-year cooperative agreement of influenza surveillance and 
conducted a review of surveillance activities from 2006-2010. 
•	 NIHE presented influenza surveillance 
data at international influenza conferences, 
including ICEID 2010, Options VII, and  
a workshop on emerging vector-borne  
and zoonotic infectious disease in  
Southeast Asia.
•	 NIHE and CDC refined the location of 
sentinel sites and data collection forms 
for the second surveillance cooperative 
agreement based on the experience and 
lessons learned from the first cooperative 
agreement implementation.
Laboratory
Vietnam has two National Influenza Centers, NIHE 
in Hanoi and Pasteur Institute in Ho Chi Minh City. 
Vietnam has been providing influenza specimens to the WHO CC Atlanta since 2006. In addition, the 
MARD National Centre for Veterinary Diagnosis has provided numerous poultry influenza samples to the 
CDC Influenza Division laboratories.
Key Laboratory Activities
•	 NIHE tested 4,400 samples collected from the outpatient sentinel sites of the National Influenza 
Surveillance System in 2010, with an influenza positivity rate of 22%.
•	 NIHE tested 132 samples from persons with severe unexplained pneumonia, detecting all 7 of 
Vietnam’s reported H5N1 cases, and 16 cases caused by other influenza subtypes.
•	 NIHE provided 50 influenza specimens to the WHO CC Atlanta.
•	 NIHE and CDC developed a new database for linking epidemiology and laboratory  
influenza data.
•	 NIHE developed a surveillance system for oseltamivir resistance, to start in 2011.
Preparedness
Technical support from CDC for pandemic preparedness started in 2006 in the form of a cooperative 
agreement with the Vietnam MOH General Department of Preventive Medicine (GDPM). The agreement 
focused on helping with the development, revision and testing of avian influenza and pandemic 
influenza preparedness plans for government, agencies, and organizations; coordinating activities and 
the sharing of information among partners, and; developing and disseminating communication messages 
and materials.
U.S. and Vietnam government officials sign a bi-lateral Letter of Intent at the IMCAPI 
meeting, between the CDC Influenza Division and the Ministry of Agriculture and Rural 
Development, to support continued partnership in surveillance and research of influenza 
and other zoonotic diseases, Hanoi, Vietnam 2010.
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Key Preparedness Activities
The following activities were undertaken by GDPM:
•	 Supported the development of a national action plan on avian influenza prevention. 
•	 Supported the updating and revision of the circular Regulating the Mechanism of Informing 
and Reporting Infectious Diseases.
•	 Conducted simulation exercises for influenza pandemic preparedness in three provinces. 
•	 Conducted a review workshop on the communicable diseases reporting system.
•	 Updated Practical Guideline on Influenza A Infection Control in Health Care Facilities.
•	 Produced and disseminated messages via mass media to increase awareness and behaviors of 
general population related to influenza prevention and control.
Training
CDC-Vietnam partners hosted the following training activities in 2010:
•	 Training on surveillance and reporting of potential pandemic threats and emerging diseases for 
preventive medicine staff at national level.
•	 Revision of training documents related 
to surveillance, prevention, control 
and treatment of influenza and 
influenza pandemics for preventive 
health workers at the provincial level.
CDC hosted the following training  
activities in 2010:
•	 Bioinformatics and phylogenetic 
workshop for laboratory personnel in 
Vietnam.
•	 Laboratory capacity-building training 
at CDC-Atlanta for personnel from the 
MARD Department of Animal Health.
The following training activities have been planned for the year 2011:
•	 Training on timely detection of, reporting of, and measures for controlling avian influenza cases 
in health care settings for health care workers.
•	 Training on influenza epidemiology and supervision capacity of preventive medicine staff at 
provincial levels.
•	 Training for provincial rapid response teams on surveillance and response to influenza 
outbreaks.
CDC Influenza Division and Ministry of Health NIHE partners attend a workshop of the CDC-
supported National Influenza Surveillance Project, Hanoi, Vietnam, 2010.
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2009 H1N1 Activities, FY 2010
The first case of 2009 H1N1 virus infection was identified in Vietnam in May 2009. The number of cases 
increased rapidly and peaked in September 2009, reaching over 10,000 cases in October 2009 before the 
MOH stopped counting all individual cases. Pandemic 2009 H1N1 virus activity largely disappeared by 
May 2010 but started increasing again in December 2010.  
Key 2009 H1N1 Activities, 2010
•	 MOH tracked and responded to pandemic 2009 H1N1 with surveillance and preparedness 
systems supported by CDC.
•	 MOH included 2009 H1N1 in the epidemiology and laboratory surveillance programs, 
demonstrating that it caused more cases of unexplained severe pneumonia than any other 
influenza subtype in 2010, including H5N1.
•	 MOH conducted genetic and molecular epidemiological analysis of the 2009 H1N1 virus, 
identifying mutations similar to those found in other locations in the world.
Special Influenza Projects and Other Notable Achievements in FY 2010 
•	 In early 2010, through the MOH-NIHE cooperative agreement the AHI initiative supported 
a joint surveillance project between MOH and MARD to detect the types and prevalence of 
influenza virus in people, pigs, and poultry living in close proximity in rural Vietnam. This was 
the first AHI project and a significant achievement for the IP in Vietnam, as well as for MOH 
and MARD.
•	 A letter of intent was signed between Vietnam MARD and U.S. Department of Health and 
Human Services (HHS) to enhance partnership at the animal-human interface of influenza and 
other zoonotic diseases surveillance and research.
•	 Six influenza laboratory and epidemiology abstracts from Vietnam partners were accepted at the 
Options for Control of Influenza VII conference, Hong Kong. 
•	 CDC Influenza Division assisted Vietnam’s first FETP class with classroom technical assistance 
and abstract review for TEPHINET and other conferences.
Public Health Importance
•	 CDC-supported work has directly enhanced collaboration between MOH and MARD, which will 
continue to benefit research on influenza and other zoonotic diseases, as well as the detection 
of and response to H5N1.
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Burden of Disease and Risk Factors
Bangladesh
Estimating the burden of influenza-associated mortality through severe acute 
respiratory infection in Matlab population-based surveillance
A recent study performed within a hospital-based surveillance platform documents a burden of nine 
influenza cases per 100 person-years among persons of all age groups in Bangladesh. This influenza 
incidence rate is similar to rates calculated from a population-based surveillance site in urban Dhaka (10 
per 100 person-years) and rates throughout Southeast Asia. These population–based efforts, however, 
have been unable to estimate influenza mortality. This longitudinal study aims to estimate the incidence 
of severe acute respiratory infection (SARI) and the mortality rate attributable to respiratory viral 
infections in Matlab, a rural sub-district of eastern Bangladesh during five months of the 2010 influenza 
season. 
Study Aims and Objectives:
•	 Estimate the mortality rate with influenza and other viral respiratory infections in this 
community-based surveillance site.
•	 Determine the sensitivity of commonly used influenza case definitions.
•	 Identify subpopulations at risk of dying with influenza. 
•	 Quantify co-infections with immune-preventable or treatable pathogens.
Approach: From June through October 2010, field staff made weekly home visits and daily hospital 
visits to report potential SARI case-patients in the community or at the hospital. A study physician 
obtained a nasopharyngeal swab from all enrolled case-patients, and collected blood for culture from 
hospitalized case-patients. All swabs were tested for influenza A and B viruses, respiratory syncytial 
virus (RSV), human metapneumovirus (hMPV), adenoviruses and human parainfluenza viruses (HPIV) 
type 1, 2 and 3 by real-time RT-PCR. Blood was tested for Streptococcus species, Staphylococcus 
species, Hemophilus species, Klebsiella pneumoniae, Enterococcus faecalis, Acinetobacter species, 
Pseudomonas species and Candida species. Deaths of any SARI case–patients were identified and 
a nested case-control study was planned to identify potential risk factors for death among SARI 
case-patients. 
Timeline: Data and sample collection was completed from June to October 2010. Data analysis and 
write-up is currently ongoing.
Progress and Findings: During the study period, 172 SARI case-patients were identified in a community 
of 113,660 persons including 13,115 children of less than 5 years of age. Among the case-patients, 141 
were children less than 5 years of age. Respiratory viruses were detected in 82 case-patients, with most 
of them being under 5 years of age. The incidence of SARI attributable to respiratory viruses among 
children younger than 5 years of age was 19.3/100,000 child-week for RSV, 3.5/100,000 child-week for 
HPIV3, 3.2/100,000 child-week for influenza and 1.8/100,000 child-week for adenovirus. The incidence 
of SARI attributable to respiratory viruses among those older than 5 years of age was 0.2/100,000 
person-week for influenza and 0.04/100,000 person-week for RSV. No death among SARI case-patients 
was reported.
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Conclusion: Respiratory viruses, and in particular RSV, are commonly associated with severe acute 
respiratory infection among children under 5 years in this rural setting. Further studies to provide 
influenza mortality data are critical to understand the burden of influenza disease in Bangladesh and 
to appropriately prioritize influenza prevention and control efforts in a country with many competing 
health priorities.
Incidence of influenza-associated mortality in Bangladesh: 2008–2009
Although data on incidence of influenza deaths could help policy makers prioritize allocation of scarce 
resources, limited information is available from Bangladesh. Influenza surveillance data and community 
surveys were leveraged to estimate the incidence of influenza mortality in Bangladesh during 2008–2009.
Study Aims and Objectives:
•	 Estimate the incidence of influenza-associated mortality during 2008-2009 within the study area.
•	 Project national death estimates attributable to influenza.
Approach: ICDDR,B in collaboration with the government of Bangladesh and funding from CDC has 
been conducting hospital-based enhanced influenza surveillance in four sentinel hospitals. Two days per 
month, surveillance physicians collect respiratory samples from hospitalized severe pneumonia (younger 
than 5 years) and severe acute respiratory infection (younger than 5 years) case-patients who reside 
in the hospitals’ catchments areas. All samples are tested for influenza virus using real-time RT-PCR. 
Twenty randomly selected unions (smallest administrative unit) from the hospitals’ catchment areas were 
identified and canvassed to identify persons who died during 2008−2009. To estimate the incidence of 
influenza-associated deaths, the number of decedents in the catchment areas who had sudden onset 
of fever and cough or sore throat within 14 days of death was multiplied by the proportion of sampled 
hospitalized case-patients who were positive for influenza at the sentinel hospitals and then this 
numerator was divided by the census population of the survey sites.
Timeline: The community survey was conducted between February and May 2010. The influenza 
surveillance is ongoing in the four sentinel sites.
Progress and Findings: Of 4,358 decedents identified, 578 (16%) had fever and cough and/or sore 
throat within 14 days of death. The annual incidence of influenza-associated death during 2008-2009 
was as follows for different age groups: 2 per 100,000 person-years (py) for children under 5 years 
of age, 5 per 100,000 py for those aged 5 to 60 years, and 87 per 100,000 py among individuals aged 
over 60 years. Assuming the rates were similar in other parts of the country, we project approximately 
15,000 influenza-associated deaths occur annually with 440 occurring among children aged less than 5 
years. The findings were presented at the Options for the Control of Influenza VII conference held in 
September 2010 and a manuscript is in preparation. 
Conclusion: The data suggests the highest burden of influenza mortality is among the elderly. Investing 
in cost-effective scalable interventions may help lower influenza disease burden. The study demonstrates 
that our method of combining community survey and influenza surveillance data can be adopted in 
other similar resource-poor settings to provide estimates of influenza-associated deaths where there is 
limited use of vital registers and many deaths occur at home. 
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Estimating the financial burden of influenza and other respiratory pathogens in 
four tertiary hospitals in Bangladesh
Recent studies suggest that influenza and other respiratory diseases are prevalent and costly in 
Bangladesh. In Kamalapur, a low income neighborhood of Dhaka, influenza caused 84.5 episodes/1,000 
children-years and was responsible for 14% of pneumonia cases among children under 5. The cost 
of having a child hospitalized for pneumonia was estimated at US $94 per illness episode and the 
cost of outpatient respiratory infections at US $3.7. Hospital expenditure exceeded 50% of the most 
families’ monthly income, thus hospitalization for respiratory diseases represents a catastrophic cost for 
patients. The economic burden of influenza in Bangladesh is believed to be similar to that found in the 
pneumonia studies.  
Study Aims and Objectives:
•	 Estimate the direct expenditures incurred by hospitalized patients who test positive for 
respiratory pathogens. 
•	 Provide policy makers from the Government of Bangladesh with initial estimates of the cost 
associated with influenza and other respiratory pathogens so as to better evaluate the value or 
respiratory illness intervention and prevention strategies.
Approach: From May 2010 to October 2010, each month we listed all patients from four tertiary 
hospitals who were hospitalized with respiratory illnesses and tested positive by rRT-PCR for any of the 
following respiratory viruses: influenza, RSV, parainfluenza type 1, 2 and 3, rhinovirus, adenovirus or 
metapneumovirus. Within 30 days of discharge from the hospital, interviewers administered a structured 
questionnaire at the patient’s residence and collected information on the total direct cost of treatment 
which included medical costs (physician consultation fees, hospital bed, medicines and diagnostic 
tests) and non-medical costs (food and travel). Prescription and discharge reports were used to estimate 
medical costs; patients helped categorize out-of-pocket medical cost or hospital-supported medical cost. 
Additionally, patients were questioned to identify the strategies used by families to meet the treatment 
costs (e.g. from monthly income, by borrowing or savings). 
Timeline: May to October 2010, spanning the annual influenza season in Bangladesh. 
Progress and Findings: The study was finished in October 2010 and preliminary analysis of the data 
focusing on inpatients has been completed. The study findings will be presented at an international 
scientific conference by a junior Bangladeshi scientist who implemented the study. Thirty-eight patients 
under 5 years of age and 34 patients over 5 years were enrolled. The median monthly household 
income was US $123. The median direct cost per episode was US $39 among patients under 5 and US 
$49 among patients over 5 years of age. On average, medical cost was 64% of the total direct cost. The 
majority of medical cost was out-of-pocket as hospital supported only a small fraction of expenses. One-
third of patients spent over 50% of their total family monthly income for the treatment of an episode of 
respiratory viral illness. Sixty percent of families borrowed money to manage the expenditure and 44% 
of those, borrowed with a mean monthly interest of 78%. Sixty percents of families reported that they 
had to reduce their monthly food expenses to manage the expenditure of treatment. 
Conclusion: Costs for hospitalizations with respiratory viral infections results in significant financial 
hardship to the families. Cost-effective prevention programs can reduce both clinical morbidity and 
related cost of treatment. 
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Longitudinal assessment of the effect of influenza on the cognitive development of 
urban poor children, Bangladesh 
Frequent, protracted, and severe influenza disease may cause cognitive developmental delays in very 
young children, as has been previously shown with other infectious pathogens. Substantiating whether 
frequent respiratory infections delay cognitive development is important because of the long-term 
implications for affected children and their communities. This protocol proposes to study, during two 
years, the association between rates of influenza disease and delayed cognitive development in a birth 
cohort of urban poor children aged less than 2 years based in Mirpur.
Study Aims and Objectives:
•	 Assess the potential association between the frequency, duration, and severity of influenza 
disease and delayed cognitive development in a birth cohort.
•	 Assess the attributable risk of secondary tobacco exposure, indoor air pollution, and infrequent 
hand washing to the frequency, duration, or severity of acute respiratory infections (ARI) and 
laboratory-confirmed influenza disease in participating birth cohort children. 
•	 Explore genome-wide associations with frequency, duration, and severity of laboratory-
confirmed influenza disease in participating children.
Approach: Participants aged 3-12 months were enrolled into the study and followed during two years 
to determine the hazard of delayed cognitive development; quantify the incidence of ARI, laboratory-
confirmed influenza, and diarrhea; administer yearly cognitive tests; and survey covariates. Field teams 
also collected socio-demographic information from each of the enrolled participants and recorded 
monthly indoor air particulate matter levels during 2009 among a subset of children. Study teams visited 
households every three days to administer a brief standard questionnaire using PDAs and determine if 
participants have developed ARI or acute diarrhea in the past three days. If field teams identified ARI 
case-patients, they requested that the children be taken to the neighborhood clinic for sampling of 
nasopharyngeal washes. Respiratory samples were tested for influenza A and B, parainfluenza 1 and 
3, RSV, adenovirus, rhinovirus, bocavirus, and human metapneumovirus by real-time RT- PCR. Blood 
samples were collected for genome-wide association analysis.
Timeline: April 2009 to March 2011.
Progress and Findings: Enrollment of the children in the study is complete and follow-up is ongoing.
From April 2009 through March 2010, 415 children were followed for a total of 307 child-years. A total 
of 273 children developed 578 episodes of ARI and respiratory viruses were detected in the majority 
of these episodes. Of the 578 episodes of ARI, 198 were diagnosed as clinical pneumonia. The annual 
incidence of pneumonia associated with different respiratory viruses were 14 episodes per 100 child-
year for RSV, followed by rhinovirus at 8, human metapneumovirus at 7, influenza at 6, adenovirus at 
2 and parainfluenza virus 3 at 2 episodes per 100 child-year. These preliminary findings confirm that 
childhood pneumonia is prevalent and that viruses are frequently identified in urban poor children aged 
less than 2 years of age with pneumonia in Bangladesh. Two manuscripts are being drafted on findings 
from the first year. Further data analysis will explore the primary objectives of this study, but the viral 
incidence data illustrates how research platforms can be leveraged and allow for time-sensitive studies 
to be performed in a cost-effective manner.
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Central America
Characterization of 2009 H1N1 cases and deaths in El Salvador, Guatemala, Costa 
Rica, Panama and Dominican Republic
During 2009, the epidemiologic and clinical characteristics of 2009 H1N1 were poorly understood. A 
priori, health authorities considered persons with risk factors for severe disease from seasonal influenza 
(i.e. children younger than 5 years of age, persons with chronic medical conditions, and persons older 
than 65 years of age) as potentially at high risk of developing complications from 2009 H1N1. To 
explore the epidemiologic characteristics of decedents infected with 2009 H1N1, ministries of health in 
Central America and Dominican Republic implemented active surveillance for 2009 H1N1 decedents.   
Study Aims and Objectives:
•	 To explore the epidemiologic characteristics of decedents infected with 2009 H1N1, ministries 
of health in Central America and Dominican Republic implemented active surveillance for 2009 
H1N1 decedents.   
Approach: Ministries of health actively searched for case-patients through rumor reporting, event-based 
surveillance, sentinel site hospitals, and death reporting systems. Upon identifying potential case-
patients, health authorities obtained verbal autopsies and clinical records (when available) to determine 
if decedents met the SARI case-definition two weeks before death. Using standardized questionnaires, 
health authorities systematically abstracted demographic and clinical information from SARI-confirmed 
decedents’ close relatives or clinical records. We described 2009 H1N1-positive SARI decedents’ 
demographic and clinical characteristics through proportions and graphical representations.   
Timeline: May to December 2010.  
Progress: The survey was completed, the databases are available, and the data analysis is ongoing. The 
manuscripts were presented in January 2011.  
Conclusion: During 2009, we identified 92 SARI decedents, all of whom were tested for respiratory 
viruses. The median age of 2009 H1N1-positive SARI decedents was 29 years and 52 (57%) were female. 
Out of 52 female decedents, 16 (31%) were pregnant. The most common pre-existing conditions 
observed were asthma, diabetes and obesity. On average, 2009 H1N1-positive SARI decedents presented 
for care a median of three days from symptom onset and died seven days from consult. The most 
common admitting diagnoses were pneumonia, bronchopneumonia, and pharyngotonsilitis. The 
most frequent pathological findings were cardiomegaly, pulmonary hemorrhage, and neutrophilic 
bronchopneumonia. The pandemic disproportionately affected the young and healthy in Central 
America and Dominican Republic. Case-patients frequently presented late for care and did not receive 
oseltamivir. Such findings were also applied to high-risk groups targeted with risk communication 
messages.
Ecological Study of Excess SARI during Influenza Pandemic in 2009; El Salvador, 
Costa Rica, Nicaragua and Guatemala (San Juan de Dios Hospital)
The occurrence of pandemic 2009 H1N1 was accompanied by doubts about the severity of the disease. 
Because of the difficulty in identifying all severe cases of influenza A (lack of resources and supplies), 
the cases of severe acute respiratory illness (SARI) were studied as a proxy for severe influenza cases. 
This study, conducted in different countries, gave a regional view of the pandemic with data from 
multiple sources such as surveillance, social security and a national hospital.
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Study Aims and Objectives:
•	 Determine the excess of SARI case admissions to hospitals during 2009 as an indirect measure 
of the impact of the pandemic.   
Approach: In Nicaragua, the data source was the daily information gathered by the Statistic Planning 
and Information Directorate of the MOH (129,586 hospital admissions between 2004 and 2009). In El 
Salvador, weekly information collected by the Morbidity and Mortality System of the Epidemiological 
Surveillance Directorate at the MOH (83,647 hospital admissions 2005-2009) was used. In Costa Rica, the 
data source was the weekly information gathered by the Social Security Fund (Caja Costarricense del 
Seguro Social) (95,413 hospital admissions from 2000 through 2009). Guatemala National Hospital San 
Juan de Dios Epidemiological Surveillance Unit provided information on a weekly basis (9,763 hospital 
admissions, period 2002-2009). Time series analyses were conducted. SARIMA model was fitted with the 
pre-pandemic data, forecasting of expected hospital admissions was generated with 95% Confidence 
Intervals.   
Timeline: March to September 2010.  
Progress: The survey was completed, the databases are available and the data analysis is ongoing. The 
manuscripts will be presented in March 2011.  
Conclusion: Excess hospital admissions were defined as: the difference between the observed hospital 
admissions in 2009 and the forecasted number of admissions generated by the model (Upper Confidence 
Interval) for each country. In the first quarter of 2009, an excess of 262 hospitals admissions was found 
for Nicaragua; this is a 10.19% excess (95% CI: 10.15-10.22). Nevertheless, during the pandemic period, 
the data did not show any excess. In El Salvador, findings revealed that an excess of 1,871 hospital 
admissions were observed between epidemiological weeks 27 and 37, or an excess of 118.66% (95% 
CI: 118.61-118.72). Costa Rica data did not show any excess of hospital admissions during 2009, and in 
Guatemala, data from San Juan de Dios Hospital revealed an excess of 32 hospital admissions, or 35.99% 
(95% CI: 34.98-36.99) between epidemiological weeks 27-30.
Cambodia
Epidemiology of Human Influenza in Kampong Cham Province, Cambodia
Active community-based surveillance covering 25 villages (cohort population around 15,000, all ages) 
in Kampong Cham province, about 130 kilometers north of Phnom Penh capital. This surveillance was 
implemented by Institut Pasteur – Cambodia (IPC) with support from U.S. CDC and was a component 
added to an existing community surveillance of febrile illness and dengue fever in the same cohort 
villages supported by the Pediatric Dengue Vaccine Initiative of the International Vaccine Institute 
(PDVI-IVI).
Study Aims and Objectives:
•	 Describe the seasonality, age distribution and transmission patterns. 
•	 Describe the burden of disease including incidence rates, hospitalization rates and mortality 
rates by age group.
Approach: In 25 target villages, villagers of all ages were eligible for the surveillance of fever illness. 
Village Teams (VT) performed weekly household visits to take a temperature reading, identify and 
document subjects having fever or history of fever during the past six days using digital thermometers 
and report them to nurses at the pediatric ward of Kampong Cham provincial hospital by phone. Fever 
is defined as a body temperature ≥37.5°C measured at armpit. 
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Nurses visited fever cases at home to conduct an interview and take a nasopharyngeal swab and blood 
samples, after obtaining signed written consent from each participant. 
For each fever episode, swab and blood samples were collected at one or two days following fever 
onset (first visit) and a second blood sample was collected at 14 days later (second visit). All specimens 
were shipped to IPC in Phnom Penh for viral detection, subtyping and serology testing. 
Timeline: March 2009 to February 2010.
Progress and Findings: A total of 4,168 fever episodes were identified with 4,114 nasopharyngeal swab 
samples obtained. A total of 1,712 (42%) swab specimens were tested; of these, 182 were positive for 
influenza A/B infections. The predominant influenza virus circulating in 2009 was H3N2 subtype (75.8%) 
followed by 2009 H1N1 (14.3%) and influenza B (9%). Seventy-nine percent of positive cases were 
among subjects younger than 20 years of age. 
By applying the total percentage of influenza-positive specimens to all detected fever cases, the 
estimated incidence of flu A or B was of 26.4 per 1,000 population (95% CI: 17.7 - 47.6). Estimated 
incidences per 1,000 by virus subtype were 20.0 (95% IC: 12.5 - 30.6) for H3N2, 3.7 (95% IC: 1.5 - 8.2) 
for 2009 H1N1, 2.5 (95% IC: 0.6 - 7.8) for influenza B, and 0.20 (95% IC: 0.01 - 0.9) for seasonal H1N1.
A clear seasonality of influenza activity was observed with increased influenza infections during July 
and November and peak detection during September – November, representing 65% of the positive 
specimens. 
Costa Rica 
Household survey to estimate the prevalence and burden of severe acute 
respiratory infection, influenza-like illness and 2009 H1N1 in Cartago, Costa Rica
Influenza epidemiology knowledge is limited in Central America, since sentinel surveillance focuses 
mainly on laboratory functions. In response to the need for better knowledge about the impact of this 
disease among the population in 2010, the Costa Rican Social Security Fund, with technical assistance 
from the Influenza Program, implemented a survey on the use of health care services in the sentinel 
surveillance platform of Cartago, Costa Rica.   
Study Aims and Objectives:
•	 Estimate crude rates of ILI and SARI among the studied population, for the last 30 days and 12 
months, respectively.  
•	 Describe health care services practices for identified persons with symptoms consistent with ILI 
and SARI definition.
•	 Estimate economic and disease burden in households with SARI and ILI identified cases.   
Approach: The survey was applied in a random sample of houses located in six cantons and 30 
districts, which serve as approximately 80% of the catchment population for health care services 
provided by the hospital Max Peralta of the province of Cartago, Costa Rica. The sample was a 
multistage model, with the first stage cluster sampling and the second stage a systematic random sample 
within each cluster, and for the different stratums. The size of the sample was n=1,500 (77% in urban 
zone, and 23% in rural zone). Data was collected in every selected house that previously completed 
informed consent, through validated and standardized questionnaires. The questionnaires asked about 
symptoms, disease burden, what kind of health care service was sought or the reason why they did 
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not request health care services, and related risk factors. Cases were identified using the WHO case 
definitions of ILI and SARI. Biological specimens were not obtained from the identified cases.   
Timeline: June to July, 2010.  
Progress: The survey was completed, the databases are available and the data analysis is ongoing. The 
manuscripts will be presented in January 2011.  
Conclusion: Of the studied households, 13.9% (209/1500) registered an ILI case, or 4.5% (291/6,453) 
of the sample population. Of the studied households, 4.4% (68/1500) reported a SARI case, which is 
equivalent to 1.5% (95/6453) of the persons in the sample. Ninety-four percent of the households had 
health insurance provided by the Costa Rican Social Security Fund, 2% had private insurance, and 4% 
did not report health insurance. Related to use of health care services, 70.6% (204/291) of the persons 
with ILI requested health care services. Among the SARI cases, 80% (76/95) requested health care 
services. The average number of work days missed by persons with ILI was 4.3 days, and on average 
there were 4.8 school days missed due to ILI. Of those with ILI, 22.85% (64/280) reported loss of income 
during the disease due to wages decrease ($40) and loss of other kind of incomes ($30). Thirty-one 
percent (87/280) of main caregivers reported loss of income during the disease ($22.5), wage discounts 
($20) and loss of other kind of income ($40).
El Salvador
Household survey on the use of health care services for respiratory infections in 
urban and rural populations within five municipalities of Santa Ana, El Salvador 
A population survey to estimate the frequency of influenza-like illness (ILI) and severe acute respiratory 
infection (SARI) and to describe the pattern of use of health care services was carried out by the 
Ministry of Health (MOH) of El Salvador in late 2009, with technical support from the CDC Central 
America and Panama (CDC-CAP) Influenza Program. This was conducted with a population sample of 
five municipalities within the catchment area of the influenza surveillance sentinel unit of Santa Ana, El 
Salvador. 
Study Aims and Objectives:
•	 Estimate the ILI frequency in the 30 days previous to the population survey.  
•	 Estimate the SARI frequency in the 12 months previous to the population survey.  
•	 Describe the pattern for the use of health care services due to ILI and SARI identified among 
the surveyed population.  
Approach: Using data from the last population census of El Salvador, the geographical area that 
captures the population seeking care at the influenza surveillance sentinel unit of Santa Ana City was 
determined. Five municipalities were selected around the sentinel hospital, which provided 80% of 
the hospital discharges due to SARI-related causes in the last three years. A two-stage cluster sampling 
using census segments for urban areas, and local maps by cantons for rural areas, was carried out. The 
sampling size was estimated in 1,680 households through a formula of proportions, and was stratified 
by urban/rural. Four  teams of previously trained surveyors were formed; they surveyed one person (the 
head of household, ideally) of every selected household, according to the programmed routes, collecting 
data from the persons who live in the house and who had lived there during the last six months, by 
means of a questionnaire previously validated and standardized. Surveyed persons were asked to 
provide informed consent.   
Timeline: November to December 2009.
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Progress: The study was completed. Databases are available. Currently, the data analysis is being 
performed. The first manuscript will be presented in February, 2011.   
Conclusion: A total of 7,683 persons were surveyed in 1,663 households (an average of 4.62 persons 
by household.). Four hundred and sixty-four (6%) ILI cases were reported during the days previous to 
the survey, and 52 (0.7%) SARI cases were reported during the 12 months previous to the survey. Two 
hundred fifteen (46.3%) people who reported ILI sought medical care, 155 (33.4%) in some health care 
facility of the MOH and 10 (2.2%) went to the SARI sentinel unit hospital of Santa Ana. Only six (11.5%) 
of the total identified SARI cases reported going to the sentinel hospital of Santa Ana. ILI is common 
among the population; nevertheless, only half of the people seek medical care in health services and 
one third of people go to a public health network facility in the country. Pneumonia and SARI are less 
frequent among the population, but a higher percentage of persons seek medical care for these diseases, 
primarily in the network of the MOH, due to the severity of those diseases.   
Influenza seasonality model established in El Salvador showing a Southern 
Hemisphere pattern during 2003-2009
In collaboration with Ministry of Health (MOH) of El Salvador, the in-country seasonality model was 
updated, using data available from 2003 to 2009.   
Study Aims and Objectives:
•	 Determine the seasonality of influenza A in El Salvador.    
Approach: An ecological time series study was conducted. Data collected by the surveillance system 
and tested with IFA, RT-PCR, and viral culture were analyzed. The following analysis methods were 
used: Simple Autocorrelation Function, Spectral Analysis, and a Generalized Linear Model. Of influenza-
suspected cases, 6,163 specimens were processed and 21.5% were positive for influenza A [95% CI: 
20.4-22.5].   
Timeline: March to June 2010.  
Progress: The survey was completed, the databases are available and the data analysis is ongoing. 
Conclusion: A total of 6,163 specimens from suspect influenza cases were processed and 21.5% were 
positive for influenza A [95% CI: 20.4-22.5]. Influenza A positivity is approximately 30% in midyear; the 
highest peak was observed in 2009 (50%) and the lowest in 2007 (20%). An increase of influenza A cases 
was observed from June until December (influence of the pandemic in 2009). If 2009 data are removed, 
then the increase of flu cases is observed from June through September (relatively wide); Simple 
Autocorrelation Function showed a sinusoidal shape that suggests an annual seasonality; the Spectral 
Density Function showed a marked oscillation around 0.08-0.09 frequency corresponding to a 12 month 
period (seasonality). The Generalized Linear Model proved seasonality. The pattern found is similar to 
the one observed in countries of the Southern hemisphere with a peak in the middle of the year.
Ecological Study of Excess ARI, SARI and Deaths due to SARI, related to Influenza 
Virus Circulation in El Salvador (2007-2009)
After influenza seasonality was determined, a study was conducted in El Salvador, a first in the Central 
American region, to determine the respiratory disease burden attributable to influenza virus circulation. 
Severe acute respiratory illness (SARI), acute respiratory infections (ARI) and deaths caused by SARI 
were studied.
Study Aims and Objectives:
•	 Correlate the circulation of influenza virus with the occurrence of ARI, SARI and deaths due to 
SARI. A time series analysis was conducted.   
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Approach: The data sources were: Daily Epidemiological Report, Online Morbidity and Mortality 
National System, and data from the National Influenza Center. Co-linearity of circulation of influenza A, 
B; parainfluenza 1, 2 and 3; human respiratory syncytial virus and adenovirus was evaluated. ARI, SARI 
and deaths due to SARI time series data was pre-whitened using Box- Jenkins models for each viral 
positivity percentage ARIMA model and respective crossed correlations were determined. A Poisson 
regression model was fitted using the robust quasi Likelihood model (step by step backwards) of 
the morbidity and mortality time series data to estimate the Attributable Risk Percent of the Positivity 
Percentage for Influenza.   
Timeline: July to September 2010.  
Progress: The survey was completed, the databases are available and the data analysis is ongoing. 
Conclusion: ARI does not demonstrate a marked seasonality, and is more frequent in children younger 
than 5 years old and young adults. Influenza was the cause of 10.4% of ARI in the general population in 
the period 2007-2009. In children younger than 1 year old, influenza caused 13.8% of ARI. In children 
1-4 years old, influenza caused 9.9% of ARI and in those older than 60 years, 7.4% of ARI. SARI has 
annual seasonality (cases increase at midyear) and is more frequent in children younger than 1 year 
old. The main diagnosis at discharge in all age groups is pneumonia. During 2007-2009, 14.2% of SARI 
cases in the general population were due to influenza. In children younger than 1 year old, influenza 
causes 20.3% of SARI and in children 1-4 years old, influenza caused 20.7% of the cases. Estimates of the 
Incidence Rate Ratio for SARI deaths due to influenza were not statistically significant in all age groups 
and in the general population.
India
Population-based, Longitudinal Burden of Disease Study of Influenza in India
The burden of disease related to influenza virus infection in India is not yet well-defined but likely 
to be substantial given that India accounts for 20% of global childhood deaths caused by respiratory 
infections. To address this issue, a population-based longitudinal study is ongoing at three sites 
(collaboration between AIIMS, Delhi; Christian Medical College, Vellore; and Vadu Rural Health Program 
at KEM Hospital, Pune) with demographic surveillance systems (DSS) to estimate the burden of 
influenza in these communities.   
Study Aims and Objectives:
•	 Estimate the incidence of laboratory-confirmed influenza among persons hospitalized for acute 
respiratory illnesses and acute exacerbations of chronic medical conditions. 
•	 Estimate the incidence of laboratory-confirmed influenza among medically attended outpatients 
seeking care for acute respiratory illnesses and acute exacerbations of chronic medical 
conditions.
•	 Characterize the clinical spectrum of inpatient and outpatient disease related to influenza, 
evaluate different clinical case definitions and syndromes to predict influenza, and describe the 
seasonality of influenza. 
•	 Determine risk factors for severe disease due to influenza, including underlying chronic 
conditions, demographics, smoking, and socioeconomic status.
•	 Describe the health care utilization of the population and define the burden of respiratory 
disease that did not seek care or refused hospitalization for severe respiratory illness, describe 
obstacles to care.
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•	 Estimate the annual mortality rate due to severe respiratory disease and influenza in the 
population.
Approach: Persons living in the DSS areas in one of the three study areas (Ballabgarh, Vadu, and 
Vellore) that seek inpatient medical attention and meet the study enrollment criteria are enrolled, and 
clinical and epidemiologic information and respiratory specimens are collected from all consenting 
persons. Each site is also conducting a community-based survey to gather health care utilization data 
as well as household risk factors and socioeconomic status. Additionally, two sites (Ballabgarh and 
Vadu) are conducting outpatient screening and enrollment to estimate the burden of non-hospitalized 
medically attended influenza disease.
Timeline: April 2009 to September 2011.
Progress and Findings: The population under surveillance at three sites is approximately 300,000. The 
facility-based surveillance for medically attended inpatients has varied greatly both in enrollment and 
percent positivity for influenza from site to site. While Vadu/Pune revealed influenza positivity of 24% 
(683/2,866), Delhi has 8 % (62/775) and Vellore has 10% (29/284). Almost half of the infections at each 
site are due to pandemic 2009 H1N1. A preliminary estimate of influenza-related hospitalizations from 
these sites, based on eligible-cause hospitalization rate of 13/1,000 population/year and 8-10% influenza 
positivity, has allowed researchers to extrapolate the data for a national estimate of approximately 1.6 
million total hospitalizations related to influenza. Studies are underway to do similar estimations from 
other sites to generate influenza disease burden and hospitalization estimates. 
Vellore, India, one of the population-based study sites for the Influenza Disease Burden in India (IDBI) study, as seen from the roof of the Christian Medical College
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Kenya
Population-based Surveillance for Influenza and Other Respiratory Diseases in 
Nairobi and Kisumu, Kenya
The Influenza Program in collaboration with the International Emerging Infections Program (IEIP) 
under KEMRI/CDC currently conducts population-based disease surveillance (PBDS) for severe acute 
respiratory illness (SARI) and influenza-like illness (ILI) in two sites in Kenya; Kibera, an informal urban 
settlement in Nairobi, and Lwak, a rural community in western Kenya. Approximately 25,000 residents 
are enrolled in each of the two sites.
Study Aims and Objectives:
•	 Characterize etiologies of acute respiratory illness in a rural community and an urban 
community in Kenya.
•	 Evaluate the burden of medically attended and home-reported influenza and other respiratory 
diseases.
•	 Provide a platform to evaluate interventions such as vaccine.
Approach: Community interviewers visit each household every week to ask residents questions  
about illness symptoms in the past week. In addition, residents have access to a free clinic, where 
surveillance is conducted for respiratory illness, including influenza, and a number of other disease 
syndromes. Patients meeting the case definition for SARI and ILI have a nasopharyngeal and 
oropharyngeal sample collected. Specimens for SARI and ILI are tested at the CDC IEIP laboratory in 
Nairobi for influenza and other viral pathogens using real -time RT- PCR. Data from weekly household 
visits, visits at the free clinics, and laboratory results are stored in a central database in CDC-Nairobi and 
at KEMRI/CDC, Kisumu.
Timeline: Surveillance for respiratory illness in the two sites began in 2006. The plan is to continue the 
project for at least five years so that seasonality, epidemiology and burden of influenza can be well-
understood, and interventions such as vaccine can be evaluated.
Progress and Findings: The study is ongoing. However, preliminary analysis has been undertaken, and 
rates of influenza, pneumonia and laboratory-confirmed influenza virus infection have been determined 
for the first three years of acute respiratory illness surveillance. Influenza virus has been shown to 
circulate year-round with a peak in activity between July and October of every year. The rates for acute 
lower respiratory illness resulting in clinic visitation were 0.36 and 0.51 episodes per year for children 
younger than 5 years and 0.0067 and 0.0026 for persons 5 years and older in Asembo and Kibera, 
respectively.
Surveillance for Hospital-acquired Infections in Kenya
Surveillance for healthcare-associated infections (HAIs) in Kenya is an initiative to build infection control 
capacity initiated by CDC-Kenya and the Kenya Ministry of Health. The surveillance for HAIs is being 
conducted at three public hospitals -- a national referral hospital, a provincial general hospital, and a 
district hospital. This surveillance will help provide data on HAIs to the Kenyan government that can 
inform infection control policy decisions.
Study Aims and Objectives:
•	 Monitor respiratory, diarrheal, and non-specific (fever-associated) HAI among patients admitted 
to selected surveillance wards at three hospitals in Kenya.
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•	 Assess the prevalence of respiratory infection in patients and health care workers  on 
surveillance wards.
•	 Describe microbiology and clinical sequelae of incident respiratory HAI on surveillance wards.
Approach: At each site, surveillance officers survey pediatric, adult general, surgical, and specialty 
wards for HAIs. Patients admitted to the hospital for more than three calendar days who develop new 
onset of fever or hypothermia or who developed new onset of cough or sore throat are considered 
to have suspected HAI. Suspected HAI cases are assessed for onset of clinical symptoms and signs 
by questionnaire and medical record review. Nasopharyngeal and oropharyngeal samples are then 
collected from these patients and sent to the CDC-Kenya laboratory in Nairobi, where they are tested 
by RT-PCR for influenza A and B, adenovirus, respiratory syncytial virus, human metapneumovirus, and 
parainfluenza virus 1, 2 and 3. Specimens positive for influenza A are subtyped by RT-PCR.
Timeline: Surveillance started in September 2009 and will continue for at least two years.
Progress and Findings: In the first 11 months of surveillance, a total of 437 case patients with suspected 
HAIs have been identified in the three hospitals. Of these suspected HAIs, 161 (36.8%) met the case 
definition for suspected respiratory HAIs, 23(5.3%) were suspected urinary tract infections, 16(3.6%) 
were suspected surgical site cases, and 12(2.8%) were suspected sepsis cases. Pandemic influenza was 
first identified in Kenya in late June 2009, and HAI surveillance documented six cases of nosocomial 
transmission of 2009 H1N1 in the three hospitals. The surveillance is ongoing; the intent is to collect 
enough data to inform the trends of HAIs in the selected facilities for the next three years.
Peru
Burden of illness and risk factors for transmission of seasonal influenza in four 
distinct regions of Peru
This study includes a prospective population-based cohort of 6,000 people to estimate incidence and 
disease burden, to assess risk factors and seasonality patterns for influenza (seasonal and pandemic 
H1N1 influenza), and to evaluate an alternative route of virus shedding. Data generated as part of 
this study will determine the most-at-risk groups for influenza, providing useful information for policy 
makers and program managers to develop prevention and control plans that are meaningful to the 
Peruvian context – and possibly that of other tropical countries in South America.
Currently two nested studies are being added. They are titled: 1) Intra-household/backyard Influenza 
Cross-Species Transmission Dynamics in Semi rural communities in Peru and 2) The effect of 
micronutrient deficiencies on frequency, severity and outcome of influenza-like illnesses.
Study Aims and Objectives:
•	 Estimate incidence of influenza.
•	 Estimate burden of influenza.
•	 Assess risk factor for influenza.
•	 Assess seasonality patterns for influenza.
•	 Describe the transmission epidemiology of influenza virus between human and domestic pigs 
and poultry in semi rural communities in Peru. (nested study)
•	 Estimate the effect of nutritional deficiencies on severity, frequency and outcome of  
influenza -like illness (ILI) infection among individuals living in semirural communities of  
Peru. (nested study)
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Approach: This prospective, population-based cohort study was implemented with 6,000 people in 
four locations that are representative of the geographic and climatic diversity of Peru (Coast, Highlands, 
Jungle and Tropical dry forest). They are being followed using an active Influenza-like Illness (ILI) 
screening through household visits three times per week since late June 2009. Once all ILI cases are 
identified, they are sampled (throat and nose swabs) for laboratory confirmation (culture and rRT-PCR). 
Finally, they receive follow-up visits for 15 days to assess the economic burden of influenza through 
questionnaires. 
Timeline: June 2009 to June 2012.
Progress and Findings: As a product of this active surveillance, we have identified 3,957 influenza-
like illness syndrome cases in a year and a half period, and 1,573 (39.8%) samples tested positive for 
influenza. Of the positive samples, 36.9% were 2009 H1N1, 27.3% and 19.7% were seasonal H3N2 and 
influenza B respectively. On average, we found higher cumulative attack rates for 2009 H1N1 (8.9%) 
when compared to seasonal H3N2 (6.7%) and influenza B (4.8%). In a one-year analysis, overall rates 
of influenza infection for children under 5 were higher for all strains, compared to other age groups. 
Influenza infection rates were highest in Tumbes, followed by Lima, Puerto Maldonado and Cusco, 
with incidence rates of 211.41, 161.74, 74.50, 47.1 episodes/1000 person-years, respectively. Chronic 
conditions (i.e., diabetes, asthma, cancer, hypertension, bronchitis) were associated with an increased 
risk for infection across the four sites, RR= 2.19 (CI: 1.77-2.71), when controlling for age and gender. 
Smoking was not associated with increased risk of infection. Presence of a chimney, exhaust duct or 
open windows in the kitchen was observed as a protective effect in Cusco, RR = 0.77 (CI: 0.61-0.97). 
Having more than two persons sleeping per room was identified as a risk factor, RR=4.42 (CI: 1.04-
18.79) in Puerto Maldonado.
West Africa
Delayed 2009 H1N1 Circulation in West Africa, May 2009-March 2010
Study Aims and Objectives:
•	 Summarize the laboratory and epidemiologic data in ten countries in Western Africa and 
Cameroon to better understand the epidemiology, introduction of and circulation of 2009 H1N1 
in this region.
Approach: The country ministries of health and influenza laboratories in the following ten countries 
in the West African region were contacted: Cameroon, Cape Verde, Côte d’Ivoire, Ghana, Guinea, Mali, 
Mauritania, Niger, Nigeria, and Senegal. Influenza surveillance laboratory data was collected from May 
4, 2009 until April 3, 2010, including laboratory diagnostic methods, the number of sentinel surveillance 
sites, number of specimens tested by week, number and percent positive for influenza by type and 
subtype, date of availability of 2009 H1N1 primers and date of first 2009 H1N1 case. The 2009 H1N1 
predominance in a country was defined as when more than 50 percent of influenza subtyped strains 
were 2009 H1N1 over a four-week period.
Progress and Findings: This summary of pandemic activity in ten West African countries and Cameroon 
suggests that established sentinel surveillance systems and laboratory capacity to detect and subtype 
influenza strains determined that introduction and widespread transmission of influenza was delayed 
in this region. This shows that up to the end of 2009, 2009 H1N1 was a small minority of all typed 
influenza strains in the region, rising to be large majority only in 2010, and several countries did not 
detect 2009 H1N1 until at least six months after emergence of the pandemic strain in April. Of the six 
countries in West Africa that detected their first 2009 H1N1 case in 2009, the pandemic strain did not 
predominate until 2010 for five of them.
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Lack of widespread transmission and little general availability of influenza vaccine suggest that 
substantial future 2009 H1N1 transmission in potentially immunologically naïve populations in the 
West African region remains possible. Vaccination and other prevention measures should be actively 
promoted, especially as health care systems in this region are often not well-equipped to treat severe 
respiratory diseases. This study highlights the importance of timely virologic surveillance in tracking 
pandemic and seasonal influenza transmission and the role of the Global Influenza Surveillance Network 
(GISN) coordinated by the WHO.
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Disease Prevention
Bangladesh
Effectiveness of 2009 H1N1 Vaccine in Bangladesh, 2010; a Program Evaluation
During 2010, WHO and other international partners donated 15.5 million doses of 2009 H1N1 
monovalent vaccine to Bangladesh in an effort to protect those at highest risk of complications from 
influenza illness. While the Government of Bangladesh vaccinated high-risk groups, we took the 
opportunity to estimate the effectiveness of the vaccine (VE) among health care workers (HCW), 
pregnant women and children. Measuring vaccine effectiveness is critical for a new vaccine as this 
estimation will help to develop recommendations or decide best use of the vaccine for future policy 
decisions.
Study Aims and Objectives:
•	 Estimate the vaccine effectiveness among health care workers, pregnant women and children 
who received 2009 H1N1 vaccine during the vaccination campaign.
Approach: Local health officials implemented a vaccination campaign during May-July 2010, with the 
technical assistance of WHO Extended Program on Immunization experts, to target prioritized high-risk 
groups (HCW, pregnant women and children more than 6 months to 5 years of age). Starting in May 
2010, 12 geographically diverse hospitals and the vaccination centers in three unions (i.e. administrative 
units of Bangladesh with about 10,000 persons each) nearest to those hospitals were visited during the 
vaccination campaign, to randomly enroll participants recorded as vaccinated. Unvaccinated individuals 
were enrolled at a 1:1 ratio from the same hospitals and the same vaccination centers as vaccinated 
participants. Following enrollment, investigators telephoned and/or visited participants weekly to obtain 
nasal and oropharyngeal swabs during episodes of influenza-like illness (ILI, defined as sudden onset 
of fever with cough or sore throat) during the influenza season (May-October). Samples were tested for 
influenza by real-time RT-PCR. 
Timeline: May to October 2010, spanning the annual influenza season in Bangladesh.
Progress and Findings: Over 500 vaccinated HCWs, 1,000 pregnant women and 300 children and their 
controls were enrolled in the study. None of the participating children tested positive for 2009 H1N1. 
Study participants who tested positive for influenza were infected with influenza A H3N2 and 2009 
H1N1 viruses as well as influenza B virus. Of seven HCWs who were infected with 2009 H1N1, two were 
vaccinated compared to five who were unvaccinated. Of 11 pregnant women who were infected with 
2009 H1N1, five were vaccinated compared to six who were unvaccinated. 
Conclusion: Although the vaccine seemed effective, low circulation of 2009 H1N1 hampered our 
ability to differentiate the proportion of 2009 H1N1 infections among vaccine recipients and those 
unvaccinated. Further studies remain to be performed to fully evaluate the vaccine effectiveness of 
influenza vaccines considered for distribution in Bangladesh.
Central America
Surveillance of adverse effects allegedly attributed to the vaccine and effectiveness 
of the influenza A(H1N1) 2009 vaccine in Central America
When the influenza A (H1N1) vaccine was developed, a system was needed to detect adverse effects 
related to the vaccine. Per international recommendations, evaluations in cohorts of prioritized 
populations were proposed. CDC Central America and Panama (CDC-CAP) Influenza Program proposed 
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to evaluate the adverse effects potentially attributable to the influenza A (H1N1) vaccine, as well as the 
vaccine effectiveness in populations at risk.   
Study Aims and Objectives:
•	 Evaluate the adverse effects allegedly attributed to the influenza A (H1N1) vaccine, as well as 
the vaccine effectiveness in populations at risk in El Salvador and Costa Rica.
Approach: In the first quarter of 2010, the influenza A (H1N1) 2009 vaccine was distributed in 
the countries of the region amidst controversy about the risks of the vaccine. An evaluation was 
implemented following people with chronic conditions, pregnant women, children, and health care 
workers to provide evidence to improve the population’s confidence, strengthen the surveillance systems 
of adverse events following immunization (AEFI), and evaluate the effects of this vaccine.   
Timeline: April to November 2010. 
Progress: The survey was completed, the databases are available and the data analysis is ongoing. 
Conclusion: In Costa Rica and El Salvador, follow-up cohorts of 10,000 vaccinated persons were 
organized. The AEFI related to the vaccine were found to be 0.2 x 10,000 applied doses. The more 
frequent AEFI were: headache (15%), pain in the vaccination place (12%), and sore throat (5%). All AEFI 
were mild and 60% were reported the first day.
Characterization of influenza vaccination policies in Nicaragua and El Salvador
CDC Central America and Panama (CDC-CAP) Influenza Program undertook a collaborative effort 
with country Ministries of Health to harmonize immunization policies and practices against influenza 
in Central America, Panama and Dominican Republic, in order to promote and strengthen preventive 
responses in the Region.   
Study Aims and Objectives:
•	 Design and validate a model and tools to characterize influenza immunization policies and 
practices in Central America.
Approach: First, the immunization program was analyzed to evaluate the facilitating aspects and/
or barriers within the program. An unfocused analysis was conducted to characterize the available 
resources and the performance of the immunization program at a sub-national level. The program’s 
performance will be evaluated through the coverage achieved in different sub-populations, and the 
coverage achieved at the district level in different districts. A third part of the evaluation consisted of 
surveying clinical personnel with regard to influenza vaccination. Checklists and surveys addressed 
participants’ knowledge and perceptions about influenza and influenza vaccination.   
Timeline: The study was performed March – August 2010.  
Progress: The survey was completed, the databases are available and the data analysis is ongoing. 
Conclusion: In Nicaragua, seasonal influenza vaccination was introduced in 2007. The immunization 
program had a budget of US $5,518,114 intended for the purchase of biologicals, and 7% is earmarked 
for the purchase of seasonal influenza vaccine. There are approximately 460,000 doses of the vaccine 
available per year. Eleven of the country’s seventeen sentinel sites were visited. The rapid assessment 
process also obtained information about vaccination coverage in health care workers (n=200) and 
other target populations for vaccination (n=195). Eighty-four percent and 31% of these individuals, 
respectively, received the seasonal influenza vaccine in 2009. The seasonal influenza vaccine was 
introduced in El Salvador in 2004. In 2009, the immunization program allocated US $2,178,100 to 
purchase the seasonal influenza vaccine. There are approximately 620,000 available doses of the vaccine 
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per year. Evaluators visited the five Health Regions of the country. In one sample (n=228) from the target 
population, 69% of health care users were vaccinated. Seventy percent of health care workers (n=240) 
were vaccinated.
Côte d’Ivoire
Awareness of the 2009 influenza A(H1N1) pandemic and willingness to be 
vaccinated among pregnant women in Ivory Coast, Africa
Study Aims and Objectives:
Prior to local distribution of pandemic vaccine in western Africa, knowledge of the 2009-10 influenza 
A (H1N1) pandemic (pH1N1) and vaccine acceptance were assessed among a diverse population of 
pregnant women.
Approach: A cross-sectional intercept survey of 411 pregnant women in four prenatal care settings was 
conducted February 15-28, 2010 in Abidjan, Ivory Coast. 
Progress and Findings: The majority (64.5%) of pregnant women said they had heard of the influenza 
pandemic, and of these, the majority (61.3%) were aware of the pandemic vaccine. However, awareness 
varied significantly by clinical setting, education, and access to media. After adjusting for other socio-
demographic factors, college-educated women were 16.8 (95% confidence interval, 3.3 – 85.2) times 
more likely to be aware of pH1N1 than women without formal educations. Of those aware of pH1N1, 
69.8% said they would accept the pandemic vaccine while they were pregnant. Although pandemic 
awareness was highest in the private prenatal care settings, acceptance of vaccine was significantly 
lower in private compared to public care settings. 
Conclusions: Gaps in knowledge about the influenza pandemic and vaccine highlight the challenges of 
pandemic preparedness in the developing world, where substantial disparities in education and media 
access are evident.  
Dominican Republic
Clinical Trial of Safety (Reactogenicity) and Immunogenicity of Needle-free Jet 
Injection of Reduced-dose, Intradermal Influenza Vaccine Administered to Infants 
and Toddlers aged six months to less than 24 months of age, in the Dominican 
Republic
This is a sequential phase I and II, controlled, double-blinded study to determine whether immune 
responses suggesting protection against influenza can safely be induced in young children by two 
reduced doses one month apart of a trivalent inactivated influenza vaccine (INF) administered by the 
intradermal (ID) route with an investigational ID spacer on a needle-free jet injector ( JI) (0.1 mL), 
compared to two standard intramuscular (IM) doses by needle-syringe (N-S) (0.25 mL). The locale is 
a developing country where financial restraints for the use of full-dose influenza vaccine would limit 
protection from an influenza pandemic threat, where N-Ss pose dangers and have drawbacks in clinical 
use and mass campaigns.
Study Aims and Objectives:
•	 Demonstrate the safety and immunogenicity of a dose-sparing intradermal (ID) method to 
allow larger numbers of young children to be protected when supplies of influenza vaccine are 
limited. 
•	 Prove the principle that needle-free jet injection can obviate the cost, time, expertise, and 
difficulty administering ID injections by the Mantoux N-S method.  
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Approach: Healthy participants were recruited from among eligible patients and their siblings attending 
immunization, outpatient, or inpatient clinics and wards of a large, public tertiary care children’s 
hospital. Participants were randomly assigned to receive two doses of Sanofi-Pasteur Vaxigrip® influenza 
vaccine by one of the three study arms: a) Group “IM-NS-0.25” (controls)  -  two full 0.25 mL doses 
administered IM by standard N-S; b) Group “ID-JI-0.1” (investigational)  -  two reduced 0.1 mL doses 
administered ID by needle-free jet injector ( JI), and c) Group “IM-NS-0.1” (investigational)  -  two 
reduced 0.1 mL doses administered IM by N-S. At the conclusion of the study, at the time of collection 
of the final blood specimen, participants in the two investigational groups that received reduced doses 
received a third “insurance” dose of the influenza vaccine via the conventional route, method, and dose, 
to ensure adequate protection. Six months after this study “graduation”, all participants received a fourth 
“bonus” booster dose for protection during the following influenza season.
Timeline: This study started in October 2006 and data collection was completed in November 2009. 
Final serologic results became available in the final quarter of 2010. Final analysis and an article for 
publication are being completed; the estimated end date for this study is December 2011.
Progress and Findings: Preliminary still-blinded results among 390 participants (out of 450), show 
that local pain was mild in 100 (26%), moderate in eight (2%), and severe in four (1%) participants. 
Systemic adverse events (AEs) were diarrhea (38%), fever ≥38.0°C (32%), loss of appetite (31%), vomiting 
(29%), sleepiness (18%), unusual crying (17%), irritability (13%), and convulsions (2%). Serious AEs 
(n=25) included: 10 asthma-related, four varicella, four febrile convulsions, one death (trauma), and six 
miscellaneous others. All AEs but one possibly-related convulsion 23 days after dose 1 were deemed 
unrelated by the Drug Safety and Monitoring Board (DSMB). HAI inverse geometric mean titers (GMTs) 
after dose 2 for multiple formulations and strains (n=207) were 193 for H1N1, 45 for H3N2, and 101 for 
B. Seroconversion was 72%, 25%, and 63%; seroprotection was 88%, 49%, and 85%, respectively. H3N2/
Brisbane/10/2007 strain responses were poor, and under investigation. Based on these preliminary 
results, it seems local AEs were tolerable, and immunity was generally good. Definitive assessment 
awaits unblinded analysis by group of all participants.
El Salvador
Cost-effectiveness of Seasonal Influenza Vaccine in El Salvador
El Salvador, one of the countries in Central America that has conducted influenza vaccination more 
consistently, evaluated the cost-effectiveness of the 2010 seasonal influenza vaccine. The evaluation 
included a study of the supplier costs of care for ILI and SARI due to influenza, the out-of-pocket 
expenses for the families, and a study on cases and controls based on influenza cases captured by 
sentinel surveillance.    
Study Aims and Objectives:
•	 Estimate seasonal influenza vaccine effectiveness in a vaccinated population younger than 2 
years and older than 60 years.
•	 Estimate direct and indirect medical costs due to ILI and SARI in influenza-confirmed cases.  
•	 Estimate the cost-effectiveness of a vaccination program against seasonal influenza, under 
different development scenarios.  
Approach: Influenza vaccine effectiveness was evaluated through paired cases and controls from 
persons who needed care due to severe acute respiratory infections (SARI) in three hospitals of the 
Sentinel Surveillance System of El Salvador. A case was defined as a child between 6 months and 2 years 
old, or an adult older than 60 years old, who met the SARI case definition, and whose results confirmed 
influenza through RT-PCR in real time, with samples taken through nasal and/or pharyngeal swab. Two 
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controls were selected for each case, paired by age. Eligibility criteria also included having a symptom 
start date three or fewer days before the consultation, and being eligible to receive the influenza vaccine 
during the 2010 influenza season. In the identified cases (n=270), a basic clinical-epidemiological data 
form was completed. Estimates of disease costs were developed through studies of SARI costs due to 
influenza and other laboratory-confirmed respiratory viruses. Supplier’s costs were determined through a 
review of clinical records of the cases and controls. The cost of clinical care was estimated based on cost 
catalogs through the Management Information System (WinSIG) of the Ministry of Health. Out-of-pocket 
expenses were determined through survey of the main caregivers and explored direct and indirect costs 
and days out of work. 
Timeline: May to October 2010.  
Progress: Identification of cases is completed, as well as the cost analysis; the databases are available. 
Manuscripts were presented in January 2011.  
Conclusion: During the 2010 influenza season the sentinel surveillance system identified 246 SARI 
case-patients; 38 tested positive for seasonal influenza (< 2y: 24, >60y: 14). Twenty-eight patients had 
complete data and 56 age-matched SARI case-patients who tested negative for seasonal influenza were 
selected. The mean value for health system spending on laboratory-confirmed influenza-related severe 
pneumonia among case-patients less than 2 years was US $2,305 (CI95% US $326 – 4,283), with a 
median value of US $417.3 (IQR US $3139 – 184) and among case-patients aged 60 years or older the 
mean value was US $1,734 (CI95% US $708 – 4,176) with a median of US $488 (IQR US $4,108 – 40). 
The estimated cost of influenza-positive SARI averted among children aged 2 years or younger and 
among persons aged greater than 60 years by the current vaccination program is US $4,507 and US 
$583.79 per event, respectively.
India
Direct and Indirect Protection by Influenza Vaccine Given to Children in India 
Influenza vaccines are in routine use in children in the United States, and although licensed in India, 
they are seldom given. Through a collaboration between the All India Institute of Medical Sciences 
(AIIMS), U.S. CDC, and the University of Alabama, a study to determine whether immunization of 
young children with trivalent influenza virus vaccine (TIV) protects immunized children and older 
non-immunized household members is being conducted in three rural villages near New Delhi, India. 
Children aged 6 months to 10 years are randomized at the household level to receive TIV or inactivated 
polio vaccine (IPV) (the control vaccine) and weekly household surveillance for febrile acute respiratory 
illness (FARI) is conducted among all household members.  
Study Aims and Objectives:
•	 Measure direct protection of children by influenza vaccine.
•	 Measure indirect protection against influenza among family members of influenza vaccine 
recipients.
•	 Define contribution of influenza virus to illness within three villages in rural Ballabgarh.
•	 Assess risk factors for more severe disease due to influenza virus.
•	 Establish a surveillance system for influenza virus infections that will be used to assess 
outcomes in subsequent influenza virus vaccine studies.
Research 239
Approach: A prospective, household randomized, controlled, observer-blinded study is being conducted 
in three rural and peri-urban villages outside of Delhi, India. The vaccination of children aged 6 months 
to 10 years with either trivalent influenza vaccine (TIV) or the control vaccine (inactivated polio vaccine 
(IPV)) will be carried out for three years, followed by weekly household surveillance for febrile acute 
respiratory illness (FARI) to assess the efficacy of influenza vaccination. The total population under 
surveillance for all three villages is approximately 17,000, with an estimated 3,700 children eligible 
for vaccination. Additionally, a small subset of vaccinated children (n=200) will be enrolled into an 
immunogenicity study which will measure their immune response to vaccination and risk factors 
affecting immunogenicity.
Timeline: September 2008 to September 2011.
Progress and Findings: Enrollment, vaccination, and surveillance activities have been successfully 
implemented with high rates of vaccine acceptance (91% of 3,700 eligible children) received at least one 
dose of vaccine, and exceptionally high rates of community acceptance for surveillance enrollment (90% 
of 17,000 persons consented to participate for weekly surveillance). Influenza positivity was identified 
among 350 (17%) of the 2,030 FARI episodes during 2010 across all age groups. Pandemic 2009 H1N1 
accounted for half of the influenza positivity. While predominant circulating strain in 2009 was pandemic 
H1N1, cocirculation of both influenza B and 2009 H1N1 was observed in 2010. The clinical trial has 
been enrolled in Clinical Trials Registry - India (CTRI); National Institute of Medical Statistics, ICMR, 
Ansari Nagar, New Delhi. # CTRI/2010/091/001235, 13-10-2010; http://164.100.72.67/Clinicaltrials/
ViewTrial.jsp?trialno=2537.
In summary, enrollment and immunization rates are high, reflecting a high community acceptance. 
Influenza vaccinations likely will have little benefits in 2009-2010 due to the pandemic, and highlight 
the importance of multi-year studies of influenza vaccine. The vaccine effectiveness study will provide 
useful data related to herd immunity and indirect protection effects in this rural setting. The second year 
of immunization is underway.
CDC’s Fatimah Dawood (left) and Katie LaFond (right) outside the National Institute of Virology in Pune, India
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Kenya
Seasonal Influenza Vaccine Effectiveness Study
Influenza vaccine has been shown to reduce influenza-associated acute respiratory illnesses (ARIs) 
in developed countries. However, little is known about the effectiveness of influenza vaccine in the 
developing world. KEMRI/CDC–Kenya, with support from the Kenya Ministry of Public Health and 
Sanitation, is conducting a three-year observational influenza vaccine effectiveness study using the 
commercially available Southern Hemisphere seasonal vaccine in two sites in Kenya; Lwak -- a rural 
site in western Kenya, and Kibera– an informal urban settlement in Nairobi. The International Emerging 
Infections Program (IEIP) under KEMRI/CDC currently conducts population-based disease surveillance 
(PBDS) for severe acute respiratory illness (SARI) and influenza-like illness (ILI) in these two sites.  
Study Aims and Objectives:
The objectives of the study are to evaluate the following:
•	 Effectiveness of the vaccine in preventing laboratory-confirmed disease.
•	 Effectiveness of the vaccine in preventing medically attended ILI and SARI, and symptomatic ILI 
and SARI reported in the community.
•	 Indirect effect of the vaccine in preventing laboratory-confirmed influenza, and ILI and SARI in 
non-immunized household members.
•	 Acceptability of influenza vaccination among community residents.
Approach: The vaccine is offered on a voluntary basis to infants from 6 months of age through 
children up to 10 years old enrolled in the IEIP study site. Sanofi Pasteur-France has donated Southern 
Hemisphere trivalent influenza vaccine for the study. Prior to the vaccination campaign a vaccination 
awareness campaign was conducted to sensitize the community on the benefits and availability of the 
influenza vaccine. 
After vaccination, the study participants are followed up with using the routine IEIP surveillance which 
includes weekly home visits where field workers ask household members questions about recent 
illnesses and deaths. The study participants also have free access to a medical clinic where free care is 
provided. At the clinic, specimens are collected from patients who have SARI or ILI. Samples are tested 
at the CDC laboratory using real-time RT-PCR for influenza virus. At the end of every year patients who 
received vaccine will be compared to patients who did not receive vaccine.
Timeline: Data from the past three years of influenza surveillance has shown that the influenza season 
in Kenya peaks July - October, and therefore most closely mirrors the Southern Hemisphere influenza 
season. The vaccine is available every year in Kenya beginning in March to coincide with the Southern 
Hemisphere influenza season. Vaccine will be offered from April- June of every year from 2010-2012.
Progress and Findings: In 2010, approximately 40% of children received the influenza vaccine in the 
two sites. In Kibera 3,962 (39.2%) out of 10,098 children eligible for vaccination received the vaccine; 
similarly, in Lwak 3,994(39.8%) out of 10,041 children eligible for vaccination received the vaccine. Data 
analysis comparing outcomes of vaccinated and unvaccinated children for the first year is ongoing. 
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Senegal
Assessment of the Effectiveness of Seasonal Trivalent Influenza Vaccine among 
Children in Senegal 
Effective influenza vaccines have been available for decades, but they have neither been studied nor 
used in tropical developing countries. A number of reports from developed countries indicate that 
influenza vaccine, when given to a limited number of persons most responsible for transmission, 
usually children, has the potential to interrupt transmission and reduce the overall influenza burden in 
a community. This study will determine whether immunization of young children (6 months to 9 years 
of age) with influenza vaccine will protect not only the immunized children but also the infants, older 
children and adults who are around them.
Study Aims and Objectives:
•	 Evaluate the total (direct plus indirect) effectiveness of TIV in reducing rates of laboratory-
confirmed symptomatic influenza among vaccinated children from villages where TIV is 
introduced compared to among vaccinated children from villages where inactivated polio 
vaccine (IPV) is introduced.
•	 Evaluate the age-specific indirect effectiveness of TIV in reducing rates of laboratory-confirmed 
symptomatic influenza among unvaccinated persons (children  younger than 6 months of age 
and children and adults older than 10 years of age) from villages where TIV is introduced 
compared to among persons from villages where IPV is introduced.
•	 Evaluate the overall (population) effectiveness of TIV in reducing rates of laboratory-confirmed 
symptomatic influenza among all persons (of any age) from villages where TIV is introduced 
compared to among all persons from villages where IPV is introduced.
•	 Evaluate the post-vaccination immune responses to influenza vaccine (as percentage 
seropositive and antibody level) among a subset of children 6-11 months, 12-35 months, 3-5 
years, and 6-8 years of age, and describe the safety profile of the TIV in a subset of children.
•	 Describe the epidemiology of influenza in the population by defining the rates of laboratory 
confirmed influenza, describe the clinical characteristics of influenza in the study population, 
and describe the etiologies of influenza-like illness in the study population.
Approach: This study is an observer-blinded Phase IV cluster-randomized trial with villages randomized 
into two groups. Children aged 6 months to 10 years in these villages receive either trivalent influenza 
vaccine (TIV) or the control vaccine, inactivated polio vaccine (IPV). In addition, some of these 
vaccinated children will be enrolled into an immunogenicity and safety subset which will measure their 
immune response to vaccination and assess reactions to the study vaccines among children in Senegal. 
A combined approach of active and passive influenza surveillance will be used to assess lab-confirmed 
influenza among vaccinated children and among consenting unvaccinated persons (older children and 
adults), in order to evaluate the effects of the vaccine in this population.
Timeline: July 2008 to June 2011.
Progress and Findings: Enrollment, vaccination, and surveillance activities are ongoing. Year 3 
vaccination will take place in May - June 2011. Surveillance activities, including administration of 
health questionnaires and nasopharyngeal specimen collection, are year-round. Twenty-eight percent 
(1,561/5,483) of those tested in 2009 were positive for influenza; all positives were influenza A (H3N2). 
Pandemic 2009 H1N1 was not detected in Niakhar until the first week of February, 2010. Preliminary 
findings were shared at two major conferences: ICEID ( July 2010) and Options (Sept 2010). 
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Thailand
Household Influenza Transmission Study (HITS)
HITS is a study to assess the effectiveness of non-pharmaceutical interventions on household 
transmission of influenza viruses. This study is being conducted at Queen Sirikit Institute for Child 
Health in Bangkok with collaboration from the Armed Forces Research Institute of Medical Sciences 
(AFRIMS).
Study Aims and Objectives:
•	 Assess the effectiveness of mask use and hand washing when practiced by susceptible persons 
to decrease influenza virus infection in the household.
•	 Determine the secondary attack rate in households with a child with laboratory-confirmed 
influenza virus infection.
•	 Determine the level of adherence to mask use and hand washing.
Approach: This is a prospective intervention trial. Children under 15 years of age with influenza virus 
infection are enrolled along with their households. A pediatric influenza virus-infected index case is 
identified and their household is then enrolled and randomized to one of three study arms: control, 
hand washing, or hand washing and mask use. Following enrollment, at days 0, 3 and 7, all household 
participants are tested for influenza viruses. The index case is assessed for influenza viral shedding and 
household members are assessed for secondary influenza infection.
Timeline: Enrollment began in April 2008 and ended in February 2011.
Progress: Enrollment is almost complete and analysis is underway. 
Suntarattiwong P, Jarman RG, Levy J, Baggett HC, Gibbons RV, Chotpitayasunondh T, Simmerman JM. 
Clinical performance of a rapid influenza test and comparison of nasal versus throat swabs to detect 
2009 pandemic influenza A (H1N1) infection in Thai children. The Pediatric Infectious Disease Journal. 
2010;29(4):366-7.
Conclusion: This study will identify generalizable and transferable information on influenza virus 
transmission prevention measures. The results will assist those involved in providing influenza 
prevention and control policy recommendations for seasonal and pandemic influenza.
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Research at the Animal-Human 
Interface
Avian Influenza Cooperative Research Centers
In 2006, five cooperative agreements were initiated to establish a set of research projects related to 
detecting, preventing, and controlling zoonotic influenza. This provides a more integrated public health 
response to avian and swine influenza by human and veterinary health services. Collaborators included 
Colorado State University, the University of Minnesota, the University of Georgia, the National Institute 
of Public Health and the Environment (The Netherlands) and Mahidol University (Thailand). 
The 2010 research activities for these Centers for Research at the Animal-Human Interface include:
Colorado State University
Study Aims and Objectives:
•	 To better understand the interspecies transmission of avian influenza in small duck flocks.
•	 To evaluate the prevalence of avian influenza virus in ducks in Indonesia.
•	 To assess the dynamics of oseltamivir exposure in ducks, since oseltamivir and its metabolites 
have been found in sewage effluent and waterways.
•	 To better understand the incidence and seasonality of influenza in Indonesia.
Approach: Ducks were experimentally infected with low pathogenic avian influenza H5 and H7 viruses. 
These dusks were then housed with common barnyard species, including rats, blackbirds and pigeons, 
to better understand how efficiently avian influenza viruses (AIVs) are transmitted between these 
species. The poultry and other species housed with the infected ducks were monitored for AIV infection. 
The pharmacokinetics of oral oseltamivir was evaluated. Ducks infected with a low pathogenic H5N2 
virus and given low levels of oseltamivir were sampled to determine if viruses with antiviral resistance 
could be obtained. 
Surveillance for influenza was performed in Indonesia. From 2009 to 2010, surveillance for AIV was 
performed on ducks in West Java, Indonesia to determine the prevalence of infection. Surveillance for 
influenza-like illness (ILI) has been performed at three community health centers in Bandung, Indonesia 
since 2008, with household mapping of ILI cases starting in 2010.
Timeline: This research will conclude in 2011.
Progress and Findings: In the experimental barnyard, the avian influenza viruses accumulated to high 
concentration in the duck pool and viruses were transmitted to other birds. This suggests the potential 
for efficient transmission of avian influenza viruses to barnyard chickens by visiting ducks. Examination 
of the pharmacokinetics of oseltamivir in ducks revealed that these values were considerably different 
from humans. Analyses of the results of this study are ongoing.
A high prevalence of avian influenza virus was found in domestic duck populations in West Java with 
frequent illness and mortality reported in flocks. Extensive movement of domestic duck flocks may 
contribute to the spread of AIV. Surveillance for ILI in humans in Bandung has enrolled over 1,500 cases 
and found influenza in 17% of the samples.
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University of Minnesota
Study Aims and Objectives:
•	 To evaluate avian, swine and human influenza virus transmission at the human-animal interface.
•	 To identify factors that facilitate influenza virus transmission from animals to humans. 
•	 Characterize human illness caused by avian and swine influenza viruses.
•	 Assess the use of interventions that interrupt transmission of influenza viruses from animals to 
humans 
Approach: Surveillance for avian influenza was conducted among backyard flock poultry flocks and 
their handlers in Minnesota and Wisconsin, as well as in an urban wild geese population living in a 
recreational area and the human users of their habitat. Swine influenza surveillance was conducted to 
detect and characterize influenza A viruses from pigs and people who work with them in large and 
small operations in the Midwest. Surveillance for influenza viruses in swine at fairs in the Midwest was 
also conducted. Personal protective equipment (PPE) and hygiene practices used by swine and poultry 
handlers were evaluated. Surveillance for avian influenza was also conducted in four rural villages in 
Thailand where highly pathogenic avian influenza H5N1 had been detected previously. An evaluation of 
PPE incorporated across the research sites of this project was conducted.
Timeline: Research was completed in 2010.  
Conclusions: This project found that the prevalence of avian influenza virus in backyard flocks and 
geese in Minnesota and Wisconsin was very low. There was no evidence of transmission of avian 
influenza virus to humans in this study. This study documented the impact and subtypes found on 
Minnesota swine production facilities. Pandemic 2009 H1N1 influenza virus was identified in pigs 
exhibited at a state fair in 2009. Barriers to the use of personal protective equipment (PPE) were 
identified, including cultural/ethnic factors related to PPE and hand washing practices among Thai 
poultry and duck owners. A self-assessment tool for markers of preparedness to respond to highly 
pathogenic avian influenza outbreak in birds was developed for use by organizations potentially 
responding to avian influenza outbreaks. This tool is available online: http://www.wildbird.umn.edu/.
Manuscripts are in production or have been submitted for this research.
University of Georgia
Study Aims and Objectives:
•	 To better understand the risk of human infection with avian influenza from an environmental 
source.
•	 To estimate avian influenza viral loads associated with environmental sources of potential public 
health significance.
•	 To identify factors that may enhance or limit persistence of type A influenza viruses in these 
environmental sources (surface water, environmental surfaces, feces and carcasses).
Approach: A quantitative risk assessment of the public health risk associated with environmental 
sources of avian influenza was performed by estimating the viral shedding of ducks and the persistence 
of virus in lake water during the year. The risk of exposure to the human population in Georgia from 
avian influenza (H5N1) was characterized using surveys of duck hunters, non-commercial poultry 
owners, taxidermists, and friends of hunter to determine knowledge and attitudes.
Timeline: Research was completed in 2010.
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Conclusions: When evaluating the risk of a person coming into contact with avian influenza viruses, it 
was found that this risk varies with the time of year and location of the lake. The peak risk was found to 
occur before the onset of seasonal flu in humans.
This research has resulted in these publications:
Stallknecht, D.E., V.H. Goekjian, B.R. Wilcox, R.L. Poulson, and J.D. Brown. 2010. Avian influenza virus 
in aquatic habitats: What do we need to learn? Avian Diseases 54: 461-465.
Harris, M. T., J.D. Brown, V. H. Goekjian, M. P. Luttrell, R. L. Poulson, B. R. Wilcox, D. E. Swayne, and D. 
E. Stallknecht.2010. Canada Geese and the epidemiology of avian influenza viruses. Journal of Wildlife 
Diseases. Journal of Wildlife Diseases 46:981-987.
Dishman,H., D. Stallknecht, and D.Cole. Duck hunter knowledge, attitudes and practices regarding 
exposure to Avian Influenza (H5N1) in Georgia, USA. 2010. Emerging Infectious Diseases 16: 1279-1281.
The National Institute of Public Health and  
the Environment (The Netherlands)
Study Aims and Objectives: 
•	 To estimate to estimate infection probabilities for persons involved in disease control on farms 
infected with highly pathogenic avian influenza virus H7N7.
•	 To estimate effectiveness of personal protective equipment and oseltamivir use on farms 
infected with highly pathogenic avian influenza virus H7N7. 
Approach: In 2003 an epidemic of highly pathogenic avian influenza H7N7 occurred in the Netherlands 
at commercial poultry farms. During this outbreak 89 confirmed human cases of avian influenza were 
identified among poultry workers and their families, including one death. This study used information 
and biologic samples collected during this outbreak to further evaluate the outbreak in humans. The 
effectiveness of personal protective equipment (PPE) and oseltamivir use during the epidemic was 
evaluated by linking databases containing information about farm visits and human infections to the use 
of oseltamivir and PPE. The infection probabilities for persons involved in disease control on infected 
farms were estimated using databases containing information on the infected farms, person-visits to 
these farms, and exposure variables (number of birds present, housing type, poultry type, depopulation 
method, period during epizootic).
Timeline: Research will be completed in 2011.
Conclusions and progress: Prophylactic treatment with oseltamivir significantly reduced the risk for 
infection of poultry workers per farm visit. Clinical inspection of poultry in the area surrounding infected 
flocks and active culling during depopulation were associated with a high infection probability, while 
low probabilities were estimated for management of biosecurity and assistance with cleaning during the 
flock depopulation. No significant association was observed between the probability of infection and the 
exposure variables, such as number of birds present, housing type, and poultry type.
This research has resulted in these publications:
te Beest DE, van Boven M, Bos MEH, Stegeman A, Koopmans MPG. Effectiveness of personal protective 
equipment and oseltamivir prophylaxis during avian influenza A (H7N7) epidemic, the Netherlands, 
2003. Emerg Infect Dis [serial on the Internet] .2010 Oct [date cited]. http://www.cdc.gov/EID/
content/16/10/1562.htm.
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Bos ME, Te Beest DE, van Boven M, van Beest Holle MR, Meijer A, Bosman A, Mulder YM, Koopmans 
MP, Stegeman A. High probability of avian influenza virus (H7N7) transmission from poultry to humans 
active in disease control on infected farms. J Infect Dis. 2010 May 1;201(9):1390-6.
Maihidol University (Thailand)
Study Aims and Objectives:
•	 To understand the incidence and prevalence of avian influenza virus infection in birds, humans 
and other animals in Thailand.
•	 To assess the transmission of avian influenza to people exposed to humans, birds and other 
animals infected with avian influenza viruses.
•	 To determine the role of migratory birds in the transmission of avian influenza virus. 
•	 To determine the diversity and phylogeny of avian influenza viruses isolated in Thailand.
Approach: Since 2004, outbreaks of highly pathogenic avian influenza virus H5N1 have occurred in 
wild and domestic birds in Thailand and numerous human cases have been identified. To determine 
the role of migratory birds in the transmission of avian influenza virus, the migratory routes of open-
billed storks, lesser whistling ducks, and laughing gulls was evaluated by the use of satellite telemetry. 
The prevalence of avian influenza in these birds and in non-migratory birds, other animals, and humans 
who shared a habitat with the migratory birds is being monitored. The diversity and phylogeny of avian 
influenza viruses isolated in Thailand during the study is being evaluated. Avian influenza viruses and 
2009 H1N1 influenza viruses were assayed to determine activity against multiple erythrocyte species.
Timeline: Research will be completed in 2011.
Conclusion: Migratory patterns of birds evaluated in this project have documented migration both 
within Thailand as well as into other parts of Asia, suggesting wild birds could bring virus into Thailand 
as well as spread it within the country. The highest hemagglutination titers for all viruses and antigens 
assayed were obtained with goose and guinea pig erythrocytes. 
Manuscripts are in production or have been submitted for this research.
Bangladesh
Evaluation of CARE’s avian influenza community-based and commercial poultry 
interventions
The purpose of this study is to evaluate the interventions of the non-governmental organization “CARE” 
to prevent avian influenza in backyard and small-scale commercial poultry farms.
Study Aims and Objectives:
•	 Assess the knowledge, attitude, and practices (KAP) of backyard poultry raisers about avian 
influenza, before and after CARE’s intervention.
•	 Evaluate pre- and post-intervention backyard poultry husbandry practices.
•	 Evaluate the impact of CARE’s intervention on KAP of small-scale commercial poultry producers.
•	 Describe the biosecurity of small-scale commercial poultry farms with and without intervention.
Approach: We conducted baseline and follow-up questionnaires on 480 backyard poultry raising 
households from intervention and control sub-districts of Tangail district. Later, we conducted a follow-
up assessment in the intervention and control areas to assess KAP and to measure possible changes 
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in the backyard poultry raisers of both areas. In addition, a questionnaire for small-scale commercial 
poultry farms was administered to 70 control farms and 70 intervention farms in Tangail district to assess 
CARE’s intervention efforts to improve biosecurity in commercial poultry.  
Timeline: This study began in April 2009. Data collection was completed December 2010.
Progress: Baseline data collection for backyard farms was completed in 2009 and follow-up data 
collection was completed in 2010. Data collection for small-scale commercial poultry farms was 
completed in December 2010. 
Conclusion: Data analysis is ongoing. A preliminary report of the findings was prepared and sent to 
CARE, which presented the findings in a poster at the ICEID meeting in Atlanta in July 2010. 
Poultry influenza surveillance
The purpose of this study is to identify outbreaks of disease in domestic poultry by conducting active 
surveillance. 
Study Aims and Objectives:
•	 Conduct active surveillance for avian influenza in live bird markets.
•	 Pilot surveillance for avian influenza in backyard poultry.
•	 Improve understanding of human interaction with backyard poultry.
Approach: This study involves monthly sampling of four rural and eight urban live bird markets. It also 
includes monthly active surveillance of backyard poultry from two rural village locations. In addition, 
a qualitative study was performed in two rural study sites to identify human interaction with backyard 
poultry relating to risk of avian influenza.
Timeline: This study began in August 2007.
Progress: From August 2007 through September 2010, over 2,200 poultry swabs from rural markets 
and communities were collected and tested for avian influenza A by rRT-PCR at ICDDR,B. We also 
characterized the seasonality of avian influenza. In addition, we collected pooled environmental samples 
from 12 live bird markets starting from May 2009 from Dhaka and rural markets and tested them for 
avian influenza A. Positive samples were then tested for H5 by rRT-PCR. In addition, we completed data 
collection and analysis for the qualitative study on human interactions with poultry in rural backyard 
farms. 
Conclusion: This study is ongoing. A poster was presented on live bird market surveillance at the ICEID 
conference in Atlanta in July 2010. We have begun manuscript preparation for both the qualitative study 
and the live bird market surveillance.
Identifying risk factors for and dispersion of avian influenza in backyard poultry 
This is a case control study with backyard poultry flocks as the primary unit of interest. 
Study Aims and Objectives:
•	 Identify risk factors for infection of backyard poultry flocks with influenza A/H5. 
•	 Assess the dispersion of influenza A/H5 virus within 10 km of affected farms.
Approach: This study aims to enroll 40 backyard case farms and five geographically matched negative 
controls per case. A questionnaire is administered to case and control farm owners in order to identify 
risk factors for flock infection with avian influenza A/H5. In addition, six backyard farms from within a 
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0.5 to 10 km radius of the affected case farms are enrolled and sampled two weeks after enrollment of 
case farms to assess the spread of the virus.  
Timeline: This study began in March 2009 and is ongoing. 
Progress: Enrollment of case farms has been lower than expected due to low rates of reporting of 
avian influenza in backyard flocks. So far, half of the targeted enrollment has been achieved (20 cases 
and their controls). The goal is to enroll 20 more case farms and their controls before finalizing the data 
analysis. Preliminary data analysis has identified a few potential risk factors.
National assessment of backyard poultry rearing practices
This is a prospective cohort study to assess poultry raising practices and to conduct active surveillance 
in backyard poultry. 
Study Aims and Objectives:
•	 Describe poultry raising practices over time.
•	 Assess the contribution of poultry raising to household income and nutrition.
•	 Describe the epidemiology of poultry illnesses.
•	 Conduct nationwide active surveillance for avian influenza in backyard poultry.
Approach: This study includes 600 households selected from a representative sample of 30 village 
clusters from across Bangladesh. Baseline and bimonthly follow-up questionnaires, as well as structured 
observations are conducted by the research team. Trained volunteers conduct backyard poultry 
surveillance in the 30 villages. They collect and report information on poultry illness and death, 
seasonality of poultry illnesses, and outcome of the sick poultry twice weekly. 
Timeline: This study began in May 2009 and is ongoing.
Progress: We have collected over 200 swab samples for avian influenza and other disease testing from 
sick chickens and ducks of the households meeting our inclusion criteria. We have collected baseline 
and follow-up information from over 45 field sites.
Conclusion: Preliminary data analysis has begun in preparation for producing a manuscript for a 
peer-reviewed journal. We found that most of the poultry raisers were not following the government 
recommended “10 steps of safe poultry raising” and are at risk of animal to human transmission of avian 
influenza.
Piloting an intervention to reduce the risk of transmission of avian influenza to 
humans in rural Bangladesh
This is a qualitative research study, the purpose of which is to develop preventive messages to reduce 
the risk of transmission of avian influenza to humans. 
Study Aims and Objectives:
•	 Develop and disseminate a set of culturally appropriate messages on sick poultry slaughtering 
and sick and dead poultry handling in order to decrease risk of avian influenza transmission to 
humans.
•	 Explore the acceptability and feasibility of the messages in the community.
Approach: We developed a set of preventive messages and disseminated them in two rural communities 
of Bangladesh, collecting data on community response to the messages to evaluate their acceptability 
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and feasibility. Courtyard meetings and posters were used to disseminate the messages and their 
acceptance was evaluated using qualitative research methods such as focused ethnography, observation, 
informal conversations, in-depth interviews, and group discussions.
Timeline: This study began in June 2009 and is ongoing.
Progress: We have performed an analysis of the research findings. Currently we are modifying the 
messages according to the study findings to make them more appropriate for the community people. We 
convened a meeting of avian influenza researchers (qualitative and quantitative) in order to focus the 
messages on the most practical and important interventions. We will disseminate the new messages in 
settings with and without high poultry mortality in order to explore the acceptance of the messages and 
change in people’s understanding and behavior. 
Seroprevalence of antibodies to avian influenza A viruses among Bangladeshi 
poultry market workers
Since its emergence in Bangladesh, highly pathogenic avian influenza A virus H5N1 continues to be a 
major threat to poultry and people. Bangladesh, a country with approximately 183 million poultry, has 
had confirmed outbreaks of H5N1 throughout the country since February 2007. In March of 2008, the 
first human case of H5N1 influenza in Bangladesh was identified through a population based human 
influenza study in Dhaka. There is great concern that new human cases of H5N1 and other avian 
influenza A types (H2, H7, H9) may remain unrecognized. Little is known about transmission patterns 
of avian influenza to humans in Bangladesh. It is unclear how many Bangladeshis who routinely handle 
poultry develop mild or subclinical infections to influenza A viruses.
Study Aims and Objectives:
•	 Quantify the baseline seroprevalence of anti-avian influenza A (e.g. H2, H5, H7, and H9) 
antibodies among Bangladeshi poultry market workers 
•	 Calculate the incidence of seroconversion among poultry workers during the one year study 
period.
•	 Guide targeted interventions aimed at decreasing the transmission of avian influenza from 
animals to humans and averting the generation of novel influenza strains with pandemic 
potential. 
Approach: This study is being performed among poultry market workers who work in markets where 
avian influenza viruses are detected during routine animal surveillance efforts. Since 2009, multiple 
samples from live- market surveillance have tested positive for H5 and unsubtypeable influenza A. 
These signals help study teams time the collection of sera 21 days after presumed exposure. Therefore, 
both pre-exposure and post-exposure paired sera specimens will be available to test for the antibodies 
to avian influenza A viruses. Serum specimens will be tested for neutralizing antibody against avian 
influenza viruses (H5, H2, H7 and H9) by microneutralization assay and confirmed by Western blot assay 
and/or modified hemagglutination-inhibition assay at CDC.
Timeline: Epidemiologic data and serum samples have been collected. Serological assays will be 
performed and data will be analyzed by the end of 2011.
Progress and Findings: Over 400 poultry markets workers from 11 live bird markets were enrolled and 
baseline sera were collected. Follow-up sera were collected from the enrolled workers in markets where 
environmental or poultry samples have tested positive for avian influenza as part of ongoing animal 
surveillance. Serum samples have been shipped to the laboratories at CDC where serologic assays will 
be performed. At the end of the study, investigators intend to quantify the incidence of seroconversion 
among poultry workers to H5N1 and other avian influenza viruses- an important issue in a country in 
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which 69% of the population raise poultry as an important protein source. The findings of the proposed 
study are expected to guide the response to H5N1 outbreaks and prevent the generation of novel 
influenza strains with pandemic potential. 
Kenya
Network analysis of the Kenyan poultry trade
This study was conducted to identify probable routes of avian influenza (AI) virus spread through the 
movement of live birds in the informal poultry trade sector. This knowledge may be applied to better 
inform prevention and control efforts in the spread of avian viruses.
Study Aims and Objectives:
•	 Design trade network based on volume, distance, and frequency of trade.
•	 Determine knowledge, attitudes, and practice of players involved in informal poultry trade.
•	 Determine currently employed hygiene and veterinary measures in the informal sector.
Approach: A cross-sectional survey of five types of players in the Kenyan poultry trade was conducted 
in 5/8 provinces with relatively high human population. Five types of players were interviewed: 
backyard farmers, market traders, middlemen, commercial farmers, and hatchery operators. 
Questionnaires addressed geographic coverage, frequency and volume of trade, trading patterns, 
transportation and handling of poultry, and biosecurity practices.
Timeline: Data collection was carried out between late 2007 and late 2008 and primary analyses were 
conducted 2010-2011. 
Progress: Analysis is complete and a primary manuscript will be published in 2011. 
Conclusion: The informal poultry trade in Kenya is dependent primarily on the sale of backyard poultry 
to middlemen and market sellers. Middlemen and market traders play a critical role in poultry transport 
in Kenya; during an AI outbreak this group should be targeted for control- and containment-related 
interventions. The use of bicycles as a primary means of transport among middlemen, however, limits 
the geographic spread of their trade, making an understanding of the connections between points in the 
network vital for interventions.
Surveillance for avian influenza viruses in live bird markets in Kenya
Influenza viruses circulating in the poultry in Kenya have not been described. Influenza surveillance 
in live bird markets (LBM) has been recognized as an effective tool in detecting influenza subtypes 
circulating in the poultry population. Qualitative risk assessment studies carried out in Kenya in 2008 
identified live bird markets as high risk points, not only for virus introduction and circulation among 
birds, due to the practices employed, but also for introduction of virus to humans working with poultry. 
Conducting surveillance at LBMs is vital to early detection of the introduction of avian influenza to the 
poultry population in Kenya. 
Study Aims and Objectives:
•	 To identify and characterize avian influenza viruses circulating in poultry traded in live bird 
markets in Kenya.
•	 Investigation of market practices that would contribute to mixing and transmission of virus 
within the market.
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Approach: Between March 2009 and February 2011, we collected samples from birds presented for sale 
in the five live bird markets in Kenya. We visited each market once a month, and collected tracheal and 
cloacal samples from 25 birds per market visit. We also collected five environmental samples in each 
market at every visit. All the specimens were tested for influenza A matrix gene by real-time reverse 
transcription-polymerase chain reaction at the BSL-3 KEMRI/CDC laboratory in Kisumu. All influenza A 
positive samples were sent to CDC-Atlanta laboratory for virus isolation and subtyping.
Timeline: The field work was carried out from March 2009 through February 2011; laboratory testing 
will continue until August 2011.
Progress and Findings: From March 24, 2009 through February 28th, 2011, we collected a total of 5,221 
cloacal and tracheal samples during 22 monthly visits to the five markets. Of these 4,176 (80%) were 
from chickens, 321 (6.1%) from ducks, 382 (7.3%) from turkeys, and 342 (6.6%) from geese. Of the 5,199 
(99.6%) samples tested, influenza A virus was detected in 42 (0.8%) of the samples. Influenza A was 
detected in 35 of 4,166 (0.8%) swabs from chicken, three of 381(0.8%) turkeys, four of 335 (1.2%) geese, 
and 0 of 317 (0%) ducks as shown in. Overall, influenza A was detected in 33 (1.3%) and nine (0.4 %) 
of oropharyngeal and cloacal swabs respectively. We collected 493 environmental samples from the 
markets. We did not detect influenza A in any of 443 specimens tested. Influenza A was detected in all 
the markets visited at one point during the surveillance period. 
Ducks, geese and turkeys stayed longest at the market; for these species, the median (min-Min)  days 
from delivery to the market to sampling time at the markets was 30 (0-90), 30 (2-90) and 28 (1-90), 
respectively. Chicken stayed in the market for a median two days (range 0- 30 days). Virus Isolation and 
subtyping of influenza A positive swabs is on-going to determine the influenza subtypes circulating in 
poultry species in Kenya.
Nigeria
Physicians’ knowledge, attitudes, and practices (KAPs) of avian influenza, infectious 
disease reporting, and information sources in Nigeria 
This study was performed to determine knowledge, attitudes, and practices (KAPs) among public sector 
physicians in Nigeria pertaining to avian influenza (AI) infection in humans, infectious disease reporting 
practices and perceived obstacles, and sources of heath information. This study is being conducted in 
collaboration from the Nigerian Federal Ministry of Health.
Study Aims and Objectives:
•	 Describe Nigerian physicians’ attitudes and practices related to disease reporting.
•	 Determine physicians’ preferred sources for acquiring new health knowledge.
•	 Assess physicians’ knowledge level of human avian influenza infection.
Approach: During November and December 2008, 245 public sector physicians from six of the nine 
largest Nigerian cities were surveyed. Survey components included basic respondent demographics, 
knowledge of avian influenza, reporting practices for avian influenza as well as other epidemic and 
notifiable diseases, perceived obstacles to reporting, and information access and preferred sources used 
by the physicians.
Timeline: Data collection was carried out in late 2008 and primary analyses were conducted  
in 2009-2010. 
Progress: Analysis is complete and a primary manuscript will be published in 2011. 
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Conclusion: Despite widespread awareness of avian influenza, including common symptoms and  
modes of transmission, physicians noted many obstacles to reporting. Physicians reported widespread 
access to information, identifying methods such as internet, cell phone, and email that could be better 
utilized to reach this population for regular updates and for crisis communications, such as epidemic or 
pandemic activity.
Peru
Influenza viral surveillance in swine populations of Peru 
Pandemic influenza viruses can result from the re-assortment of circulating human influenza and avian 
influenza. In these instances, pigs are often incriminated as serving as mixing vessels, since these 
animals may serve as hosts for productive infections of avian, swine and human viruses. Implementing 
surveillance in swine populations will help us assess the different influenza strains circulating among 
these populations.
Study Aims and Objectives:
•	 To determine the different strains of influenza (swine, avian and human) circulating in Peruvian 
swine populations.
Approach: We are performing serological and virological surveillance to monitor and study informal 
and formal swine farms and slaughter houses. Studies are conducted in multiple locations in Peru (i.e. 
Tumbes, Cuzco, Lima, Puerto Maldonado). This study uses the infrastructure and workforce that is 
already established by other NAMRU-6 studies. Nasal/tracheal swabs are collected and serosurveillance 
of influenza virus exposition in the Peruvian pig population are planned to be conducted three times 
a year. RT-PCR, viral culture, and cDNA sequencing will be used to determine influenza infection 
outcomes as well as hemagglutination inhibition (HAI) and microneutralization (MN).
Timeline: March 2009 to December 2010.
Progress and Findings: In collaboration with the Veterinary School of San Marcos University, we have 
found evidence of infection by serology (9.1%, n=959) and virus isolation (1.04%, n=288) of human 
influenza 2009 H1N1 in community backyard slaughtered pigs in Tumbes-Peru (data not published). 
None of the serum-positive pigs were positive by virus isolation by egg culturing and real-time RT-PCR, 
suggesting that these pigs were previously exposed and later recovered from human 2009 H1N1 
infection. It certainly raises concerns about how much exposure rural communities may have with 
animals. Additional studies are necessary to elucidate the epidemiological relationships and ecology 
of the human-animal interaction in these settings, which will provide key information for strategies of 
control and prevention of illness.
Knowledge, Attitudes and Practices about Avian Influenza (AI) in wild birds and 
poultry holders at Peruvian Wet Markets
Wet markets, also known as live-animal markets, provide optimal conditions for amplification and 
transmission of disease agents such as influenza. Such markets are quite common in developing 
countries of Asia and South America and are characterized by the presence of animals in densely 
packed cages with poor hygienic conditions. In addition to wild birds, local populations often bring 
domestically raised poultry to marketplaces for sale and slaughter. Furthermore, illegal trade of wild 
birds at wet markets introduces a new and poorly studied potential risk. This study was conducted 
in the main cities of coastal and rainforest regions of Peru. Populations included wild/exotic bird and 
poultry handlers in wet markets. 
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Study Aims and Objectives:
•	 To assess the knowledge, attitudes and practices of wild bird holders and poultry workers 
regarding AI.
•	 To establish baseline data for development of educational and preventive intervention methods 
in this population.
•	 Approach: This study targeted individuals selling avian species (domestic poultry, wild-caught 
and exotic) in live animal markets in seven Peruvian cities. A standardized questionnaire was 
administered to each participant inquiring about their general knowledge regarding how AI 
is most commonly transmitted and ways to prevent infection. Furthermore, we explored the 
common attitudes and practices related to animal husbandry or management of birds.
Timeline: September 2009 to January 2010.
Progress and Findings: The study ended in January 2010. One hundred and sixty-six participants were 
enrolled, thirty percent of them were aware of AI, but only 49% understood how AI could be transmitted 
among poultry. Fifty percent understood that AI could be transmitted to humans; however, only 5% were 
aware that an AI infection can cause severe complications or death. We are in process of complementing 
this study with an observational component to have a better assessment of the practices performed by 
this population.
Occupational Exposure to Zoonotic Influenza in Peru
In an effort to have a better understanding of zoonotic influenza transmission in humans with intense 
occupational exposure to swine and avian species (i.e. backyard poultry, backyard swine, informal 
and formal poultry and swine farmers, slaughter houses, live bird markets, game birds breeders, etc.),  
controlled, cross-sectional and prospective (two-year) cohort studies of zoonotic influenza transmission 
among a total of up to 1,500 adults intensively exposed to swine and birds are being conducted.
Study Aims and Objectives:
•	 Study the prevalence of antibodies against AI and SI among humans, particularly against  
those strains which have been shown to possess the ability to cross the human/avian/swine 
species barrier. 
•	 Estimate the incidence of zoonotic influenza infection. 
•	 Determine risk factors for zoonotic influenza infection.
•	 Study the presence of influenza infection among avian and swine species. 
•	 Determine which strains are circulating in these populations.
Approach: The study is being conducted in areas of Peru with large concentrations of potentially 
exposed humans. The study population includes any subject that is exposed to swine and/or avian 
species because of their occupation (e.g., veterinarians, poultry/swine farmers, poultry/swine vendors 
at live markets, slaughterhouse fighting cock breeders.) Questionnaires and serum samples from 
participants will be obtained at 0, 12, 24, and 36 months. Active surveillance for ILI among human 
subjects and related animal populations will be performed. When an ILI case is found, respiratory 
and serum samples will be collected. Serologic testing (HAI and MN), RT-PCR, viral culture, and 
cDNA sequencing will be used to determine influenza infection outcomes. By understanding zoonotic 
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influenza transmission in these specific populations, pandemic planning can be strengthened by 
including measures that will prevent influenza transmission within this population and to other at 
risk-populations.
Timeline: This study began enrollment on February 2011 and will finish follow-up on February 2013.
Progress and Findings: Two sites, Tumbes (north coast) and Pucallpa (central jungle), are actively 
enrolling participants. No testing has been performed yet.
Surveillance for Avian Influenza in Live Bird Markets of Peru 
Previous studies have shown that wild birds in Peru may serve as competent reservoirs for influenza 
strains, although there has not been an outbreak of highly-pathogenic avian influenza detected to date. 
Furthermore, this risk may be increased if these birds and domestic poultry (or other species such as 
swine) are housed together or kept in close proximity to one another. The surveillance of live bird 
markets will allow us to assess the direct threat to human health and the threat to livestock posed by 
avian influenza and other zoonotic diseases. It will also allow us to monitor the international biosecurity 
threat posed by these markets, as part of the international wildlife trade chain. 
Study Aims and Objectives:
•	 Determine whether or not avian influenza (AI; either high or low pathogenic types) is present 
in live bird markets of Peru.
•	 If AI is present, determine which types are circulating. 
•	 Collaborate with additional projects to determine evidence of exposure to AI among the bird 
market worker population, and to examine and compare the knowledge, attitudes and practices 
associated with AI among live bird market workers.
Approach: We are testing birds for avian influenza and other diseases in Peruvian markets and in 
birds seized during government confiscations. The study includes wild-caught birds being offered 
for sale, exotic cage birds and domestic avian species. All samples are collected with the consent of 
the bird seller. Tracheal and cloacal swabs are collected from the birds and placed in viral transport 
media (VTM). Samples will be refrigerated until arrival to the lab, where they will be kept at –70°C 
until processed for viral isolation. Positive isolates, if any, will be analyzed by RT-PCR for confirmation, 
followed by sequencing for molecular characterization.
Timeline: The study is in its fourth year of execution and is expected to end by March 2012.
Progress and Findings: To date, 19 live bird markets and 11 confiscations have been monitored and 
sampled among seven cities in Peru. More than 2,500 samples (oral, cloacal, fecal swabs and feces) have 
been obtained from 1,600 birds of 77 avian species. None of these samples has been positive for AI. 
Seventy samples were positive for Newcastle disease (Paramyxovirus type 1). Among samples collected 
from groups of animals (fecal swabs and pooled fecal samples), 80 samples showed parasites (Coccidia, 
Ascaridia, Capillaria and Giardia). Campylobacter jejunii, Aeromonas hydrophila and Salmonella sp. and 
other antibiotic-resistant bacterial strains have been isolated from ducks, chickens and wild species (e.g., 
white-winged parakeets, American kestrels).
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Development and Validation of 
Diagnostics
Kenya
Comparison of nasopharyngeal and oropharyngeal swabs for the diagnosis of  
eight respiratory viruses by real-time reverse-transcription polymerase chain 
reaction assays
Many acute respiratory illness surveillance systems collect and test nasopharyngeal (NP) and/or 
oropharyngeal (OP) swab specimens, yet there are limited data assessing the relative measures of 
performance for NP versus OP specimens. We compared the yield of NP and OP swabs for detecting 
eight respiratory viruses by quantitative real time-polymerase chain reaction (qRT-PCR). Sensitivities of 
the two specimen types varied by virus. Neither specimen type was consistently more effective than the 
other for virus identification.  
Study Aims and Objectives: 
•	 Evaluate the comparative yields of NP and OP swabs in detecting influenza by qRT-PCR.
•	 Determine the sensitivities of NP and OP swabs for other key respiratory viruses.
•	 Characterize the respiratory viruses circulating in the study population.
Approach: Paired NP and OP swabs were separately collected from pediatric and adult patients with 
influenza-like illness or severe acute respiratory illness from two respiratory surveillance sites in Kenya. 
NP and OP specimens from each patient were separately tested by singleplex qRT-PCR for eight 
viral pathogens: adenovirus, influenza A virus, influenza B virus, human metapneumovirus (hMPV), 
parainfluenza viruses (PIV) 1 – 3, and respiratory syncytial virus (RSV). Positive influenza A samples 
were also subtyped as 2009 influenza A pandemic (H1N1) virus, influenza A (H3N2) virus (H3N2), and 
seasonal influenza A (H1N1) virus. An individual was defined as positive for a specific virus if the viral 
nucleic acid was detected in either swab.  
Timeline: Specimens were collected from June 9, 2009 to August 31, 2010; data were analyzed and a 
manuscript has been developed. 
Findings: Of 2,331 paired NP/OP specimens 1,402 (60.1%) were positive for at least one virus. Overall, 
OP swabs were significantly more sensitive than NP swabs for adenovirus and 2009 influenza A 
pandemic (H1N1) virus. NP specimens were more sensitive for influenza B virus, parainfluenza virus 
2, and parainfluenza virus 3. There was no significant difference between the two methods for human 
metapneumovirus, influenza A (H3N2) virus, parainfluenza virus 1, or respiratory syncytial virus. For 
respiratory disease surveillance programs using qRT-PCR that aim to maximize sensitivity for a large 
number of viruses, collecting combined NP and OP specimens would be the ideal approach.  
Viral shedding in patients infected with pandemic influenza A (H1N1) virus in 
Kenya, 2009
We evaluated the duration of pH1N1 virus shedding in patients in Nairobi, Kenya. Nasopharyngeal (NP) 
and oropharyngeal (OP) specimens were collected from consenting laboratory-confirmed pH1N1 cases 
every two days during October 14 -November 25, 2009, and tested at the CDC-Kenya laboratory by real-
time RT-PCR.
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Two hundred eighty-five NP/OP specimens were collected from patients with acute respiratory illness, 
140(49%) specimens tested positive for pH1N1; 106(76%) patients consented and were enrolled.  The 
median age was 6 years (Range: 4 months-41 years). The median duration of pH1N1 detection after 
illness onset was 8 days. Viable pH1N1 virus was isolated from 133/168 (79%) of rRT-PCR-positive 
specimens. Viral RNA was detectable in 18(17%) and virus isolated in 7(7%) of specimens collected from 
patients after all their symptoms had resolved. 
Study Aims and Objectives:
•	 Determine the duration of pH1N1 virus shedding.
•	 Determine the correlation between real time reverse transcriptase results and virus isolation.
•	 Determine the correlation between pH1N1 virus detection and age, gender, and/or HIV status.
Approach: The study was carried out in Kibera, a large informal settlement in Nairobi. Since 2005, CDC-
Kenya and the Kenya Medical Research Institute (KEMRI) have conducted intensive population-based 
infectious disease surveillance within two villages in Kibera with a population of 28,000 people. Persons 
enrolled in the surveillance are able to attend a field clinic within the site, where they are provided with 
free care for any acute illness.
Consenting patients presenting to the clinic with signs and symptoms of ILI and SARI had oropharyngeal 
(OP) and nasopharyngeal specimens collected. Patients who were positive for pH1N1 were contacted at 
their homes by field workers and requested to return to the clinic for follow up every two days. During 
their initial return visit, written informed consent to participate in the study was obtained. During the 
initial visit and subsequent visits, a trained clinician recorded signs and symptoms and collected both NP 
and OP specimens. Patients who had two consecutive rRT-PCR negative specimens were released from 
the study.  
Timeline: The study period was from October 14 to November 25, 2009.
Progress and Findings: During the study period, 285 NP/OP specimens were collected from patients 
presenting with ILI or SARI at the Kibera Clinic. Of these specimens, 140(49%) tested positive for 
pH1N1 by rRT-PCR. One hundred and six (76%) pH1N1-positive patients consented and were enrolled. 
The median age was 6 years (Range: 4 months-41 years); only two patients, both asthmatic, received 
oseltamivir. The median duration of pH1N1 detection after illness onset was eight days (95% CI: 7-10 
days) for rRT-PCR and three days (Range: 0-13 days) for viral isolation. Viable pH1N1 virus was isolated 
from 133/168 (79%) of rRT-PCR-positive specimens. Viral RNA was detectable in 18 (17%) and virus 
isolated in seven (7%) of specimens collected from patients after all their symptoms had resolved. Thus, 
we concluded that the median duration of pH1N1 virus detection in this cohort was eight days, similar 
to what has been described in studies in other areas of the world. In our study, some patients who were 
no longer symptomatic may continue to shed viable pH1N1 virus.
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Monitoring and Evaluation
Under the cooperative agreements made between CDC’s Influenza Division and its partner countries, 
the Division supports the monitoring and evaluation (M&E) of activities associated with international 
Influenza program implementation. The purpose of M&E in this context is to:
•	 Demonstrate accountability for the resources used by programs to key stakeholders; CDC and 
the countries which receive funding.
•	 Document each country’s capability and capacity for influenza surveillance, diagnostics and 
pandemic preparedness in order to:
 ˏ identify program strengths and opportunities for improvement.
 ˏ provide a mechanism to measure progress toward defined objectives and thereby 
demonstrate meaningful improvement in public health function over time.
•	 Guide ongoing investment in influenza surveillance, diagnostics and pandemic preparedness 
globally.
•	 Inform strategic and programmatic planning for countries and target technical assistance 
provided by CDC.
•	 Standardize and systematize practices.
•	 Identify good practices that can be shared between countries.
The Influenza Division has developed three M&E tools which are described below.
National Inventory of Core Capabilities for Pandemic 
Influenza Preparedness and Response
Purpose: A comprehensive tool by which countries can systematically and quantitatively measure their 
capability and capacity to respond to an influenza pandemic.  
Tool: The tool covers 12 distinct domains, defined as ‘core capabilities’ and each capability is assigned 
a composite score based on the quality, coverage and timeliness of four related indicators. For example, 
‘Infection Control’ is a core capability measured against (i) standards of infection control by level of 
health-care system (ii) integration of infection control training for staff (iii) availability of logistical 
resources for infection control and (iv) level of institutionalization of infection control efforts. The end-
points for the core capabilities are not identical which allows for variation in public health priorities 
across countries with differing resource constraints. For a copy of the tool, please visit www.cdc.gov/flu/
international/tools.htm.
Implementation: Between May and October of 2008, 40 countries completed baseline assessments, 
facilitated by CDC staff. A further 12 countries participated in late 2009 and early 2010 to establish 
baselines. As of November 2010, 36 countries of the initial 40 countries which participated had repeated 
the tool at approximately a two year interval, allowing for comparing baseline and subsequent scores.  
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Outcomes: Comparison of the data for the 36 countries between 2008 (baseline) and 2010  
revealed the following:
•	 Total (aggregate) scores for the tool moved in a positive direction indicating an overall 
improvement in pandemic preparedness for each country over the period.
•	 Looking at all countries in aggregate, all 12 core capabilities showed statistically significant 
improvement from baseline.
•	 Examining each indicator in aggregate, 47 of 50 indicators showed statistically significant 
progress from 2008 to 2010.
Further to this:
•	 The assessments in 2008 helped countries to identify and target areas for preparedness 
improvement which in turn strengthened their ability to respond to the 2009 H1N1 pandemic.
•	 At the same time, the 2009 outbreak offered an enormous opportunity for countries to test their 
pandemic response with the outcomes captured when they repeated the tool in 2010.
•	 Identifying areas for Influenza improvement is also enhancing capacity-building for other 
infectious diseases as well as encouraging compliance with International Health Regulations 
(IHR).
•	 Using the tool to document progress is helping countries advocate for continued support.
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International Influenza Laboratory Capacity Review
Purpose: A tool designed for countries to assess their capability and capacity to perform influenza 
diagnostics and best laboratory practices. 
Tool: The tool consists of 10 sections for assessment including, virology and molecular biology 
techniques, availability and use of equipment and reagents, specimen collection and reporting, staff 
training in diagnostic procedures, laboratory safety and equipment maintenance and methods for quality 
control. The results from these sections form the basis for creating laboratory capacity summary reports 
for countries. For a copy of the tool, please visit www.cdc.gov/flu/international/tools.htm.
Implementation: Between September 2009 and November 2010, 41 countries completed baseline 
assessments, facilitated by staff from the CDC and Association of Public Health Laboratories (APHL).  
Outcomes: The tool served to highlight overall laboratory strengths while recommendations were 
provided by reviewers where opportunities for improvement presented themselves. For example, of 
the 10 countries which participated in the Africa region, six laboratories do not perform virus isolation 
but all have expressed interest and readiness to receive technical assistance in these methods. Likewise, 
across all regions, many countries received specific recommendations for improving the biosafety of 
their laboratories. The tool has also allowed CDC and its collaborating countries to assess regional gaps 
and develop both individual and regional plans for improving laboratory capacity. 
International Influenza Surveillance Assessment Tool
Purpose: A tool designed to standardize and systematize the review of national surveillance systems.  
The tool helps CDC and partners to clarify the objectives and structure of their surveillance systems, 
such that recommendations and technical assistance can be targeted to meet system goals such as, 
conducting data quality checks and establishing built-in laboratory and epidemiologic data integration.
Tool: The tool consists of six checklists covering national, central and sentinel site levels and covers all 
ILI and SARI related surveillance. For example, it includes a review of data management, analysis and 
reporting procedures. The tool uses a standard format for creating surveillance capacity summary reports 
where recommendations for countries can be provided. For a copy of the tool, please visit www.cdc.
gov/flu/international/tools.htm.
Implementation:  Between March and October 2010, the tool was piloted in nine countries  
by CDC staff.
Outcomes: Lessons learned from the pilot countries were used to refine and finalize the tool.  The tool 
served to highlight overall surveillance strengths and recommendations for improvement in the pilot 
countries in which it was implemented. The finalized tool will be implemented in additional countries 
from late-2011.
The covers of the three monitoring and evaluation tools used for international Influenza 
programs. From left to right, the National Inventory of Core Capabilities for Pandemic 
Influenza Preparedness and Response, the International Influenza Laboratory Capacity 
Review and the International Influenza Surveillance Assessment Tool.
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Meetings and 
Training
Meetings and Training 261
Meetings
First African Network for Influenza Science and 
Epidemiology (ANISE) Meeting
Location: Campus of National Institute of Communicable Diseases; Johannesburg, South Africa.
Dates: December 7 – 9, 2009.
Originally scheduled for May 2009 but postponed due to the 2009 H1N1 pandemic, the symposium  
was a collaborative effort organized by the NICD, CDC-Atlanta, CDC-Kenya, WHO-Geneva, WHO-African 
Regional Office, Institut Pasteur, the Naval Medical Research Unit No.3 in Cairo, and the U.S. Department 
of Defense’s Global Emerging Infection Surveillance Program. Participants from more than twenty 
countries in Southern, East, West, Central and North Africa presented their surveillance data and  
original research.
Goals
The symposium highlighted the wide range of influenza surveillance and research that has been 
conducted throughout Africa in the last few years. 
Agenda
Presenters included laboratory scientists, medical doctors, epidemiologists, veterinarians, doctoral 
students, and a behavioral scientist. More than 40 oral presentations were delivered over the course  
of two and a half days, and an additional 20 posters were presented. Oral and poster presentations 
focused on:
•	 Seasonal influenza surveillance.
•	 Pandemic H1N1 surveillance and outbreak response.
•	 Antiviral drug resistance.
•	 Animal-human interface research. 
Additionally, scientists and epidemiologists from the NICD, WHO and CDC gave plenary lectures on:
•	 The global epidemiology and viral evolution of the 2009 H1N1 pandemic.
•	 The challenges of laboratory testing for 2009 H1N1.
•	 The various approaches to quantifying the burden of influenza worldwide, and in  
Africa specifically.
Outcome
Broad participation and the breadth of the research presented at the symposium illustrated the depth 
of influenza work that is occurring currently in Africa, a continent where information about influenza 
has historically been quite limited. The diverse reports of surveillance, detection, and response to 2009 
H1N1 influenza in Africa showed that efforts by governments and international organizations to ramp up 
pandemic preparedness in Africa over the past few years have produced real results. The abstracts from 
the meeting can be found at 
http://www.team-psa.com/afss2009/presentations.asp.
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WHO Eastern Mediterranean Regional Meeting
Location: Grand Hyatt Cairo; Cairo, Egypt. 
Dates: January 18 – 19, 2010.
Countries represented: Egypt, Morocco, and Pakistan.
Co-sponsors/other participants: WHO EMRO; NAMRU-3; Egypt Ministry of Health.
Goals
The regional meeting was held to focus on pandemic influenza surveillance and response, community 
mitigation and CDC programmatic issues. The meeting goals were to update regional partners on overall 
surveillance goals, to review and discuss pandemic 2009 H1N1 response and activity, to discuss lessons 
learned and strategies to improve surveillance activities, and to address navigation of CDC cooperative 
agreement requirements.
Agenda
The topics selected for the meeting agenda included recommendations from country partners. The 
agenda was developed to provide an opportunity for participants to receive CDC updates on priority 
areas, to highlight progress that projects have made in establishing sentinel surveillance, to discuss 
future program and technical needs to strengthen laboratory and epidemiologic capacity, and to 
participate in a mini-workshop on community mitigation.
Key Agenda Topics
•	 Influenza Surveillance and Response – The United States Experience and Future of Global 
Influenza Vaccinations.
•	 Influenza Surveillance and Response – WHO EMRO Regional Perspective.
•	 Pandemic 2009 H1N1 Influenza Update and the Future of Surveillance Post-Pandemic.
•	 Burden of Disease.
•	 Country Presentations.
•	 CDC Surveillance Review Tool.
•	 Sustainability and Future Plans.
•	 Navigating Cooperative Agreements.
•	 Community Mitigation Mini-Workshop.
Outcome
Country and WHO EMRO partners had the opportunity to discuss country and regional efforts to build 
capacity for influenza surveillance in a small group setting. Partners discussed what worked well in 
their surveillance networks during the pandemic. They also had the opportunity to discuss areas where 
technical assistance from CDC, WHO, and others would be needed to further improve  
influenza surveillance.
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Noteworthy Outcomes
•	 Country partners had the opportunity to highlight progress made in developing national 
sentinel surveillance systems and lessons learned.
•	 Participants gained knowledge of community mitigation strategies with a scientific basis and the 
implementation plan for the surveillance review tool.
•	 Participants contributed suggestions for agenda topics for the July 2010 Influenza Division 
International Partners and Burden of Disease Meeting. 
WHO European Regional Meeting
Location: Grand Hyatt Cairo; Cairo, Egypt. 
Date: January 19 – 20, 2010.
Countries represented: Armenia, Georgia, Kazakhstan, Moldova, Romania, and Ukraine.
Co-sponsors/other participants: WHO EURO, PATH, NAMRU-3, Egypt Ministry of Health.
Goals
The regional meeting was held to focus on pandemic influenza surveillance and response, community 
mitigation and CDC programmatic issues. The meeting goals were to update regional partners on overall 
surveillance goals, to review and discuss pandemic 2009 H1N1 response and activity, to discuss lessons 
learned and strategies to improve surveillance activities, and to address navigation of CDC cooperative 
agreement requirements.
Agenda
The topics selected for the meeting agenda included recommendations from country partners. The 
agenda was developed to provide an opportunity for participants to receive CDC updates on priority 
areas, to highlight progress that projects have made in establishing sentinel surveillance, to discuss 
future program and technical needs to strengthen laboratory and epidemiologic capacity, and to 
participate in a mini-workshop on community mitigation.
Key Agenda Topics
•	 Overview of 2009 Pandemic Surveillance in the European Region.
•	 Influenza Surveillance and Response- the United States Experience.
•	 Burden of Disease.
•	 Future of Global Influenza Vaccination and the Future of Surveillance Post- Pandemic 2009 
H1N1.
•	 Country Presentations and Individual Country Meetings.
•	 CDC Surveillance Review Tool.
•	 Sustainability and Future Plans.
•	 Navigating Cooperative Agreements.
•	 Community Mitigation Mini-Workshop.
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Outcome
Country and WHO EURO partners had the opportunity to discuss country and regional efforts to  
build capacity for influenza surveillance in a small group setting. Partners discussed what worked well in 
their surveillance networks during the pandemic. They also had the opportunity to discuss areas where 
technical assistance from CDC, WHO, and others would be needed to further improve  
influenza surveillance.
Noteworthy Outcomes
Country partners were able to highlight progress made in developing national sentinel surveillance 
systems and lessons learned.
Participants gained knowledge of community mitigation strategies with a scientific basis and the 
implementation plan for the surveillance review tool.
Participants contributed suggestions for agenda topics for the July 2010 Influenza Division International 
Partners and Burden of Disease Meeting.
WHO South-East Asia Regional Meeting 
Location: Le Meridian Hotel; Kochi, India.
Date: February 22 – 24, 2010.




The South-East Asia Regional meeting “Pandemic and Seasonal Influenza Surveillance and Response: 
Lessons Learned,” brought CDC, WHO SEARO and cooperative agreement grantees from the South-
East Asia Region together. Goals of the meeting were to showcase surveillance efforts in the region, to 
demonstrate how surveillance data can be analyzed and used effectively, to describe lessons learned 
from the 2009 H1N1 influenza pandemic and to discuss what countries could do differently in the future. 
Agenda
The agenda included presentations, discussions, questions and answers, round table discussions and 
troubleshooting with experts from surveillance, health care systems, and communication. Countries 
reported on their routine surveillance systems and their epidemiologic and virologic 2009 H1N1 data 
and changes and modifications that were made after the pandemic. A highlight was hearing about 
vaccine production in India from Dr. Lalit Kant.
Key Agenda Topics
•	 Experiences and lessons learned from the pandemic with regards to surveillance, health care 
systems, laboratory and communications -- what worked and what didn’t.  
 ˏ U.S. Experience: Challenges and Changes.
 ˏ Health Care Systems.
 ˏ Laboratory.
 ˏ Communication Strategies/Messaging.
 ˏ Was the pandemic what we planned for?
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•	 Pandemic and seasonal influenza research and what the research suggests.   
 ˏ Bangladesh, Ongoing Research, Preliminary Findings.
 ˏ India, Influenza Disease Burden and Vaccine Effectiveness.
 ˏ Thailand, HITS Study Results. 
 ˏ Indonesia, Epidemiology of Avian Influenza in Indonesia.
 ˏ India’s plans for vaccine production.
 ˏ Vaccines and Vaccinations, currently and into the future.
Outcomes
•	 Participants found it valuable to learn about each country’s surveillance system. Discussion of 
this topic presented an opportunity to think through how they might adjust their own country’s 
surveillance system.  
•	 Participants found it valuable to hear from leading experts and to make new contacts  
from other countries. Some participants were able to arrange visits to other countries for 
laboratory training.
•	 Country staff were able to meet with CDC staff and seek their assistance regarding 
epidemiology, research, their cooperative agreement, clinical systems and pandemic response.
PAHO Regional Meeting
Location: Sheraton Maria Isabel Hotel and Towers, Mexico City, Mexico.
Date: April 12 – 14, 2010.
Countries represented: Argentina, Brazil, Mexico, Paraguay, and Peru.
Co-sponsors: PAHO.
Goals
The purpose of the meeting was to bring together representatives from the CDC, PAHO and the CDC-
funded influenza grantees from Argentina, Brazil, Mexico, Paraguay and Peru to identify strategies for 
effective implementation of influenza sentinel surveillance and to review surveillance data and pandemic 
preparedness activities. The meeting provided an opportunity for the PAHO region to discuss the 
implementation of their pandemic influenza plans during the 2009 H1N1 pandemic. Countries were able 
to discuss the strengths, challenges and lessons learned during the pandemic.  
Agenda
The meeting’s agenda was built on CDC and country presentations with group discussions to learn 
from each other and to share past experiences. Issues included discussing the ability to decrease future 
pandemics through rapid detection of, accurate confirmation of and effective response to future novel 
influenza viruses. The meeting provided an opportunity to discuss the need to establish estimates of 
preventable disease burden and the need to make evidenced-based decisions on vaccine introduction. 
There were discussions about the need to increase vaccine production and the need to introduce 
vaccines for advance seasonal and pandemic prevention of influenza. 
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Key Agenda Topics
•	 Each country presented on their strengths and the challenges they encountered  
during the pandemic.
•	 Each country discussed their plans to include influenza vaccine in their future  
immunization activities.
•	 Each country discussed their plans to apply for the next CDC influenza cooperative agreement 
with new goals and objectives based on their past experiences and the need to sustain their 
present influenza program.  
Outcome
The PAHO Region will continue working together to better understand influenza vaccine utilization, 
coverage and needs in the region. Due to funding restraints, the PAHO Region needs to continue to 
streamline and standardize influenza surveillance and vaccination policies using evidenced-based data 
gathered in partnership with regional countries.
Noteworthy Outcomes
•	 Countries shared their influenza communication campaigns. 
•	 Several countries that shared borders discussed methods to improve cross-border influenza 
surveillance programs.
•	 The need was identified to develop new methods of sustaining the countries’ influenza 
programs in light of to future decreases in CDC funding.
WHO Western Pacific Regional Meeting
Location: Pan Pacific Hotel; Manila, Philippines.
Date: May 6 – 7, 2010.
Countries represented: Cambodia, China, Fiji, Laos, Mongolia, Papua New Guinea, Philippines, 
Secretariat of the Pacific Community (SPC), and Vietnam.
Co-sponsors: WHO WPRO.
Goals
The CDC- WPRO partners meeting was an opportunity for CDC-funded cooperative agreement partners 
to share experiences and discuss lessons learned from the 2009 pandemic. Other meeting goals included 
discussion of sustainability of surveillance programs with decreasing CDC funds, ongoing laboratory 
support, and upcoming epidemiologic surveillance assessments. The meeting was followed by WHO’s 
regional meeting of WPRO partners where their new FluID epidemiological reporting system was 
introduced and updates on the FluNet virus database were provided.
Agenda
Items covered by the agenda included CDC support of partners in the regional, epidemiologic 
surveillance assessment, laboratory support QandA, sustainability, and future plans for partner programs. 
Other items included planning for the July 2010 Influenza Division International Partners and Burden 
of Disease Meeting. A full day was devoted to country accounts of lessons learned from the 2009 H1N1 
experience. The meeting was wrapped up with a discussion of what sorts of technical assistance, 
guidance, and direction would be most helpful to cooperative agreement partners.
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Key Agenda Topics
•	 Sustainability and future plans for cooperative agreements and national surveillance systems.
•	 Laboratory support.
•	 Epidemiology surveillance assessment.
•	 Technical assistance to cooperative agreement partners.
•	 Lessons learned from 2009 pandemic. 
Outcome
The meeting allowed many countries in the Region to discuss their plans for sustainability and to share 
lessons learned from the 2009 H1N1 pandemic. 
Influenza Division International Partners and  
Burden of Disease Meeting
Location: Hyatt Regency Downtown; Atlanta, USA.
Date: July 9 – 11, 2010.
The CDC Influenza Division International Partners and Burden of Disease Meeting was held over two 
and a half days at the Hyatt Regency in downtown Atlanta. Over 300 invitees attended from 59 countries 
spread over all six WHO regions. Attendees came from Ministries of Health, National Influenza Centers, 
WHO, universities, research institutions, and world-wide CDC offices.
The first day of the meeting, Friday, July 9, opened with a welcome from CDC Director Dr. Thomas 
Frieden. Plenary session topics on Friday afternoon included:
•	 2009 Pandemic Response.
•	 Pandemic Communications.
•	 Influenza Laboratory Response during the Pandemic.
•	 Capturing Global Data for Decisions.
•	 Influenza Policy Issues and Priorities.
•	 The Continuing Threat of H5N1 and Novel Influenza A Viruses.
•	 Improving Global Vaccine Strain Selection.
•	 Monitoring and Evaluation Global Progress.
•	 Monitoring and Evaluation from a Country Perspective.
Day two began with an overview of International Flu Vaccine Studies, with reports from India, Senegal, 
and Kenya. The morning then broke into tracks, which covered the following topics:
•	 U.S. Flu Vaccine Studies – plenary session.
•	 Managing Cooperative Agreements – breakout, 47 attendees.
•	 Animal-Human Interface – breakout, 75 attendees.
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Saturday afternoon began with a plenary session focusing on disease burden estimation. The afternoon 
then broke into tracks, which included the following topics:
•	 Non-Pharmaceutical Interventions – breakout, 45 attendees.
•	 Training and Review Tools – breakout, 64 attendees.
•	 Poster Session.
Over 70 posters were submitted for the poster session, including five exemplary examples from 
Madagascar, Cambodia, Kyrgyzstan, Brazil, and Laos, whose authors were awarded scholarships to 
attend the meeting.  
On Sunday morning, Dr. Lalit Kant of the Indian Council of Medical Research gave the keynote address 
on pandemic influenza vaccines. As with previous days, the meeting eventually broke into tracks, which 
covered the following: 
•	 Estimating Disease Burden – plenary session.
•	 Electronic Data Systems for Surveillance – breakout, 42 attendees.
•	 International Shipping and Biosafety Issues – breakout, 21 attendees.
•	 Beyond Influenza: Full Respiratory Disease Diagnostics – breakout, 52 attendees.
Dr. Marc-Alain Widdowson wrapped up the meeting Sunday afternoon after the plenary session on 
disease burden estimation in China, Peru, and Nicaragua. Most attendees from the International Partners 
meeting stayed on for the International Conference on Emerging Infectious Disease (ICEID) that began 
directly after the partners meeting. Plans are in the works for the Influenza Division International 
Partners meeting to become an annual event.
Partners Meeting for Research and Other Activities  
at the Animal-Human Interface
Location: Emory Conference Center, Atlanta, United States`.
Date: August 23 – 24, 2010.
Countries represented: Bangladesh, India, Indonesia, Peru., and the USA
Goals
This was the third annual meeting of the Avian Influenza Cooperative Research Centers. Our goal was to 
provide updates on the international influenza research and surveillance activities at the animal-human 
interface performed by scientists from the Avian Influenza Cooperative Research Centers, U.S. CDC, and 
other partners. Our second goal was to enhance coordination and communication among investigators 
to advance scientific knowledge about virus transmission among and between animals and humans.
Agenda
The meeting agenda allowed investigators from the Avian Influenza Cooperative Research Centers, 
USDA, USAID, NIH and other international and U.S. partners to present and discuss up-to-date research 
and surveillance findings for novel zoonotic, swine, avian, and human influenza. The agenda was 
developed to provide an opportunity for participants to hear updates from CDC investigators, discuss 
priority areas of research, and identify critical needs for more research activities.
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Key Agenda Topics
•	 CDC—One Health.
•	 Each investigator presented updates on research and surveillance activities at the  
animal-human interface.
•	 After a Pandemic: What did we learn and what might we expect?
•	 Revisiting the notion of influenza epicenters.
•	 Roundtable discussion of international animal-human interface research and enhanced 
surveillance priorities.
Outcome
The presentations at this meeting highlighted the breadth of activities being performed internationally 
at the animal-human interface, but also brought forth discussions of additional research and enhanced 
animal surveillance that needs to be performed to improve preparedness, detection, and response to 
zoonotic disease infection. 
Noteworthy Outcomes
•	 This was the third and final meeting as the Avian Influenza Research Centers and provided a 
means for each center to showcase their results.
•	 International animal and human influenza experts were able to network and a working group 
was formed.
•	 Increased swine influenza virus surveillance was identified as a priority area of activity.
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Laboratory Training
Pandemic Preparedness Team, Immunology and 
Pathogenesis Branch, Influenza Division—Serology Training
Location: CDC; Atlanta, USA.   
Date: March 8 – 26, 2010.
Countries represented: Bangladesh, Indonesia, and Senegal.
Co-sponsors: None.
Goals
This workshop was organized by CDC scientists to provide essential material on serological assays for 
detection of antibodies to influenza viruses, with an emphasis on detection of human antibodies to 
pandemic H1N1 influenza viruses. Vic Veguilla covered protocols including egg inoculations for virus 
growth, virus harvesting, virus titrations, microneutralization assay, RDE treatment of sera, treatment 
of red blood cells, and hemagglutination-inhibition assay, among others. Participants were engaged in 
lectures as well as hands-on experience.
Agenda/Set-up
The curriculum for this training workshop was developed by Vic Veguilla to teach the principles of 
influenza serology assays. The course took place in BSL-2 facilities at CDC in Atlanta, Georgia.       
Outcome
Participants became familiar with various serological assays, WHO guidelines for serologic diagnosis and 
detection of human influenza infection, and developed skills for trouble-shooting serological assays.
Pandemic Preparedness Team, Immunology and 
Pathogenesis Branch, Influenza Division – Serology Training
Location: InDRE; Mexico City, Mexico.   
Date: March 31 – April 23, 2010.
Countries represented:  Mexico.
Co-sponsors: None.
Goals
This workshop was organized by CDC scientists to provide essential material on serological assays for 
detection of antibodies to influenza viruses, with an emphasis on detection of human antibodies to 
pandemic H1N1 influenza viruses. Vic Veguilla covered protocols including egg inoculations for virus 
growth, virus harvesting, virus titrations, microneutralization assay, RDE treatment of sera, treatment 
of red blood cells, and hemagglutination-inhibition assay, among others. Participants were engaged in 
lectures as well as hands-on experience.
Agenda/Set-up
The curriculum for this training workshop was developed by Vic Veguilla to teach the principles of 
influenza serology assays. The course took place in BSL-2 facilities at InDRE in Mexico City, Mexico.
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Outcome
Participants became familiar with various serological assays, WHO guidelines for serologic diagnosis 
and detection of human influenza infection, as well as develop skills for trouble-shooting serological 
assays. In addition, participants were able to develop a workflow for performing national influenza 
seroprevalence studies.
Molecular Epidemiology and Sequencing Workshop for the 
Analysis of Avian Influenza Viruses in Africa 
Location: NAMRU-3; Cairo, Egypt.
Date: April 12 – 23, 2010.
Countries represented:  Egypt and Oman.
Co-sponsors: NAMRU-3.
Goals
This one week workshop was organized by CDC scientists to train individuals in phylogenetics and 
bioinformatics for the analysis of highly pathogenic H5N1 avian influenza viruses circulating in Africa. 
Todd Davis and Pierre Rivailler provided a combination of both lectures and computer-based laboratory 
sessions to train NAMRU-3 laboratory staff in methods for sequencing viral genes, complete genome 
sequence analysis and influenza phylogenetics. Other topics included assessment of emerging influenza 
virus threats and characterization of H5N1 viruses isolated in humans and poultry.      
Agenda/Set-up
The curriculum for this training workshop was developed by Todd Davis and Pierre Rivailler to teach 
the principles of full genome sequencing/phylogenetics to NAMRU-3 staff. The course was taught in a 
computer laboratory setting with ten participants working as staff scientists in the NAMRU-3 molecular 
virology laboratory.       
Outcome
Ongoing collaborations between CDC and NAMRU-3 scientists continue to characterize the molecular 
and antigenic characteristics and evolution of H5N1 viruses in Africa. Data from these studies support 
research to develop H5N1 pre-pandemic vaccine candidates.      
Serological Training for CDC/KEMRI
Location: Nairobi, Kenya.




The goal of this training was to provide support, troubleshooting and hands-on assistance for a 
serological study conducted in Kenya. The training, conducted by Amanda Balish, CDC, was needed to 
address consistent errors in performing the assay. 
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Agenda/Set-up






The laboratorians were able to successfully perform the serological testing. Follow up results analysis 
was performed for the remaining serum not tested during training.
Molecular Epidemiology and Sequencing Workshop for the 
Analysis of H5N1 and Seasonal Influenza Viruses in Vietnam
Location: Pasteur Institute-Nha Trang; Nha Trang,Vietnam (PI-Nha Trang).   
Date: June 8 – 12, 2010.
Countries represented:  Vietnam.
Co-sponsors: Pasteur Institute-Nha Trang.
Goals
This laboratory training was initiated to review and improve the sequencing and bioinformatics capacity 
of the Pasteur Institute-Nha Trang as a regional reference laboratory for central Vietnam. The training 
was conducted by Dr. Todd Davis, CDC, with coordination and support from the WHO WPRO office 
(Dr. Mendsaikhan Jamsran) to review and enhance the laboratory’s influenza sequencing, bioinformatics, 
and overall research capacity. Training was implemented to build upon and improve the capacity 
of PI-Nha Trang to fulfill its mission as a regional reference laboratory and to provide the necessary 
support to other regional and provincial influenza diagnostic laboratories in Vietnam. 
Agenda/Set-up
Dr. Davis provided CDC full genome sequencing primers to PI-Nha Trang for sequencing seasonal, 
pandemic, and avian influenza viruses. Primers and protocols were tested in the PI-Nha Trang 
laboratories to demonstrate functionality and to perform sequence analysis using existing and 
recommended sequence analysis software. Data obtained from the training was used to demonstrate 
phylogenetic/bioinformatic tools to improve data analysis and interpretation.
Outcome
PI-Nha Trang leadership developed algorithms to determine which genes/number of samples would 
be sequenced each year with an emphasis on HA (genetic drift studies) and NA (antiviral resistance 
studies). Archival and new data generated has been shared with Vietnamese NICs and/or WHO CCs for 
surveillance/epidemiologic research. Influenza virus isolates of interest and sequence data continue to 
be shared with WHO CCs and submitted to sequence databases when appropriate.
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Phylogenetic and Bioinformatics Workshop for the Analysis 
of Seasonal, Pandemic and Avian Influenza Virus
Location: Pasteur Institute; Ho Chi Minh City, Vietnam.
Date: June 14 – 25, 2010.
Countries represented: Cambodia, Indonesia, Lao PDR, Singapore, Thailand, and Vietnam.
Co-sponsors: Pasteur Institute, Ho Chi Minh City.
Goals
The U.S. CDC, in collaboration with the Pasteur Institute, Ho Chi Minh City, initiated an effort to 
provide critically needed training for regional influenza research centers. This two-week workshop 
was developed to train individuals in phylogenetics and bioinformatics for the analysis of seasonal, 
pandemic and avian influenza. CDC and regional scientists provided instruction in a hands-on manner 
using a combination of both lectures and computer-based laboratory sessions. Specific topics included 
molecular diagnostic procedures to detect influenza in clinical, veterinary, and environmental samples, 
database utilization, methods for sequencing viral genes, complete genome sequence analysis and 
influenza phylogenetics. Other topics included molecular characterization of virus isolates, sequence-
based surveillance activities and assessment of emerging influenza virus threats.      
Agenda/Set-up
Todd Davis, Pierre Rivailler, Catherine Smith and Rebecca Garten each developed curriculum and 
provided formal instruction in sequence database utilization and bioinformatics resources, introduction 
to sequence alignment software for data analysis, and phylogenetic software applications. The ten day 
course with more than 30 participants was taught using a series of lectures, demonstrations, computer 
lab practicals and group projects. 
Outcome
Participants developed the use of phylogenetic analysis tools and resources to support influenza virus 
research and to strengthen seasonal and animal influenza surveillance and pandemic risk assessment 
activities. All participants developed independent research skills for the identification, characterization, 
and analysis of seasonal, pandemic and avian influenza. Several research collaborations between 
participants and instructors resulted from the course.   
Cell Culture, Isolation and Troubleshooting
Location: Laboratorio de Virus Respiratorios; Lima, Peru.




The goal of this training was to provide support and provide troubleshooting in cell culture and 
the isolation of influenza viruses. Amanda Balish, CDC, provided support in the areas of biosafety, 
biosecurity and immunofluorscence.
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Agenda/Set-up
The agenda was flexible so that the day-to-day activities of the laboratory could be reviewed. 
Key Topics/Set-up
•	 Propagation of the MDCK cell line.
•	 Isolation of influenza viruses.
•	 Troubleshooting.
•	 Review of biosafety and biosecurity.
Outcome
The issue with the laboratory’s current cell line was identified and the laboratory was sent new cell 
culture. The procedures were adjusted to reflect what was learned in the laboratory training. The 
laboratory has submitted many isolated samples to the CDC for influenza surveillance since the training.
Noteworthy Outcomes
The laboratorians learned quickly and were able to integrate changes and suggestions into their standard 
operating procedures.
Cell Culture, Isolation and Troubleshooting
Location: Central Laboratory of Public Health; Ascuncion, Paraguay.




The goal of this training was to provide support and provide troubleshooting in cell culture  
and the isolation of influenza viruses. Amanda Balish, CDC, provided support in the areas of  
biosafety and biosecurity.
Agenda/Set-up
The agenda was flexible so that the day-to-day activities of the laboratory could be reviewed. 
Key Topics/Set-up
•	 Propagation of the MDCK cell line.
•	 Isolation of influenza viruses.
•	 Troubleshooting.
•	 Review of biosafety and biosecurity.
Outcome
The issue with the laboratory’s current cell line was identified and the laboratory was sent new cell 
culture. The procedures were adjusted to reflect what was learned in the laboratory training. The 
laboratory has submitted many isolated samples to the CDC for influenza surveillance since the training.
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Noteworthy Outcomes
The laboratorians learned quickly and were able to integrate changes and suggestions into their standard 
operating procedures.
Influenza Biosafety and Virus Isolation Training 
Location: NIHRD Laboratories; Jakarta, Indonesia.




This training was requested by the National Institute of Health Research Development (NIHRD) for 
assistance in virus isolation, serological assays, standard operating procedures and biosafety in a 
new BSL-3 facility for influenza surveillance and research. Laboratory assessment and training were 
conducted by Thomas Rowe, CDC. The training was held in order to provide guidance and expertise 
on influenza laboratory practices that are consistent with WHO/CDC influenza laboratories. NIHRD has 
expressed interest in becoming a WHO Influenza Collaborating Center and has requested assistance in 
strengthening their program to be in line with WHO influenza laboratories.
Agenda/Set-up
The training program was divided into three areas: 1) Influenza virus isolation troubleshooting, 2) 
influenza safety training, and 3) Development of BSL-3 safety program for a newly constructed BSL-
3-enhanced HPAI laboratory. The goal of part 1 of the training was to identify areas in the laboratory 
which may contribute to the reduced rate of virus isolation. The goal of part 2 of the training was to 
provide basic influenza training which is consistent with WHO and CDC guidelines for working with 
seasonal, novel, and highly-pathogenic avian influenza. The goal of part 3 was to aid in the setup of the 
new BSL-3 enhanced HPAI laboratory and development of a laboratory/safety program.
Outcome
The training and assessment was well received by the members of the NIHRD influenza laboratory. 
Several areas for improvement were identified which would allow for greater recovery of virus as well 
as for quicker data turnaround time to provide needed epidemiological and virological information to 
Indonesia sentinel laboratories and WHO.
Noteworthy Outcomes
CDC and WHO were requested to provide technical assistance in virus isolation and areas of laboratory 
management. Additionally, key areas were identified for improvement and included features related to 
the BSL-3 enhanced HPAI laboratory, laboratory methodologies, and data management.
276 Influenza Division International Activities  |  Fiscal Year 2010 Annual Report
Thomas Rowe (CDC) with participants from the Biosafety and Virus Isolation Training in front of Indonesia’s new National Institute of Health Research and Development 
laboratories, Jakarta, Indonesia, 2010.
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Epidemiology and Surveillance 
Training
Sentinel Site Surveillance Training
Location: Addis Ababa, Ethiopia.
Date: February 2010.
Conducted by the CDC international influenza team in partnership with the University of North Carolina 
Gillings School of Global Public Health and the Council for State and Territorial Epidemiologists (CSTE)
Goals
The course had two goals: to pilot the influenza sentinel site surveillance materials and to train 
participants on how to set up and run an effective influenza sentinel surveillance system. The audience 
consisted of surveillance officers and any other public health professionals involved in the influenza 
surveillance system. The training consisted of PowerPoint presentations, break-out sessions, and a set 
of pocket cards meant to help reference key topics in the field. The training was used as a forum for 
QandA and discussion about ways to improve Ethiopia’s surveillance system. At the end of the training, 
participants filled out an evaluation of the course which was used to improve the training materials for 
future use.
Agenda/Set-up
The training occurred over the course of one day and covered the following topics:
•	 background and objectives.
•	 case definitions.
•	 mechanics of sentinel surveillance.
•	 roles and responsibilities.
•	 data reports and analysis.
•	 system monitoring.




Trainees gave positive feedback on the training course. Next steps include putting the materials through 
CDC clearance, posting the materials online, and translating the materials into French and Spanish.
Noteworthy Outcomes
The training stimulated discussion amongst participants on how to improve their surveillance systems. 
Also, the training materials can serve as a useful reference for participants. Positive feedback was 
received when participants evaluated the training.
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Sentinel Site Surveillance Training
Location: Kigali, Rwanda.
Date: June 2010.
Conducted by Members of the CDC international influenza team.
Goals
The course had two goals: to pilot the influenza sentinel site surveillance materials and to train 
participants on how to set up and run an effective influenza sentinel surveillance system. The audience 
consisted of surveillance officers and any other public health professionals involved in the influenza 
surveillance system. The training consisted of PowerPoint presentations, break-out sessions, and a set 
of pocket cards meant to help reference key topics in the field. The training was used as a forum for 
QandA and discussion about ways to improve Rwanda’s surveillance system. At the end of the training, 
participants filled out an evaluation of the course which was used to improve the training materials  
for future use.
Agenda/Set-up
The training occurred over the course of one day and covered the following topics:
•	 background and objectives.
•	 case definitions.
•	 mechanics of sentinel surveillance.
•	 roles and responsibilities.
•	 data reports and analysis.
•	 system monitoring.




Trainees gave positive feedback on the training course. Next steps include putting the materials through 
CDC clearance, posting the materials online, and translating the materials into French and Spanish.
Noteworthy Outcomes
The training stimulated discussion amongst participants on how to improve their surveillance systems. 
Also, the training materials can serve as a useful reference for participants. Positive feedback was 
received when participants evaluated the training.  
Writing Workshops
Location: Nairobi, Kenya.
Date: March, 2010; October 2010. 
Conducted by epidemiology professors from University of California, San Francisco. 
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Goals
To help local and regional epidemiologists and laboratory staff finalize their influenza-related 
manuscripts for publication. 
Agenda/Set-up
Short lectures were conducted that outlined the approach to different aspects of writing manuscripts. A 
significant portion of the time was dedicated to allowing writers complete their analyses and draft their 
manuscripts. Writers met with mentors on a daily basis to go over their papers.
Outcome
A number of manuscripts were completed. 
Noteworthy Outcomes
At least 12 manuscripts have been submitted for publication in peer-reviewed journals and others are 
nearing completion.
Training for Epi Info™ 3.5.1 Tool
Location: Addis Ababa, Ethiopia.
Date: September 2010.
Conducted by Epi Info Atlanta team.
Goals
The overall objectives of the training were to provide a comprehensive overview and hands-on 
workshop in using the suite of tools available within Epi Info. 
Agenda/Set-up
During the training, students learned how to create survey questionnaires, enter and analyze data 
from multiple sources and visualize the results through graphs, maps and other presentation methods 
supported by Epi Info. 
Outcome
Four-day training sessions were successfully completed in Addis Ababa, Ethiopia. Training concentrated 
on helping participants to improve the following abilities: read and analyze multiple data sets submitted 
by different health facilities at the national level; understand check codes functionalities in order to be 
able to incorporate business rules into Epi Info data entry screens for data validation; export subsets 
of data into different data formats like Excel, Text, HTML and Access; merge/import multiple files into 
a single master database, and; understand Epi Info menu files (.MNU) in order to develop customized 
applications using Epi Info.
Noteworthy Outcomes
The team successfully demonstrated how to: import Excel data into an MS Access database using Epi 
Info, export data to different formats including Excel, Text and Access, and create Epi Info customizable 
menus. The Epi Info team in Atlanta will continue to provide technical assistance to partners in Ethiopia 
through the Community of Users forum as well as through direct email communications.
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Acronyms
2009 H1N1 2009 Pandemic Influenza A (H1N1)
AFR WHO African Region
AFRO WHO Africa Regional Office
AI Avian Influenza
AHI Avian and Human Influenza 
AMR WHO Region of the Americas
APHIS Animal and Plant Health Inspection Service (USDA)
APHL Association of Public Health Laboratories
ARI Acute Respiratory Illness
BEP Biosecurity Engagement Program
BSL Biosafety level 
CARE Cooperative for Assistance and Relief Everywhere
CDC  Centers for Disease Control and Prevention
CDC-CAP CDC Central America and Panama
CoAG Cooperative Agreement
DFA Direct Immunofluorescence
DoD Department of Defense
DVM Doctor of Veterinary Medicine
ECDC European Centers for Disease Control
EMR WHO Eastern Mediterranean Region 
EMRO WHO Eastern Mediterranean Regional Office
EOC Emergency Operations Center
EQAP  WHO External Quality Assessment Program
EUR WHO European Region
EURO WHO European Regional Office
FAO Food and Agriculture Organization
FDA United States Food and Drug Administration
FETP Field Epidemiology Training Program
FELTP Field Epidemiology and Laboratory Training Program
FY Fiscal Year
References 291
FMOH Federal Ministry of Health
GDD CDC Global Disease Detection
GDP Gross Domestic Product
GEIS Global Emerging Infections Surveillance (DoD)
GIP WHO Global Influenza Program
GISN WHO Global Influenza Surveillance Network 
GOARN WHO Global Outbreak Alert and Response Network
HA Hemagglutinin (a protein on the surface of the influenza virus)
HAI (or HI) Hemagglutination Inhibition Assay
HAI Health care-associated Infection; Human Animal Interface
HHS United States Department of Health and Human Services
HPAI High Pathogenic Avian Influenza
IATA International Air Transport Association
ICEID International Conference on Emerging Infectious Disease
ID CDC Influenza Division
IDSR Integrated Disease Surveillance and Response
IHR International Health Regulations
IFA Immunofluorescence, Indirect Antibody Staining
IEC Information, Education and Communication
IEIP International Emerging Infections Program 
ILI  Influenza-Like Illness
IRR Influenza Reagent Resource 
LCD-TV Liquid-crystal Display Television
LPAI Low Pathogenic Avian Influenza
MD Medical Doctor
MDCK Madin-Darby Canine Kidney Cells
MN Microneutralization Assay 
MOH Ministry of Health
MPA Master of Public Administration
MPH Master of Public Health
MSc Master of Science
NA Neuraminidase (a protein on the surface of the influenza virus) 
292 Influenza Division International Activities  |  Fiscal Year 2010 Annual Report
NAI Neuraminidase Inhibitors
NAMRU United States Naval Medical Research Unit
NCIRD National Center for Immunization and Respiratory Diseases
NGO Non-Government Organization
NI  Neuraminidase Inhibition Assay
NIC National Influenza Center
NP Nasopharyngeal swab
NRP National Response Plan
NVAC National Vaccine Advisory Committee
NVPO National Vaccine Program Office
OIE World Organisation for Animal Health (Office International des Épizooties)
OP Oropharyngeal swab
PAHO Pan American Health Organization
PATH Program Appropriate Technology in Health
PCR Polymerase Chain Reaction
PPE Personal Protective Equipment
Pro-MED Program for Monitoring Emerging Diseases Electronic Outbreak Reporting System
QA Quality Assurance
QC Quality Control
QMS Quality Management System
RRT Rapid Response Team
RSV Respiratory Syncytial Virus
RT-PCR Reverse Transcriptase Polymerase Chain Reaction
SADC South African Development Community
SARI Severe Acute Respiratory Infection
SARS Severe Acute Respiratory Syndrome
SEAR WHO South-East Asia Region 
SEARO WHO South-East Asia Regional Office
SMS Short Messaging Service
SOP Standard Operating Procedure
SPC Secretariat of the Pacific Community
TB Tuberculosis
References 293
UNICEF United Nations Children’s Fund
UPS Uninterruptable Power Supply
USAID  United States Agency for International Development
USDA United States Department of Agriculture
VTM Viral Transport Media
WFP World Food Program
WPRO WHO Western Pacific Regional Office
WPR WHO Western Pacific Region
WHO World Health Organization
WHO CC World Health Organization Collaborating Center for Reference and Research on Influenza 
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